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  et	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  publication	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  basis	   for	   the	   interaction	  of	  ribosomal	  protein	  S1	  with	  the	  E.	  coli	  ribosome.	  I	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  the	  ErmCL-­‐stalled	  ribosome	  complex,	  performed	  the	  cryo-­‐EM	  analysis	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  and	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  of	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   of	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   proline-­‐rich	   antimicrobial	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  Onc112	   bound	   to	   the	  Thermus	   thermophilus	   ribosome	   as	  well	   as	   biochemical	   analyses,	  unraveling	  the	  mode	  of	  Onc112-­‐mediated	  translation	  inhibition.	  I	  performed	  the	  disome	  assays	   showing	   that	  Onc112	  destabilizes	   the	  70S	  post-­‐initiation	   complex	   and	  prepared	  figures	  4b-­‐e	  of	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  manuscript.	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   third-­‐generation	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   mode	   of	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   binding,	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   mechanism	   of	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  tetracycline	  resistance	  mechanisms,	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  4	  (Arenz	  et	  al.,	  2015)	  This	   publication	   reports	   a	   cryo-­‐EM	   structure	   of	   TetM	   in	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   with	   a	   translating	  ribosome	  at	  3.9	  Å	  resolution.	  I	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  TetM!RNC	  complex,	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  the	  cryo-­‐EM	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  reconstructed	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  refined	  the	  complex	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  for	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   to	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   and	   the	   design	   of	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  all	  figures	  and	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  writing	  this	  manuscript.	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  5	  (Arenz	  et	  al.,	  2014)	  This	   publication	   reports	   the	   molecular	   basis	   for	   erythromycin-­‐dependent	   ribosome	  stalling	   during	   translation	   of	   the	   ErmBL	   leader	   peptide.	   I	   used	   the	   disome	   system	   to	  purify	  ErmBL-­‐SRCs	  and	  performed	  the	  cryo-­‐EM	  analysis	   to	  reconstruct	   the	  ErmBL-­‐SRC.	  Beside	  my	  contribution	  to	  interpret	  the	  map	  and	  biochemical	  data,	  I	  built	  the	  molecular	  model	  for	  ErmBL-­‐SRC.	  I	  prepared	  all	  figures	  and	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  writing	  this	  manuscript.	  	  
Publication	  6	  (Arenz	  et	  al.,	  2014)	  This	   publication	   provides	   the	   first	   near-­‐atomic	   resolution	   structure	   of	   a	   drug-­‐stalled	  ribosome	   and	   unravels	   how	  drug	   sensing	   by	   the	   ribosome	   induces	   translational	   arrest	  during	   translation	   of	   the	   ErmCL	   leader	   peptide	   via	   active	   site	   perturbation.	   I	   used	   the	  previously	  established	  disome	  system	  to	  purify	  ErmCL-­‐SRCs	  and	  performed	  the	  cryo-­‐EM	  analysis	   to	   reconstruct	   the	  ErmCL-­‐SRC.	   I	   performed	   the	  model	  building	   for	  ErmCL-­‐SRC	  and	  contributed	  to	  interpretation	  of	  structural	  and	  biochemical	  data,	  prepared	  all	  figures	  and	  assisted	  in	  writing	  this	  manuscript.	  	  




2D	   	   	   	   	   two-­‐dimensional	  A	   	   	   	   	   adenine	  AAP	   	   	   	   	   arginine	  attenuator	  peptide	  aa-­‐tRNA	   	   	   	   aminoacyl-­‐tRNA	  A-­‐site	   	   	   	   	   acceptor	  site	  ASL	   	   	   	   	   anticodon	  stem	  loop	  C	   	   	   	   	   cytosine	  CMV	   	   	   	   	   cytomegalovirus	  DC	   	   	   	   	   decoding	  center	  Cs	   	   	   	   	   spherical	  aberration	  CTH	   	   	   	   	   C-­‐terminal	  helix	  DNA	   	   	   	   	   deoxyribonucleic	  acid	  EF	   	   	   	   	   elongation	  factor	  EM	   	   	   	   	   electron	  microscopy	  Erm	   	   	   	   	   erythromycin	  methyltransferase	  E-­‐site	   	   	   	   	   exit	  site	  FRET	   	   	   	   	   fluorescence	  resonance	  energy	  transfer	  G	   	   	   	   	   guanine	  GAC	   	   	   	   	   GTPase-­‐associated	  center	  GDP	   	   	   	   	   guanosin-­‐5’-­‐diphosphate	  GTP	   	   	   	   	   guanosin-­‐5’-­‐triphosphate	  h#	   	   	   	   	   helix	  #	  of	  small	  ribosomal	  subunit	  H#	   	   	   	   	   helix#	  of	  large	  ribosomal	  subunit	  IC	   	   	   	   	   initiation	  complex	  IF	   	   	   	   	   initiation	  factor	  kDa	   	   	   	   	   kilodalton	  LSU	   	   	   	   	   large	  subunit	  MDa	   	   	   	   	   megadalton	  MIC	   	   	   	   	   minimal	  inhibition	  concentration	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The	  ribosome	  translates	  the	  genetic	  code	  stored	  in	  the	  codon	  sequence	  of	  the	  mRNA	  into	   proteins,	   which	   represents	   a	   central	   step	   in	   all	   living	   organisms.	   Using	   cryo	  electron	  microscopy	  (cryo-­‐EM)	  this	  work	  sheds	  light	  on	  several	  aspects	  of	  translation.	  We	  provide	  the	  first	  structural	  basis	  for	  the	  interaction	  of	  ribosomal	  protein	  S1	  with	  the	   ribosome,	   extending	   our	   insight	   into	   how	   S1	   enables	   translation	   initiation	   on	  highly	   structured	   mRNAs.	   Since	   the	   ribosome	   is	   the	   major	   target	   for	   antibiotics	  within	   bacterial	   cells,	   we	   unraveled	   how	   the	   proline-­‐rich	   antimicrobial	   peptide	  Onc112,	   representing	   a	   potentially	   new	   class	   of	   clinically	   used	   antibiotics,	   binds	   to	  the	   ribosome	  and	   inhibits	   translation.	  Bacterial	   resistance	   to	  all	   classes	  of	   clinically	  used	  antibiotics	   is	  quickly	  spreading	  and	  represents	  a	  major	  threat	  to	  public	  health.	  We	   gained	   profound	   insight	   into	   the	   molecular	   mechanism	   of	   the	   widespread	  ribosome	   protection	   protein	   (RPP)	   TetM-­‐mediated	   tetracycline	   resistance,	   by	  obtaining	   a	   high-­‐resolution	   cryo-­‐EM	   reconstruction	   of	   TetM	   bound	   to	   a	   translating	  ribosome.	   Another	  mechanism	   by	  which	   bacteria	   become	   resistant	   is	   based	   on	   the	  principle	   of	   target	   modification.	   For	   example,	   specialized	   Erm-­‐type	  methyltransferases	   methylate	   the	   macrolide	   binding	   site	   within	   the	   ribosome	   exit	  tunnel	  and	  thus	  confer	  macrolide	  resistance.	  Expression	  of	  these	  resistance	  enzymes	  is	   strictly	   regulated	   by	   drug-­‐dependent	   translation	   attenuation	   on	   short	   upstream	  open	  reading	  frames	  encoding	  leader	  peptides.	  Thereby,	  the	  amino	  acid	  sequence	  of	  the	   nascent	   peptide,	   together	   with	   the	   presence	   of	   macrolides,	   is	   a	   crucial	  determinant	   necessary	   for	   stalling	   to	   occur.	   By	   using	   cryo-­‐EM	   on	   stalled	   ribosome	  complexes	   (SRCs),	   we	   unraveled	   for	   the	   first	   time	   how	   the	   nascent	   leader	   peptide	  intimately	  interacts	  with	  the	  ribosome	  and	  the	  tunnel-­‐bound	  macrolide	  to	  generate	  a	  stalling	  signal,	  which	  is	  then	  communicated	  to	  the	  peptidyl	  transferase	  center	  (PTC)	  to	  arrest	  translation	  of	  the	  leader	  peptide,	  thus	  leading	  to	  induction	  of	  expression	  of	  the	   resistance	   enzyme.	   Moreover,	   we	   revealed	   that	   depending	   on	   the	   amino	   acid	  sequence	  of	   the	  nascent	  peptide,	   the	  mechanisms	  by	  which	   the	   ribosomal	  PTC	  gets	  inactivated	  is	  completely	  distinct.	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1 Introduction Almost	  50	  years	  ago,	  Francis	  Crick	  published	  the	  hypothesis	  of	  the	  central	  dogma	  of	  molecular	  biology	  (Crick,	  1970).	  The	  central	  dogma	  describes	  that	  sequential	  genetic	  information	   stored	   in	   DNA	   is	   transferred	   from	  DNA	   polymers	   to	   RNA	   polymers	   to	  amino	   acid	   polymers,	   so	   called	   proteins.	   During	   transcription,	   genetic	   information	  stored	   as	   DNA	   sequence	   is	   transcribed	   into	   the	   corresponding	   RNA	   sequence	   by	  specialized	  DNA-­‐dependent	  RNA	  polymerases.	  RNA	  molecules	  play	  numerous	  roles	  in	  the	  cell.	  They	  can	  act	  as	  regulators	  of	  gene	  expression,	  serve	  as	  structural	  scaffolds	  or	  function	  as	  enzymes.	  The	  destination	  of	  most	  of	  the	  cellular	  RNA	  molecules	  is	  to	  carry	  the	  genetic	  code	  to	  build	  a	  specific	  protein.	  Such	  RNA	  molecules	  are	  called	  messenger	  RNAs	   (mRNAs).	   In	   the	   process	   of	   translation,	   macromolecular	   machines	   read	   the	  genetic	  code	  stored	   in	  nucleotide	   triplets	   (codons)	  (Crick	  et	  al.,	  1961)	  of	   the	  mRNA	  sequence	  and	  translate	  this	  information	  into	  an	  amino	  acid	  sequence	  of	  a	  protein.	  The	  macromolecular	   machines	   responsible	   for	   translation	   were	   discovered	   in	   1955	   by	  George	  Palade	  on	  electron	  microscopy	  images	  of	  acinar	  cells	  of	  rat	  pancreas	  (Palade,	  1955)	  and	  were	  initially	  named	  Palade	  particles.	  Later,	  these	  particles	  were	  renamed	  to	  “Ribosomes”	  (McQuillen	  et	  al.,	  1959).	  The	  function	  of	  ribosomes	  is	  conserved	  in	  all	  three	   domains	   of	   life,	   however	   species-­‐specific	   differences	   in	   their	   molecular	  architecture	  exist.	  These	  differences	  are	  exploited	  for	  example	  by	  various	  antibiotics	  that	  exclusively	  bind	  and	  inhibit	  prokaryotic	  ribosomes.	  	  	  
1.1 The	  Bacterial	  Ribosome	  In	   all	   three	   kingdoms	   of	   life,	   the	   ribosome	   is	   responsible	   for	   the	   biosynthesis	   of	  polypeptides	  by	   translation	  of	  mRNA	  sequences.	  The	  bacterial	   ribosome	  consists	  of	  the	  30S	   subunit	   (small	   subunit,	   SSU)	   and	   the	  50S	   subunit	   (large	   subunit,	   LSU)	   that	  reversibly	   join	   together	   to	   form	   the	   70S	   ribosome	   with	   a	   total	   molecular	   mass	   of	  approximately	   2.5	  megadalton	   (MDa).	   In	   bacteria,	   such	   as	  Escherichia	   coli,	   the	   30S	  ribosomal	  subunit	   is	  composed	  of	  the	  16S	  ribosomal	  RNA	  (rRNA)	  and	  21	  ribosomal	  proteins	  (rProteins),	  whereas	  the	  50S	  ribosomal	  subunit	   is	   formed	  by	  23S	  rRNA,	  5S	  rRNA	   and	   33	   rProteins	   (Fig.	   1).	   The	   two	   subunits	   have	   different	   roles	   during	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Figure	  1	  |	  The	  prokaryotic	  ribosome.	  (A)	  Overview	  of	  the	  Escherichia	  coli	  70S	  ribosome	  (Dunkle	  et	  al.,	   2011)	   with	   30S	   subunit	   colored	   in	   yellow	   and	   50S	   subunit	   in	   grey.	   (B)	   Table	   of	   assembly	  components	  of	  the	  70S	  ribosome	  as	  well	  as	  the	  30S	  and	  50S	  subunits.	  (C)	  Schematic	  representation	  of	  the	   prokaryotic	   ribosome	   bound	   with	   three	   tRNAs	   showing	   the	   30S	   subunit	   (yellow),	   50S	   subunit	  (grey),	  A-­‐site	  tRNA	  (orange),	  P-­‐site	  tRNA	  (cyan),	  E-­‐site	  tRNA	  (pink)	  and	  mRNA	  (black).	  The	  PTC	  on	  the	  50S	  subunit	  is	  depicted	  as	  dashed-­‐lined	  sphere.	  	  	  




Figure	   2	   |	   Overview	  of	   the	   prokaryotic	   translation	   cycle.	  During	   Initiation	  (green),	   the	  70S-­‐IC	   is	  formed,	  involving	  IF1,	  IF2,	  IF3,	  mRNA,	  initiator	  tRNA	  and	  both	  30S	  and	  50S	  ribosomal	  subunits.	  In	  the	  Elongation	   phase,	   incoming	   tRNAs	   are	   delivered	   by	   EF-­‐Tu	   to	   the	   A-­‐site	   of	   the	   ribosome.	   After	  accommodation	  of	  the	  A-­‐site	  tRNA,	  the	  ribosome	  catalyzes	  peptide	  bond	  formation	  and	  transfers	   the	  peptide	  attached	   to	   the	  P-­‐site	   tRNA	  onto	   the	  A-­‐site	   tRNA,	   thereby	  elongating	   the	  nascent	  peptide	  by	  one	  amino	  acid.	  The	  ribosome	  adopts	  the	  ratcheted	  state	  with	  tRNAs	  in	  hybrid	  states.	  EF-­‐G	  mediates	  translocation	  of	  the	  mRNA	  by	  one	  codon	  and	  translocation	  of	  the	  tRNAs	  from	  the	  A-­‐	  to	  the	  P	  and	  from	  the	  P-­‐	   to	   the	  E-­‐site.	   If	  a	   sense	  codon	   is	  displayed	   in	   the	  empty	  A-­‐site,	  a	  new	  round	  of	   the	  elongation	  cycle	  occurs.	  As	  soon	  as	  a	  stop	  codon	  emerges	  in	  the	  A-­‐site,	  translation	  Termination	  is	  mediated	  by	  the	  action	  of	  RF1,	  RF2	  and	  RF3.	  During	  ribosome	  Recycling,	  RRF	  and	  EF-­‐G	  cooperate	  to	  split	  the	  ribosome	  for	  translation	  initiation	  on	  the	  next	  mRNA.	  Figure	  modified	  from	  (Sohmen	  et	  al.,	  2009).	  	  
1.2.1 Initiation Initiation	   of	   translation	   is	   the	   rate-­‐limiting	   step	   during	   translation	   of	   mRNA	  molecules	   into	   proteins	   (Laursen	   et	   al.,	   2005).	   Prokaryotic	   translation	   initiation	  requires	   formation	  of	   the	  30S	   initiation	   complex	   (30S-­‐IC),	  which	   involves	   the	   three	  initiation	  factors	  IF1,	  IF2	  and	  IF3,	  as	  well	  as	  mRNA	  and	  the	  formylated	  initiator	  fMet-­‐tRNAfMet	   (Fig.	   3).	   The	   methionyl-­‐tRNA	   transformylase-­‐mediated	   formylation	   of	   the	  initiator	   tRNA	   distinguishes	   initiator	   fMet-­‐tRNAfMet	   from	   elongation	   Met-­‐tRNAMet	  
Introduction	  	  
12	  
(Guillon	  et	  al.,	  1992;	  Lee	  et	  al.,	  1991;	  Seong	  and	  RajBhandary,	  1987).	  The	  main	  goal	  of	  30S-­‐IC	   formation	   is	   to	   position	   the	   initiator	   fMet-­‐tRNAfMet	   in	   a	   P/I	   state	  (peptidyl/initiation	   state)	   binding	   the	   start	   codon	   of	   the	  mRNA	   in	   the	   P-­‐site	   of	   the	  SSU	  (Allen	  et	  al.,	  2005;	  Antoun	  et	  al.,	  2006;	  Julian	  et	  al.,	  2011).	  Subsequently,	  the	  LSU	  joins	   to	   form	   the	   70S	   initiation	   complex	   (70S-­‐IC)	   (Fig.	   3).	   70S-­‐IC	   formation	   is	  accompanied	  by	  the	  dissociation	  of	  initiation	  factors	  IF1-­‐3	  from	  the	  ribosome,	  leaving	  the	   fMet-­‐tRNAfMet	  positioned	   in	   the	  P/P	  state	  and	  thereby	  priming	   the	  ribosome	  for	  initiation	  of	  translation	  elongation	  (Marshall	  et	  al.,	  2009).	  	  During	   initiation,	   IF1	   and	   IF3	   ensure	   fidelity	   of	   the	   process,	   whereas	   IF2	   recruits	  fMet-­‐tRNAfMet.	  IF3	  binds	  to	  the	  E-­‐site	  of	  the	  30S	  subunit	  (Fig.	  3)	  to	  form	  the	  IF3-­‐30S	  complex	  and	  thereby	  prevents	  premature	  50S	  subunit	  joining	  before	  association	  with	  IF1,	  IF2,	  mRNA	  and	  initiator	  tRNA	  (Dallas	  and	  Noller,	  2001;	  Grunberg-­‐Manago	  et	  al.,	  1975;	   Karimi	   et	   al.,	   1999;	   Subramanian	   and	   Davis,	   1970).	   The	   interaction	   of	   the	  Shine-­‐Dalgarno	  (SD)	  sequence	  (Shine	  and	  Dalgarno,	  1974)	  of	  canonical	  mRNAs	  with	  the	  3’	  end	  of	  the	  16S	  rRNA	  (anti-­‐SD)	  places	  the	  start	  codon	  in	  the	  P-­‐site	  and	  allows	  for	  subsequent	  association	  of	  fMet-­‐tRNAfMet	  ,	  IF1	  and	  IF2	  (Demeshkina	  et	  al.,	  2010;	  Jenner	  et	   al.,	   2010b;	   Kaminishi	   et	   al.,	   2007).	   Discrimination	   of	   the	   initiator	   tRNA	   is	  performed	  by	  IF3	  through	  monitoring	  of	  three	  unique	  G:C	  base	  pairs	  in	  fMet-­‐tRNAfMet	  (Hartz	   et	   al.,	   1990;	   Hartz	   et	   al.,	   1989;	   O'Connor	   et	   al.,	   2001;	   Risuleo	   et	   al.,	   1976;	  Sussman	   et	   al.,	   1996).	   Furthermore,	   the	   presence	   of	   IF3	   is	   required	   to	   ensure	   the	  fidelity	  of	  the	  codon-­‐anticodon	  interaction	  in	  the	  P-­‐site	  of	  the	  SSU	  (Milon	  et	  al.,	  2008).	  IF1	  binds	  at	  the	  A-­‐site	  of	  the	  SSU	  (Carter	  et	  al.,	  2001;	  Julian	  et	  al.,	  2011;	  Simonetti	  et	  al.,	   2008)	  where	   it	   stabilizes	   IF2	   binding	   (Moreno	   et	   al.,	   1999)	   and	   accelerates	   IF2	  dependent	   fMet-­‐tRNAfMet	  recruitment	   (Gualerzi	   and	  Pon,	  1990;	  Laursen	  et	  al.,	  2005;	  Zucker	   and	  Hershey,	   1986).	   The	  GTPase	   IF2	   binds	   to	   the	   acceptor	   stem	  and	   to	   the	  fMet	  moiety	  of	  the	  initiator	  fMet-­‐tRNAfMet	  (Guenneugues	  et	  al.,	  2000),	  as	  well	  as	  to	  IF1	  and	  ribosomal	  protein	  S12	  (Julian	  et	  al.,	  2011).	  Notably,	  the	  interaction	  between	  IF1	  and	   IF2	   is	  not	  conserved	   (Kapralou	  et	  al.,	  2008).	  Binding	  of	   initiation	   factors	   to	   the	  SSU	  stabilizes	  a	  swiveled	  conformation	  of	  the	  head	  with	  respect	  to	  the	  body	  (Julian	  et	  al.,	   2011).	   The	   LSU	   joins	   the	   30S-­‐IC	   in	   ratcheted	   conformation	   to	   form	   the	   70S-­‐IC	  (Allen	  et	  al.,	  2005).	  Formation	  of	   the	  70S-­‐IC	  activates	  GTP	  hydrolysis	  by	   IF2,	  which	  leads	   to	  unratcheting	  of	   the	   ribosome	  allowing	   the	  conformational	   transition	  of	   the	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fMet-­‐tRNAfMet	   from	   the	  P/I	   state	   to	   the	  accommodated	  P/P-­‐state.	  At	   the	   same	   time,	  the	   IF´s	   dissociate	   from	   the	   complex	   thus	   turning	   the	   ribosome	   into	   its	   translation	  elongation	  competent	  conformation	  (Marshall	  et	  al.,	  2009).	  	  	  
	  
Figure	  3	  |	  Localization	  of	  IF1,	  IF2	  and	  IF3	  in	  prokaryotic	  30S-­‐	  and	  70S-­‐inititation	  complexes.	  (A)	  Crystal	   structure	   of	   IF1	   (red)	   bound	   to	   the	   30S	   subunit	   (blue)	   (Carter	   et	   al.,	   2001).	   (B)	   Cryo-­‐EM	  structure	   of	   30S-­‐IC	   with	   IF1	   (red),	   fMet-­‐tRNAfMet	  (red)	   and	   IF2	   (green)	   (Simonetti	   et	   al.,	   2008).	   (C)	  Cryo-­‐EM	   structure	   of	   the	   70S-­‐IC	   (Allen	   et	   al.,	   2005)	  with	   IF1	   (red),	   fMet-­‐tRNAfMet	  (red),	   IF2	   (green),	  H69	  (yellow,	  occupies	   the	  density	  annotated	  as	   IF3	   in	   (Allen	  et	  al.,	  2005))	  and	  overlay	  of	  shifted	   IF1	  position	  (black)	  in	  (A).	  (D)	  Cryo-­‐EM	  structure	  of	  the	  30S-­‐IC	  showing	  density	  for	  IF3	  (orange)	  (Julian	  et	  al.,	   2011).	   (E)	   Comparison	   of	   tRNA	   position	   in	   the	   30S-­‐IC	   (30S!mRNA!fMet-­‐tRNAfMet!IF1!IF2!GTP)	  (Simonetti	   et	   al.,	   2008)	  with	   those	   observed	   in	   70S	   post-­‐initiation	   complex	   (Yusupova	   et	   al.,	   2006).	  Figure	  modified	  from	  (Julian	  et	  al.,	  2011;	  Myasnikov	  et	  al.,	  2009;	  Simonetti	  et	  al.,	  2008).	  	  	   During	   canonical	   initiation,	   initial	   mRNA	   recognition	   and	   unfolding	   of	  structured	   mRNAs	   is	   a	   crucial	   step	   preceding	   30S-­‐IC	   formation.	   Interestingly,	   the	  ribosomal	  protein	  S1	  plays	  a	  major	  role	  in	  these	  early	  steps	  of	  translation.	  Ribosomal	  protein	  S1	  is	  the	  largest	  ribosomal	  protein	  with	  a	  mass	  of	  61.1	  kDa	  and	  is	  essential	  for	  translation	  initiation	  in	  Gram-­‐negative	  bacteria	  (Sorensen	  et	  al.,	  1998).	  S1	  contributes	  to	  an	   initial	  positioning	  of	   the	  mRNA	  at	   the	  ribosome	  by	   interaction	  with	   their	  A/U	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rich	  5’	  untranslated	  region	  (UTR)	  (Boni	  et	  al.,	  1991).	  Furthermore	  S1	  was	  shown	  to	  have	   an	   implication	   in	   unfolding	   secondary	   structures	   of	   certain	   mRNAs	   and	   thus	  enables	  30S-­‐IC	   formation	  on	  highly	  structured	  mRNAs	  (Duval	  et	  al.,	  2013;	  Qu	  et	  al.,	  2012).	  However,	  translation	  initiation	  on	  leaderless	  mRNAs	  (lmRNAs)	  lacking	  the	  5’	  UTR	  does	  not	  depend	  on	  S1	  (Moll	  et	  al.,	  2002;	  Tedin	  et	  al.,	  1997).	  Due	  to	  the	  intrinsic	  flexibility	   of	   the	   six-­‐domain	   protein,	   complete	   structural	   information	   regarding	   its	  binding	  mode	  to	  the	  ribosome	  has	  remained	  elusive.	  Publication	  1	  of	  this	  cumulative	  thesis	  provides	  the	  first	  insight	  into	  the	  structural	  basis	  for	  the	  interaction	  of	  protein	  S1	  with	  the	  Escherichia	  coli	  ribosome	  (Byrgazov	  et	  al.,	  2015).	  	  	  
1.2.2 Elongation Unlike	   initiation,	   termination	   and	   recycling,	   the	   translation	   elongation	   cycle	   is	  conserved	   in	   all	   three	   kingdoms	   of	   life.	   After	   initiation,	   the	   ribosomal	   P-­‐site	   is	  occupied	  by	   the	   initiator	   fMet-­‐tRNAfMet	  whereas	   the	  A-­‐site	  remains	  empty.	  The	  next	  aa-­‐tRNA	  is	  delivered	  to	  the	  empty	  A-­‐site	  as	  a	  ternary	  complex	  together	  with	  GTPase	  elongation	  factor	  Tu	  (EF-­‐Tu)	  and	  its	  cofactor	  guanosin-­‐5’-­‐triphosphate	  (GTP)	  (Fischer	  et	  al.,	  2015;	  Schmeing	  et	  al.,	  2009;	  Schuette	  et	  al.,	  2009;	  Voorhees	  and	  Ramakrishnan,	  2013).	  Initial	  binding	  of	  the	  ternary	  complex	  is	  mediated	  by	  interaction	  of	  EF-­‐Tu	  with	  ribosomal	  protein	  L7/L12	  and	  notably	   is	  mRNA	   independent	   (Diaconu	  et	   al.,	   2005;	  Rodnina	  et	   al.,	   1996).	  The	   ternary	   complex	  binds	   in	  a	   conformation	   that	  allows	   the	  anticodon	  stem	  loop	  (ASL)	  of	   the	  tRNA	  to	  bind	   into	  the	  decoding	  center	  on	  the	  SSU	  whereas	  the	  aminoacylated	  3’-­‐acceptor	  stem	  is	  still	  bound	  to	  EF-­‐Tu.	  In	  this	  state,	  the	  tRNA	   is	   bound	   in	   the	   A/T	   state	   and	   adopts	   a	   bent	   conformation	   (Blanchard	   et	   al.,	  2004a;	  Fischer	  et	  al.,	  2015;	  Schmeing	  et	  al.,	  2009;	  Schuette	  et	  al.,	  2009;	  Stark	  et	  al.,	  1997;	  Valle	  et	  al.,	  2002).	  	  
Decoding	   of	  mRNA	   codons	   by	   complementary	   anticodons	   of	   cognate	   tRNAs	  links	   the	   genetic	   code	   directly	   to	   the	   amino	   acid	   sequence	   of	   encoded	   proteins.	   To	  ensure	   translational	   fidelity,	   the	   ribosome	  discriminates	  between	   cognate	   and	  non-­‐cognate	  tRNA	  binding	  by	  monitoring	  the	  interaction	  between	  the	  A-­‐site	  codon	  of	  the	  mRNA	   and	   the	   anticodon	   of	   the	   tRNA	   (still	   bound	   to	   EF-­‐Tu)	   within	   the	   decoding	  center	   (Ogle	   and	   Ramakrishnan,	   2005).	   Binding	   of	   a	   cognate	   tRNA	   leads	   to	  complementary	   Watson-­‐Crick	   base-­‐pair	   codon-­‐anticodon	   interactions.	   Following	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codon	   recognition,	   nucleotides	   A1492	   and	   A1493	   (E.	   coli	   numbering	   is	   used	  throughout	  this	  thesis)	  adopt	  a	  conformation	  flipped-­‐out	  of	  helix	  44	  (h44)	  of	  the	  16S	  rRNA	  and	  together	  with	  G530	  monitor	  the	  correct	  Watson-­‐Crick	  geometry	  of	  the	  first	  two	   base-­‐pairs	   of	   the	   codon-­‐anticodon	   interaction	   in	   the	   form	   of	   A-­‐minor	   motifs	  (Nissen	  et	  al.,	  2001;	  Ogle	  et	  al.,	  2001).	  	  At	  the	  third	  nucleotide	  position	  of	  the	  codon	  a	  wobble	   pair	   (e.g.	   G!U)	   is	   tolerated.	   This	   allows	   a	   single	   tRNA	   to	   decode	   multiple	  codons	  that	  only	  differ	  in	  the	  third	  anticodon	  position,	  thus	  providing	  an	  explanation	  for	  the	  degeneracy	  of	  the	  genetic	  code	  (Crick,	  1966).	  Recognition	  of	  a	  correct	  codon-­‐anticodon	   interaction	   triggers	   large-­‐scale	   conformational	   changes	   in	   the	   ribosome	  that	  induce	  a	  domain	  closure	  of	  the	  30S	  involving	  movement	  of	  the	  shoulder	  towards	  EF-­‐Tu.	   These	   structural	   rearrangements	   are	   propagated	   to	  EF-­‐Tu,	  which	  ultimately	  leads	   to	   stimulation	   of	   GTP	   hydrolysis	   (Ogle	   et	   al.,	   2002;	   Schmeing	   et	   al.,	   2011;	  Schuette	   et	   al.,	   2009;	   Voorhees	   et	   al.,	   2010).	   GTPase	   activity	   is	   controlled	   by	  positioning	  the	  catalytic	  histidine	  84	  (H84)	  of	  EF-­‐Tu	  in	  proximity	  to	  the	  phosphate	  of	  A2662	   of	   the	   sarcin-­‐ricin	   loop	   (SRL)	   in	  H95	   of	   the	   23S	   rRNA.	   This	   enables	  H84	   to	  coordinate	  a	  water	  molecule	  for	  nucleophilic	  attack	  on	  the	  γ-­‐phosphate	  of	  GTP,	  which	  is	   then	  hydrolyzed	  (Voorhees	  et	  al.,	  2010).	  GTP	  hydrolysis	  and	   inorganic	  phosphate	  (Pi)	  release	  cause	  structural	  rearrangements	  in	  EF-­‐Tu	  leading	  to	  dissociation	  of	  EF-­‐Tu	  from	  the	  ribosome	  and	  thus	  allowing	  the	  tRNA	  to	  transition	  from	  the	  A/T-­‐state	  into	  the	  A/A-­‐state.	  During	  accommodation,	  the	  acceptor	  stem	  of	  the	  tRNA	  moves	  into	  the	  A-­‐site	  of	  the	  PTC	  in	  the	  large	  ribosomal	  subunit	  (Blanchard	  et	  al.,	  2004c;	  Douthwaite	  et	  al.,	  1983;	  Sanbonmatsu	  et	  al.,	  2005;	  Schmeing	  et	  al.,	  2009;	  Voorhees	  et	  al.,	  2010).	  This	  process	  is	  accelerated	  by	  supporting	  conformational	  rearrangements	  in	  the	  LSU	  that	  establish	  guiding	  interactions	  with	  the	  anticodon	  stem	  loop	  and	  the	  elbow	  region	  of	  the	  tRNA	  (Jenner	  et	  al.,	  2010a).	  	  For	   a	   long	   time	   the	   hypothesis	   was	   widely	   accepted	   that	   exclusively	   the	  binding	   of	   cognate	   tRNAs	   induce	   the	   domain	   closure	   on	   the	   SSU,	   leading	   to	   higher	  rates	   of	   GTP	   hydrolysis	   for	   cognate	   compared	   with	   near-­‐cognate	   or	   non-­‐cognate	  tRNA	  binding	  (Gromadski	  and	  Rodnina,	  2004;	  Ogle	  et	  al.,	  2001;	  Ogle	  et	  al.,	  2002;	  Pape	  et	  al.,	  1999).	  However,	  the	  initial	  structural	  studies	  were	  based	  on	  crystal	  structures	  of	  30S	  subunits	  in	  complex	  with	  incomplete	  U6	  hexanucleotide	  mRNA	  molecules	  and	  ASL	  mimicking	  tRNAs	  (Ogle	  et	  al.,	  2001;	  Ogle	  et	  al.,	  2002).	  Notably,	  the	  P-­‐site	  codon	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was	   mimicked	   by	   the	   3’	   end	   of	   the	   16S	   rRNA,	   which	   forced	   the	   U6	   mRNA	   to	  exclusively	   bind	   to	   the	   A-­‐site	   and	   downstream,	   creating	   an	   artificial	   conformation	  where	  the	  mRNA	  was	  not	  covalently	  linked	  between	  the	  A-­‐site	  and	  the	  P-­‐site	  codons.	  Moreover,	  clear	  density	  for	  the	  near-­‐cognate	  ASL	  and	  codon	  could	  only	  be	  observed	  in	  the	  presence	  of	  paromomycin	  (Ogle	  et	  al.,	  2002),	  which	  might	  effect	  the	  mismatch	  conformation	   on	   the	   30S.	   Recent	   crystal	   structures	   of	   complete	   cognate	   or	   near-­‐cognate	   tRNAs	   bound	   to	   the	   full	   70S	   ribosome,	   both	   of	   which	   induced	   the	   closed	  conformation	   of	   the	   SSU,	   are	   challenging	   the	   hypothesis	   of	   how	   the	   ribosome	  distinguishes	  cognate	  tRNAs	  from	  near-­‐cognate	  or	  non-­‐cognate	  tRNAs	  (Demeshkina	  et	   al.,	   2012).	   The	   authors	   suggest	   that	   despite	   extensive	   contacts	  with	   the	  A-­‐minor	  groove	   of	   the	   codon-­‐anticodon	   helix,	   nucleotides	   A1492,	   A1493	   and	   G530	   do	   not	  discriminate	   cognate	   and	   near-­‐cognate	   tRNAs,	   since	   they	   appear	   not	   to	   directly	  monitor	  the	  correct	  Watson-­‐Crick	  geometry	  (Demeshkina	  et	  al.,	  2012),	  as	  suggested	  previously	   (Ogle	   et	   al.,	   2001;	  Ogle	   et	   al.,	   2002).	   Interestingly	   these	   structures	   show	  that	   the	  ribosome	  forces	  a	  G!U	  wobble	  pair	  at	   the	   first	  or	  second	  codon	  position	  to	  adopt	  Watson-­‐Crick	  base	  pair	  geometry	  (Fig.	  4).	  To	  achieve	  Watson-­‐Crick	  geometry,	  the	  ribosome	  stabilizes	  an	  energetically	  unfavorable	  tautomer	  of	  the	  nucleotide.	  The	  authors	   suggested	   that	   this	   energetic	   penalty	   is	   then	   used	   by	   the	   ribosome	   to	  discriminate	  cognate	  from	  near-­‐cognate	  tRNAs	  (Demeshkina	  et	  al.,	  2012).	  	  




Figure	   4	   |	   Codon-­‐anticodon	   interactions	   in	   the	   decoding	   center	   of	   the	   70S	   ribosome.	   (A-­‐F)	  Codon-­‐anticodon	  interactions	  at	  the	  (A,B)	  first,	  (C,D)	  second	  and	  (E,F)	  third	  codon	  position	  of	  (A,C,E)	  cognate	   and	   (B,D,F)	   near-­‐cognate	   tRNAs.	   (G)	   Superposition	   of	   near-­‐cognate	   codon-­‐anticodon	  interactions	   from	   the	  70S	   structure	   (Demeshkina	   et	   al.,	   2012)	  with	   a	   30	  nucleotide-­‐long	  mRNA	  and	  from	  the	  30S	  structure	  (Ogle	  et	  al.,	  2001)	  with	  a	  short	  mRNA	  fragment,	  showing	  the	  shift	  of	  the	  first	  nucleotide	  of	  the	  A-­‐site	  codon	  and	  the	  static	  nature	  of	  A1493.	  Figure	  modified	  from	  (Demeshkina	  et	  al.,	  2012).	  
	  
Peptide	  bond	  formation	  between	  the	  incoming	  amino	  acid	  attached	  to	  the	  A-­‐site	   tRNA	   and	   the	   nascent	   polypeptide	   attached	   to	   the	   P-­‐site	   tRNA	   represents	   the	  main	   function	   of	   the	   ribosome.	   Upon	   accommodation	   of	   the	   A-­‐site	   tRNA,	   the	   PTC	  located	  in	  domain	  V	  of	  the	  23S	  rRNA	  catalyzes	  the	  peptidyl	  transfer	  reaction	  rapidly,	  with	   a	   rate	   that	   is	   approximately	   2x107-­‐fold	   increased	   compared	   with	   the	   rate	   of	  spontaneous	  peptide	  bond	  formation	  in	  solution	  (Sievers	  et	  al.,	  2004).	  The	  ribosome	  is	   supposed	   to	   act	   as	   an	   entropy	   trap	   by	   precisely	   positioning	   the	   aminoacylated	  tRNA	   CCA-­‐end	   substrates	   for	   trans-­‐esterification	   and	   formation	   of	   a	   new	   peptide	  bond	  (Sievers	  et	  al.,	  2004).	  	  In	  line	  with	  this	  hypothesis,	  the	  50S	  subunit	  alone	  retains	  the	   ability	   to	   catalyze	   peptide	   bond	   formation	   even	   in	   the	   absence	   of	   elongation	  factors	  (Monro,	  1967;	  Schmeing	  et	  al.,	  2002;	  Traut	  and	  Monro,	  1964;	  Wohlgemuth	  et	  al.,	  2006).	  Positioning	  of	   the	   tRNAs	   is	   facilitated	  by	  stabilizing	   interactions	  between	  23S	   rRNA	   nucleotides	   and	   the	   tRNA	   CCA-­‐ends.	   The	   P-­‐site	   CCA	   end	   is	   stabilized	   by	  Watson-­‐Crick	  base	  pairs	  of	  nucleotides	  C74	  and	  C75	  with	  P-­‐loop	  nucleotides	  G2251	  and	  G2252,	  respectively,	  whereas	  A76	  stacks	  onto	  the	  ribose	  of	  A2451	  and	  hydrogen	  bonds	  with	  A2450.	  The	  A-­‐site	  C74	  and	  C75	  interact	  with	  A-­‐loop	  nucleotides,	  whereby	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C74	   stacks	   upon	  U2555	   and	   C75	   forms	   a	  Watson-­‐Crick	   base	   pair	  with	   G2553.	   A76	  interacts	  with	  G2583	  in	  form	  of	  a	  class	  I	  A-­‐minor	  motif	  (Hansen	  et	  al.,	  2002c;	  Kim	  and	  Green,	  1999;	  Nissen	  et	  al.,	  2000;	  Polikanov	  et	  al.,	  2014b;	  Voorhees	  et	  al.,	  2009).	  	  Proper	  tRNA	  accommodation	  into	  the	  A-­‐site	  leads	  to	  conformational	  changes	  within	  the	   PTC,	   as	   revealed	   by	   crystal	   structures	   of	  Haloarcula	  marismortui	  50S	   subunits	  bound	  with	  minimal	   CCA	   analogs	   (Schmeing	   et	   al.,	   2005a;	   Schmeing	   et	   al.,	   2005d).	  Namely,	  23S	  rRNA	  nucleotides	  G2583,	  U2584,	  U2585	  undergo	  a	  shift	  of	  1-­‐2	  Å,	  while	  U2506	   rotates	   by	   90°	   to	   provide	   space	   for	   A-­‐tRNA	   accommodation	   into	   the	   PTC	  (Schmeing	   et	   al.,	   2005a;	   Schmeing	   et	   al.,	   2005d).	   These	   conformational	   changes	  convert	  the	  PTC	  into	  its	  induced	  state	  by	  exposing	  the	  peptidyl-­‐tRNA	  ester	  for	  peptide	  bond	   formation,	  which	   occurs	   through	   nucleophilic	   attack	   of	   the	  α-­‐amino	   group	   of	  the	  A-­‐tRNA	  onto	  the	  carbonyl-­‐carbon	  of	  the	  aminoacyl	  ester	  of	  the	  peptidyl-­‐tRNA	  in	  the	  P-­‐site	  (Polikanov	  et	  al.,	  2014b).	  Recent	  crystal	  structures	  of	  Thermus	  thermophilus	  70S	   ribosomes	   in	   the	  pre-­‐and	  post-­‐catalysis	   state	   revealed	   that	   the	  PTC	  adopts	   the	  same	   conformation	   when	   complete	   tRNA	   substrates	   are	   bound	   (Polikanov	   et	   al.,	  2014b;	  Voorhees	  et	  al.,	  2009).	  	  The	   nature	   of	   the	   chemical	  mechanism	   of	   peptide	   bond	   formation	   has	   been	   under	  debate	   for	   many	   years.	   Three	   different	   catalytic	   mechanism	   have	   been	   proposed,	  ranging	   from	   acid-­‐base	   catalysis	   (Muth	   et	   al.,	   2000;	   Nissen	   et	   al.,	   2000)	   over	  substrate-­‐assisted	   catalysis	   (Dorner	   et	   al.,	   2003;	   Weinger	   et	   al.,	   2004)	   to	   the	   now	  generally	  accepted	  hypothesis	  that	  the	  ribosome	  acts	  as	  an	  entropic	  trap	  to	  facilitate	  the	   reaction	   (Sievers	   et	   al.,	   2004).	  Despite	   initial	   suggestions,	   biochemical	   evidence	  showed	  that	  the	  N6	  atom	  of	  23S	  rRNA	  nucleotide	  A2451	  located	  in	  hydrogen-­‐bonding	  distance	   to	   the	  α-­‐amino	  group	   is	  not	  essential	   for	  peptide	  bond	   formation	  (Muth	  et	  al.,	   2000;	   Nissen	   et	   al.,	   2000;	   Polacek	   et	   al.,	   2001;	   Youngman	   et	   al.,	   2004).	   These	  findings	   strongly	   argue	   against	   a	   possible	   acid-­‐base	   catalysis	   reaction	   for	   peptide	  bond	  formation	  (Bieling	  et	  al.,	  2006).	  	  The	  rate-­‐limiting	  step	  during	  catalysis	  is	  the	  formation	  of	  a	  transition	  state	  following	  nucleophilic	   attack	  of	   the	  α-­‐amino	   group	  onto	   the	   carbonyl-­‐carbon	  of	   the	  peptidyl-­‐tRNA	   (Hiller	   et	   al.,	   2011;	   Kuhlenkoetter	   et	   al.,	   2011).	   Rapid	   break-­‐down	   of	   the	  transition	   state	   transfers	   the	   peptide	   from	   the	   P-­‐site	   tRNA	   onto	   the	   amino	   acid	  attached	   to	   the	  A-­‐site	   tRNA,	   leaving	   a	   peptidyl-­‐tRNA	   in	   the	  A-­‐site	   and	   a	  deacylated	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tRNA	   in	   the	   P-­‐site.	   However,	   the	   precise	   contributions	   of	   residues	   within	   the	   PTC	  during	  peptide	  bond	  formation	  still	  remain	  unclear,	  as	  does	  the	  structural	  nature	  of	  the	   intermediate	  state	   (Hiller	  et	  al.,	  2011;	  Kingery	  et	  al.,	  2008;	  Kuhlenkoetter	  et	  al.,	  2011;	  Schmeing	  et	  al.,	  2005a).	  	  Recent	   advances	   in	   understanding	   the	   molecular	   mechanism	   of	   peptide	   bond	  formation	  are	  based	  on	  high-­‐resolution	  crystal	  structures	  of	  a	  Thermus	  thermophilus	  70S	   ribosome	   in	  both	  pre-­‐attack	  and	  post-­‐catalysis	   states	   (Polikanov	  et	   al.,	   2014b).	  Three	  water	  molecules	   trapped	   in	   the	   PTC	   before	   catalysis	   allowed	   the	   authors	   to	  suggest	  a	  proton	  wire	  mechanism	  that	  couples	  aa-­‐tRNA	  accommodation	  and	  peptide	  bond	  formation	  (Fig.	  5).	  Both	  tRNAs,	  23S	  rRNA	  nucleotides	  A2451,	  U2584,	  C2063	  and	  A2602	   as	   well	   as	   the	   N-­‐terminus	   of	   ribosomal	   protein	   L27	   contribute	   to	   the	  coordination	  of	  the	  water	  molecules.	  L27and	  N6	  of	  A2602	  activate	  a	  water	  molecule	  (W1)	  to	  initiate	  the	  proton	  wire	  via	  the	  2’	  OH	  of	  A2451	  to	  the	  2’	  OH	  of	  the	  P-­‐site	  A76,	  which	   deprotonates	   the	  α-­‐amino	   group	   for	   concerted	   nucleophilic	   attack	   onto	   the	  ester	  carbonyl	   carbon	   (Fig.	   5).	  The	   tetrahedral	   intermediate	   state	   is	   stabilized	  by	  a	  second	  water	  molecule	  (W2),	  which	  donates	  a	  proton	  to	  the	  negatively	  charged	  ester	  carbonyl	  carbon.	  Breakdown	  of	  the	  intermediate	  state	  occurs	  via	  protonation	  of	  the	  3’	  ester	   oxygen	   of	   the	   leaving	   group	   via	   a	   third	  water	   (W3)	   and	   a	   partially	   reversed	  proton	  wire	  via	  the	  2’OH	  of	  P-­‐site	  A76,	  the	  2’OH	  of	  A2451	  back	  to	  W1	  (Polikanov	  et	  al.,	  2014b)	  (Fig.	  5).	  The	  concerted	  action	  of	  de-­‐protonation	  of	  the	  α-­‐amino	  group	  and	  the	  nucleophilic	  attack	  is	  in	  agreement	  with	  previous	  reports	  (Kingery	  et	  al.,	  2008),	  as	  well	   as	   the	   tetrahedral	   structure	   of	   the	   intermediate	   state	   (Hiller	   et	   al.,	   2011).	   The	  central	   role	   of	   the	   2’OH	   of	   the	   P-­‐site	   A76	   during	   peptide	   bond	   formation	   is	   in	  agreement	  with	   structural	   (Hansen	  et	   al.,	   2001)	   and	  biochemical	   evidence	   showing	  that	  substitution	  of	   this	  hydroxyl-­‐group	  by	   fluorine	  or	  hydrogen	   leads	   to	  a	  102-­‐106-­‐fold	  reduction	  of	  the	  catalysis	  rate	  (Dorner	  et	  al.,	  2003;	  Weinger	  et	  al.,	  2004;	  Zaher	  et	  al.,	   2011).	   However,	   translation	   experiments	   performed	   in	   the	   presence	   of	   desoxy-­‐A76	  tRNASer	  showed	  that	  production	  of	  full	  peptides	  was	  still	  possible,	  but	  notably	  at	  lower	  rates	  (Koch	  et	  al.,	  2008).	  L27	  is	  the	  nearest	  ribosomal	  protein	  to	  the	  PTC	  and	  is	  supposed	  to	  contribute	  to	  catalysis	  by	  stabilizing	  the	  23S	  rRNA	  as	  well	  as	  both	  tRNAs	  (Voorhees	   et	   al.,	   2009)	   and	  by	   coordination	   and	   activation	   of	  W1	   (Polikanov	   et	   al.,	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2014b).	  Consistently,	  deletion	  or	  N-­‐terminal	  truncation	  of	  L27	  by	  three	  amino	  acids	  decreases	  the	  rate	  of	  translation	  (Maguire	  et	  al.,	  2005).	  	  
	  
Figure	  5	  |	  Possible	  pathway	  for	  peptide	  bond	  formation.	  (A)	  Overview	  of	  CCA-­‐ends	  of	  A-­‐site	  tRNA	  (orange)	  and	  P-­‐site	  tRNA	  (green)	  in	  the	  pre-­‐peptide	  bond	  formation	  state	  (Polikanov	  et	  al.,	  2014b).	  (B)	  Simultaneous	  deprotonation	  of	  the	  A-­‐site	  tRNA	  α-­‐amine	  and	  nucleophilic	  attack	  onto	  the	  P-­‐site	  tRNA	  carbonyl	   carbon.	   (C)	   Formation	   of	   a	   tetrahedral	   intermediate	   state	   with	   water	   molecules	   (yellow)	  involved	   in	  proton	  transfer	  along	  a	  proton	  wire.	   (D)	  Breakdown	  of	   the	   intermediate	  state	  via	  partial	  reversal	  of	  the	  proton	  transfer	  results	  in	  peptidyl-­‐tRNA	  in	  the	  A-­‐site	  and	  deacylated	  tRNA	  in	  the	  P-­‐site.	  Figure	  modified	  from	  (Polikanov	  et	  al.,	  2014b).	  	  
Translocation.	   After	   peptide	   bond	   formation,	   the	   A-­‐site	   is	   bound	   by	   the	  peptidyl-­‐tRNA	   lengthened	  by	  one	  amino	  acid	  and	   the	  P-­‐site	   is	  bound	  by	  deacylated	  tRNA.	   In	   order	   to	   allow	   the	   next	   round	   of	   elongation,	   the	   tRNAs	   together	  with	   the	  mRNA	  have	  to	  move	  with	  respect	  to	  the	  ribosome,	  namely	  to	  shift	  the	  peptidyl-­‐tRNA	  from	  the	  A-­‐site	  to	  the	  P-­‐site	  and	  the	  deacylated	  tRNA	  from	  the	  P-­‐site	  to	  the	  E-­‐site.	  The	  mRNA	   shifts	   precisely	   by	   one	   codon,	   placing	   the	   next	   codon	   in	   the	   A-­‐site.	  Translocation	  is	  catalyzed	  by	  the	  GTPase	  elongation	  factor	  G	  (EF-­‐G)	  and	  provides	  an	  empty	  A-­‐site,	  which	   in	   turn	  allows	  binding	  and	  accommodation	  of	   the	  next	  cognate	  aa-­‐tRNA	   and	   thus	   the	   elongation	   cycle	   to	   proceed.	   However,	   the	   ribosome	   has	   an	  intrinsic	  capability	  to	  translocate	  tRNAs	  both	  forward	  and	  backward	  (Gavrilova	  et	  al.,	  1976;	  Konevega	  et	  al.,	  2007;	  Shoji	  et	  al.,	  2006).	  The	  function	  of	  EF-­‐G	  is	  to	  accelerate	  and	  direct	  the	  process	  in	  forward	  direction	  (Frank	  and	  Gonzalez,	  2010;	  Rodnina	  et	  al.,	  1997).	  	  In	  the	  pre-­‐translocation	  (PRE)	  state	  the	  3’-­‐ends	  of	  A-­‐	  and	  P-­‐site	  tRNA	  spontaneously	  move	  back	  and	  forth	  between	  the	  P-­‐	  and	  E-­‐sites	  on	  the	  LSU,	  respectively,	  while	  their	  ASLs	   remain	   anchored	  within	   the	   A-­‐	   and	   P-­‐sites	   on	   the	   SSU.	   This	   tRNA	  movement	  with	  respect	  to	  the	  LSU	  but	  not	  with	  respect	  to	  the	  SSU	  creates	  A/P	  and	  P/E	  hybrid	  tRNA	  binding	  states	  (Moazed	  and	  Noller,	  1989;	  Munro	  et	  al.,	  2007;	  Semenkov	  et	  al.,	  
Introduction	  	  
21	  
1992;	   Sharma	   et	   al.,	   2004).	   The	   spontaneous	   formation	   of	   tRNA	   hybrid	   states	   is	  driven	  by	  decreased	  affinity	   for	  peptidyl-­‐tRNA	   in	   the	  A-­‐site	  and	  deacylated	   tRNA	   in	  the	  P-­‐site	  by	  approximately	  1000-­‐fold	   (Semenkov	  et	  al.,	  2000;	  Sharma	  et	  al.,	  2004).	  Two	   independent	   tRNA	   hybrid	   states	   were	   identified	   using	   single-­‐molecule	  fluorescence	  resonance	  energy	   transfer	   (FRET)	  measurements	  (Munro	  et	  al.,	  2007).	  In	   hybrid	   state	   1	   (H1)	   both	   tRNAs	   adopt	   hybrid	   states	   (A/P	   and	   P/E),	   whereas	   in	  hybrid	  state	  2,	  only	  the	  P-­‐site	  tRNA	  is	  shifted	  to	  the	  P/E	  hybrid	  state	  while	  the	  A-­‐site	  tRNA	  adopts	  the	  classical	  A/A	  conformation	  (Munro	  et	  al.,	  2007).	  On	  the	  time	  scale,	  formation	  of	  the	  A/P	  hybrid	  state	  occurs	  after	  the	  movement	  of	  the	  deacylated	  tRNA	  from	  the	  P-­‐	  to	  the	  E-­‐site	  (Pan	  et	  al.,	  2007;	  Walker	  et	  al.,	  2008).	  	  The	  E-­‐site	  on	  the	  50S	  subunit	   sterically	   occludes	   binding	   of	   peptidyl-­‐tRNA	   and	   thus	   ensures	   that	  translocation	  occurs	  only	  after	  completed	  peptide	  bond	  formation	  (Rheinberger	  and	  Nierhaus,	  1983;	  Schmeing	  et	  al.,	  2003).	  Formation	  of	   tRNA	  hybrid	  states	   is	  coupled	  to	  a	   large-­‐scale	  conformational	  rotation	  (ratcheting)	  of	  the	  SSU	  ~3-­‐10°	  counterclockwise	  relative	  to	  the	  LSU	  (Agirrezabala	  et	  al.,	  2008;	  Frank	  and	  Agrawal,	  2000;	  Julian	  et	  al.,	  2008;	  Valle	  et	  al.,	  2003).	  During	  the	  next	  step	  of	  translocation,	  the	  mRNA	  and	  the	  ASLs	  move	  by	  one	  codon	  with	  respect	  to	  the	  SSU.	  This	  process	  is	  catalyzed	  by	  the	  GTPase	  EF-­‐G,	  which	  binds	  together	  with	  GTP	  and	  stabilizes	  the	  ratcheted	  state	  of	  the	  ribosome	  (Blanchard	  et	  al.,	  2004c;	  Dorner	  et	  al.,	  2006;	  Munro	  et	  al.,	  2010;	  Spiegel	  et	  al.,	  2007).	  It	  has	  been	  shown	  that	  EF-­‐G	  binds	  to	   both	   the	   ratcheted	   and	   non-­‐ratcheted	   states	   of	   the	   ribosome,	   but	   translocation	  occurs	   via	   hybrid	   state	   formation	   for	   both	   scenarios	   (Chen	   et	   al.,	   2011a;	   Pulk	   and	  Cate,	  2013).	  	  Rotation	  around	  two	  hinges	  (Mohan	  et	  al.,	  2014)	  of	  the	  SSU	  head	  relative	  to	  the	  body	  (head	   swiveling)	   opens	   a	   constriction	   which	   allows	   the	   passage	   of	   the	   mRNA	   and	  ASLs	   through	   the	  SSU	   (Ratje	  et	   al.,	   2010;	  Savelsbergh	  et	   al.,	   2000;	  Yamamoto	  et	   al.,	  2014;	   Zhang	   et	   al.,	   2009).	  Domain	   IV	   of	   EF-­‐G,	   overlapping	   the	  A-­‐site	   on	   the	   SSU,	   is	  crucial	   to	   facilitate	   GTP-­‐dependent	   translocation	   by	   disrupting	   interactions	   of	   the	  codon-­‐anticodon	   duplex	   with	   the	   DC	   (Liu	   et	   al.,	   2014).	   Translocation	   of	   tRNAs	  through	   the	   ribosome	   proceeds	   via	   a	   series	   of	   intermediate	   states	   including	   intra-­‐subunit	  hybrid	  states	  on	  the	  SSU,	  where	  the	  mRNA	  and	  ASLs	  simultaneously	  bind	  to	  the	  A-­‐	   and	  P-­‐site	   (ap/P)	   and	   to	   the	   P-­‐	   and	   the	  E-­‐site	   (pe/E)	   (Ramrath	   et	   al.,	   2013;	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Ratje	  et	  al.,	  2010).	  Following	  GTP	  hydrolysis	  and	  Pi	  release,	  the	  30S	  head	  swivel	  and	  the	   ratcheting	   is	   reversed,	   EF-­‐G	   dissociates	   and	   leaves	   the	   ribosome	   in	   the	   post-­‐translocation	   (POST)	   state	   with	   tRNAs	   bound	   in	   the	   classical	   P/P	   and	   E/E	   sites	  (Ermolenko	   and	   Noller,	   2011;	   Ratje	   et	   al.,	   2010).	   The	   tRNA	   in	   the	   E-­‐site	   then	  dissociates	   spontaneously	   from	   the	   ribosome	   (Chen	   et	   al.,	   2011b;	   Semenkov	   et	   al.,	  1996;	   Uemura	   et	   al.,	   2010;	  Wettstein	   and	   Noll,	   1965).	   Yet,	   dissociation	   appears	   to	  depend	  on	  the	  buffer	  conditions	  in	  vitro	  and	  hasn´t	  been	  addressed	  in	  vivo.	  Recently,	  a	  plethora	  of	  high-­‐resolution	  crystal	  structures	  or	  cryo	  electron	  microscopy	  reconstructions	  of	  EF-­‐G	  bound	  to	   the	  ribosome	   in	   the	  PRE	  state	  (Brilot	  et	  al.,	  2013;	  Chen	   et	   al.,	   2013;	   Lin	   et	   al.,	   2015;	   Pulk	   and	   Cate,	   2013;	   Tourigny	   et	   al.,	   2013),	   in	  intermediate	  states	   (Zhou	  et	  al.,	  2013,	  2014)	  of	   translocation	  and	   in	   the	  POST	  state	  (Lin	  et	  al.,	  2015)	  have	  advanced	  the	  current	  understanding	  of	  the	  precise	  structural	  rearrangements	  during	  EF-­‐G-­‐catalyzed	  translocation	  (Fig.	  6).	  The	  structures	  of	  EF-­‐G	  bound	  ribosome	  in	  the	  PRE	  state	  verified	  the	  previous	  suggestion	  that	  the	  mechanism	  of	   GTPase	   activation	   is	   very	   similar	   for	   EF-­‐Tu	   and	   EF-­‐G.	   Interaction	   with	   the	   SRL	  (H95)	  opens	   the	  hydrophobic	  gate	   in	   the	  G-­‐domain	  of	  EF-­‐G	  and	  places	   the	  catalytic	  histidine	   into	   the	   active	   site,	   where	   it	   initiates	   hydrolysis	   of	   the	   γ-­‐phosphate	   from	  GTP.	   However,	   the	   chemical	   nature	   of	   the	   hydrolysis	   reaction	   is	   controversially	  discussed	   (Chen	   et	   al.,	   2013;	   Liljas	   et	   al.,	   2011;	   Tourigny	   et	   al.,	   2013).	   The	   latest	  crystal	   structures	   of	   dityromycin-­‐captured	  EF-­‐G	  bound	   in	   the	  PRE	   and	  POST	   states	  revealed	  an	  entirely	  new	  conformation	  of	  EF-­‐G	  in	  the	  PRE	  state.	  Surprisingly,	  EF-­‐G	  is	  bound	  to	  the	  ribosome	  in	  a	  compacted	  state,	  where	  domain	  IV	  is	  buried	  within	  EF-­‐G,	  being	   far	  away	   from	  the	  A-­‐site	  on	   the	  SSU	  (Lin	  et	  al.,	  2015)	   (Fig.	   6).	  This	   structure	  could	   provide	   novel	   insight	   into	   possible	   structural	   transitions	   of	   EF-­‐G	   that	   might	  occur	   during	   GTPase-­‐dependent	   translocation.	   Notably,	   in	   this	   study	   an	   EF-­‐G-­‐L9	  fusion	   protein	   was	   co-­‐crystallized	   together	   with	   ribosomes.	   Although	   the	   authors	  claim	  that	  the	  chimeric	  fusion	  protein	  does	  not	  interfere	  with	  the	  conformation	  of	  EF-­‐G	   bound	   in	   the	   POST	   state,	   it	   cannot	   be	   excluded	   that	   the	   observed	   PRE	   state	  represents	   a	   non-­‐physiological	   state	   of	   EF-­‐G	   bound	   to	   the	   ribosome.	   Interestingly,	  recent	   FRET	   experiments	   showed	   that	   EF-­‐G	   adopts	   predominantly	   a	   compact	  conformation	   in	  solution	  and	   infrequently	   transitions	   to	  an	  elongated	  conformation	  (Salsi	   et	   al.,	   2015).	   In	   contrast,	   EF-­‐G	   binding	   to	   either	   pre-­‐translocation	   or	   post-­‐
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translocation	   ribosomes	   stabilizes	   the	   elongated	   form	   of	   EF-­‐G,	   however	   the	   data	  demonstrated	   that	   two	   compacted	   conformations	   of	   EF-­‐G	   on	   the	   ribosome	   could	  transiently	   occur.	   The	   authors	   suggested	   that	   EF-­‐G	   might	   initially	   sample	   the	  ribosome	  in	  a	  compacted	  state	  and	  transition	  to	  the	  elongated	  conformation	  prior	  to	  GTP	  hydrolysis	  and	  translocation	  (Salsi	  et	  al.,	  2015),	  which	  supports	  the	  structure	  of	  the	  compacted	  EF-­‐G	  bound	  to	  the	  PRE	  state	  ribosome	  (Lin	  et	  al.,	  2015).	  	  
	  
Figure	   6	   |	   Conformational	   rearrangements	   of	   EF-­‐G	   during	   translocation.	   (A-­‐F)	  Overviews	   and	  isolated	  views	  of	  EF-­‐G	  bound	   in	   the	  (A,B)	  PRE-­‐state	   to	  non-­‐rotated	  ribosomes	  with	  EF-­‐G	   in	  compact	  conformation	  and	  tRNAs	  in	  the	  A-­‐site	  (orange),	  P-­‐site	  (green)	  and	  E-­‐site	  (pink)	  (Lin	  et	  al.,	  2015),	  and	  (C,D)	  in	  the	  PRE-­‐state	  to	  rotated	  ribosomes	  bearing	  a	  peptidyl-­‐tRNA	  in	  the	  A/T	  hybrid	  state	  (orange)	  and	  a	  deacylated	  tRNA	  (pink)	  in	  the	  P/E	  hybrid	  state	  (Brilot	  et	  al.,	  2013),	  as	  well	  as	  (E,F)	  in	  the	  non-­‐rotated	  POST	  state	  with	  translocated	  tRNAs	  in	  the	  P-­‐site	  (green)	  and	  E-­‐site	  (pink)	  (Lin	  et	  al.,	  2015).	  (F)	  Interdomain	  rearrangements	  of	  EF-­‐G	  during	  translocation.	  Superposition	  of	  the	  PRE-­‐state	  (grey)	  and	  the	  POST-­‐state	  conformation	  of	  EF-­‐G	  (color-­‐coded)	  by	  alignment	  of	  domains	  I	  and	  II	  of	  EF-­‐G	  (Lin	  et	  al.,	  2015).	  	  
1.2.3 Termination Class	  I	  termination	  release	  factors	  1	  (RF1)	  or	  2	  (RF2)	  recognize	  mRNA	  stop	  codons	  in	  the	  A-­‐site	  of	   the	  SSU	  and	  trigger	   translation	   termination	  by	  mediating	  hydrolysis	  of	  the	  P-­‐site	  peptidyl-­‐tRNA	  and	  subsequent	  peptide	  release	   (Caskey	  et	  al.,	  1968;	   Jin	  et	  al.,	   2010).	   In	   a	   following	   step,	   the	   class	   I	   release	   factors	   are	   removed	   from	   the	  ribosome	   with	   the	   help	   of	   the	   GTPase	   class	   II	   release	   factor	   RF3	   in	   a	   GTPase-­‐dependent	  manner	  (Freistroffer	  et	  al.,	  1997;	  Zavialov	  et	  al.,	  2001).	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Early	   mutagenesis	   studies	   showed	   that	   class	   I	   release	   factors	   contain	   two	   distinct	  regions	   responsible	   for	   stop	   codon	   recognition	   and	   peptidyl-­‐tRNA	   hydrolysis.	   The	  conserved	  GGQ	  motif	  was	  shown	  to	  be	  important	  for	  hydrolysis	  (Frolova	  et	  al.,	  1999;	  Mora	   et	   al.,	   2003;	   Seit	   Nebi	   et	   al.,	   2000;	   Shaw	   and	   Green,	   2007),	   whereas	   the	  tripeptide	  motifs	  PxT	  (PAV	  or	  PVT)	  in	  RF1	  and	  SPF	  in	  RF2	  appear	  to	  be	  important	  for	  stop	  codon	  recognition	  (Ito	  et	  al.,	  2000;	  Scarlett	  et	  al.,	  2003).	  RF1	  and	  RF2	  differ	  with	  respect	   to	   stop	   codon	   recognition	   (RF1	   recognizes	   UAG/UAA;	   RF2	   recognizes	  UGA/UAA)	   (Scolnick	   et	   al.,	   1968),	   but	   both	   mediate	   peptidyl-­‐tRNA	   hydrolysis	   by	  placing	   their	   universally	   conserved	   GGQ-­‐motif	   into	   the	   PTC	  where	   it	   positions	   and	  activates	   a	  water	  molecule	   for	   nucleophilic	   attack	   onto	   the	   peptidyl-­‐ester	   carbonyl	  carbon	   (Klaholz,	  2011;	  Petry	  et	   al.,	   2008).	   Structures	  of	  RF1	   (Laurberg	  et	   al.,	   2008;	  Petry	  et	  al.,	  2005)	  (Fig.	  7),	  RF2	  (Jin	  et	  al.,	  2010;	  Klaholz	  et	  al.,	  2003;	  Korostelev	  et	  al.,	  2008;	  Petry	  et	  al.,	  2005;	  Rawat	  et	  al.,	  2003;	  Weixlbaumer	  et	  al.,	  2008)	  and	  RF3	  (Gao	  et	  al.,	   2007;	   Jin	   et	   al.,	   2011;	   Zhou	  et	   al.,	   2012b)	  bound	   to	   the	   ribosome	  have	   revealed	  profound	   insight	   into	   the	   structural	   determinants	   of	   stop	   codon	   recognition	   and	  translation	   termination.	   Selective	   discrimination	   of	   the	   second	   codon	   position	   A2	  (UAG/UAA)	   by	   RF1	   is	  mediated	   hydrogen	   bonding	   interactions	   between	   P184	   and	  T186	  (PxT	  motif)	  with	  the	  first	  two	  stop	  codon	  bases	  (Laurberg	  et	  al.,	  2008)	  (Fig.	  7).	  RF2	  monitors	  the	  second	  codon	  position	  G2	  via	  interactions	  between	  G2	  and	  S193	  of	  the	  SPF	  motif,	  and	  specifically	  via	   interaction	  of	  the	  2-­‐amino	  group	  of	  G2	  (absent	   in	  adenines)	   with	   residues	   T203	   and	   S204.	   The	   capability	   of	   RF2	   to	   recognize	   both	  adenine	  (A2)	  and	  a	  guanine	  (G2)	  in	  the	  second	  codon	  position	  is	  based	  on	  the	  flexible	  character	  of	  the	  serine	  side	  chain	  (SPF	  motif)	  that	  is	  able	  to	  interact	  either	  with	  A2	  or	  G2	   (Korostelev	   et	   al.,	   2008;	   Korostelev	   et	   al.,	   2010;	   Weixlbaumer	   et	   al.,	   2008).	   In	  contrast,	   specific	   discrimination	   of	   the	   first	   codon	   position	  U1	   (uridine	   in	   all	   three	  stop	  codons)	   is	  mediated	  by	  a	  common	  GxxE	  motif	   in	  helix	  5	  of	   the	  release	   factors.	  The	   nucleotide	   in	   the	   third	   codon	   position	   is	   rotated	   and	   stacks	   on	   G530	   upon	  RF1/RF2	   binding,	   due	   to	   insertion	   of	   a	   conserved	   histidine	   (H193	   in	   RF1,	  H215	   in	  RF2)	   between	   codon	   positions	   2	   and	   3	   (Fig.	   7).	   RF1	   interacts	   with	   A3	   or	   G3	   by	  interactions	  involving	  T194	  and	  Q181,	  while	  RF2	  uses	  the	  hydroxyl	  group	  of	  T194	  to	  monitor	   A3	   (Korostelev	   et	   al.,	   2008;	   Korostelev	   et	   al.,	   2010;	   Laurberg	   et	   al.,	   2008;	  Weixlbaumer	  et	  al.,	  2008).	  Binding	  of	  release	  factors	  induce	  conformational	  changes	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in	   the	   DC	   (G530,	   A1492	   and	   A1493)	   that	   are	   distinct	   compared	   to	   those	   during	  decoding	   of	   sense	   codons	   by	   tRNAs	   (Ogle	   et	   al.,	   2001;	   Youngman	   et	   al.,	   2007).	   For	  example,	   stacking	   interactions	   between	  16S	   rRNA	  nucleotide	  A1493	   and	  23S	   rRNA	  nucleotide	  A1913	  as	  well	  as	  between	  16S	  rRNA	  nucleotide	  G530	  and	  the	   third	  stop	  codon	  base	  are	  observed	  (Korostelev	  et	  al.,	  2008;	  Laurberg	  et	  al.,	  2008;	  Weixlbaumer	  et	  al.,	  2008).	  	  
	  
Figure	  7	   |	  Decoding	  of	  UAA	  stop	   codon	  by	   release	   factor	  1.	   (A-­‐B)	  Overview	  of	  RF1	  bound	  to	  the	  ribosome	  with	  P-­‐site	  tRNA	  (orange),	  E-­‐site	  tRNA	  (red)	  and	  mRNA	  (green)	  (Laurberg	  et	  al.,	  2008).	  (C)	  Domain	  architecture	  of	  RF1	  with	  GGQ	  motif	  and	  PVT	  motif	  highlighted	  in	  red.	  (D)	  Conformation	  of	  the	  DC	  upon	  RF2	  (yellow)	  binding	  showing	  mRNA	  (green),	  16S	  rRNA	  nucleotides	  G530,	  A1492	  and	  A1493	  (blue)	  and	  23S	  rRNA	  nucleotide	  A1913	  (grey)	  (Korostelev	  et	  al.,	  2008).	  (E)	  Interaction	  of	  RF1	  (yellow)	  with	   the	   first	   two	   stop	   codon	   nucleotides	   (green)	   (Laurberg	   et	   al.,	   2008).	   (F)	   Interaction	   of	   RF1	  (yellow)	  with	   the	   third	   stop	   codon	  nucleotide	   (green)	   (Laurberg	   et	   al.,	   2008).	   Figure	  modified	   from	  (Korostelev,	  2011;	  Laurberg	  et	  al.,	  2008).	  	  The	   conformation	   of	   class	   I	   release	   factors	   in	   solution	   was	   shown	   to	   be	   in	   an	  equilibrium	  between	  a	  closed	  and	  an	  open	  form	  (Vestergaard	  et	  al.,	  2001;	  Zoldak	  et	  al.,	  2007).	  In	  the	  closed	  conformation,	  the	  GGQ	  motif	  and	  the	  PxT/SPF	  motif	  are	  only	  23	  Å	  apart	  from	  each	  other.	  Due	  to	  the	  small	  distance,	  simultaneous	  interaction	  of	  the	  PxT/SPF	  motif	  with	   the	  stop	  codon	  and	   the	  GGQ	  motif	  with	   the	  PTC	   is	  not	  possible	  (Vestergaard	   et	   al.,	   2001;	   Zoldak	   et	   al.,	   2007).	   Ribosome	   binding	   induces	  conformational	  changes	  in	  RF1	  and	  RF2	  that	  stabilize	  the	  open	  conformation,	  which	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allows	   the	   concurrent	   insertion	   of	   the	   GGQ	   motif	   into	   the	   PTC	   upon	   stop	   codon	  recognition	   (Klaholz,	   2011).	   Proper	   placement	   of	   the	   GGQ	  motif	   within	   the	   PTC	   is	  crucial	  for	  hydrolysis	  of	  the	  peptidyl-­‐tRNA	  and	  thus	  release	  of	  the	  newly	  synthesized	  peptide	   (Frolova	   et	   al.,	   1999;	   Shaw	   and	   Green,	   2007).	   The	   two	   glycine	   residues	  thereby	  sterically	  allow	  the	  GGQ	  motif	  to	  slip	  into	  the	  PTC,	  adjacent	  to	  the	  P-­‐site	  A76	  (Shaw	  and	  Green,	  2007).	  It	  has	  been	  shown	  that	  it	  is	  not	  the	  amino	  acid	  side	  chain	  of	  Q230	   of	   the	   GGQ	   motif	   that	   is	   responsible	   to	   mediate	   hydrolysis	   (Seit-­‐Nebi	   et	   al.,	  2001;	   Shaw	   and	   Green,	   2007),	   but	   rather	   the	   backbone	   nitrogen	   of	   Q230	   that	  accounts	  for	  the	  catalytic	  activity	  of	  RF1	  and	  RF2	  by	  interacting	  with	  the	  3’OH	  of	  A76	  (Laurberg	   et	   al.,	   2008).	   However,	   loss	   of	   the	   posttranslational	   N5-­‐methylation	   of	  Q230	   reduces	   the	   efficiency	   of	   peptide-­‐release	   (Dincbas-­‐Renqvist	   et	   al.,	   2000)	   and	  therefore	  favors	  a	  model	  where	  the	  glutamine	  side	  chain,	  together	  with	  the	  backbone	  amine,	   the	   2’OH	   of	   A76	   and	   A2451	   directly	   coordinate	   a	   water	   molecule	   for	  nucleophilic	  attack	  (Jin	  et	  al.,	  2010;	  Klaholz,	  2011;	  Weixlbaumer	  et	  al.,	  2008).	  	  After	   hydrolysis	   of	   the	   nascent	   chain,	   the	   class	   II	   release	   factor	   RF3	   binds	   to	   the	  ribosome	   and	   promotes	   dissociation	   of	   RF1	   and	   RF2	   from	   the	   ribosome	   in	   a	   GTP-­‐dependent	   manner	   (Freistroffer	   et	   al.,	   1997;	   Grentzmann	   et	   al.,	   1998).	   RF3!GTP	  binding	   to	   RF1/RF2!ribosome	   complexes	   stabilizes	   the	   ratcheted	   state	   of	   the	  ribosome	  with	  tRNAs	  in	  hybrid	  states	  (Ermolenko	  et	  al.,	  2007;	  Gao	  et	  al.,	  2007;	  Jin	  et	  al.,	  2011;	  Klaholz	  et	  al.,	  2004;	  Zhou	  et	  al.,	  2012b).	  The	  ratcheted	  conformation	  of	  the	  ribosome	  creates	  a	  series	  of	  steric	  clashes	  between	  RF	  domains	  I	  and	  IV	  with	  the	  L11	  stalk	   and	   the	   30S	   head,	   respectively,	   which	   are	   supposed	   to	   contribute	   to	   the	  destabilization	  of	  the	  RFs	  (Gao	  et	  al.,	  2007).	  However,	  RF3!GTP	  binding	  to	  POST	  state	  ribosomes	   would	   result	   in	   the	   same	   clashes.	   Together	   with	   the	   architectural	  similarity	  between	  RF3!GDP	  and	  EF-­‐TU!GTP,	  it	  has	  been	  argued	  that	  RF3	  might	  bind	  to	   the	   ribosome	   in	   its	   GDP	   bound	   conformation	   (Gao	   et	   al.,	   2007;	   Zavialov	   et	   al.,	  2001).	  However,	  stable	  binding	  of	  RF3!GDP	  to	  ribosomes	  is	  not	  observed	  (Jin	  et	  al.,	  2011;	  Pel	  et	  al.,	  1998).	  Possibly,	  the	  post-­‐termination	  ribosome	  spontaneously	  adopts	  the	   ratcheted	   state,	   which	   is	   subsequently	   sampled	   and	   stabilized	   by	   RF3!GTP,	  leading	   to	  dissociation	  of	  RF1	  and	  RF2	  (Zhou	  et	  al.,	  2012a).	  A	   recent	   study	  showed	  that	  GTP	  hydrolysis	  by	  RF3	  is	  independent	  of	  the	  functional	  state	  of	  the	  ribosome	  and	  that	   RF3!GTP	   binds	   and	   hydrolyzes	   GTP	   on	   both	   pre-­‐	   and	   post-­‐termination	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complexes.	  However,	  peptide	  release	  stabilizes	  RF3!GTP	  binding	  to	  the	  ribosome	  due	  to	  formation	  of	  the	  ratcheted	  state	  of	  the	  ribosome	  (Peske	  et	  al.,	  2014).	  Interestingly,	  the	   binding	   position	   of	   the	   G	   domain	   of	   RF3	   to	   the	   SRL	   (H95)	   differs	   from	   the	  positions	   observed	   for	   EF-­‐Tu	   and	   EF-­‐G	   (Gao	   et	   al.,	   2009;	   Schmeing	   et	   al.,	   2009;	  Voorhees	  et	  al.,	  2010),	  which	  suggests	  more	  than	  one	  common	  mechanism	  leading	  to	  GTPase	  activation	  on	  translational	  GTPases	  exists	  (Zhou	  et	  al.,	  2012b).	  	  
1.2.4 Recycling After	  RF3-­‐mediated	  dissociation	  of	  class	  I	  release	  factors,	  the	  ribosome	  is	  still	  bound	  to	   mRNA	   and	   deacylated	   tRNA	   in	   the	   P-­‐site.	   Recycling	   of	   the	   mRNA!tRNA!70S	  complex	  is	  necessary	  to	  allow	  a	  new	  round	  of	  peptide	  synthesis.	  During	  recycling,	  the	  ribosome	   is	   split	   into	  subunits	  by	   the	  combined	  action	  of	   ribosome	  recycling	   factor	  (RRF)	   and	   EF-­‐G	   in	   a	   GTP-­‐dependent	  manner	   (Agrawal	   et	   al.,	   2004;	   Hirashima	   and	  Kaji,	   1973;	   Karimi	   et	   al.,	   1999;	   Lancaster	   et	   al.,	   2002;	   Peske	   et	   al.,	   2005).	   The	   first	  detailed	   structural	   insight	   into	   RRF	   binding	   to	   ribosomes	   was	   based	   on	   a	   crystal	  structure	  of	  domain	   I	  of	  Escherichia	  coli	  RRF	  bound	  to	  Deinococcus	  radiodurans	  50S	  subunit	   and	   allowed	   a	   mechanistic	   description	   of	   RRF-­‐induced	   conformational	  rearrangements	   in	  H69	   of	   intersubunit	   bridge	   B2a	   (Wilson	   et	   al.,	   2005b).	   A	   recent	  crystal	  structure	  of	  RRF	  bound	  to	  a	  complete	  ribosome	  showed	  that	  RRF	  was	  bound	  to	  the	  ribosomal	  P-­‐site,	  stabilizing	  the	  ratcheted	  conformation	  of	   the	  ribosome	  with	  deacylated	   tRNA	   in	   the	   P/E	   hybrid	   state	   (Dunkle	   et	   al.,	   2011;	  Weixlbaumer	   et	   al.,	  2007).	  Binding	  of	  EF-­‐G	  to	  the	  RRF!mRNA!tRNA!70S	  complex	  subsequently	  splits	  the	  ribosome	  into	  subunits	  upon	  GTP	  hydrolysis	  (Barat	  et	  al.,	  2007;	  Ito	  et	  al.,	  2002;	  Pai	  et	  al.,	  2008;	  Peske	  et	  al.,	  2005;	  Zavialov	  et	  al.,	  2005).	  Binding	  of	  IF3	  to	  the	  30S	  subunit	  leads	  to	  dissociation	  of	  mRNA	  and	  deacylated	  tRNA	  and	  simultaneously	  prevents	  re-­‐association	  with	   the	   50S	   subunit	   (Dallas	   and	  Noller,	   2001;	  Grunberg-­‐Manago	   et	   al.,	  1975;	  Karimi	  et	  al.,	  1999;	  Singh	  et	  al.,	  2005;	  Subramanian	  and	  Davis,	  1970).	  Thereby,	  IF3	   directly	   links	   the	   last	   steps	   in	   translation	   termination	   to	   the	   first	   steps	   of	  translation	  initiation.	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1.3 Antibiotics	  Antibiotics	   are	   small	   compounds	   that	   inhibit	   bacteria	   by	   inducing	   either	   cell	   death	  (bactericidal	   antibiotics)	   or	   inhibition	   of	   growth	   (bacteriostatic	   antibiotics).	   More	  than	   85	   years	   ago,	   Sir	   Alexander	   Fleming	   discovered	   the	   first	   antibiotic	   penicillin	  (Fleming,	  1929)	  in	  Penicillium	  fungi	  species,	  for	  which	  he	  received	  the	  Nobel	  Prize	  in	  1945.	  Since	  their	  discovery,	  antibiotics	  revolutionized	  the	  field	  of	  medicine	  by	  using	  them	  as	   potent	   agents	   against	   a	   huge	   variety	   of	   infectious	   diseases.	  However	   upon	  exposure,	   antibiotic	   resistance	   among	   bacteria	   spreads	   extraordinary	   fast,	   making	  antibiotics	  powerless	   against	   these	  pathogens	   (Hede,	  2014).	   In	  order	   to	  provide	  an	  update	   on	   the	   latest	   in	   the	   evolution	   of	   antimicrobial	   resistance	   and	   healthcare-­‐associated	  infection,	  the	  Center	  for	  Disease	  Prevention	  and	  Control	  (ECDC)	  annually	  publishes	  an	  epidemiological	  report.	  It	  is	  alarming	  that	  the	  percentages	  of	  organisms	  exhibiting	  antimicrobial	  resistance	  to	  multiple	  antibiotics	  continuously	  increase.	  For	  example,	   the	   percentile	   occurrence	   of	   methicillin-­‐resistant	   Staphylococcus	   aureus	  (MRSA)	   among	   Staphylococcus	   aureus	   isolates	   is	   determined	   to	   be	   around	   25%	   in	  many	  European	   countries.	  Moreover,	   Gram-­‐negative	   pathogens	   like	  Escherichia	  coli	  and	  Klebsiella	  pneumoniae,	  the	  major	  causative	  organisms	  of	  urinary	  and	  respiratory	  tract	   infection,	   significantly	   follow	   the	   trend	   in	   acquiring	   multi-­‐drug	   resistance.	  Frighteningly,	   only	   a	   few	   last-­‐line	   antibiotics,	   such	   as	   carbapenems	  are	   available	   to	  treat	  patients	  infected	  with	  multi-­‐drug	  resistant	  bacteria.	  However,	  also	  carbapenem-­‐resistant	   bacteria	   are	   already	   spreading	   due	   to	   frequent	   carbapenem	   usage	   when	  other	   antibiotics	   are	   non-­‐effective.	   The	   fast	   progression	   of	   antibiotic	   resistance	  among	  bacteria	  greatly	  emphasizes	  the	  importance	  of	  discovery	  and	  development	  of	  new	  potent	  antimicrobial	  agents.	  Despite	  the	  discovery	  of	  many	  classes	  of	  antibiotics	  in	   the	   decades	   after	   their	   discovery,	   only	   a	   few	   antibiotics	   like	   lipopeptides	   and	  oxazolidinones	   (Linezolid)	   (Fischbach	   and	   Walsh,	   2009)	   were	   introduced	   into	  medical	   usage	   in	   the	   past	   40	   years.	   In	   contrast,	   resistance	   to	   all	   known	   classes	   of	  antibiotics	  has	  emerged	  within	  only	  a	  few	  years	  after	  their	  introduction	  into	  clinical	  usage	   (Clatworthy	   et	   al.,	   2007).	  The	  huge	  discrepancy	  between	   the	  development	  of	  resistances	   and	   the	   development	   of	   new	   potent	   antimicrobial	   agents	   is	   a	   serious	  threat	   for	   public	   health.	   It	   is	   therefore	   crucial	   to	   study	   and	   to	   understand	   the	  molecular	  mechanisms	  causing	  antibiotic	  resistance.	  Especially	  a	  structural	  view	  on	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antibiotic	  target	  sites	  paves	  the	  way	  for	  the	  development	  of	  new	  antimicrobial	  agents	  that	   overcome	   bacterial	   resistance	   by	   either	   synthesis	   of	   novel	   compounds	   or	   by	  chemical	  modification	  of	  known	  and	  naturally	  occurring	  antibiotics	  (Kohanski	  et	  al.,	  2010).	  The	   antimicrobial	   activity	   of	   antibiotics	   is	   based	   on	   their	   ability	   to	   disruptively	  interfere	  with	   a	   variety	   of	   fundamental	   biochemical	   processes	  within	   the	   bacterial	  cell.	   Cell	   wall	   synthesis	   (β-­‐lactams,	   glycopeptides,	   lipopeptides),	   DNA	   replication	  (fluoroquinolones),	   DNA	   transcription	   into	   RNA	   (rifamycins)	   and	   protein	   synthesis	  (aminoglycosides,	  tetracyclines,	  macrolides,	  streptogramins,	  phenicols)	  are	  the	  major	  targets	   for	   the	   different	   classes	   of	   antibiotics	   (Kohanski	   et	   al.,	   2010).	   The	   bacterial	  ribosome	   is	   an	   important	   target	   for	  many	   classes	  of	   antibiotics	   that	   inhibit	  peptide	  synthesis	   (Wilson,	   2004;	   Wilson,	   2009,	   2014).	   The	   main	   antibiotic	   binding	   sites	  within	   the	   ribosome	  are	   localized	   to	   the	  DC,	   the	  PTC,	   the	  GTPase-­‐associated	   center	  (GAC)	  and	  to	  the	  peptide	  exit	  tunnel.	  Hence,	  all	  four	  major	  functions	  of	  the	  ribosome,	  namely	  decoding,	  peptide	  bond	  formation,	  GTPase	  activation	  and	  progression	  of	  the	  nascent	   chain	   are	   subject	   to	   antibiotic-­‐mediated	   inhibition	   (Wilson,	   2009)	   (Fig.	   8).	  Antibiotics	  binding	  near	   the	  DC	  on	   the	  SSU	  mainly	   inhibit	   translation	  by	   interfering	  with	  tRNA	  delivery	  to	  the	  A-­‐site	  (tetracyclines,	  streptomycins)	  or	  by	  disturbing	  EF-­‐G-­‐dependent	  mRNA	  and	   tRNA	   translocation	   (aminoglycosides,	   neomycin,	   pactamycin,	  spectinomycin,	   amicoumycin	   A,	   negamycin,	   dityromycin,	   hygromycin	   B,	   viomycin,	  capreomycin),	   or	   by	   blocking	   initiator	   tRNA	   binding	   to	   the	   P-­‐site	   (edeine,	  kasugamycin).	   PTC	   targeting	   antibiotics	   prevent	   peptide	   bond	   formation	   by	  overlapping	   the	   A-­‐site	   (chloramphenicol,	   lincosamides,	   oxazolidinones,	   puromycin,	  sparsomycin),	   P-­‐site	   (blasticidin	   S,	   bactobolin	   A)	   or	   both	   A-­‐	   and	   P-­‐site	  (pleuromutilins,	  streptogramin	  A).	  Antibiotics	  binding	  to	  the	  GAC	  on	  the	  LSU	  inhibit	  translation	  by	  interfering	  with	  binding	  of	  the	  translational	  GTPases	  EF-­‐Tu,	  EF-­‐G	  and	  IF2	   (thiopeptides).	   Ribosome	   exit	   tunnel-­‐targeting	   antimicrobial	   compounds	  (macrolides,	  streptogramin	  B)	  impair	  progression	  of	  the	  nascent	  polypeptide	  through	  the	  LSU,	  which	   leads	  to	  translation	   inhibition	  by	  peptidyl-­‐tRNA	  drop-­‐off	  (Amunts	  et	  al.,	  2015;	  Bulkley	  et	  al.,	  2014;	  Polikanov	  et	  al.,	  2014a;	  Polikanov	  et	  al.,	  2014l;	  Wilson,	  2014).	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During	   my	   research,	   I	   mainly	   focused	   on	   three	   classes	   of	   antibiotics	   including	  tetracycline,	   the	   founding	   member	   of	   the	   tetracycline	   class	   of	   antibiotics,	  erythromycin,	  the	  founding	  member	  of	  the	  macrolide	  class	  of	  antibiotics,	  and	  Onc112,	  a	  ribosome-­‐targeting	  proline-­‐rich	  antimicrobial	  peptide	  (PrAMP).	  Sections	  1.3.1-­‐1.3.3	  provide	  a	  more	  detailed	  introduction	  into	  these	  antimicrobial	  agents.	  	  
	  
Figure	   8	   |	   Overview	   of	   antibiotics	   inhibiting	   the	   prokaryotic	   translation	   cycle.	   Overview	   of	  antibiotics,	   inhibiting	   translation	   initiation	   (green),	   translation	   elongation	   (yellow)	   and	   translation	  termination/recycling	  (red)	  of	  the	  prokaryotic	  translation	  cycle.	  Figure	  modified	  from	  (Sohmen	  et	  al.,	  2009).	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1.3.1 Proline-rich Antimicrobial Peptides Antimicrobial	   peptides	   are	   part	   of	   the	   innate	   immune	   response	   of	   all	  multicellular	  organisms	   (Andreu	   and	   Rivas,	   1998;	   Casteels	   et	   al.,	   1989;	   Li	   et	   al.,	   2014;	   Zasloff,	  2002).	   The	   huge	   variety	   of	   small	   antimicrobial	   peptides	   among	   the	   plethora	   of	  multicellular	  organisms	  can	  be	  grouped	  based	  on	  chemical-­‐structural	  criteria	  of	   the	  peptides	  (Boman,	  1995).	  In	  general,	  antimicrobial	  peptides	  fall	  into	  two	  major	  classes	  (i)	  linear	  peptides	  and	  (ii)	  cyclic	  peptides.	  Members	  of	  linear	  peptides	  can	  adopt	  (iii)	  
α-­‐helical	   or	   (iv)	   linear	   structures	   due	   to	   high	   content	   of	   specific	   amino	   acids	   like	  proline	  (Pro),	  arginine	  (Arg)	  or	  tryptophan	  (Trp)	  (Boman,	  1995).	  Among	  the	  diversity	  of	   peptides	   with	   antimicrobial	   activity,	   the	   subclass	   of	   proline-­‐rich	   antimicrobial	  peptides	   (PrAMPs)	   stands	   out	   as	   a	   potential	   new	  weapon	   to	   treat	   bacterial	   strains	  that	  acquired	  resistances	  to	  conventional	  antibiotics	  used	  in	  clinical	  practice	  (Li	  et	  al.,	  2014).	   Remarkably,	   PrAMPs	   specifically	   inhibit	   intracellular	   targets,	   in	   contrast	   to	  other	   antimicrobial	   peptides,	   which	   kill	   pathogens	   by	   lysing	   their	   cell	   membrane	  (Scocchi	  et	  al.,	  2011).	  Specific	  inhibition	  of	  bacterial	  growth	  while	  leaving	  eukaryotic	  cells	  unaffected	  is	  the	  main	  basic	  property	  characterizing	  a	  potent	  antibiotic.	  PrAMPs	  achieve	   this	   species	   specificity	   and	   therefore	   exhibit	   low	   toxicity	   (Hansen	   et	   al.,	  2012),	   for	   example,	   by	   selective	   import	   into	   bacterial	   cells	   through	   specialized	  transporters,	  such	  as	  SbmA	  located	  in	  the	  inner	  membrane	  of	  Gram-­‐negative	  bacteria,	  which	  are	  absent	  in	  mammalian	  cells	  (Mattiuzzo	  et	  al.,	  2007;	  Runti	  et	  al.,	  2013).	  	  Inside	   the	   cell,	   PrAMPs	  were	   shown	   to	   target	   the	  70	  kDa	  heat	   shock	  protein	  DnaK,	  leading	  to	  protein	  misfolding	  (Otvos,	  2005).	  Accordingly,	  PrAMPs	  can	  even	  inactivate	  bacterial	  peptide	  toxins	  by	  inhibiting	  their	  proper	  folding	  (Otvos	  et	  al.,	  2014).	  Crystal	  structures	  of	  PrAMPs	  bound	  to	  Escherichia	  coli	  DnaK	  provide	  structural	   insight	   into	  their	   mode	   of	   interaction	   (Zahn	   et	   al.,	   2013;	   Zahn	   et	   al.,	   2014).	   Recently,	   a	   new	  intracellular	   target	   for	  PrAMPs	  was	   identified	   (Krizsan	  et	  al.,	  2014).	  Due	   to	   the	   low	  affinity	  of	  PrAMPs	  to	  the	  chaperone	  DnaK	  and	  based	  on	  the	  observation,	  that	  mutant	  cells,	   lacking	   DnaK,	   are	   equally	   or	   slightly	   more	   susceptible	   to	   apidaecins	   and	  oncocins,	  the	  authors	  suggested	  that	  DnaK	  is	  most	  likely	  not	  the	  biologically	  relevant	  target	   for	   PrAMPs.	   Instead,	   the	   authors	   biochemically	   showed	   that	   insect-­‐derived	  PrAMPs	  like	  apidaecins	  and	  oncocins	  bind	  with	  nanomolar	  dissociation	  constants	  to	  the	   70S	   ribosome	   leading	   to	   inhibition	   of	   protein	   synthesis	   (Krizsan	   et	   al.,	   2014).	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Publication	   2	   of	   this	   cumulative	   thesis	   reports	   the	   first	   crystal	   structure	   of	   the	  proline-­‐rich	   antimicrobial	   peptide	   Onc112	   bound	   to	   Thermus	   thermophilus	   70S	  ribosomes	   at	   3.1	   Å	   resolution.	   The	   structure	   reveals	   that	   Onc112	   binds	  within	   the	  ribosome	   exit	   tunnel	   and	   extends	   towards	   the	   PTC,	   overlapping	   the	   A-­‐site	   and	  thereby	   prevents	   translation	   by	   inhibiting	   A-­‐site	   tRNA	   accommodation.	   Onc112	  allows	  translation	  initiation,	  but	  destabilizes	  the	  70S	  initiation	  complex,	  presumably	  by	  mediating	  fMet-­‐tRNAfMet	  dissociation	  (Seefeldt	  et	  al.,	  2015).	  	  	  
1.3.2 Tetracyclines In	  the	  1950-­‐1960´s,	   tetracycline	  antibiotics	  were	  introduced	  into	  clinical	  practice	  as	  the	   first	   class	   of	   broad-­‐spectrum	  antibiotics	   showing	   effectivity	   against	   both	  Gram-­‐positive	   and	   Gram-­‐negative	   bacteria.	   The	   first	  members	   of	   this	   class	   of	   antibiotics,	  chlortetracycline	  (Duggar,	  1948),	  oxytetracycline	  (Finlay	  et	  al.,	  1950)	  and	  tetracycline	  (Backus	   et	   al.,	   1954;	   Conover	   et	   al.,	   1953;	   Perlman	   et	   al.,	   1960)	   are	   naturally	  produced	   by	   Streptomyces	   species	   (the	   largest	   genus	   of	   actinobacteria)	   and	   are	  therefore	  called	  first-­‐generation	  tetracyclines.	  All	  members	  of	  this	  class	  of	  antibiotics	  share	  a	  common	  structural	  core,	  consisting	  of	  four	  aromatic	  rings	  (naphtacene	  core)	  (Stephens	   et	   al.,	   1952).	   Superior	   pharmacokinetic	   properties,	   water-­‐solubility	   and	  oral	  availability	  caused	  tetracyclines	  to	  be	  preferentially	  used	  in	  clinical	  practice	  and	  agriculture	   to	   treat	   bacterial	   infections.	   However,	   due	   to	   the	   extensive	   use	   of	  tetracyclines,	   bacteria	   quickly	   became	   resistant.	   To	   improve	   pharmacokinetic	   and	  antimicrobial	   activity	   of	   tetracyclines,	   second-­‐generation	   tetracyclines,	   such	   as	  doxycycline	   (Stephens	   et	   al.,	   1963)	   and	  minocycline	   (Martell	   and	   Boothe,	   1967)	   as	  well	   as	   the	   third-­‐generation	   tetracyclines	   tigecycline	   (Petersen	   et	   al.,	   1999),	  omadacycline	   (Draper	   et	   al.,	   2013)	   and	   eravacycline	   (Grossman	   et	   al.,	   2012),	  were	  semi-­‐synthetically	   produced	   by	   chemical	   modification	   of	   their	   respective	   parent	  compounds.	   Strikingly,	   third-­‐generation	   tetracyclines	   like	   tigecycline	   exhibit	   an	  increased	  binding	  affinity	  to	  the	  ribosome	  (up	  to	  100-­‐fold)	  compared	  to	  tetracycline	  (Grossman	  et	  al.,	  2012;	   Jenner	  et	  al.,	  2013;	  Olson	  et	  al.,	  2006)	  and	  inhibit	  growth	  of	  both	   susceptible	   and	   resistant	   bacterial	   strain	   at	   similar	   minimal	   inhibitory	  concentrations	  (Barden	  et	  al.,	  1994;	  Sum	  et	  al.,	  1994;	  Testa	  et	  al.,	  1993).	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Tetracyclines	   bind	   to	   multiple	   sites	   on	   the	   ribosome	   (Anokhina	   et	   al.,	   2004;	  Brodersen	  et	  al.,	  2000;	  Pioletti	  et	  al.,	  2001),	  however	  the	  primary	  binding	  site	  (Tet1)	  is	  localized	  to	  the	  A-­‐site	  of	  the	  small	  subunit	  overlapping	  the	  DC	  (Connell	  et	  al.,	  2002;	  Jenner	   et	   al.,	   2013).	   Binding	   to	   Tet1	   involves	   multiple	   hydrogen	   bonds	   to	   the	  backbone	  of	  h34	  and	  h31	  of	  the	  16S	  rRNA,	  the	  coordination	  of	  two	  magnesium	  (Mg2+)	  ions	  as	  well	   as	  a	   stacking	   interaction	  of	   ring	  D	  with	  C1054	   (Brodersen	  et	   al.,	   2000;	  Jenner	  et	  al.,	  2013;	  Pioletti	  et	  al.,	  2001).	  These	  interactions	  are	  nucleotide	  sequence-­‐unspecific	   and	   therefore	   explain	   the	   broad-­‐spectrum	   activity	   of	   this	   class	   of	  antibiotics.	  Tetracyclines	  inhibit	  translation	  by	  interfering	  with	  EF-­‐Tu-­‐mediated	  tRNA	  delivery	   to	   the	   ribosome	   by	   sterically	   occluding	   A-­‐site	   ASL	   binding	   to	   the	   DC	  (Blanchard	  et	  al.,	  2004a;	  Jenner	  et	  al.,	  2013;	  Suarez,	  1965).	  Bacterial	   resistance	   to	   tetracyclines	   is	   mainly	   conferred	   by	   four	   different	  mechanisms.	  The	  most	  common	  strategy	  used	  by	  Gram-­‐negative	  and	  Gram-­‐positive	  bacteria	   is	   tetracycline	   efflux	   i.e.	   actively	   pumping	   the	   drug	   out	   of	   the	   cell.	  Tetracycline	   efflux	   pumps	   (e.g.	   TetA)	   act	   as	   proton/tetracycline	   antiporters	   by	  exchanging	  a	  proton	  (H+)	  for	  a	  tetracycline	  molecule	  against	  a	  concentration	  gradient	  (Guillaume	   et	   al.,	   2004;	   Piddock,	   2006).	   Another	   strategy	   conferring	   tetracycline	  resistance	   is	   the	   expression	   of	   monooxygenase	   enzymes	   (e.g.	   TetX)	   that	   inactivate	  tetracycline	   by	   hydroxylation	   (Speer	   et	   al.,	   1991;	   Yang	   et	   al.,	   2004).	   Furthermore,	  mutations	  in	  the	  16S	  ribosomal	  RNA	  confer	  tetracycline	  resistance.	  For	  example	  the	  single	   mutation	   G1058C	   in	   h34	   (Ross	   et	   al.,	   1998)	   as	   well	   as	   the	   triple	   mutation	  A965U/G966U/A967U	  in	  h31	  (Dailidiene	  et	  al.,	  2002;	  Trieber	  and	  Taylor,	  2002)	  were	  identified	   in	   Propionibacterium	   acnes	   and	  Helicobacter	   pylori,	   respectively.	   In	   both	  cases,	   tetracycline	   resistance	   is	   mediated	   by	   perturbation	   of	   the	   drug	   binding	   site	  causing	  a	  significantly	  decreased	  affinity	  of	   tetracycline	   to	   the	  ribosome	  (Nonaka	  et	  al.,	   2005).	   Another	   class	   of	   widespread	   tetracycline	   resistance	   genes	   encodes	   so-­‐called	   ribosome	   protection	   proteins	   (RPPs)	   that	   confer	   resistance	   by	   directly	  dislodging	   tetracycline	   from	   its	   binding	   site.	   The	   best-­‐studied	   members	   of	   RPPs,	  
Enterococcus	   faecalis	   TetM	   and	   Campylobacter	   jejuni	   TetO	   share	   more	   than	   75%	  sequence	   identity.	   RPPs	   display	   homology	   to	   the	   GTPase	   EF-­‐G	   (~25%	   identity	   and	  ~35%	   similarity)	   and	   similarly	   bind	   to	   the	   ribosome	   in	   a	   GTP-­‐dependent	   manner	  (Burdett,	  1991;	  Connell	  et	  al.,	  2003a;	  Dantley	  et	  al.,	  1998;	  Taylor	  et	  al.,	  1995;	  Trieber	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et	   al.,	   1998).	   Subsequent	   GTP	   hydrolysis	   leads	   to	   factor	   dissociation	   from	   the	  ribosome	  but	  is	  not	  strictly	  required	  for	  tetracycline	  release	  (Burdett,	  1991;	  Connell	  et	   al.,	   2003a;	  Trieber	  et	   al.,	   1998).	   Structural	   information	  on	   the	  binding	  mode	  and	  the	  molecular	  mechanism	  of	  tetracycline	  release	  is	  based	  on	  cryo-­‐EM	  reconstructions	  of	  TetO	  or	  TetM	  bound	  to	  empty	  or	  non-­‐translating	  ribosomes	  at	  resolutions	  ranging	  from	  7.2–16	  Å	  (Dönhöfer	  et	  al.,	  2012;	  Li	  et	  al.,	  2013;	  Spahn	  et	  al.,	  2001)	  (Fig.	  9).	  	  	  
	  
Figure	  9	  |	  Overview	  of	  available	  cryo-­‐EM	  structures	  of	  RPP-­‐bound	  ribosomes.	  (A)	  First	  cryo-­‐EM	  structure	  of	  TetO	  (red)	  bound	  to	  E.	  coli	  70S	  ribosome	  (blue)	  containing	  P-­‐site	  tRNA	  (green)	  at	  ~16	  Å	  resolution	   (Spahn	   et	   al.,	   2001).	   (B)	   Cryo-­‐EM	   structure	   of	   TetO	   (blue)	   bound	   to	  E.	  coli	   70S	   ribosome	  (30S,	  yellow;	  50S	  grey,	  P-­‐site	  tRNA,	  green)	  at	  ~10	  Å	  resolution	  (Li	  et	  al.,	  2013).	  (C)	  Cryo-­‐EM	  structure	  of	   TetM	   (orange)	   bound	   to	   vacant	  E.	   coli	   70S	   ribosome	   (30S,	   yellow;	   50S	   grey)	   at	   ~7	   Å	   resolution	  (Dönhöfer	  et	  al.,	  2012).	  	  The	   initial	   structure	   showed	   TetO	   bound	   to	   the	   POST	   state	   ribosome	   occupying	   a	  similar	  binding	  site	  as	  EF-­‐G	  (Spahn	  et	  al.,	  2001).	  Due	  to	  the	  absence	  of	  density	  near	  the	   tetracycline	   binding	   site,	   the	   mechanism	   of	   drug-­‐release	   was	   proposed	   to	   be	  indirect	   (Spahn	   et	   al.,	   2001).	   The	   later	   structures	   at	   higher	   resolution	   however	  showed	   electron	   density	   within	   the	   A-­‐site	   on	   the	   SSU	   overlapping	   the	   tetracycline	  binding	   site	   and	   therefore	   contradicted	   the	   previously	   proposed	   mechanism	   and	  suggested	  that	  RPPs	  directly	  dislodge	  tetracycline	  from	  its	  binding	  site	  (Dönhöfer	  et	  al.,	   2012;	   Li	   et	   al.,	   2013).	   The	   7.2	   Å	   resolution	   structure	   of	   TetM	   bound	   ribosomes	  allowed	  a	  homology	  model	  based	  on	  EF-­‐G	   to	  be	  built	   and	  docked	   into	   the	   cryo-­‐EM	  density.	  The	  reconstruction	  revealed	  that	  the	  C-­‐terminal	  extension	  in	  TetM,	  which	  is	  absent	   in	   EF-­‐G,	   adopts	   a	   helical	   structure	   and	   binds	   to	   the	   ribosome	   near	   the	   DC	  (Dönhöfer	  et	  al.,	  2012).	  The	  docked	  homology	  model	  further	  suggested	  that	  residues	  in	   loop	   III	   of	   TetM	   domain	   IV	   overlap	   the	   tetracycline	   binding	   site.	   Mutagenesis	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studies	  identified	  two	  tyrosine	  residues	  (Y506	  and	  Y507)	  in	  loop	  III	  of	  domain	  IV	  that	  are	  critical	   for	   in	  vivo	  TetM	  activity,	  when	  both	  are	  mutated	  to	  alanine	  (Dönhöfer	  et	  al.,	   2012).	   Similar	   studies	   using	   TetO	   reported	   that	   even	   the	   single	  mutant	   Y507A	  abolishes	  TetO	  activity,	  which	  indicated	  possible	  differences	  between	  TetM	  and	  TetO	  (Li	  et	  al.,	  2013).	  Recently,	  a	  revision	  of	  the	  TetO	  Y507A	  mutation	  demonstrated	  only	  a	  reduction	  of	  the	  minimal	  inhibition	  concentration	  (MIC)	  like	  reported	  previously	  for	  TetM,	   and	   only	   the	   Y506A/Y507A	   double	   mutation	   abolished	   TetO	   activity	  completely	  (Nguyen	  et	  al.,	  2014).	  Due	  to	   the	  high	  sequence	  conservation	  of	  RPPs	   in	  this	  region,	  it	  seems	  likely	  that	  both	  TetM	  and	  TetO	  retain	  reduced	  activity	  with	  single	  mutants	   of	   Y507	   and	   that	  mutation	   of	   both	   Y506	   and	   Y507	   is	   required	   to	   abolish	  activity	  of	  RPPs.	  	  However,	  the	  precise	  molecular	  mechanism	  by	  which	  RPPs	  dislodge	  tetracycline	  from	  the	  ribosome	  and	  in	  particular	  the	  implication	  of	  Y506	  and	  Y507	  in	  this	  process	  remained	  unclear	  due	  to	  the	  limited	  resolution	  (Dönhöfer	  et	  al.,	  2012;	  Li	  et	  al.,	  2013).	  Publication	  4	  of	  this	  cumulative	  thesis	  reports	  a	  high-­‐resolution	  (3.9	  Å)	  cryo-­‐EM	   reconstruction	   of	   TetM	   bound	   to	   translating	   ribosomes,	   which	   provides	   a	  much	   more	   detailed	   insight	   into	   the	   interaction	   of	   TetM	   with	   the	   Escherichia	   coli	  ribosome.	  For	  example,	  the	  structure	  revealed	  that	  a	  proline	  residue	  (P509)	  located	  at	   the	   tip	   of	   loop	   III	   is	   directly	   involved	   in	   tetracycline	   release	   and	   that	   the	   two	  tyrosine	   residues	   are	   instead	   important	   for	   stabilizing	   the	   conformation	   of	   loop	   III	  (Arenz	  et	  al.,	  2015).	  	  	  
1.3.3 Macrolides 
Overview.	  The	  clinically	  important	  class	  of	  macrolide	  antibiotics	  consists	  of	  a	  number	  of	  polyketide	  compounds,	  which	  specifically	  inhibit	  many	  Gram-­‐positive	  and	  Gram-­‐negative	  bacterial	  pathogens	  (Gaynor	  and	  Mankin,	  2003;	  Kannan	  and	  Mankin,	  2012;	   Katz	   and	   Ashley,	   2005;	   Mankin,	   2008;	   Poehlsgaard	   and	   Douthwaite,	   2003;	  Takashima,	  2003;	  Wilson,	  2009,	  2014).	  The	  first	  generation	  macrolide	  erythromycin	  A	   is	   naturally	   produced	   by	   Saccharopolyspora	   erythraea	   and	   represents	   the	   first	  member	  of	  macrolides	  introduced	  into	  clinical	  practice	  in	  the	  1950’s	  (McGuire	  et	  al.,	  1952).	   Second-­‐generation	   macrolides	   like	   clarithromycin,	   roxithromycin	   and	  azithromycin	  are	  produced	  semi-­‐synthetically	  by	  chemical	  modification	  of	  the	  parent	  compounds	  and	  show	   improved	  pharmacokinetic	  and	  antimicrobial	  properties.	  The	  
Introduction	  	  
36	  
increasing	   spread	   of	   macrolide	   resistance	   has	   led	   to	   the	   development	   of	   third	  generation	   macrolides,	   namely	   the	   ketolides	   (e.g.	   telithromycin),	   which	   are	   more	  effective	  against	  susceptible	  as	  well	  as	  some	  resistant	  bacterial	  strains.	  The	  chemical	  structure	   of	   macrolides	   comprises	   a	   common	   12-­‐16-­‐member	  macrolactone	   ring	   to	  which	   different	   amino	   sugars	   are	   attached	   to	   various	   positions.	   For	   example	  erythromycin	   consists	   of	   the	   14-­‐member	  macrolactone	   ring	  with	   C3’-­‐cladinose	   and	  C5’-­‐desosamine	   sugar	   modifications.	   In	   comparison,	   the	   macrolactone	   ring	   of	   the	  ketolide	   telithromycin	   lacks	   the	   C3’-­‐cladinose	   sugar	   and	   instead	   carries	   a	   C3’-­‐keto	  group	  and	  a	  11,12	  cyclic	  carbamate	  with	  an	  extended	  alkyl-­‐aryl	  arm.	  
Target	   binding	   site.	   Macrolides	   bind	   to	   empty	   or	   initiating	   ribosomes	  (Contreras	  and	  Vazquez,	  1977;	  Pestka,	  1974;	  Tai	  et	  al.,	  1974)	  at	   the	  entrance	  of	   the	  exit	   tunnel	   as	   was	   suggested	   via	   chemical	   foot-­‐printing	   showing	   protection	   of	   23S	  rRNA	  nucleotide	  A2058	  and	  A2059	  (Moazed	  and	  Noller,	  1987;	  Poulsen	  et	  al.,	  2000;	  Rodriguez-­‐Fonseca	   et	   al.,	   1995)	   (Fig.	   10).	   Crystal	   structures	   of	   macrolide-­‐bound	  ribosomes	  confirmed	  that	  the	  C5’-­‐sugar	  moiety	  interacts	  with	  nucleotides	  A2058	  and	  A2059,	   which	   places	   the	   macrolides	   near	   the	   tunnel	   entrance	   in	   proximity	   to	   the	  tunnel	  constriction	  formed	  by	  ribosomal	  proteins	  L4	  and	  L22,	  with	  the	  macrolactone	  ring	  lying	  flat	  against	  the	  tunnel	  wall	  (Bulkley	  et	  al.,	  2010;	  Dunkle	  et	  al.,	  2010;	  Hansen	  et	  al.,	  2002a;	  Tu	  et	  al.,	  2005).	  This	  contrasts	  with	  an	  early	  structure	  of	  erythromycin	  bound	  to	  Deinococcus	  radiodurans	  50S,	  which	  showed	  a	  different	  conformation	  of	  the	  lactone	   ring,	   pointing	   into	   the	   tunnel	   lumen	   (Schlünzen	   et	   al.,	   2001).	   Surprisingly,	  later	   structures	   of	   14-­‐membered	  macrolides	   bound	   to	   the	  Deinococcus	   radiodurans	  50S	  showed	  the	  lactone	  ring	  lying	  flat	  against	  the	  tunnel	  wall	  (Belousoff	  et	  al.,	  2011;	  Pyetan	  et	  al.,	  2007).	  Importantly,	  species-­‐specific	  differences	  in	  the	  binding	  mode	  of	  macrolides	  exist	  (Wilson,	  2011).	  For	  example,	  different	  binding	  positions	  of	  the	  alky-­‐aryl	   arm	   of	   the	   ketolide	   telithromycin	   were	   observed	   in	   crystal	   structures	   of	  telithromycin	   bound	   to	   Haloarcula	   marismortui	   and	   Deinococcus	   radiodurans	   50S	  subunits	   (Wilson	   et	   al.,	   2005a)	   and	   Escherichia	   coli	   70S	   ribosomes	   (Dunkle	   et	   al.,	  2010).	   The	   different	   binding	   location	   of	   the	   alkyl-­‐aryl	   arm	   can	   be	   explained	   by	  species-­‐specific	   differences	   of	   the	   rRNA	   nucleotides	   interacting	   with	   this	   moiety	  (Wilson,	  2011).	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Mode	  of	  action.	  In	  general,	  macrolides	  inhibit	  protein	  synthesis	  by	  interfering	  with	  the	  progression	  of	  the	  nascent	  chain	  through	  the	  ribosome	  exit	  tunnel	  (Tenson	  et	   al.,	   2003).	   After	   synthesis	   of	   small	   oligopeptides	   consisting	   of	   6-­‐8	   amino	   acids,	  oligopeptidyl-­‐tRNAs	  drop	  off	  of	  the	  ribosome	  (Menninger	  and	  Otto,	  1982;	  Otaka	  and	  Kaji,	  1975;	  Tenson	  et	  al.,	  2003).	  Thereby,	  the	  length	  of	  the	  oligopeptide	  chain	  before	  induction	  of	  drop-­‐off	  strongly	  depends	  on	  the	  nature	  of	  the	  macrolide	  bound	  within	  the	  exit	   tunnel.	  For	  example	   telithromycin,	   lacking	   the	  C3’-­‐cladinose	  provides	  more	  space	   for	   the	   nascent	   chain	   and	   therefore	   allows	   synthesis	   of	   longer	   (9-­‐10	   amino	  acids)	   oligopeptides	   before	   peptidyl-­‐tRNA	   drop-­‐off	   (Tenson	   et	   al.,	   2003).	   However,	  the	   general	   principle	   that	   macrolides	   simply	   plug	   the	   ribosome	   exit	   tunnel	   and	  prevent	  total	  peptide	  synthesis	  has	  been	  challenged	  recently	  by	  the	  observation	  that	  some	   peptides	   were	   able	   to	   bypass	   the	   drug	   in	   the	   tunnel	   and	   become	   fully	  synthesized	   (Kannan	   et	   al.,	   2012).	   Interestingly,	   comparative	   analyses	   of	   cellular	  protein	   contents	   after	   exposure	  with	   either	   erythromycin	   or	   telithromycin	   showed	  that	   telithromycin	   allowed	   synthesis	   of	   quantitatively	   more	   peptides	   compared	   to	  erythromycin	  (Kannan	  et	  al.,	  2012).	  This	  finding	  makes	  sense,	  since	  the	  macrolides	  do	  not	  sterically	  occupy	  the	  full	  diameter	  of	  the	  ribosomal	  tunnel	  but	  instead	  leave	  space	  for	  the	  peptide	  to	  pass	  by.	  Since	  the	  ketolide	  telithromycin	  does	  not	  contain	  the	  bulky	  C3’-­‐cladinose	   sugar,	   it	   seems	   logical	   to	   assume	   that	   telithromycin	   provides	   more	  space	   to	   the	   nascent	   chain	   to	   pass	   by	   the	   drug	   compared	   to	   erythromycin	   and	  therefore	   allows	   synthesis	   of	   more	   proteins.	   To	   enable	   a	   protein	   to	   pass	   by	   the	  macrolide,	   its	   N-­‐terminal	   amino	   acid	   residues	   seem	   to	   be	   important.	   For	   example	  swapping	   the	   N-­‐terminal	   12	   amino	   acids	   between	   the	   macrolide-­‐insensitive	   HNS	  protein	  and	  the	  sensitive	  OsmC	  protein	  rendered	  OsmC	  highly	  resistant	  to	  macrolide-­‐induced	  translation	  inhibition	  (Kannan	  et	  al.,	  2012).	  Due	  to	  the	  absence	  of	  sequence	  homology	  between	  the	  N-­‐termini	  of	  macrolide-­‐resistant	  proteins,	   it	  seem	  likely	  that	  the	  N-­‐termini	   of	  macrolide	   resistant	   peptides	   adopt	   a	   defined	   conformation	  within	  the	  exit	  tunnel	  that	  allows	  their	  N-­‐termini	  to	  thread	  through	  the	  small	  pore	  in	  a	  drug-­‐obstructed	   tunnel.	  Collectively,	   these	   findings	   suggest	   a	   far	  more	   complex	   interplay	  between	  the	  amino	  acid	  sequence	  of	  the	  nascent	  chain,	  the	  ribosomal	  tunnel	  and	  the	  macrolide	  in	  order	  to	  determine	  the	  fate	  of	  a	  translating	  ribosome.	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Resistance.	   Resistance	   to	   macrolides	   can	   be	   conferred	   by	   a	   number	   of	  different	   mechanisms	   (Wilson,	   2014).	   Translation	   of	   the	   originally	   identified	   34	  nucleotides	   long	   23S	   rRNA	   fragment	   E-­‐RNA34	   (harbors	   pentapeptide	   mini-­‐gene	  coding	  for	  the	  so-­‐called	  E-­‐peptide)	  as	  well	  as	  translation	  of	  random	  mini-­‐gene	  library-­‐derived	   specific	   pentapeptides	   causes	   low-­‐level	   macrolide	   resistance	   (Tenson	   and	  Mankin,	  2001;	  Tenson	  et	  al.,	  1997).	  However,	  neither	  overexpression	  of	  the	  E-­‐peptide	  nor	   in	   vitro	   addition	   of	   synthetic	   E-­‐peptides	   (Tenson	   et	   al.,	   1996)	   confers	  erythromycin	  resistance,	  ruling	  out	  the	  possibility	  that	  pentapeptides	  act	  by	  directly	  sequestering	   the	  drug.	  According	   to	   the	   current	  model,	   during	   their	   own	   synthesis,	  the	   nascent	   pentapeptides	   dislodge	   the	   drug	   from	   its	   binding	   site	   via	   direct	  interaction	   and,	   following	   their	   release,	   sweep	   it	   along	   to	   remove	   it	   from	   the	  ribosome	   in	   a	   “bottle	   brush”	   model	   of	   action	   (Lovmar	   et	   al.,	   2006;	   Tenson	   and	  Mankin,	   2001;	   Tenson	   et	   al.,	   1997;	   Tripathi	   et	   al.,	   1998).	   This	   mechanism	   would	  provide	  time	  for	   the	  ribosome	  to	  translate	  cellular	  mRNAs	   into	  polypeptides,	  which	  occupy	  the	  ribosomal	  tunnel	  and	  thus	  prevent	  rebinding	  of	  the	  drug	  (Andersson	  and	  Kurland,	   1987).	   A	   later	   study	   demonstrated	   that	   class	   I	   release	   factor-­‐dependent	  translation	   termination	  of	   the	  pentapeptide	   is	   crucial	   for	   erythromycin	  dissociation	  from	   the	   ribosome	   (Lovmar	   et	   al.,	   2006).	   However,	   the	   originally	   identified	  pentapeptide	   is	   encoded	   within	   segments	   of	   the	   23S	   rRNA	   that	   is	   not	   normally	  translated.	  The	  association	  of	  the	  rRNA	  with	  rProteins	  as	  well	  as	  extensive	  secondary	  structures	   within	   the	   23S	   rRNA	   prevent	   translation	   of	   the	   23S	   rRNA-­‐encoded	  pentapeptide	   (Tenson	   and	   Mankin,	   2001),	   which	   raises	   the	   question	   whether	  erythromycin-­‐resistance	   proteins	   represent	   a	   biologically	   relevant	   resistance	  mechanism.	   Spontaneous	   deletions	   of	   specific	   nucleotides	   of	   the	   23S	   rRNA	   were	  shown	  to	  cause	  erythromycin	  resistance	  (Dam	  et	  al.,	  1996;	  Douthwaite	  et	  al.,	  1989;	  Douthwaite	   et	   al.,	   1985),	   presumably	   by	   altering	   the	   secondary	   structure	   of	  pentapeptide-­‐containing	   rRNA	   regions,	   which	   possibly	   enables	   pentapeptide	  expression.	  	  The	  most	   frequent	   resistance	  mutation	   A2058G	   in	   the	   23S	   rRNA	   causes	   high-­‐level	  resistance	   to	   most	   macrolides,	   including	   ketolides	   (Vester	   and	   Douthwaite,	   2001),	  and	   explains	   the	   natural	   macrolide	   resistance	   of	   eukaryotic	   ribosomes	   carrying	   a	  guanine	  nucleotide	  in	  this	  position.	  However,	  mutation	  of	  A2058	  to	  G	  does	  not	  confer	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resistance	   to	   yeast	   ribosomes	   and	   thus	   suggests	   that	  more	   factors	   are	   involved	   in	  mediating	  macrolide	   resistance	   to	  eukaryotic	   ribosomes	   (Bommakanti	   et	   al.,	   2008).	  Moreover,	  A2058G	  mutation	  does	  not	  confer	  resistance	  to	  ketolides	  in	  Streptococcus	  
pneumoniae	   (Canu	   et	   al.,	   2002;	   Farrell	   et	   al.,	   2003).	   In	   Pneumococcus	   species,	   the	  resistance	   mutation	   A2059G	   is	   found	   more	   frequently	   compared	   to	   the	   A2058G	  mutation	   (Franceschi	   et	   al.,	   2004;	   Vester	   and	   Douthwaite,	   2001).	   Furthermore,	  mutations	   in	   rProteins	   L4	   and	   L22	   confer	   macrolide	   resistance	   presumably	   by	  perturbation	   of	   the	   23S	   rRNA	   conformation	   comprising	   the	   drug-­‐binding	   site	  (Chittum	  and	  Champney,	  1994;	  Gregory	  and	  Dahlberg,	  1999;	  Wittmann	  et	  al.,	  1973).	  Macrolide	  efflux	  mediated	  by	  MefA	  and	  MsrA	  macrolide	  efflux	  pumps	  (Roberts	  et	  al.,	  1999;	  Ross	  et	  al.,	  1990)	  as	  well	  as	  macrolide	  modification	  for	  example	  by	  macrolide	  phosphorylases	   of	   the	   Mph	   family	   are	   further	   sources	   of	   high-­‐level	   resistance	  (Roberts	   et	   al.,	   1999).	  Modification	   of	   23S	   rRNA	  nucleotides	   by	  methyltransferases	  for	   example	   is	   another	   common	   strategy	   conferring	   macrolide	   resistance.	  Methylation	  of	  G748	  by	  RlmA	  (II)	  methyltransferase	  renders	  the	  producing	  organism	  resistant	  to	  tylosin	  (in	  combination	  with	  monomethylated	  A2058)	  (Douthwaite	  et	  al.,	  2004).	  Erythromycin	  resistance	  methyltransferases	  (Erms)	  methylate	  or	  dimethylate	  the	   macrolide	   binding	   nucleotide	   A2058	   at	   the	   N6	   position,	   which	   would	   lead	   to	  steric	   clashes	   with	   the	   C5’-­‐monosaccharide	   and	   therefore	   reduces	   the	   affinity	   of	  macrolides	  to	  the	  ribosome	  and	  confers	  resistance	  (Hansen	  et	  al.,	  2002a)	  (Fig.	  10).	  	  	  
	  
Figure	  10	  |	  Overview	  of	  the	  macrolide	  binding	  site	  within	  the	  ribosome	  exit	   tunnel.	  (A)	  Figure	  modified	   from	   (Ramu	   et	   al.,	   2009)	   showing	  macrolide	   (red)	  within	   the	   ribosome	   exit	   tunnel	   (grey)	  near	  the	  PTC	  (PT	  center).	  The	  nascent	  peptide	  is	  shown	  in	  green,	  the	  P-­‐site	  peptidyl-­‐tRNA	  in	  blue	  and	  the	  macrolide	  in	  red.	  (B)	  Erythromycin	  (red)	  hydrogen	  bonds	  with	  nucleotide	  A2058	  of	  the	  23S	  rRNA	  (Dunkle	   et	   al.,	   2010).	   (C)	   Methylation	   or	   dimethylation	   (green)	   of	   A2058	   by	   Erm-­‐type	  methyltransferases	  interferes	  with	  drug	  binding.	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Expression	   of	   genes	   coding	   for	   Erms	   are	   inducible	   via	   macrolide-­‐dependent	  translation	  attenuation	  on	  upstream	  open	  reading	  frames	  (Horinouchi	  and	  Weisblum,	  1980;	  Iordanescu,	  1976;	  Shivakumar	  et	  al.,	  1980;	  Weisblum,	  1995).	  This	  mechanism	  ensures	  that	  expression	  of	  the	  resistance	  gene	  is	  only	  induced	  in	  the	  presence	  of	  the	  drug.	   Interestingly,	   ketolide-­‐mediated	   induction	   of	   ErmC	   does	   not	   use	   ribosome	  stalling	  on	  ErmCL,	  but	  rather	  ribosome	  frameshifting	  at	  the	  upstream	  ORF	  to	  induce	  expression	   of	   ErmC	   (Gupta	   et	   al.,	   2013a).	   The	   tight	   regulation	   of	   Erm	   expression	  could	   be	   explained	   by	   the	   recent	   finding	   that	   permanent	   methylation	   of	   A2058	   is	  associated	   with	   a	   huge	   fitness	   cost	   for	   the	   bacterial	   cell	   (Gupta	   et	   al.,	   2013b),	  probably	  due	  to	  de-­‐regulation	  of	  translation.	  
Stalling.	   In	   addition	   to	   the	   abilities	   of	   macrolides	   to	   induce	   peptidyl-­‐tRNA	  drop-­‐off	  or	  allow	  synthesis	  of	  specific	  peptides,	  macrolides	  can	  also	  induce	  ribosome	  stalling	   during	   translation	   of	   specific	   peptide	   sequences.	   The	   principle	   of	   nascent	  polypeptide-­‐mediated	  translation	  attenuation	  occurs	   in	  many	  organisms	  to	  regulate	  expression	   of	   certain	   genes	   (Wilson	   and	   Beckmann,	   2011).	   Nascent	   polypeptide-­‐mediated	   translation	   regulation	   can	   be	   an	   intrinsic	   property	   of	   the	   nascent	   chain,	  such	   that	   the	   amino	   acid	   sequence	   of	   the	   nascent	   chain,	   for	   example	   polyproline	  sequences	   (Doerfel	  et	  al.,	  2013;	  Peil	  et	  al.,	  2013;	  Starosta	  et	  al.,	  2014;	  Tanner	  et	  al.,	  2009;	  Ude	   et	   al.,	   2013;	  Woolstenhulme	   et	   al.,	   2013),	   is	   sufficient	   to	   slow	  down	   the	  rates	  of	  translation	  and	  in	  some	  cases	  even	  induce	  translation	  arrest	  (Ito	  and	  Chiba,	  2013).	   Therefore,	   the	   ribosome	   exit	   tunnel	   seems	   not	   to	   be	   just	   a	   passive	   conduit	  through	   which	   nascent	   polypeptides	   pass	   during	   synthesis,	   but	   rather	   closely	  monitors	  and	  interacts	  with	  the	  amino	  acid	  residues	  of	  the	  nascent	  chain	  in	  order	  to	  communicate	   with	   the	   PTC	   to	   modulate	   the	   rate	   of	   translation	   (Wilson	   and	  Beckmann,	   2011).	   Nucleotide	   residues	   of	   the	   23S	   rRNA	   comprising	   the	  wall	   of	   the	  ribosomal	   tunnel	  could	  potentially	  be	   involved	   in	  sensing	  nascent	  polypeptides.	  For	  example	  mutation	   of	   nucleotides	   U1782,	   U2609,	   A2503,	   U2586	   or	   A2062	   does	   not	  influence	   peptide	   synthesis,	   but	   severely	   affect	   the	   ribosomes	   ability	   to	   halt	  translation	  in	  response	  to	  specific	  nascent	  polypeptides	  (Vázquez-­‐Laslop	  et	  al.,	  2011).	  Ribosome	   stalling	   often	   occurs	   during	   translation	   of	   small	   upstream	   open	   reading	  frames	  (ORFs)	  to	  regulate	  expression	  of	  downstream	  genes	  in	  the	  operon,	  which	  are	  transcriptionally	   or	   translationally	   repressed	   (Fig.	   11).	   Well-­‐studied	   examples	   are	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the	  MifM	   (Chiba	   et	   al.,	   2009;	   Sohmen	  et	   al.,	   2015)	   and	  SecM	   (Bhushan	  et	   al.,	   2011;	  Goldman	   et	   al.,	   2015;	   Gumbart	   et	   al.,	   2012;	   Nakatogawa	   and	   Ito,	   2002;	   Tsai	   et	   al.,	  2014;	  Wilson	  and	  Beckmann,	  2011)	  leader	  peptides.	  	  	  
	  
Figure	   11	   |	   Regulation	   of	   gene	   expression	   by	   ribosome	   stalling.	   (A)	   Ribosome	   stalling	   during	  translation	  termination	  on	  the	  TnaC	  leader	  peptide	  prevents	  rho-­‐dependent	  transcription	  termination	  and	  allows	   transcription	   and	  expression	  of	   the	  downstream	   tnaA/B	   genes.	   (B)	  Ribosome	  elongation	  stalling	   during	   translation	   of	   SecM,	   MifM,	   ErmCL	   and	   Cat86	   leader	   peptides	   leads	   to	   structural	  rearrangements	   of	   the	   respective	   mRNAs,	   which	   consequently	   expose	   the	   previously	   inaccessible	  Shine-­‐Dalgarno	   (SD)	   sequences	   of	   the	   downstream	   genes	   allowing	   their	   expression.	   (C)	   Ribosome	  stalling	  during	  translation	  termination	  on	  upstream	  open	  reading	  frames	  (uORFs)	  of	  cytomegalovirus	  (CMV)	   and	   arginine	   attenuator	   peptide	   (AAP)	   prevents	   scanning	   and	   thus	   expression	   of	   their	  respective	  downstream	  genes.	  Figure	  modified	  from	  (Wilson	  and	  Beckmann,	  2011).	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MifM-­‐stalling.	   The	  MifM	   leader	   peptide	   consists	   of	   95	   amino	   acids,	   whereas	   the	   C-­‐terminal	   residues	   69-­‐89	  were	   shown	   to	   be	   critical	   for	   stalling	   (Chiba	   et	   al.,	   2009).	  Interestingly,	   translation	   stalls	   at	   four	   specific	   sites	   in	   the	  MifM	   leader	  peptide	   and	  biochemical	  experiments	  revealed	  that	  residues	  R69,	  I70,	  W73,	  I74,	  M80,	  N81,	  as	  well	  as	  the	  C-­‐terminal	  DEED	  (86-­‐89)	  motif	  are	  important	  for	  translation	  arrest	  (Chiba	  and	  Ito,	  2012;	  Chiba	  et	  al.,	  2009).	  Surprisingly	  it	  was	  shown,	  that	  translation	  of	  MifM	  leads	  to	  ribosome	  stalling	  in	  a	  species-­‐specific	  manner,	  as	  MifM	  induces	  stalling	  on	  Bacillus	  
subtilis,	   but	   not	   on	   E.	   coli	   ribosomes	   (Chiba	   et	   al.,	   2011).	   Notably,	   nucleotides	  comprising	  the	  ribosomal	  tunnel	  are	  highly	  conserved	  between	  B.	  subtilis	  and	  E.	  coli,	  which	  raises	  the	  question	  of	  how	  the	  species-­‐specificity	  of	  MifM	  is	  achieved.	  A	  recent	  publication	  reported	  a	  high-­‐resolution	  structure	  of	  a	  MifM-­‐stalled	  ribosome	  (Fig.	  12)	  with	   D89	   in	   the	   P-­‐site,	   which	   biochemically	   identified	   a	   single	   B.	   subtilis-­‐specific	  residue	  Met90	  of	  L22	  being	  responsible	   to	  modulate	   the	  species	   specificity	  of	  MifM	  (Sohmen	  et	  al.,	  2015).	  Indirect	  contact	  of	  MifM	  with	  L22	  Met90	  together	  with	  further	  interactions	   between	   critical	   residues	   of	   MifM	   and	   nucleotides	   in	   the	   ribosomal	  tunnel	  possibly	  stabilize	  the	  MifM	  nascent	  chain	  in	  a	  special	  conformation,	  placing	  the	  side	  chain	  of	  Glu87	  of	  MifM	  in	  a	  position,	  which	  prevents	  A-­‐site	  tRNA	  accommodation	  to	   the	   PTC	   and	   therefore	   peptide	   bond	   formation	   leading	   to	   translation	   arrest	  (Sohmen	  et	   al.,	   2015).	   In	   the	  natural	   context,	   the	   ribosome	  manages	   to	   incorporate	  the	  next	  amino	  acid,	  although	  at	  lower	  rates	  (Chiba	  and	  Ito,	  2012;	  Chiba	  et	  al.,	  2009),	  which	   leads	   to	   the	   assumption	   that	   Glu87	   is	   not	   solely	   responsible	   for	   translation	  arrest,	   especially,	   since	   single	  mutation	  of	  Glu87	  does	  not	   prevent	   stalling	   to	   occur	  (Chiba	   and	   Ito,	   2012).	   The	   observed	   SD-­‐anti-­‐SD	   helix	   in	   MifM-­‐stalled	   ribosome	  complex	  (SRC)	  might	  contribute	  to	  the	  stalling	  event	  (Sohmen	  et	  al.,	  2015),	  similar	  to	  induction	  of	  ribosome	  pausing	  mediated	  by	  internal	  SD-­‐like	  sequences	  in	  bacteria	  (Li	  et	  al.,	  2012).	  Notably,	  MifM-­‐stalled	  ribosomes	  are	  unreactive	  to	  release	  factors	  (Chiba	  and	   Ito,	   2012;	   Chiba	   et	   al.,	   2009),	   probably	   due	   to	   the	   steric	   overlap	   of	   A2602	   in	  MifM-­‐SRC	   with	   the	   GGQ	   motif	   of	   RF2,	   which	   is	   proposed	   to	   prevent	   RF2	  accommodation	  into	  the	  PTC.	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SecM-­‐stalling.	  The	  SecM	  leader	  peptide	  sequence	  is	  170	  codons	  long	  and	  precedes	  the	  downstream	  gene	   secA.	   The	   ribosome	  stalls	  during	   translation	  of	   SecM	  at	   the	  165th	  codon	  position	  with	   a	   glycine	   codon	   in	   the	  P-­‐site	   and	   a	  proline	   codon	   in	   the	  A-­‐site	  (Muto	   et	   al.,	   2006;	  Woolhead	   et	   al.,	   2006).	   Specific	   residues	   within	   the	   C-­‐terminal	  amino	  acid	  sequence	  F150xxxxWIxxxxGIRAG165	  together	  with	  the	  spacing	  in	  between	  them	  are	  known	  to	  be	  critical	  for	  stalling	  (Nakatogawa	  and	  Ito,	  2001,	  2002).	  In	  detail,	  cysteine-­‐mutagenesis	   studies	   showed	   that	   only	   R163	   is	   indispensible	   for	   stalling,	  whereas	   the	   flanking	   residues	   play	   a	   secondary	   role,	   presumably	   to	   position	   R163	  into	  a	  specific	  location	  inside	  the	  tunnel	  (Yap	  and	  Bernstein,	  2009).	  It	  has	  been	  shown	  that	   the	   proline-­‐tRNAPro	   in	   the	   A-­‐site	   is	   required	   for	   efficient	   stalling	   (Muto	   et	   al.,	  2006;	   Nakatogawa	   and	   Ito,	   2002),	   however	   peptide	   bond	   formation	   between	   the	  peptidyl-­‐tRNA	   and	   the	   proline-­‐tRNAPro	  in	   the	   A-­‐site	   still	   occurs	   slowly	   (Muto	   et	   al.,	  2006).	   Biochemical	   evidence	   shows	   that	   mutation	   of	   tunnel	   components	   A2058G,	  A2062U,	  A2503G	  (Lawrence	  et	  al.,	  2008;	  Nakatogawa	  and	  Ito,	  2002;	  Vazquez-­‐Laslop	  et	  al.,	  2010)	  as	  well	  as	  insertion	  of	  single	  adenine	  residues	  between	  A749-­‐A753	  and	  furthermore	  insertions,	  deletions	  or	  mutations	  in	  L22	  and	  L4	  (Lawrence	  et	  al.,	  2008;	  Nakatogawa	   and	   Ito,	   2002)	   alleviates	   ribosome	   stalling	   on	   SecM.	   Cryo-­‐EM	  reconstructions	   of	   SecM-­‐stalled	   ribosomes	   at	   ~11	   Å	   (Mitra	   et	   al.,	   2005)	   and	   ~6	   Å	  resolution	   (Bhushan	   et	   al.,	   2011)	   are	   available	   (Fig.	   12).	   The	   former	   structure	  suggested	  that	  the	  SecM	  nascent	  chain	  induces	  larger	  scale	  conformational	  changes	  in	  the	  23S	  rRNA	  by	   interaction	  with	  A2058	  and	  A749-­‐A753	  (Mitra	  et	  al.,	  2006),	  which	  alter	  the	  correct	  geometry	  in	  the	  PTC	  required	  for	  peptide	  bond	  formation.	  The	  better	  resolved	   structure	   however	   did	   not	   support	   this	   cascade	   of	   rRNA	   conformational	  changes	   but	   instead	   visualized	   direct	   interaction	   between	   critical	   residues	   of	   SecM	  with	  nucleotides	  of	  the	  ribosomal	  tunnel	  as	  well	  as	  a	  shift	  of	  2	  Å	  in	  the	  peptidyl-­‐tRNA	  ester	  linkage,	  which	  moves	  the	  peptidyl-­‐ester	  further	  away	  from	  the	  A-­‐site	  tRNA	  and	  thereby	   alters	   the	   geometry	   within	   the	   PTC	   leading	   to	   inhibition	   of	   peptide	   bond	  formation	  (Bhushan	  et	  al.,	  2011).	  Within	  the	  limitations	  of	  a	  ~6	  Å	  map,	  SecM	  appears	  to	  interact	  with	  nucleotides	  U2609,	  U2585	  and	  A2062	  comprising	  the	  ribosome	  exit	  tunnel.	  A2062	  is	  a	  highly	  flexible	  nucleotide	  (Fulle	  and	  Gohlke,	  2009)	  and	  is	  stabilized	  in	  a	  conformation	  with	  the	  base	  lying	  flat	  against	  the	  tunnel	  wall	  probably	  via	  the	  key	  interaction	  with	   the	   critical	   SecM	   residue	   Arg163	   (Bhushan	   et	   al.,	   2011).	   By	   being	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stabilized	   in	  this	  defined	  conformation,	  A2062	  potentially	  communicates	  to	  the	  PTC	  via	  A2503	  to	  inhibit	  peptide	  bond	  formation	  (Vazquez-­‐Laslop	  et	  al.,	  2010),	  eventually	  by	   shifting	   the	   peptidyl-­‐tRNA	   ester.	   Supporting	   the	   hypothesis,	   mutation	   of	   either	  A2062	  (Vazquez-­‐Laslop	  et	  al.,	  2010)	  or	  Arg163	  (Nakatogawa	  and	  Ito,	  2002;	  Yap	  and	  Bernstein,	   2009)	   abolishes	   SecM-­‐dependent	   ribosome	   stalling.	   Ribosomal	   stalling	  could	  be	  additionally	  influenced	  by	  the	  identity	  of	  the	  tRNA	  in	  the	  A-­‐site,	  since	  proline	  naturally	   shows	   slower	   rates	   of	   peptide	   bond	   formation	   compared	   to	   other	   amino	  acids	  (Pavlov	  et	  al.,	  2009).	  In	  contrast	  to	  MifM,	  SecM	  might	  therefore	  affect	  the	  P-­‐site	  rather	   than	   the	   A-­‐site	   illustrating	   that	   nascent	   peptide-­‐mediated	   ribosome	   stalling	  might	  be	  inducible	  via	  different	  mechanisms	  culminating	  in	  inhibition	  of	  the	  PTC.	  	  Further	  underlining	   the	  complex	  and	   impressive	  ability	  of	   the	   ribosome	   to	  monitor	  the	  amino	  acid	  sequence	  and	  structure	  of	  growing	  polypeptides,	  nascent	  polypeptide-­‐mediated	  translation	  regulation	  can	  also	  depend	  on	  the	  presence	  of	  a	  small	  ligand	  or	  cofactor	  bound	  in	  the	  ribosome	  exit	  tunnel	  (Ramu	  et	  al.,	  2009;	  Vazquez-­‐Laslop	  et	  al.,	  2011;	   Vazquez-­‐Laslop	   et	   al.,	   2008).	   Well-­‐characterized	   examples	   are	   the	   free	   L-­‐tryptophan-­‐dependent	   ribosome	   stalling	   during	   translation	   of	   TnaC	   and	   the	  macrolide-­‐dependent	   ribosome	   stalling	   during	   translation	   of	   Erm-­‐type	   leader	  peptides.	  
TnaC-­‐stalling.	   One	   of	   the	   best-­‐studied	   examples	   is	   the	   24	   amino	   acid-­‐long	   leader	  peptide	  TnaC,	  which	  requires	  the	  presence	  of	  free	  L-­‐tryptophan	  (L-­‐Trp)	  for	  stalling	  to	  occur	  (Bischoff	  et	  al.,	  2014;	  Gong	  and	  Yanofsky,	  2002;	  Seidelt	  et	  al.,	  2009).	  Unlike	  for	  stalling	  on	  Erm	   leader	  peptides,	   ribosome	  stalling	  during	   translation	  of	  TnaC	   in	   the	  presence	   of	   free	   L-­‐Trp	   does	   not	   induce	  mRNA	   rearrangements,	   but	   rather	   leads	   to	  transcription	  anti-­‐termination	  and	  therefore	  expression	  of	  downstream	  genes	  (Gong	  and	   Yanofsky,	   2002).	   Ribosomes	   translating	   the	   TnaC	   leader	   peptide	   stall	  with	   the	  last	   sense	   codon	  of	   TnaC	   (P24)	   in	   the	  P-­‐site	   and	   the	  UGA	   stop	   codon	   in	   the	  A-­‐site.	  Therefore,	  unlike	  MifM	  of	  SecM,	  TnaC	  induces	  stalling	  during	  translation	  termination	  by	  preventing	  RF2-­‐mediated	  peptide	  release	  (Gong	  and	  Yanofsky,	  2002).	  Numerous	  biochemical	  experiments	  determined	  residues	  P24,	  D16	  and	  W12	  of	  TnaC,	  as	  well	  as	  their	   relative	   spacing,	   to	   be	   critical	   for	   the	   ribosome	   to	   respond	   to	   free	   L-­‐Trp	   by	  inactivation	  of	  the	  PTC	  (Cruz-­‐Vera	  et	  al.,	  2005;	  Cruz-­‐Vera	  and	  Yanofsky,	  2008;	  Gong	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and	   Yanofsky,	   2002).	   The	   first	   structural	   insight	   into	   TnaC-­‐stalled	   ribosomes	   was	  provided	   by	   a	   cryo-­‐EM	   reconstruction	   at	   5.8	   Å	   (Seidelt	   et	   al.,	   2009).	   The	   structure	  highlighted	   that	   TnaC	   adopts	   a	   defined	   conformation	  within	   the	   exit	   tunnel,	  which	  stabilizes	   U2585	   and	   A2602	   in	   defined	   positions	   that	   would	   sterically	   prevent	  accommodation	  of	   release	   factors	   into	   the	  PTC	  and	   thereby	   translation	   termination	  (Seidelt	   et	   al.,	   2009).	   However,	   despite	   the	   identification	   of	   critical	   interactions	  between	  TnaC	  and	  the	  ribosomes,	  the	  resolution	  was	  not	  sufficient	  to	  localize	  the	  L-­‐tryptophan	  cofactor	  and	  therefore	  a	  detailed	  explanation	  of	  L-­‐Trp-­‐induced	  ribosome	  stalling	  during	  translation	  of	  TnaC	  remained	  elusive.	  Recently,	  a	  high-­‐resolution	  cryo-­‐EM	  reconstruction	  of	  the	  TnaC-­‐SRC	  at	  3.8	  Å	  (Fig.	  12)	  revealed	  the	  binding	  sites	  of	  two	  tryptophan	   molecules	   bound	   within	   the	   ribosomal	   tunnel	   and	   provided	   detailed	  insight	   into	   the	   interactions	   between	   TnaC	   and	   components	   of	   the	   ribosomal	   exit	  tunnel	  (Bischoff	  et	  al.,	  2014).	  Interestingly,	  the	  two	  L-­‐Trp	  molecules	  are	  bound	  ~15-­‐20	   Å	   distant	   from	   the	   PTC,	  which	   contrasts	   initial	   suggestions	   that	   the	   tryptophan	  binding	   site	   is	   located	   directly	   within	   the	   A-­‐site	   of	   the	   PTC,	   overlapping	   the	  sparsomycin	   binding	   site	   (Cruz-­‐Vera	   et	   al.,	   2006;	   Cruz-­‐Vera	   et	   al.,	   2007;	   Cruz-­‐Vera	  and	  Yanofsky,	  2008).	  The	  observed	  binding	  site	  for	  the	  L-­‐Trp	  molecules	  in	  proximity	  to	  A2058	  of	  the	  23S	  rRNA	  and	  I19	  of	  TnaC	  (Bischoff	  et	  al.,	  2014)	  nicely	  agrees	  with	  more	  recent	  studies	  suggesting	  that	  these	  two	  residues	  play	  an	  important	  role	  for	  L-­‐Trp	  binding	  and	  subsequent	  inhibition	  of	  the	  PTC	  (Martinez	  et	  al.,	  2014).	  In	  detail,	  the	  TnaC	  nascent	  polypeptide	  creates	  two	  hydrophobic	  pockets	  within	  the	  exit	  tunnel	  to	  accommodate	  the	  two	  L-­‐Trp	  molecules	  W1	  and	  W2.	  W1	  is	  sandwiched	  between	  D21,	  V20	  and	  I19	  of	  TnaC	  on	  the	  one	  side,	  and	  U2586	  on	  the	  tunnel	  side,	  whereas	  W2	  is	  bound	  in	  a	  pocket	  formed	  by	  TnaC	  residues	  V20	  and	  I15	  and	  by	  A2058/A2059	  of	  the	  23S	  rRNA.	  Interestingly,	  W2	  binding	  to	  TnaC	  structurally	  mimics	  the	  ribosome-­‐bound	  ketolide	  telithromycin	  in	  this	  region	  (Dunkle	  et	  al.,	  2010),	  which	  induces	  translational	  arrest	   during	   translation	   of	   certain	   leader	   peptides	   (Vázquez-­‐Laslop	   et	   al.,	   2011),	  suggesting	  a	  more	  general	  role	  of	  A2058/A2059	  and	  U2609/A752	  in	  nascent	  chain-­‐dependent	   translation	   regulation.	   Accordingly,	   mutagenesis	   of	   U2609,	   A752	   and	  A2058	  severely	  affects	  stalling	  efficiency	  during	  translation	  of	  TnaC	  (Cruz-­‐Vera	  et	  al.,	  2005;	  Cruz-­‐Vera	  and	  Yanofsky,	  2008;	  Gong	  and	  Yanofsky,	  2002).	  Nucleotides	  U2585	  and	  A2602	  within	  the	  PTC	  adopt	  positions	  that	  would	  sterically	  clash	  with	  the	  GGQ	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motif	   of	   RF2	   and	   thereby	   interfere	   with	   RF2-­‐mediated	   peptidyl-­‐hydrolysis	   of	   the	  TnaC	  nascent	  chain	  (Bischoff	  et	  al.,	  2014).	  Collectively,	  critical	  amino	  acid	  residues	  in	  TnaC	   appear	   to	   establish	   defined	   interactions	   with	   the	   ribosomal	   tunnel,	   thereby	  forming	  two	  binding	  sites	  for	  L-­‐Trp	  molecules,	  binding	  of	  which	  is	  then	  allosterically	  communicated	   to	   the	   PTC	   to	   stabilize	   U2585	   and	   A2602	   in	   conformations	  incompatible	   with	   RF2-­‐mediated	   translation	   termination.	   The	   example	   of	   TnaC-­‐stalling	   clearly	   illustrates	   the	   complexity	   of	   the	   communication	   between	   nascent	  chain,	  ribosomal	  tunnel	  and	  small	  molecule	  co-­‐factors	  to	  allosterically	  inactivate	  the	  PTC.	  	  
	  
Figure	  12	  |	  Overview	  of	  cryo-­‐EM	  structures	  of	  MifM-­‐,	  SecM-­‐,	  and	  TnaC-­‐stalled	  ribosomes.	  (A-­‐C)	  Comparison	  of	  cryo-­‐EM	  structures	  of	  (A)	  MifM-­‐SRC	  (Sohmen	  et	  al.,	  2015),	  (B)	  SecM-­‐SRC	  (Bhushan	  et	  al.,	  2011)	  and	  (C)	  TnaC-­‐SRC	  (Bischoff	  et	  al.,	  2014),	  with	  50S	  subunits	  (grey)	  cut	  in	  order	  to	  display	  the	  path	  of	  the	  respective	  nascent	  polypeptide	  chains	  passing	  through	  the	  ribosomal	  tunnel.	  	  	  
Erm-­‐type-­‐stalling.	  Macrolide-­‐dependent	  ribosome	  stalling	  during	  translation	  of	  Erm-­‐type	  leader	  peptides	  was	  initially	  discovered	  to	  regulate	  expression	  of	  the	  inducible	  downstream	   macrolide	   resistance	   methyltransferase	   ErmC	   (Horinouchi	   and	  Weisblum,	   1980;	   Iordanescu,	   1976;	   Shivakumar	   et	   al.,	   1980;	   Weisblum,	   1995).	   In	  general,	   in	   the	   absence	   of	   erythromycin,	   ErmC	   expression	   is	   inhibited	   since	   the	   SD	  sequence	   and	   start	   codon	   of	   ErmC	   are	   sequestered	   in	   a	   stem	   loop	   structure	   of	   the	  mRNA,	   which	   prevents	   translation	   initiation.	   At	   sub-­‐inhibitory	   concentrations	   of	  erythromycin,	  ribosomes	  translating	  the	  ErmCL	  leader	  peptide	  become	  stalled,	  which	  causes	  a	   change	   in	   the	  mRNA	  secondary	  structure	   so	   that	   the	  SD	  sequence	  and	   the	  start	   codon	   of	   the	   ermC	   gene	   become	   exposed,	   allowing	   ribosome	   binding	   and	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induction	   of	   ErmC	   expression.	   To	   date,	   numerous	   Erm-­‐type	   leader	   sequences	  regulating	  downstream	  resistance	  genes	  have	  been	   identified	   in	  multiple	  organisms	  (Ramu	  et	  al.,	  2009;	  Vázquez-­‐Laslop	  et	  al.,	  2011).	  Notably,	  the	  amino	  acid	  sequence	  of	  the	  different	  leader	  peptides	  is	  very	  diverse	  and	  can	  be	  grouped	  into	  several	  classes,	  depending	   on	   a	   common	   C-­‐terminal	   amino	   acid	   sequence	  motif	   critical	   for	   stalling	  (Ramu	   et	   al.,	   2009;	   Vázquez-­‐Laslop	   et	   al.,	   2011).	   Despite	   the	   common	  mechanism	  used	  by	  all	  Erm-­‐type	  leader	  peptides	  to	  stall	  translation	  in	  order	  to	  induce	  expression	  of	   downstream	   resistance	   genes,	   they	   vary	   significantly	   in	   terms	   of	   biochemical	  properties,	   like	   drug-­‐specificity,	   A-­‐site	   tRNA	   specificity	   and	   dependency	   on	   certain	  nucleotides	  of	  the	  ribosomal	  tunnel	  (Vázquez-­‐Laslop	  et	  al.,	  2011).	  How	  the	  macrolide-­‐bound	  ribosome	  senses	  the	  presence	  of	  specific	  structures	  and	  amino	  acid	  sequences	  of	   different	   nascent	   polypeptides	  within	   the	   exit	   tunnel	   and	   how	   these	   signals	   are	  communicated	   to	   the	  PTC	   to	   stall	   translation	   are	  hot	   topics	   in	   the	   field.	   In	   general,	  Erm-­‐type	   leader	   peptides	   are	   rather	   short,	   with	   stalling	   sites	   between	   codon	  positions	   6-­‐16	   (Ramu	   et	   al.,	   2009).	   For	   simplicity	   reasons,	   the	   following	   section	  focuses	   on	   main	   differences/similarities	   between	   ErmAL1	   (MCTSIAVVP-­‐EA;	   IAVV	  peptides),	   ErmBL	   (MLVFQMRNVDP-­‐KA;	   miscellaneous	   peptides),	   ErmCL	  (MGIFSIFVIP-­‐SA;	   IFVI	   peptides)	   and	   ErmDL	   (MTHSMRLP-­‐RA;	   RLR	   peptides),	  representing	   members	   of	   the	   four	   main	   stalling	   motif	   classes	   of	   Erm-­‐type	   leader	  peptides	  (stalling	  motif	  =	  critical	  residues)	  (Vázquez-­‐Laslop	  et	  al.,	  2011).	  	  Studies	   on	   the	   ErmDL	   leader	   peptide,	   which	   belongs	   to	   the	   RLR-­‐class	   of	   stalling	  peptides,	   revealed	   that	   unlike	   for	   ErmCL	   (Vazquez-­‐Laslop	   et	   al.,	   2008),	   N-­‐terminal	  truncation	  of	  the	  leader	  peptide	  to	  yield	  the	  minimal	  tripeptide	  stalling-­‐motif	  MRLP-­‐RA,	   retains	   its	   ability	   to	   respond	   to	   the	   presence	   of	   both	   erythromycin	   and	  telithromycin	  (Sothiselvam	  et	  al.,	  2014).	  The	  authors	  claimed	  that	  the	  MRL	  tripeptide	  is	  too	  short	  to	  directly	  contact	  the	  tunnel-­‐bound	  drug	  and	  further	  could	  not	  identify	  critical	   residues	   comprising	   the	   tunnel	   wall.	   Consequently,	   the	   macrolide	   was	  suggested	   to	   allosterically	   induce	   conformations	   within	   the	   PTC,	   which	   allow	   the	  ribosome	   to	   respond	   to	   RLR	   stalling	   sequences	   (Sothiselvam	   et	   al.,	   2014).	   In	   fact,	  chemical	  probing	  analyses	  as	  well	  as	  molecular	  dynamics	  simulations	  demonstrated	  that	   solely	   the	   binding	   of	   a	   macrolide	   to	   the	   ribosome,	   in	   the	   absence	   of	   nascent	  polypeptide,	   changes	   the	   chemical	   protection	   pattern	   and	   the	   computed	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conformational	   freedom	  of	   nucleotides	  U2585	   and	  A2602,	  which	   play	   critical	   roles	  during	   peptide	   bond	   formation	   (Schmeing	   et	   al.,	   2005d;	   Voorhees	   et	   al.,	   2009).	  Therefore,	   the	   authors	   concluded	   that	   drug	   binding	   allosterically	   predisposes	   the	  ribosome	   to	   respond	   to	   specific	   amino	   acid	   sequences	   of	   the	   nascent	   chain	  (Sothiselvam	   et	   al.,	   2014).	   To	   address	   the	   mechanism	   of	   macrolide	   action	   on	   a	  genome-­‐wide	   level,	   recent	   ribosome	   profiling	   experiments	   performed	   with	  azithromycin	  (Davis	  et	  al.,	  2014),	  erythromycin	  or	  telithromycin-­‐treated	  (Kannan	  et	  al.,	  2014)	  cells	  were	  performed.	  The	  profiling	  data	  revealed	  that	  in	  the	  presence	  of	  the	  drug,	   translation	  of	  most	   genes	  proceeds	  past	   the	  5’-­‐codons	   and	   is	   arrested	  during	  translation	   of	   specific	   amino	   acid	   sequence	  motifs	   located	  more	   distal	   in	   the	   open	  reading	   frames,	   suggesting	   that	  macrolides	   inhibit	   protein	   synthesis	   in	   a	   sequence-­‐specific	  manner	   (Davis	  et	  al.,	  2014;	  Kannan	  et	  al.,	  2014).	   Interestingly,	   the	  profiling	  experiments	   identified,	   amongst	   others,	   the	   stalling	  motif	   R/K	   x	   R/K,	  which	   nicely	  corresponds	  to	   the	  stalling	  motif	  present	   in	  RLR-­‐class	   leader	  peptides	  (e.g.	  ErmDL).	  However,	  not	  every	  R/K	  x	  R/K	  motif	  encountered	  by	  a	  drug-­‐bound	  ribosome	  induces	  translation	  arrest,	  which	  suggests	   that	   the	  variable	  N-­‐terminal	   context	  of	   the	  R/K	  x	  R/K	   motif	   is	   critical	   to	   turn	   the	   motif	   into	   a	   stalling-­‐motif	   (Kannan	   et	   al.,	   2014).	  Moreover,	  erythromycin	   (Kannan	  et	  al.,	  2014)	  or	  azithromycin-­‐treated	  (Davis	  et	  al.,	  2014)	  cells	  display	  a	  broader	  variety	  of	  arrest	  motifs	  compared	  with	   telithromycin-­‐treated	  cells	  (Kannan	  et	  al.,	  2014).	  	  Despite	   all	   Erm-­‐type	   leader	   peptides	   requiring	   the	   presence	   of	   a	  macrolide	   bound	  within	   the	   exit	   tunnel	   to	   induce	   translation	   arrest,	   the	   chemical	   nature	   of	   the	  macrolide,	   especially	   the	   presence	   of	   the	   C3’-­‐cladinose	   sugar,	   plays	   a	   role	   during	  induction	  of	  stalling.	  For	  example	  the	  C3’-­‐cladinose	  sugar	  is	  crucial	  to	  induce	  stalling	  during	  translation	  of	  ErmAL1	  and	  ErmCL,	  whereas	  in	  contrast,	  stalling	  on	  ErmBL	  and	  ErmDL	  leader	  peptides	  is	  also	  inducible	  by	  the	  ketolide	  telithromycin,	  which	  lacks	  the	  C3’-­‐cladinose	  sugar	   (Sothiselvam	  et	  al.,	  2014;	  Vazquez-­‐Laslop	  et	  al.,	  2011;	  Vázquez-­‐Laslop	   et	   al.,	   2011;	   Vazquez-­‐Laslop	   et	   al.,	   2008).	   These	   results	   suggest	   that	  ErmAL1/ErmCL	   and	   ErmBL/ErmDL	   nascent	   chains	   might	   follow	   different	   paths	  within	   the	   drug-­‐obstructed	   ribosome	   exit	   tunnel,	   which	   might	   be	   directed	   by	   the	  presence	   or	   absence	   of	   the	   C3’-­‐cladinose	   sugar	   of	   erythromycin.	   Differences	   in	   the	  path	  of	  the	  nascent	  chain	  might	  lead	  to	  different	  key	  interactions	  between	  the	  nascent	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polypeptides	  and	  nucleotides	  comprising	  the	  tunnel	  wall.	  For	  example,	  mutagenesis	  of	  A2062	  and	  A2503	  abolishes	  stalling	  during	  translation	  of	  ErmAL1	  and	  ErmCL,	  but	  has	  no	  effect	  on	  ErmBL	  and	  ErmDL-­‐mediated	   translation	  arrest	   (Vázquez-­‐Laslop	  et	  al.,	  2011;	  Vazquez-­‐Laslop	  et	  al.,	  2008).	  Furthermore,	  differences	  in	  the	  degree	  of	  PTC	  inactivation	  exist.	  For	  example,	  drug-­‐dependent	  stalling	  on	  ErmAL1	  can	  be	  alleviated	  by	  mutation	  of	  the	  A-­‐site	  codon	  to	  A,	  F,	  M	  or	  C	  (Ramu	  et	  al.,	  2011),	  thus	  making	  the	  A-­‐site	  selective	  for	  accommodation	  of	  only	  certain	  aa-­‐tRNAs	  that	  would	  lead	  to	  peptide	  bond	  formation.	  In	  contrast,	  drug-­‐dependent	  stalling	  on	  ErmCL	  inhibits	  peptide	  bond	  formation	  irrespective	  of	  the	  identity	  of	  the	  A-­‐site	  amino	  acid	  and	  therefore	  induces	  a	  restrictive	  A-­‐site	  (Ramu	  et	  al.,	  2011).	  Interestingly,	  the	  amino	  acid	  in	  the	  -­‐2	  position	  (A	  in	  ErmAL1;	  F	  in	  ErmCL)	  plays	  a	  critical	  role	  in	  determining	  the	  fate	  of	  the	  A-­‐site,	  since	   swapping	   this	   residue	  between	  ErmAL1	  and	  ErmCL	   turns	   the	  A-­‐site	   selective	  for	  ErmCL_F7A	  (Ramu	  et	  al.,	  2011).	  However,	  the	  structural	  changes	  within	  the	  PTC	  leading	  to	  this	  change	  in	  A-­‐site	  specificity	  remain	  unclear.	  Publications	  5	  (Arenz	  et	  al.,	  2014b),	  6	  (Arenz	  et	  al.,	  2014a)	  and	  7	  (Arenz,	  2015)	  of	  this	  cumulative	  thesis	  report	  the	   first	   high-­‐resolution	   cryo-­‐EM	   structures	   of	   drug-­‐stalled	   ribosomes	   during	  translation	   of	   ErmBL	   (Arenz	   et	   al.,	   2014b;	   Arenz,	   2015)	   and	   ErmCL	   (Arenz	   et	   al.,	  2014a)	   leader	   peptides,	   providing	   the	   first	   structural	   insight	   into	   the	   complex	  interplay	  between	  nascent	  peptide,	   the	   tunnel-­‐bound	  macrolide	  and	  components	  of	  the	  exit	   tunnel	   to	   inactive	  the	  PTC.	  The	  structures	  essentially	  show	  that	  ErmBL	  and	  ErmCL	   nascent	   chains	   follow	   different	   paths	   through	   the	   ribosome.	   The	   ErmCL	  nascent	   chain	   directly	   senses	   the	   presence	   of	   erythromycin	   (Arenz	   et	   al.,	   2014a),	  whereas	  the	  ErmBL	  nascent	  peptide	  adopts	  a	  different	  conformation	  within	  the	  exit	  tunnel	   following	   a	   path	   far	   away	   from	   erythromycin.	   (Arenz	   et	   al.,	   2014b;	   Arenz,	  2015).	   Moreover,	   the	   structures	   show	   differences	   in	   the	   conformation	   of	   A2062	  (Arenz	   et	   al.,	   2014a;	   Arenz	   et	   al.,	   2014b;	   Arenz,	   2015),	   which	   agrees	   well	   with	  biochemical	  evidence	  demonstrating	  the	  differential	  importance	  of	  this	  nucleotide	  for	  stalling	  (Vázquez-­‐Laslop	  et	  al.,	  2011;	  Vazquez-­‐Laslop	  et	  al.,	  2008).	  Most	  interestingly,	  the	  structures	  of	  ErmBL	  and	  ErmCL-­‐stalled	  ribosomes	  reveal	  dramatic	  differences	  in	  the	  conformation	  of	  the	  inactivated	  PTC,	  thereby	  highlighting	  that	  ErmBL	  and	  ErmCL	  nascent	  chains	   inactivate	   the	  PTC	  via	   two	  distinct	  mechanisms	  (Arenz	  et	  al.,	  2014a;	  Arenz	  et	  al.,	  2014b;	  Arenz,	  2015).	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2 Objectives of These Studies 	  
Ribosomal	  protein	  S1	  (Publication	  1)	  S1	   is	   known	   to	   be	   intrinsically	   very	   flexible	   (Chu	   and	   Cantor,	   1979;	   Moore	   and	  Laughrea,	  1979),	  explaining	   the	  absence	  of	  structural	  data	  of	   the	   full-­‐length	  protein	  bound	   to	   the	   ribosome.	   Previous	   biochemical	   experiments	   suggested	   that	   the	   N-­‐terminal	   region	   of	   S1	   (residues	   1-­‐106;	   S1106)	  mediates	   S1	   binding	   to	   the	   ribosome	  (Byrgazov	  et	  al.,	  2012;	  Lauber	  et	  al.,	  2012)	  via	  interaction	  with	  ribosomal	  protein	  S2	  (Boni	  et	  al.,	  1982;	  Moll	  et	  al.,	  2002).	  The	  aim	  of	  this	  work	  was	  to	  provide	  a	  structural	  basis	  of	  the	  interaction	  between	  S1	  and	  S2,	  which	  anchors	  S1	  on	  the	  ribosome,	  and	  to	  extend	   our	   insight	   into	   how	   S1	   enables	   translation	   initiation	   of	   highly	   structured	  mRNAs.	  	  	  
Proline-­‐rich	  antimicrobial	  peptides	  (Publication	  2)	  Proline-­‐rich	   antimicrobial	   peptides	   (PrAMPs)	   are	   produced	   by	   the	   innate	   immune	  response	  and	  exhibit	  activity	  against	  various	  Gram-­‐negative	  pathogens.	  Due	  to	  their	  low	  toxicity,	  PrAMPs	  represent	  a	  potent	  new	  class	  of	  antibiotics.	  Recently	  biochemical	  experiments	  demonstrated	  that	  Onc112,	  a	  19-­‐residue	  member	  of	  the	  oncocin	  family	  of	   PrAMPs	   targets	   the	   70S	   ribosome	   and	   inhibits	   translation	   (Krizsan	   et	   al.,	   2014).	  The	  aim	  of	  this	  project	  was	  to	  obtain	  a	  high-­‐resolution	  structure	  of	  an	  Onc112-­‐bound	  ribosome	   to	  determine	   the	  PrAMP	  binding	   site	  on	   the	   ribosome	  and,	   together	  with	  biochemical	   experiments,	   to	   unravel	   the	   mode	   of	   action	   by	   which	   PrAMPs	   inhibit	  translation.	  	  	  
Tetracycline	  resistance	  (Publication	  3	  and	  4)	  Tetracycline	   resistance	   can	   be	   mediated	   by	   specialized	   proteins	   like	   TetM,	   which	  confer	  resistance	  by	  dislodging	  the	  clinically	  important	  tetracycline	  from	  its	  binding	  site	  on	  the	  SSU	  of	  the	  ribosome.	  However,	  due	  to	  the	  low	  resolution	  of	  previous	  cryo-­‐EM	   reconstructions	   of	   TetM-­‐bound	   ribosomes,	   detailed	   insight	   into	   TetM-­‐mediated	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tetracycline	   resistance	   remained	   elusive.	   By	   using	   translating	   instead	   of	   vacant	  ribosomes	   as	   substrates	   for	   TetM	   binding,	   we	   aimed	   to	   improve	   complex	  homogeneity	   for	   state-­‐of-­‐the-­‐art	   cryo-­‐EM	   analysis.	   The	   goal	   was	   to	   obtain	   a	  sufficiently	   high-­‐resolved	   reconstruction	   of	   TetM-­‐bound	   ribosomes	   to	   unravel,	  together	  with	  complementing	  biochemical	  experiments,	  the	  molecular	  mechanism	  by	  which	  TetM	  dislodges	  tetracycline	  from	  its	  binding	  site	  and	  thus	  confers	  resistance.	  	  	  	  
Macrolide-­‐dependent	  ribosome	  stalling	  (Publications	  5,	  6	  and	  7)	  The	   presence	   of	   subinhibitory	   concentrations	   of	   clinically	   important	   macrolide	  antibiotics	  induces	  ribosome	  stalling	  during	  translation	  of	  Erm-­‐type	  leader	  peptides,	  resulting	   in	   induction	   of	   expression	   of	   downstream	   macrolide	   resistance	   genes.	  Despite	  a	  lot	  of	  biochemical	   information	  on	  drug-­‐dependent	  ribosome	  stalling	  being	  available,	  structural	  insight	  into	  the	  complex	  interplay	  between	  nascent	  polypeptide,	  the	   ribosomal	   exit	   tunnel	   and	   the	   tunnel-­‐bound	   macrolide	   was	   lacking.	   Here	   we	  aimed	  to	  rectify	  this	  situation	  by	  determination	  of	  high-­‐resolution	  cryo-­‐EM	  structures	  of	  drug-­‐stalled	  ribosomes,	  providing	  insight	  into	  the	  molecular	  mechanism	  by	  which	  translation	   of	   Erm-­‐type	   leader	   peptides	   is	   arrested	   in	   the	   presence	   of	   macrolides	  antibiotics.	  Moreover,	  we	   aimed	   to	   address	   interesting	   differences	   among	   different	  drug-­‐stalled	   ribosomes,	   like	   drug-­‐specificity	   and	   A-­‐site	   specificity,	   which	   strongly	  depend	  on	  the	  amino	  acid	  sequence	  of	  the	  peptide	  being	  translated.	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3 Cumulative Thesis: Summary of Publications 	  
3.1 Publication	  1	  |	   	  Structural	  Basis	  for	  the	  Interaction	  of	  Protein	  
S1	  with	  the	  Escherichia	  coli	  Ribosome	  Konstantin	  Byrgazov,	  Irina	  Grishkovskaya,	  Stefan	  Arenz,	  Nicolas	  Coudevylle,	  Hannes	  Temmel,	  Daniel	  N.	  Wilson,	  Kristina	  Djinovic-­‐Carugo	  and	  Isabella	  Moll.	  	  	  
Nucleic	  Acids	  Research.	  43,	  661-­‐673	  (2014).	  	  The	   six-­‐domain	   ribosomal	  protein	   S1	   is	   essential	   for	   translation	   initiation	   in	  Gram-­‐negative	  bacteria	  (Sorensen	  et	  al.,	  1998).	  Previous	  experiments	  suggested	  that	  the	  N-­‐terminal	  region	  of	  S1	  (residues	  1-­‐106;	  S1106)	  is	  necessary	  and	  sufficient	  (Byrgazov	  et	  al.,	  2012;	  Lauber	  et	  al.,	  2012)	   for	   interaction	  with	  ribosomal	  protein	  S2	  (Boni	  et	  al.,	  1982;	   Moll	   et	   al.,	   2002).	   However,	   high-­‐resolution	   structural	   information	   on	   the	  binding	  mode	  of	  S1	   to	   the	  ribosome	   is	  unavailable,	  due	   to	   the	   intrinsic	   flexibility	  of	  the	   protein.	   By	   using	   a	   combination	   of	   NMR,	   X-­‐ray	   crystallography,	   cryo-­‐EM	   and	  biochemical	   studies,	   we	   gained	   profound	   insight	   in	   the	   structure	   and	   molecular	  interactions	   of	   the	   N-­‐terminal	   domain	   S1	   when	   bound	   to	   the	   ribosome.	  Multidimensional	  heteronuclear	  NMR	  studies	  on	  S1106,	  S186	  and	  S119-­‐86	  revealed	  that	  the	   N-­‐terminal	   (1-­‐18;	   S1NTS)	   and	   C-­‐terminal	   (87-­‐106)	   linkers	   of	   D1	   (19-­‐86)	   are	  disordered	  in	  solution.	  In	  vivo	  binding	  assays	  demonstrated	  that	  the	  flexible	  S1NTS	  is	  the	   crucial	   element	   of	   S1	   required	   for	   ribosome	   binding.	   To	   unravel	   the	  molecular	  interaction	   pattern	   of	   S1NTD	   (1-­‐86)	   to	   S2,	   a	   chimeric	   fusion	   protein	   S2-­‐S1NTD	   was	  crystallized.	   Interestingly,	   the	   resulting	   2-­‐3	  Å	   structure	   showed	   that	   the	   S1NTS	   folds	  upon	  binding	  to	  S2	  and	  adopts	  a	  α-­‐helical	  structure,	  which	  is	  connected	  to	  the	  four	  β-­‐stranded	   globular	   domain	   D1	   of	   S1	   (S1D1)	   via	   a	   flexible	   seven	   amino	   acid	   linker.	  Notably,	   the	   fold	   of	   S1D1	   resembles	   a	   truncated	   oligosaccharide/oligonucleotide-­‐binding	  (OB)	  fold	  and	  is	  therefore	  different	  compared	  to	  the	  OB-­‐fold	  of	  D3-­‐D6	  of	  S1.	  Interaction	   between	   S1NTD	   and	   S2	   is	   established	   via	   both	   π-­‐stacking	   interactions	  involving	   phenylalanine	   residues	   of	   S1NTH	   as	  well	   as	   via	   two	   salt	   bridges	   involving	  Asp39	   and	   Lys43	   of	   S1D1.	   Thereby,	   direct	   interaction	   with	   S1D1	  stabilizes	   residues	  Asp188	  and	  Asp205	  of	   the	   S2	   zinc	   (Zn2+)	  binding	  pocket	   in	   their	   Zn2+	   coordinating	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conformation.	  Pull-­‐down	  experiments	  using	  either	  tagged	  ribosomes	  or	  tagged	  S1NTD	  variants	   revealed	   that	   the	   S1NTD-­‐D2	   interaction	   is	   primarily	   based	   on	   π-­‐stacking	  interactions	  between	  S1NTH	  and	  S2.	  In	  vitro	  competition	  assays	  between	  S1NTH	  and	  full	  length	  S1	  suggested	  that	  S1NTH	  competes	  with	  full	  length	  S1	  for	  the	  same	  binding	  site.	  Accordingly,	  by	  competing	  with	  native	  S1,	  addition	  of	  10-­‐to	  50-­‐fold	  molar	  excess	  of	  S1NTS	  over	  ribosomes	  inhibited	  in	  vitro	  translation	  of	  ompA	  mRNA,	  which	  was	  shown	  to	  be	  strictly	  dependent	  on	  the	  presence	  of	  S1	  (Tedin	  et	  al.,	  1997).	  Furthermore,	  we	  determined	  a	  cryo-­‐EM	  structure	  of	  a	  programmed	  E.	  coli	  ribosome	  at	  8	  Å	  resolution.	  Additional	   density	   adjacent	   to	   S2	   was	   attributed	   to	   parts	   of	   S1,	   since	   S2-­‐based	  alignment	   of	   the	   S2-­‐S1NTD	   crystal	   structure	   perfectly	   placed	   S1D1	   into	   one	   of	   the	  additional	  densities.	  The	  cryo-­‐EM	  structure	  reveals	  contact	  sites	  between	  S1NTD	  and	  S2	   in	   the	   same	   regions	   as	   expected	   from	   S2-­‐S1NTD	   crystal	   structure,	   as	   well	   as	  additional	  contacts	  of	  S1NTD	  with	  the	  mRNA	  and	  the	  3’-­‐end	  of	  the	  16S	  rRNA.	  Thereby,	  the	   cryo-­‐EM	   structure	   suggests	   that	   the	   chimeric	   S2-­‐S1NTD	   fusion	   complex	   is	  physiologically	  relevant.	  	  	  
3.2 Publication	  2	  |	   The	   Proline-­‐rich	   Antimicrobial	   Peptide	  
Onc112	   Inhibits	   Translation	   by	   Blocking	   and	   Destabilizing	  
the	  Post-­‐initiation	  Complex	  A.	   Carolin	   Seefeldt*,	   Fabian	   Nguyen*,	   Stéphanie	   Antunes*,	   Natacha	  Pérébaskine,	  Michael	  Graf,	  Stefan	  Arenz,	  Kishore	  K.	   Inampudi,	  Céline	  Douat,	  Gilles	  Guichard,	  Daniel	  N.	  Wilson	  and	  C.	  Axel	  Innis.	  	  
Nature	  Structural	  &	  Molecular	  Biology.	  10.1038/nsmb.3034	  (2015).	  	  Innate	   immune	   response-­‐derived	   proline-­‐rich	   antimicrobial	   peptides	   are	   active	  against	  various	  pathogens	  and	  due	  to	  their	  low	  toxicity	  represent	  a	  potent	  new	  class	  of	   antibiotics.	   Onc112,	   a	   19-­‐residue	   member	   of	   the	   oncocin	   family	   of	   proline-­‐rich	  antimicrobial	  peptides,	  targets	  the	  70S	  ribosome	  and	  inhibits	  translation	  (Krizsan	  et	  al.,	   2014).	   This	   publication	   reports	   a	   3.1	  Å	   crystal	   structure	   of	   Onc112	   bound	   to	  
Thermus	  thermophilus	  70S	  ribosomes	   in	  complex	  with	  deacylated	   tRNAfMet	   in	   the	  P-­‐site,	   providing	   the	   first	   structural	   insight	   into	   the	  mechanism	   of	   Onc112-­‐mediated	  translation	   inhibition.	  We	   identified	  Onc112	  binding	  within	   the	  upper	   region	  of	   the	  ribosome	   exit	   tunnel	   in	   a	   reverse	   orientation,	   such	   that	   the	   N-­‐terminal	   residues	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overlap	   the	   binding	   site	   for	   the	   CCA-­‐end	   of	   the	  A-­‐site	   tRNA,	   interfering	  with	  A-­‐site	  tRNA	  binding	  and	  resulting	  in	  translation	  inhibition.	  Onc112	  binding	  to	  the	  ribosome	  resembles	  an	  induced	  fit,	  involving	  stabilization	  of	  defined	  conformations	  of	  normally	  flexible	   nucleotides	  U2506,	   U2585	   and	  A2062.	   An	   extensive,	   stabilizing	   network	   of	  hydrogen	   bonds	   between	   the	   N-­‐terminal	   10	   residues	   and	   components	   of	   the	   23S	  rRNA	   is	   observed,	   whereas	   the	   C-­‐terminal	   residues	   appear	   to	   be	   flexible.	   We	  demonstrated	  that	  C-­‐terminally	  truncated	  versions	  of	  Onc112	  retain	  reduced	  activity	  to	   inhibit	   in	  vitro	   translation	  reactions,	  but	   loose	   their	  antimicrobial	  activity	   in	  vivo.	  To	   unravel	   the	   mode	   of	   Onc112	   action,	   we	   employed	   ribosome	   toe-­‐printing	  experiments	   to	   demonstrate	   that	   Onc112	   inhibits	   translation	   after	   70S	   initiation	  complex	   formation.	   Onc112	   further	   destabilizes	   the	   70S	   initiation	   complex,	   as	  observed	  by	  monitoring	  disome	  formation	  upon	  translation	  of	  a	  dicistronic	  mRNA	  in	  
vitro	   in	  the	  presence	  of	  Onc112,	  presumably	  because	  Onc112	  sterically	  clashes	  with	  fMet-­‐tRNAfMet	   causing	   it	   to	   dissociate	   from	   the	   ribosome.	   Finally,	   in	   vivo	   growth	  inhibition	   experiments	   confirmed	   that	   SbmA	   is	   indeed	   the	   inner	   membrane	  transporter	  necessary	  for	  Onc112	  uptake	  into	  Gram-­‐negative	  bacteria.	  	  
3.3 Publication	  3	  |	  	  Tetracycline	   Antibiotics	   and	   Resistance	  
Mechanisms	  Fabian	   Nguyen,	   Agata	   L.	   Starosta,	   Stefan	   Arenz,	   Daniel	   Sohmen,	   Alexandra	  Dönhöfer	  and	  Daniel	  N.	  Wilson.	  	  
Biological	  Chemistry.	  395,	  559-­‐575	  (2014).	  	  The	  ribosome	   is	  one	  of	   the	  main	   targets	   for	  antibiotics	  within	  a	  bacterial	  cell.	  The	  large	  family	  of	  tetracycline	  antibiotics	  represents	  one	  of	  the	  most	  frequently	  applied	  class	   in	   clinical	   practice	   to	   treat	   a	   variety	   of	   bacterial	   infectious	   diseases.	   Our	  publication	   reviews	   the	   development	   of	   first-­‐,	   second-­‐	   and	   third-­‐generation	  members	  of	   tetracyclines	  and	  describes	   their	  mode	  of	   ribosome	  binding	  and	   their	  mechanism	  of	  action.	  Additionally,	  we	  review	  diverse	  mechanisms	  that	  give	  rise	  to	  bacterial	   resistance	   to	   tetracyclines,	   such	   as	   drug	   efflux,	   drug	  modification,	   target	  mutation	  and	  ribosome	  protection	  proteins.	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3.4 Publication	  4	  |	  	  Cryo-­‐EM	   Structure	   of	   the	   Tetracycline	  
Resistance	   Protein	   TetM	   in	   Complex	   with	   a	   Translating	  
Ribosome	  at	  3.9	  Å	  Resolution	  Stefan	  Arenz,	  Fabian	  Nguyen,	  Roland	  Beckmann	  and	  Daniel	  N.	  Wilson.	  	  
Proceedings	  of	  the	  National	  Academy	  of	  Sciences.	  112,	  5401-­‐5406	  (2014).	  	  The	  tetracycline	  resistance	  protein	  TetM	  belongs	  to	  the	  family	  of	  ribosome	  protection	  proteins	   (RPPs)	   that	   confer	   resistance	   by	   dislodging	   the	   clinically	   important	  tetracycline	   from	   its	   binding	   site	   on	   the	   SSU	   of	   the	   ribosome.	   Current	   knowledge	  about	   RPP	   action	   is	   based	   on	   7.2-­‐16	  Å	   resolution	   cryo-­‐EM	   reconstructions	   of	   RPP-­‐bound	   vacant	   or	   non-­‐translating	   ribosomes.	   However,	   due	   to	   lack	   of	   resolution,	  detailed	  insight	  into	  RPP-­‐mediated	  tetracycline	  resistance	  remained	  elusive.	  By	  using	  state-­‐of-­‐the-­‐art	  cryo-­‐EM	  and	  multi-­‐particle	  reconstruction	  of	  ribosome	  nascent	  chain	  complexes	   (RNCs)	   bound	   with	   TetM,	   we	   obtained	   a	   3.9	  Å	   reconstruction	   of	  TetM!RNC.	  The	  structure	  allowed	  TetM	  contacts	  with	  the	  ribosome	  to	  be	  revealed,	  a	  backbone	  model	   for	  TetM	  bound	  to	  an	  E.	  coli	   ribosome	  to	  be	  built	  and	  the	  previous	  model	   of	   TetM	   action	   to	   be	   revised.	  We	   overcame	   previous	   complex	   heterogeneity	  problems	   (Dönhöfer	   et	   al.,	   2012)	   by	   using	   defined	   substrate	   ribosomes	   (stalled	  during	  translation	  of	  ErmCL,	  trapped	  in	  non-­‐rotated	  state,	  bearing	  a	  peptidyl-­‐tRNA	  in	  the	  P-­‐site	  and	  an	  empty	  A-­‐site)	  for	  Enterococcus	  faecalis	  TetM	  binding	  in	  the	  presence	  of	  the	  non-­‐hydrolysable	  GTP	  analog	  GDPCP.	  The	  structure	  reveals	   interaction	  of	  the	  conserved	  and	  functionally	  critical	  C-­‐terminal	  helix	  (CTH)	  of	  TetM	  with	  A1913	  of	  H69	  in	  the	  decoding	  center,	  which	  adopts	  a	  defined	  position	  similar	  to	  that	  observed	  when	  A-­‐site	  tRNA	  is	  bound	  to	  ribosome.	  Moreover,	  decoding	  center	  nucleotides	  A1492	  and	  A1493	   appear	   to	   flip	   out	   of	   h44	   of	   the	   16S	   rRNA,	   which	   confirms	   the	   previous	  suggestion	  based	  on	  the	  7.2	  Å	  TetM!70S	  structure	  (Dönhöfer	  et	  al.,	  2012),	  however	  the	   splayed	   conformation	   of	   A1492	   and	   A1493	   is	   distinct	   from	   all	   previously	  observed	   conformations.	   Unlike	   in	   previous	   reconstructions	   of	   TetM/TetO!70S	  complexes,	   the	   density	   for	   loop	   III	   of	   domain	   IV	   of	   TetM	   was	   unambiguous	   and	  resolved	  to	  3.5	  Å	  resolution,	  allowing	  the	  register	  and	  orientation	  of	  bulky	  side	  chains	  to	  be	  accurately	  determined.	  The	   fully	  conserved	  proline	  residue	  509	   located	  at	   the	  tip	   of	   loop	   III	   stacks	   upon	   C1054	   of	   h34	   comprising	   the	   tetracycline	   binding	   site	  
Cumulative	  Thesis	  	  
56	  
(Brodersen	  et	  al.,	  2000;	  Jenner	  et	  al.,	  2013;	  Pioletti	  et	  al.,	  2001)	  and	  would	  sterically	  clash	   with	   ribosome-­‐bound	   tetracycline.	   In	   contrast	   to	   previous	   suggestions	   that	  Y506	   and	   Y507	   are	   directly	   involved	   in	   dislodging	   the	   drug	   from	   the	   ribosome,	  analysis	  of	   the	  structure	  combined	  with	   in	  vivo	  growth	   inhibition	  assays	  of	  selected	  TetM	  loop	  III	  mutants	  provided	  evidence	  that	  Y506	  and	  Y507	  are	   involved	   in	   intra-­‐domain	   interactions	   that	  appear	   to	  stabilize	   the	   functional	   conformation	  of	   loop	   III.	  Collectively,	  we	  suggest	  that	  RPPs	  use	  P509	  at	  the	  tip	  of	  loop	  III	  instead	  of	  Y506/Y507	  to	   interact	  with	   the	   tetracycline	   binding	   site	   nucleotide	   C1054	   and	   thus	   to	   directly	  dislodge	  tetracycline	  from	  the	  ribosome.	  	  
3.5 Publication	  5	  |	  	  Molecular	   Basis	   for	   Erythromycin-­‐dependent	  
Ribosome	   Stalling	   During	   Translation	   of	   the	   ErmBL	   Leader	  
Peptide	  Stefan	   Arenz,	   Haripriya	   Ramu,	   Pulkit	   Gupta,	   Otto	   Berninghausen,	   Roland	  Beckmann,	  Nora	  Vázquez-­‐Laslop,	  Alexander	  S.	  Mankin	  and	  Daniel	  N.	  Wilson.	  	  
Nature	  Communications.	  5:	  3501	  (2014).	  	  The	   presence	   of	   subinhibitory	   concentrations	   of	   the	   clinically	   important	  macrolide	  erythromycin	   induces	   ribosome	   stalling	   during	   translation	   of	   the	   ErmBL	   leader	  peptide,	  resulting	  in	  induction	  of	  expression	  of	  the	  downstream	  macrolide	  resistance	  methyltransferase	  ErmB.	  We	  show	  by	  northern	  blotting	  that	  the	  ribosome	  is	  unable	  to	   catalyze	   peptide	   bond	   formation	   between	   the	   P-­‐site	   peptidyl-­‐tRNAAsp	   and	   the	  incoming	   A-­‐site	   Lys-­‐tRNALys,	   which	   causes	   the	   ribosome	   to	   stall	   during	   elongation	  with	  codon	  10	  (D10)	  in	  the	  P-­‐site	  and	  K11	  in	  the	  A-­‐site.	  As	  a	  major	  achievement,	  our	  publication	  provides	  the	  first	  structural	  insight	  into	  drug-­‐dependent	  stalled	  ribosome	  complexes	   (SRCs)	   and	   expands	   profoundly	   the	   mechanistic	   understanding	   of	   the	  complex	   interplay	   between	   nascent	   polypeptide,	   the	   tunnel-­‐bound	   drug	   and	  nucleotides	   comprising	   the	   tunnel	   wall	   to	   generate	   a	   stalling	   signal,	   which	   is	   then	  communicated	   to	   the	   PTC	   to	   arrest	   translation.	   We	   developed	   an	   in	   vitro	   disome	  system,	  which	  allows	  highly	  specific	  purification	  of	  drug-­‐dependent	  SRCs	  that	  cannot	  be	   purified	   using	   N-­‐terminal	   affinity	   tagging	   due	   to	   the	   short	   (10	   amino	   acids)	  nascent	  peptide	  residing	  inside	  the	  tunnel.	  Multiparticle	  cryo-­‐EM	  allowed	  us	  to	  obtain	  a	   reconstruction	  of	   the	  ErmBL-­‐SRC	  at	  4.5	  Å	   resolution	   in	   the	   ribosomal	   core,	  which	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meant	  that	  our	  structure	  was	  one	  of	  best-­‐resolved	  cryo-­‐EM	  structures	  reported	  at	  the	  time,	   since	   revolutionizing	   improvements	   in	   the	   field	  of	   cryo-­‐EM	   like	  application	  of	  direct	  electron	  detectors	  and	  Cs-­‐correctors	  were	  not	  available	  to	  us	  at	  that	  stage.	  The	  structure	   reveals	   a	   unique	   path	   of	   the	   nascent	   ErmBL	  peptide,	  which	   bypasses	   the	  tunnel-­‐bound	  drug.	  In	  perfect	  agreement	  with	  the	  absence	  of	  direct	  contact	  between	  ErmBL	  and	  erythromycin,	  toe-­‐printing	  experiments	  confirmed	  that	  azalides	  and	  even	  ketolides	  lacking	  the	  C3’-­‐cladinose	  sugar	  induce	  ribosome	  stalling	  during	  translation	  of	   ErmBL.	   Alanine	   scanning	   mutagenesis	   biochemically	   identified	   the	   C-­‐terminal	  residues	  R7,	  V9	  and	  D10	  of	  ErmBL	  being	  critical	  for	  stalling.	  Strikingly,	  based	  on	  the	  structure,	  these	  residues	  appear	  to	  interact	  with	  nucleotides	  U2586	  (R7)	  and	  U2585	  (V9,	   D10)	   comprising	   the	   tunnel	   wall.	   Further	   toe-­‐printing	   studies	   confirmed	   the	  functional	  interaction	  between	  R7	  and	  U2586,	  since	  nucleotide	  alterations	  of	  U2586	  restored	   stalling	  during	   translation	   of	   the	  ErmBL	  R7A	  mutant.	   This	   key	   interaction	  between	  nascent	  chain	  and	  ribosome	  seems	  to	  be	  communicated	  to	  the	  PTC,	  where	  V9	   and	   D10	   of	   ErmBL	   appear	   to	   interact	   with	   U2585,	   thereby	   stabilizing	   the	  uninduced	  state	  of	  the	  PTC.	  We	  proposed	  that	  the	  uninduced	  conformation	  of	  the	  PTC	  corrupts	   accommodation	   of	   the	   A-­‐site	   bound	   Lys-­‐tRNALys	   into	   the	   PTC	   resulting	   in	  inhibition	  of	  peptide	  bond	  formation.	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3.6 Publication	  6	  |	  	  Drug	   Sensing	   by	   the	   Ribosome	   Induces	  
Translational	  Arrest	  via	  Active	  Site	  Perturbation	  Stefan	  Arenz,	   Sezen	  Meydan,	  Agata	  L.	   Starosta,	  Otto	  Berninghausen,	  Roland	  Beckmann,	  Nora	  Vázquez-­‐Laslop	  and	  Daniel	  N.	  Wilson.	  	  
Molecular	  Cell.	  56,	  446-­‐452	  (2014).	  	  Ribosome	   stalling	   during	   translation	   of	   the	   Staphylococcus	   aureus	   ErmCL	   leader	  peptide	  is	   induced	  by	  the	  clinically	   important	  erythromycin	  and	  leads	  to	  expression	  of	   the	   downstream	  macrolide	   resistance	  methyltransferase	   ErmC.	  We	  modified	   the	  previously	  established	  in	  vitro	  disome	  system	  to	  prepare	  a	  homogeneous	  population	  of	  ErmCL-­‐SRCs	   for	  subsequent	  analysis	  by	  cryo-­‐EM.	  Using	  high-­‐quality	  Cs-­‐corrected	  cryo-­‐EM	   images	   of	   the	   ErmCL-­‐SRC	   derived	   from	   a	   direct	   electron	   detector,	  multiparticle	  reconstruction	  yielded	  a	  3.9	  Å	  resolution	  map	  of	  ErmCL-­‐SRC.	  The	  high	  resolution	  (3.5	  Å	  in	  the	  ribosomal	  core)	  enabled	  a	  detailed	  view	  on	  the	  conformation	  of	   the	   PTC	   and	   the	   mechanistic	   interplay	   between	   ErmCL,	   erythromycin	   and	  nucleotides	   of	   the	   tunnel	  wall.	   Unlike	   ErmBL,	   the	   ErmCL	   nascent	   chain	   appears	   to	  directly	  sense	  the	  presence	  of	  erythromycin	  via	  interaction	  between	  the	  backbones	  of	  invariant	   I6/F7	   in	   ErmCL	   and	   the	   critical	   C3’-­‐cladinose	   sugar	   of	   erythromycin.	  Overall,	   four	   major	   sites	   of	   interaction	   between	   ErmCL	   and	   the	   ribosome	   are	  observed,	   such	   as	   critical	   residues	   V8/F7	   interacting	   with	   U2506,	   invariant	   I6	  interacting	  with	  U2586	  and	  presumably	  I3	  interacting	  with	  the	  critical	  A2062,	  which	  is	  stabilized	  in	  a	  different	  conformation	  compared	  with	  the	  ErmBL-­‐SRC.	  We	  showed	  by	  toe-­‐printing	  that	  mutagenesis	  of	  U2586	  partially	  rescued	  the	  stalling-­‐deficiency	  of	  the	  ErmCL	  I6A	  mutant,	  which	  suggests	  a	  functional	  interplay	  between	  I6	  and	  U2586.	  The	   interactions	   with	   U2586,	   U2506,	   A2062	   and	   the	   C3’-­‐cladinose	   sugar	   of	  erythromycin	  stabilize	  the	  nascent	  chain	   in	  a	  conformation,	  which	  precludes	  U2585	  to	   adopt	   its	   canonical	  position	   and	  promotes	  U2585	   to	   flip	   into	   a	  novel,	   previously	  unseen	  conformation.	  The	  flipped	  position	  of	  U2585	  together	  with	  shifted	  P-­‐site	  tRNA	  A76	  and	  shifted	  nucleotide	  A2602	  perturbs	  the	  conformation	  of	  the	  PTC,	  reducing	  its	  ability	  to	  stably	  bind	  and	  accommodate	  A-­‐site	  tRNA,	  which	  culminates	  in	  translation	  arrest.	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3.7 Publication	  7	  |	  	  Alternate	  Conformation	  of	  a	  Nascent	  Chain	  in	  
the	   Ribosomal	   Tunnel	   Induces	   P-­‐tRNA	   Perturbation	   and	  
Inhibition	  of	  Peptide	  Bond	  Formation	  	  Stefan	  Arenz,	  C.	  Axel	  Innis,	  Roland	  Beckmann	  and	  Daniel	  N.	  Wilson.	  	  
Unpublished	  manuscript	  (2015).	  	  The	  previous	  cryo-­‐EM	  reconstruction	  of	  the	  ErmBL-­‐SRC	  (section	  3.4)	  was	  resolved	  to	  4.5-­‐6.6	  Å.	  At	  this	  resolution,	  neither	  density	  for	  amino	  acid	  side	  chains,	  nor	  separation	  of	   density	   for	   individual	   rRNA	   nucleotides	   can	   be	   observed,	   which	   profoundly	  restricts	   a	   detailed	   mechanistic	   understanding	   of	   molecular	   interactions	   between	  amino	  acid	  side	  chains	  of	   the	  nascent	  ErmBL	  peptide	  with	   individual	  nucleotides	  of	  the	   tunnel	   wall	   and	   the	   tunnel-­‐bound	   macrolide.	   Based	   on	   this	   relatively	   low-­‐resolution	   structure,	   we	   suggested	   that	   ErmBL	   stabilizes	   the	   PTC	   in	   an	   uninduced	  conformation,	   which	   prevents	   A-­‐site	   tRNA	   accommodation	   and	   therefore	   peptide	  bond	  formation.	  In	  order	  to	  deepen	  our	  insight	  into	  the	  mechanism	  of	  ErmBL-­‐stalling,	  we	   subjected	   the	  ErmBL-­‐SRC	   to	   state-­‐of-­‐the-­‐art	   cryo-­‐EM	  and	   received	  high	  quality,	  Cs-­‐corrected	  images	  acquired	  by	  a	  direct	  electron	  detection	  camera.	  Two	  maps	  of	  the	  ErmBL-­‐SRC,	  in	  presence	  and	  absence	  of	  A-­‐site	  tRNA,	  were	  reconstructed	  and	  resolved	  to	  3.1-­‐3.6	  Å.	  At	  this	  resolution,	  most	  amino	  acid	  side	  chains	  are	  resolved,	  density	  for	  bases	   of	   rRNA	   is	   separated,	   and	   even	   the	   lysine	   amino	   acid	   attached	   to	   the	   A-­‐site	  tRNA	  is	  visible.	  The	  drastically	  improved	  resolution	  of	  the	  ErmBL-­‐SRC	  maps	  allowed	  us	  to	  build	  a	  molecular	  model	  for	  ErmBL-­‐SRC	  and	  to	  provide	  detailed	  insight	  into	  the	  complex	  interplay	  between	  nascent	  chain,	  drug	  and	  the	  ribosome	  to	  inactive	  the	  PTC.	  According	   to	   our	  previous	   observation,	   the	  path	  of	   ErmBL	  adopts	   the	   same	  unique	  conformation	   within	   the	   tunnel,	   which	   allows	   the	   nascent	   chain	   to	   bypass	  erythromycin	   without	   contacting	   it.	   The	   high	   resolution	   of	   the	   map	   enabled	   us	   to	  identify	   in	   total	   nine	   hydrogen	   bonds	   between	   the	   C-­‐terminal	   residues	   R7,	   N8	   and	  D10	  of	  ErmBL	  with	  the	  ribosome	  exit	  tunnel,	  while	  the	  N-­‐terminal	  three	  residues	  of	  ErmBL	  are	  flexible	  and	  disordered.	  Notably,	   the	  positively	  charged	  side	  chain	  of	  the	  critical	   ErmBL	   residue	   R7	   is	   well	   resolved	   and	   is	   stabilized	   within	   a	   negatively	  charged	   rRNA	   pocket	   formed	   by	   23S	   rRNA	   nucleotides	   A2063,	   A2441,	   A2439	   and	  U2586.	  Strikingly,	  we	  observed	  that	  the	  side	  chain	  of	  D10,	  which	  is	  esterified	  to	  the	  P-­‐
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4.1 Interaction	  of	  Protein	  S1	  with	  the	  Escherichia	  coli	  Ribosome	  The	   six-­‐domain	   ribosomal	   protein	   S1	   is	   able	   to	   unwind	   model	   RNA	   duplexes	   and	  secondary	  structures	  in	  the	  absence	  of	  ribosomes	  (Bear	  et	  al.,	  1976;	  Kolb	  et	  al.,	  1977;	  Qu	  et	  al.,	  2012;	  Rajkowitsch	  and	  Schroeder,	  2007;	  Studer	  and	  Joseph,	  2006;	  Thomas	  et	  al.,	  1978),	  as	  well	  as	  to	  unfold	  mRNA	  secondary	  structures	  on	  the	  ribosome	  (Duval	  et	   al.,	   2013).	   S1	   is	   known	   to	   be	   intrinsically	   very	   flexible	   (Chu	   and	   Cantor,	   1979;	  Moore	  and	  Laughrea,	  1979),	  which	  made	  structural	  analysis	  of	  the	  full-­‐length	  protein	  bound	  to	  the	  ribosome	  impossible.	  We	  provide	  evidence	  that	  the	  N-­‐terminal	  segment	  of	  S1	  folds	  partially	  into	  a	  α-­‐helix	  upon	  binding	  to	  S2,	  which	  is	  crucial	  to	  anchor	  S1	  on	  the	   ribosome.	   In	   contradiction	   to	  previous	   studies	   suggesting	   that	  D1	  and	  D2	  of	   S1	  have	  no	  RNA-­‐binding	  ability	  (Subramanian,	  1983),	  we	  observe	  interaction	  of	  D1	  with	  the	   3’-­‐end	   of	   ribosomal	   16S	   rRNA	   and	   mRNA,	   possibly	   contributing	   to	   the	  stabilization	  of	  S1	  on	  the	  ribosome.	  However,	  due	  to	  the	   low	  resolution	  of	  the	  cryo-­‐EM	  map,	   a	  detailed	  account	   for	   the	   residues	   involved	   in	   these	   interactions	   remains	  elusive.	   Furthermore,	   we	   observe	   additional	   electron	   density	   extending	   from	   S1D1,	  which	  would	  fit	  in	  dimension	  to	  the	  size	  of	  the	  second	  domain	  D2	  of	  S1.	  Interestingly,	  this	  density	  is	  directly	  placed	  at	  the	  entrance	  of	  the	  mRNA	  channel	  and	  the	  fusion	  of	  density	  strongly	  suggests	   interactions	  between	  S1D2	  with	  both	  16S	  rRNA	  and	  the	  5’-­‐end	   of	   mRNA.	   The	   strong	   interactions	   between	   S1D1	   and	   S1D2	   with	   the	   ribosome	  confirm	  previous	  studies	  showing	  that	  D1	  and	  D2	  of	  S1	  provide	  the	  boundary	  to	  the	  ribosome	  (Subramanian,	  1983).	  Confirming	  our	  placement	  of	  D1	  and	  D2,	  a	   recently	  published	  cryo-­‐EM	  structure	  of	  a	  SecM-­‐stalled	  ribosome	  showed	  density	  attributable	  to	  S1D1	  and	  S1D2	   in	   the	  same	  position	  compared	  to	  our	  structure	  (Park	  et	  al.,	  2013).	  However,	   a	   third	  density	   similar	   in	   size	   and	   shape	   connected	   to	  density	   for	   S1D2	   is	  visible	   and	   might	   represent	   S1D3,	   indicating	   that	   S1D3	   could	   be	   more	   stabilized	  compared	  to	  D4-­‐D6	  of	  S1,	  which	  agrees	  with	  a	  more	  recent	  study	  showing	  that	  D1-­‐D3	  of	   S1	   are	   needed	   to	   retain	   full	   30S	   binding	   activity	   of	   S1	   (Duval	   et	   al.,	   2013).	   The	  flexibility	   of	  D3-­‐D6	  of	   S1	   (Boni	   et	   al.,	   1991;	   Subramanian,	   1983)	  might	   allow	   S1	   to	  recruit	   specific	  mRNAs	   to	   the	   ribosome	  at	   the	   initiation	   step.	  Beside	   the	  possibility	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that	   S1	   interacts	   with	   mRNAs	   on	   the	   ribosome,	   it	   was	   also	   shown	   that	   in	   some	  situations	  S1	  interacts	  with	  mRNAs	  in	  the	  absence	  of	  ribosomes	  (Qu	  et	  al.,	  2012)	  and	  facilitates	  mRNA	  delivery	  to	  the	  ribosome	  (Duval	  et	  al.,	  2013).	  	  According	  to	  our	  crystal	  structure,	  residue	  K43	  of	  S1	  interacts	  directly	  with	  D188	  of	  S2,	  which	  contributes	  to	  the	  coordination	  of	  the	  Zn2+	  ion	  residing	  in	  the	  Zn2+	  binding	  pocket	  of	  S2.	  It	  is	  tempting	  to	  speculate	  that	  the	  S1-­‐S2	  interaction	  can	  be	  regulated	  by	  the	  presence	  or	   absence	  of	  Zn2+.	   In	   this	   regard,	   the	   intracellular	  Zn2+	   concentration	  might	   modulate	   ribosome	   specificity	   to	   translate	   leaderless	   mRNAs	   (lmRNAs)	   and	  thus	  change	  the	  entire	  translatome.	  It	  seems	  likely	  that	  depending	  on	  the	  intracellular	  Zn2+	   concentration,	   S1	   containing	   and	   S1-­‐deficient	   ribosomes	   are	   simultaneously	  present	   in	   the	  cell.	  This	  would	  contribute	   to	  ribosome	  heterogeneity,	  which	  may	  be	  important	   for	   bacteria	   to	   quickly	   and	   efficiently	   adapt	   to	   changing	   environmental	  conditions.	  For	  example	  during	  stress	  conditions	  in	  E.	  coli,	  the	  toxin	  MazF	  is	  activated	  and	  cleaves	  specific	  mRNAs	  at	  their	  5’-­‐end	  to	  generate	  lmRNAs	  (Vesper	  et	  al.,	  2011).	  Therefore	   it	   seems	   logical	   that	   bacteria	   down-­‐regulate	   the	   association	   of	   S1	   to	   the	  ribosome	   at	   increasing	   concentrations	   of	   lmRNAs	   to	   ensure	   their	   predominant	  translation.	  In	  fact,	  free	  S1	  accumulates	  during	  stationary	  growth	  phase	  (Ramagopal,	  1976).	   It	   seems	   likely	   that	   S1	   binding	   to	   the	   ribosome	   can	   be	   regulated	   by	  posttranslational	   modifications.	   Accordingly,	   the	   acetylation	   pattern	   of	   some	  ribosomal	  proteins	  including	  S1	  and	  S2	  changes	  in	  stationary	  growth	  phase	  (Yu	  et	  al.,	  2008).	  Furthermore	  it	  was	  shown,	  that	  residues	  T2	  and	  S44	  of	  S1	  are	  phosphorylated	  during	  growth	  in	  minimal	  medium	  in	  the	  late	  stationary	  phase	  (Soares	  et	  al.,	  2013),	  which	  potentially	   interferes	  with	   S1	   binding	   to	   S2.	  Detailed	   biochemical	   analysis	   is	  required	  to	  elucidate	  whether	  modifications	  of	  the	  N-­‐terminal	  segment	  of	  S1	  indeed	  generates	  ribosome	  heterogeneity	   for	   fine-­‐tuning	  protein	  synthesis.	  Generation	  of	  a	  high-­‐resolution	   structure	   of	   the	   first	   domains	   of	   S1	   bound	   to	   the	   ribosome,	   for	  example,	   by	   using	   direct	   electron	   detector-­‐derived	   high-­‐quality	   cryo-­‐EM	   images,	  would	  certainly	  expand	  out	  current	  understanding	  of	  the	  molecular	  interactions	  of	  S1	  with	  the	  16S	  rRNA,	  mRNA	  as	  well	  as	  other	  ribosomal	  proteins	  besides	  S2.	  However,	  due	  to	  the	  flexibility	  of	  S1,	  higher	  resolution	  might	  be	  limited	  to	  D1	  and	  possibly	  D2.	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4.2 Proline-­‐rich	  antimicrobial	  peptides	  Our	  studies	  show	  that	  the	  proline-­‐rich	  antimicrobial	  peptide	  Onc112	  binds	  within	  the	  ribosome	  exit	  tunnel	  and	  sterically	  prevents	  accommodation	  of	  tRNAs	  into	  the	  A-­‐site	  of	   the	   PTC	   and	   thereby	   inhibit	   translation.	   Additionally,	   we	   provide	   biochemical	  evidence	   that	   Onc112	   inhibits	   translation	   at	   the	   step	   after	   70S	   initiation	   complex	  formation.	  Toe-­‐printing	  assays	  were	  used	  to	  monitor	  the	  position	  of	  the	  ribosome	  on	  the	  mRNA	  and	  showed	  that	  all	  ribosomes	  are	  positioned	  with	  the	  AUG	  start	  codon	  in	  the	  P-­‐site,	  indicative	  for	  initiating	  ribosome	  unable	  to	  enter	  the	  elongation	  phase.	  We	  suggest	  that	  Onc112	  binding	  to	  the	  ribosome	  destabilizes	  the	  70S	  initiation	  complex	  by	  interfering	  with	  fMet-­‐tRNAfMet	  binding	  to	  the	  ribosomal	  P-­‐site,	  which	  might	  lead	  to	  P-­‐site	  tRNA	  destabilization	  and	  subsequent	  dissociation	  from	  the	  ribosome.	  However,	  due	  to	  the	  high	  pH	  required	  for	  crystallization	  of	  ribosomes,	   the	   initiator	  tRNA	  gets	  hydrolyzed	   during	   crystallization,	   which	   prevents	   structural	   analysis	   of	   the	  interfering	   interplay	   between	   the	   formyl-­‐methionine	   residue	   and	  Onc112.	   It	   seems	  possible	  that	  the	  binding	  position	  of	  Onc112	  to	  ribosomes	  containing	  fMet-­‐tRNAfMet	  in	  the	   P-­‐site	   deviates	   from	   the	   binding	   position	   observed	   in	   our	   structure	   bearing	  deacylated	   tRNAfMet	   in	   the	   P-­‐site.	   However,	   due	   to	   the	   instability	   of	   the	   complex,	  simultaneous	  presence	  of	   fMet-­‐tRNAfMet	   and	  Onc112	  appears	   rather	  unlikely,	  which	  makes	   structural	   analysis	   of	   the	   complex	   by	   other	   techniques,	   such	   as	   cryo-­‐EM,	  challenging.	  We	  further	  suggest	  that	  positively	  charged	  residues	  within	  the	  full-­‐length	  Onc112,	  particularly	  the	  C-­‐terminus,	  are	  necessary	  for	  SbmA-­‐mediated	  import	  across	  the	   inner	   membrane	   of	   Gram-­‐negative	   pathogens.	   However	   it	   remains	   unclear	   by	  which	  mechanism	  Onc112	  gets	  imported	  into	  the	  periplasmic	  space.	  Since	  diffusion	  of	  the	   polar	   Onc112	   through	   the	   lipid-­‐bilayer	   of	   the	   outer	   membrane	   should	   be	  impossible,	   certain	   outer	   membrane	   pores	   could	   facilitate	   Onc112	   import,	   yet,	  genomic	  screens	  for	  resistance	  mutations	  exclusively	  identified	  SbmA	  as	  being	  critical	  for	   PrAMP	   import	   (Mattiuzzo	   et	   al.,	   2007).	   Crystal	   structures	   of	   other	   PrAMPs	   like	  drosocin,	   pyrrhocoricin	   and	   apidaecin	   bound	   to	   the	   ribosome	   are	   necessary	   to	  investigate	   whether	   all	   ribosome-­‐targeting	   PrAMPs	   share	   the	   same	   binding	   site	  within	   the	   ribosome	   exit	   tunnel,	   which	   seems	   likely	   due	   to	   their	   high	   sequence	  similarity.	  The	  23S	   rRNA	  nucleotides	   comprising	   the	  PrAMP	  binding	   site	   are	  highly	  conserved,	   suggesting	   that	   eukaryotic	   ribosomes	   might	   be	   a	   target	   for	   Onc112	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binding,	  as	  well.	  Yet,	  Onc112	  exhibits	  a	  low	  toxicity	  to	  eukaryotic	  cells,	  possibly	  due	  to	   the	   absence	   of	   the	   transporter	   SbmA,	   responsible	   for	   uptake	   in	   bacteria.	   The	  binding	   site	   for	   Onc112	   overlaps	   with	   the	   binding	   site	   for	   other	   50S-­‐targeting	  antibiotics,	   like	   chloramphenicol,	   pleuromutilins,	   lincosamides	   and	   macrolides,	  therefore	  resistance	  mutations	   for	  antibiotics	   like	  chloramphenicol	  or	  erythromycin	  could	   confer	   cross-­‐resistance	   to	  PrAMPs.	  But	  due	   to	   the	  extended	  binding	   interface	  between	  Onc112	  and	   several	   nucleotides	  of	   the	  23S	   rRNA,	   it	   seems	   rather	  unlikely	  that	   single	   rRNA	   mutations	   could	   confer	   resistance	   to	   Onc112.	   Structural	   and	  biochemical	   analysis	   of	   critical	   residues	   in	   these	   PrAMPs	   would	   expand	   our	  understanding	   about	   the	   molecular	   mechanism	   of	   ribosome	   binding	   and	   cellular	  import,	   which	  might	   enable	   the	   development	   of	   second-­‐generation	   PrAMPs,	   which	  could	  overcome	  cross-­‐resistances	  and	  exhibit	   improved	  pharmacokinetic	  properties	  as	  well	  as	  reduced	  toxicity	  for	  application	  in	  clinical	  practice.	  	  	  
4.3 TetM-­‐mediated	  Tetracycline	  Resistance	  	  Our	  structure	  of	  TetM-­‐bound	  RNCs	  revealed	  that	  P509	  located	  at	  the	  tip	  of	  loop	  III	  in	  domain	   IV	   overlaps	   in	   position	   with	   ring	   D	   of	   tetracycline	   and	   thereby	   dislodges	  tetracycline	   from	   the	   ribosome	   to	   confer	   resistance.	   It	   would	   be	   interesting	   to	  supplement	   the	   complex	   with	   tetracycline	   in	   order	   to	   structurally	   investigate	  whether	   TetM	   and	   tetracycline	   can	   be	   bound	   simultaneously	   to	   the	   ribosome.	  However,	   biochemical	   evidence	   suggests	   that	   TetM	   removes	   tetracycline	   upon	  binding	  to	  the	  ribosome,	  since	  GTP-­‐hydrolysis	  is	  not	  strictly	  required	  for	  drug-­‐release	  (Burdett,	  1996;	  Trieber	  et	  al.,	  1998).	  Due	  to	  the	  inability	  of	  TetM	  to	  confer	  resistance	  to	  third-­‐generation	  tetracyclines	  like	  tigecycline	  (Bergeron	  et	  al.,	  1996;	  Chopra,	  2002;	  Grossman	  et	  al.,	  2012;	   Jenner	  et	  al.,	  2013),	   the	  use	  of	   tigecycline	   seems	  much	  more	  likely	  to	  capture	  a	  state	  where	  TetM	  and	  the	  drug	  are	  simultaneously	  bound	  on	  the	  ribosome.	   Importantly,	   biochemical	   evidence	   that	   TetM	   fails	   to	   dislodge	   tigecycline	  from	   the	   ribosome	   is	   still	   lacking.	   Notably,	   in	   the	   previous	   reconstruction	   of	   the	  TetM!70S	  complex,	  the	  binding	  reaction	  was	  performed	  in	  the	  additional	  presence	  of	  tigecycline.	  Despite	  the	  low	  resolution	  of	  the	  map,	  it	  could	  be	  concluded	  that	  presence	  of	  TetM	  and	  tigecycline	  are	  mutually	  exclusive	  (Dönhöfer	  et	  al.,	  2012),	  possibly	  due	  to	  the	  ability	  of	  TetM	  to	  remove	  tigecycline	  from	  the	  ribosome.	  Since	  it	  is	  proposed	  that	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TetM	   prevents	   rebinding	   of	   tetracycline	   by	   inducing	   conformational	   changes	   of	  nucleotides	  comprising	  the	  drug	  binding	  site	  (such	  as	  C1054)	  that	  persist	  after	  TetM	  dissociation	   (Connell	   et	   al.,	   2003a;	   Connell	   et	   al.,	   2003d;	   Connell	   et	   al.,	   2002;	  Dönhöfer	   et	   al.,	   2012),	   it	  might	   be	   also	   possible	   that	   these	   conformational	   changes	  selectively	  prevent	  rebinding	  of	  tetracycline.	  Tigecycline	  rebinding	  may	  however	  still	  be	  possible	  due	  to	  its	  higher	  affinity	  compared	  to	  tetracycline.	  Within	  the	  limits	  of	  the	  resolution	   of	   our	  map,	   TetM	   does	   not	   appear	   to	   induce	   conformational	   changes	   in	  C1054,	   but	   it	   is	   possible	   that	   such	   conformational	   rearrangements	   occur	   after	   GTP	  hydrolysis	  and	  upon	  TetM	  dissociation	  from	  the	  ribosome.	  It	  is	  also	  possible	  that	  by	  stabilizing	  A1492	  and	  A1493	  of	  the	  decoding	  center	  in	  the	  flipped-­‐out	  conformation,	  TetM	  action	  promotes	  ternary	  complex	  binding	  similar	  to	  the	  action	  of	  the	  antibiotic	  paromomycin,	   before	   tetracycline	   rebinding	   occurs.	   Collectively,	   it	   remains	   unclear	  whether	   tigecycline	   overcomes	   TetM	   action	   by	   persisting	   on	   the	   ribosome,	   or	   by	  selectively	  rebinding	  to	  a	  deformed	  binding	  site.	  Mutagenesis	  studies	  of	  TetM	  might	  identify	   a	   mutant	   TetM,	   which	   also	   confers	   resistance	   to	   third-­‐generation	  tetracyclines,	  such	  as	  tigecycline.	  At	  a	  resolution	  between	  3.5-­‐4.5	  Å,	  many	  side	  chains	  of	  TetM	  residues	  are	  not	  visible,	  which	  only	  allowed	  us	  to	  build	  a	  backbone	  model	  for	  TetM.	   One	   open	   question	   that	   remains	   addresses	   the	   conformational	   state	   of	   the	  GTPase	  center	  of	  TetM.	  It	  seems	  highly	  likely	  that	  the	  conformation	  is	  very	  similar	  to	  EF-­‐Tu	  and	  EF-­‐G,	  however	  while	  TetM	  displays	  higher	  sequence	  similarity	  to	  EF-­‐G,	  the	  conformational	  state	  on	  the	  ribosome	  resembles	  closer	  EF-­‐Tu	  since	  ET-­‐Fu	  also	  binds	  a	   non-­‐ratcheted	   ribosome.	   Therefore,	   differences	   regarding	   the	   position	   of	   the	  catalytic	  histidine	  and	  its	  interaction	  with	  the	  GTP	  binding	  pocket	  might	  exist.	  Despite	  the	  observation	  that	  our	  structure	  exhibits	  density	  for	  the	  nucleotide	  GTP,	  the	  precise	  interactions	  within	  its	  binding	  site	  remain	  elusive	  due	  to	  the	  limiting	  resolution	  of	  the	  map.	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4.4 Macrolide-­‐dependent	  Ribosome	  Stalling	  Our	   publications	   demonstrate	   that	   the	   amino	   acid	   sequence	   of	   a	   nascent	   peptide	  directly	   determines	   its	   conformation	   and	   the	   path	   it	   follows	   through	   the	  erythromycin-­‐bound	   ribosome	   exit	   tunnel.	   Following	   a	   defined	   path	   is	   favored	   by	  intimate	   interactions	   between	   the	   nascent	   chain	   and	   either	   components	   of	   the	   exit	  tunnel	   or	   erythromycin	   or	   both.	   The	   placement	   of	   the	   nascent	   chain	   within	   the	  tunnel,	   together	   with	   its	   specific	   interactions	   generates	   a	   stalling	   signal,	   which	   is	  communicated	  to	  PTC	  to	  arrest	   translation	  by	   inhibition	  of	  peptide	  bond	  formation.	  Interestingly,	   our	   studies	   show	   that	   the	   stalling	   signal	   can	   be	   diverse	   and	   strongly	  depends	  on	  the	  amino	  acid	  sequence	  of	  the	  nascent	  chain.	  Remarkably,	  translation	  of	  both	  ErmBL	  and	  ErmCL	  leads	  to	  inhibition	  of	  peptide	  bond	  formation	  at	  the	  stall-­‐site,	  but	   the	   mechanism	   of	   PTC	   inactivation	   differs	   fundamentally.	   While	   the	   ErmBL	  nascent	   chain	   generates	   a	   stalling	   signal	   that	   leads	   to	   perturbation	   of	   the	  P-­‐site	   by	  shifting	  the	  A76	  ribose	  of	   the	  P-­‐site	  tRNA,	  the	  stalling	  signal	  generated	  by	  ErmCL	  is	  communicated	  to	  the	  A-­‐site,	  where	  U2585	  rotates	  by	  180°	  and	  A2602	  together	  with	  the	  P-­‐site	  tRNA	  shifts	  in	  position,	  thereby	  globally	  deforming	  the	  A-­‐site	  to	  prevent	  A-­‐site	  tRNA	  accommodation	  and	  thereby	  peptide	  bond	  formation.	  Within	  the	  following	  sections,	  individual	  features	  of	  drug-­‐stalled	  ribosomes,	  like	  the	  (i)	  path	  of	  the	  nascent	  chain,	   (ii)	   contacts	   within	   the	   ribosomal	   tunnel,	   (iii)	   drug-­‐specificity,	   (iv)	  conformation	  of	  the	  PTC	  and	  (v)	  A-­‐site	  specificity,	  are	  comparatively	  discussed.	  	  
Paths	   of	   nascent	   chains.	  The	   initial	  map	  of	   the	  ErmBL-­‐SRC	  was	  resolved	  to	  4.5	   Å	   in	   the	   ribosomal	   core.	   At	   this	   resolution,	   the	   cryo-­‐EM	   density	   of	   the	   ErmBL	  nascent	  polypeptide	  was	  fragmented	  and	  appears	  as	  a	  thin	  tube,	  without	  hints	  for	  the	  positions	  of	  amino	  acid	  side	  chains.	  Therefore,	  interactions	  could	  only	  be	  interpreted	  based	  on	   fusion	  of	  density	   indicating	  proximity	  between	  regions	  within	   the	  nascent	  chain	   and	   regions	   within	   the	   ribosomal	   tunnel.	   The	   absence	   of	   fusion	   of	   density	  between	  ErmBL	  and	  the	  C3’-­‐cladinose	  sugar	  of	  erythromycin	  suggested	  that	  ErmBL	  does	   not	   contact	   the	   drug,	   however,	   it	   could	   not	   be	   excluded	   that	   a	   side	   chain	   of	  ErmBL	   is	   involved	   in	   interacting	   with	   erythromycin.	   In	   contrast,	   the	   recent	   high-­‐resolution	  reconstruction	  of	  the	  ErmBL-­‐SRC	  at	  3.1	  Å	  in	  the	  ribosomal	  core	  allowed	  a	  precise	   atomic	  model	   for	   ErmBL	   including	   side	   chains	   to	   be	   built.	   Remarkably,	   the	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overall	  path	  based	  on	  the	  low-­‐resolution	  map	  is	  nearly	  identical	  to	  the	  path	  at	  higher	  resolution,	   indicating	   that	   the	   rough	   placement	   of	   the	   ErmBL	   nascent	   chain	   in	   the	  low-­‐resolution	  map	  was	  valid	  and	  reliable.	  According	  to	  the	  initial	  reconstruction,	  the	  high-­‐resolution	   map	   does	   not	   indicate	   direct	   contact	   between	   ErmBL	   and	  erythromycin,	  but	  it	  should	  be	  noted,	  that	  the	  side	  chain	  for	  residue	  N8	  is	  not	  visible	  in	  the	  recent	  structure.	  Most	  favored	  rotamers	  of	  N8	  would	  sterically	  clash	  with	  the	  desosamine	   sugar	  of	   erythromycin	  possibly	   forcing	  N8	   to	   adopt	  multiple	  other	   less	  defined	  states,	  explaining	  the	  absence	  of	  density.	  Most	  importantly,	  N8	  does	  not	  play	  an	  important	  role	  in	  stalling	  since	  it	  can	  be	  mutated	  to	  A	  without	  affecting	  the	  stalling	  efficiency	  (Arenz	  et	  al.,	  2014b),	  thus	  making	  the	  absence	  of	  density	  for	  the	  side	  chain	  negligible.	  The	  high-­‐resolution	  structure	  unambiguously	  shows	  that	  the	  side	  chain	  of	  D10	  is	  rotated	  by	  180°	  when	  compared	  with	  the	  side	  chain	  positions	  observed	  in	  all	  other	   available	   structures	   of	   ribosomes	   bearing	   an	   acylated	   P-­‐site	   tRNA.	   It	   seems	  possible	  that	  the	  rotation	  around	  D10	  directs	  the	  path	  of	  ErmBL	  away	  from	  the	  drug,	  but	   it	   is	   entirely	   unclear	   what	   causes	   the	   rotation	   and	   when	   it	   occurs	   during	  translation.	   The	   observation	   that	   the	   C-­‐terminal	   Asp	   amino	   acid	   in	   the	   MifM-­‐SRC	  adopts	  the	  canonical	  position	  (Sohmen	  et	  al.,	  2015)	  suggests	  that	  the	  rotation	  of	  D10	  in	   ErmBL	   is	   initiated	   by	   the	   presence	   of	   erythromycin,	   which	   forces	   ErmBL	   into	   a	  specific	  conformation,	  culminating	  in	  the	  rotation	  of	  D10.	  If	  the	  rotation	  is	  caused	  by	  the	   interplay	   between	   drug	   and	   peptide,	   the	   question	   remains	  whether	   D10	   is	   the	  first	   amino	   acid	   to	   rotate,	   or	   whether	   the	   preceding	   amino	   acids	   V9,	   N8,	   R7	   were	  rotated,	  too?	  To	  speculatively	  answer	  this	  question,	  it	  seems	  more	  likely	  that	  D10	  is	  the	  first	  amino	  acid	  to	  rotate	  and	  that	  this	  rotation	  directly	   leads	  to	  perturbation	  of	  the	   P-­‐site	   A76	   ribose	   and	   therefore	   to	   inactivation	   of	   the	   PTC.	   To	   address	   this	  question	  experimentally,	  translation	  of	  ErmBL	  could	  be	  artificially	  stopped	  at	  various	  steps	   preceding	   the	   stall-­‐site	   and	   each	   complex	   could	   be	   subjected	   to	   cryo-­‐EM	   to	  obtain	   a	   pseudo	   time-­‐resolved	   structural	   view	   on	   translation	   of	   the	   ErmBL	   leader	  peptide.	  Compared	   to	   ErmBL,	   the	   ErmCL	   nascent	   peptide	  was	   resolved	   to	   3.5	   Å	   and	  follows	   a	   fundamentally	   different	   path	   through	   the	   ribosomal	   exit	   tunnel,	   directly	  contacting	   the	   C3’-­‐cladinose	   of	   erythromycin	   and	   overlapping	   with	   the	   canonical	  position	  of	  U2585.	  At	  this	  resolution,	  bulky	  side	  chains	  can	  be	  seen,	  for	  example,	  the	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position	   of	   the	   critical	   F7	   is	   unambiguous.	   In	   contrast,	   side	   chains	   of	   the	   critical	  surrounding	  hydrophobic	  amino	  acids	  I9,	  V8	  and	  I6	  are	  barely	  visible.	  Due	  to	  the	  lack	  of	  resolution,	  atomic	  details	  on	  the	  interaction	  between	  the	  ErmCL	  backbone	  and	  the	  C3’-­‐cladinose	  of	  erythromycin	  remain	  elusive.	  It	  should	  be	  noted	  that	  the	  N-­‐terminal	  1-­‐3	   amino	   acids	   of	   both	   ErmBL	   and	   ErmCL	   appear	   to	   be	   disordered,	   however,	  biochemical	  evidence	  suggests	  that	  they	  play	  an	  important	  role	  in	  stalling,	  possibly	  a	  steric	   role,	   since	   N-­‐terminal	   truncation	   mutants	   fail	   to	   induce	   stalling	   (Vazquez-­‐Laslop	  et	  al.,	  2008).	  It	  remains	  unclear,	  how	  erythromycin	  contributes	  to	  the	  path	  of	  the	  nascent	  peptides,	  but	  presumably	  by	  narrowing	  down	  the	  diameter	  of	  the	  tunnel,	  the	   conformational	   space	   for	   the	   nascent	   chain	   to	   adopt	   a	   define	   conformation	   is	  limited	  and	  thereby	  the	  nascent	  chain	  is	  forced	  into	  its	  specific	  intra-­‐tunnel	  location.	  It	   would	   be	   interesting	   to	   visualize	   the	   conformation	   of	   the	   nascent	   chains	   in	   the	  absence	  of	  erythromycin,	  for	  example,	  by	  stalling	  the	  ribosome	  artificially	  at	  the	  same	  position	  during	  translation	  of	  the	  leader	  peptide.	  Artificial	  stalling	  could	  be	  achieved	  via	  different	  approaches:	  The	  mRNA	  could	  be	  truncated	  after	  the	  stall-­‐site,	  but	  due	  to	  recycling	  mechanisms	   in	   lysate-­‐based	   in	   vitro	   translation	   systems,	   this	   approach	   is	  limited	   to	   the	   use	   in	   the	   expensive	   PURE	   system.	   Furthermore,	   truncation	   of	   the	  mRNA	   would	   exclude	   the	   presence	   of	   A-­‐site	   tRNA,	   which	   could	   contribute	   to	   the	  conformation	   adopted	   by	   the	   PTC.	   The	   more	   reasonable	   way	   to	   artificially	   stall	  ribosomes	  at	  a	  defined	  site	  is	  based	  on	  the	  lack	  of	  charged	  tRNAs	  decoding	  the	  A-­‐site	  codon,	  either	  by	  deprivation	  of	  the	  A-­‐site	  encoded	  amino	  acid	  from	  the	  system	  and/or	  by	   application	   of	   aminoacyl-­‐tRNA	   synthetase	   inhibitors,	   which	   specifically	   prevent	  the	  A-­‐site	  tRNA	  from	  being	  charged	  with	  the	  amino	  acid.	  	  	  
Contacts	   of	   the	  nascent	   chain.	  Contacts	  between	  the	  nascent	  chain	  and	  the	  ribosome	   and/or	   the	  macrolide	   stabilize	   the	   conformation	   and	   the	   path	   of	   nascent	  polypeptides	   within	   the	   ribosome	   exit	   tunnel.	   Based	   on	   the	   low-­‐resolution	  reconstruction	   of	   the	   ErmBL-­‐SRC,	   a	   number	   of	   contacts	   between	   ErmBL	   and	   the	  ribosome	  could	  be	  identified,	  at	  least	  within	  the	  limits	  of	  the	  resolution.	  Although	  the	  identity	   of	   the	   interacting	   residues	   remained	   ambiguous,	  we	   proposed	   interactions	  between	  D10/V9	  of	  ErmBL	  with	  U2585,	  R7	  with	  U2586	  and	  an	  interaction	  between	  F4	   and	   U2609.	   Strikingly,	   we	   confirmed	   these	   interactions	   in	   the	   high-­‐resolution	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reconstruction	   and	   were	   further	   able	   to	   more	   precisely	   map	   the	   atomic	   regions	  involved	   in	  these	   interactions.	  Based	  on	  our	   initial	  publication	  showing	  a	   functional	  interaction	   between	   U2586	   and	   R7,	   we	   assumed	   that	   the	   side	   chain	   of	   R7	   might	  interact	   directly	   with	   the	   base	   of	   U2586,	   probably	   via	   stacking	   interaction.	   In	  contrast,	  we	  observe	  that	  the	  positively	  charged	  side	  chain	  of	  R7	  appears	  to	  interact	  with	   the	   sequence-­‐independent	   ribose	   2’-­‐OH	   of	   U2586,	   which	   contributes	   to	   a	  negatively	   charged	   pocket	   stabilizing	   the	   side	   chain	   of	   R7.	   Yet,	   the	   backbone	   of	   R7	  potentially	  hydrogen	  bonds	  with	  the	  nucleobase	  of	  U2586,	  which	  might	  be	  disrupted	  by	  conformational	  changes	  upon	  mutation	  of	  R7	  to	  alanine.	  Therefore	  we	  assume	  that	  secondary	  mutations	  of	  U2586,	  which	  rescue	  the	  stalling	  deficiency	  of	  the	  ErmBL	  R7A	  mutant,	  establish	  new	   interactions	  with	   the	  ErmBL	  backbone	  and	   thus	  stabilize	   the	  nascent	  chain	  in	  a	  conformation	  that	  enables	  the	  stalling	  signal	  to	  be	  communicated	  to	   the	   PTC	   to	   arrest	   translation.	   A	  major	   difference	   between	   ErmBL	   and	   ErmCL	   is	  their	   dependency	   on	   the	   23S	   rRNA	   nucleotides	   A2062	   and	   A2503.	   While,	   ErmCL	  stalling	   is	   strongly	   reduced	   in	   presence	   of	   A2062U	   or	   A2503G	   mutations,	   stalling	  during	  translation	  of	  ErmBL	  remains	  unaffected	  (Ramu	  et	  al.,	  2009).	  Accordingly,	  our	  structures	   show	   that	   A2062	   adopts	   a	   very	   different	   orientation	   in	   ErmCL-­‐SRC	  compared	   to	   ErmBL-­‐SRC,	   while	   the	   position	   of	   A2503	   is	   unchanged	   in	   both	  structures.	  Direct	   interaction	  between	  ErmCL	  and	  A2062	   is	  observed,	  while	  ErmBL	  does	   not	   interact	  with	   A2062,	   explaining	  why	   stalling	   on	   ErmBL	   is	   not	   affected	   by	  mutation	  of	  A2062.	  ErmCL	  stabilizes	  A2062	  in	  a	  conformation	  enabling	  N7	  of	  A2062	  to	  interact	  with	  the	  exocyclic	  amino	  group	  A2503,	  suggesting	  that	  the	  N-­‐terminus	  of	  ErmCL	   may	   play	   a	   steric	   role	   to	   induce	   the	   previously	   noted	   interaction	   between	  A2062	   and	   A2503	   (Vazquez-­‐Laslop	   et	   al.,	   2010).	   However,	  within	   the	   limits	   of	   the	  resolution,	   we	   do	   not	   see	   conformational	   changes	   defining	   previously	   proposed	  relays	  from	  A2062/A2503	  back	  up	  to	  the	  PTC	  (Vazquez-­‐Laslop	  et	  al.,	  2010).	  Thereby,	  we	   suggest	   that	   A2062/A2503	   affect	   the	   conformational	   state	   of	   the	   PTC	   via	   the	  ErmCL	  nascent	  chain.	  	  
Drug-­‐specificity.	  Toe-­‐printing	  experiments	  show	  that	  the	  C3’-­‐cladinose	  sugar	  of	  erythromycin	   is	  crucial	   to	  arrest	   translation	  on	  ErmCL	  since	  the	  absence	  or	  even	  small	  alterations	  of	  the	  cladinose	  sugar,	  abolish	  stalling	  (Vazquez-­‐Laslop	  et	  al.,	  2011).	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In	   contrast,	   we	   show	   that	   ribosome	   stalling	   during	   translation	   of	   ErmBL	   is	   also	  inducible	   by	   ketolides	   like	   telithromycin,	   which	   lack	   the	   C3’-­‐cladinose	  moiety.	   The	  differential	  drug-­‐specificity	  of	   the	   two	  peptides	   is	  probably	  due	   to	   their	  differential	  behavior	   in	  sensing	  the	  tunnel-­‐bound	  drug.	  While	  ErmCL	  directly	   interacts	  with	  the	  cladinose,	   ErmBL	   follows	   a	   path	   distant	   from	   the	   cladinose	   preventing	   direct	  interaction.	  	  It	   would	   be	   interesting	   to	   investigate	   whether	   mutations	   introduced	   in	   the	   leader	  peptides	  are	  able	   to	  modulate	   their	  drug-­‐specificity.	   It	   is	   tempting	   to	  speculate	   that	  mutagenesis	  of	  D10	  in	  ErmBL	  to	  a	  bulky	  amino	  acid	   like	  tyrosine	  would	  prevent	   its	  unusual	  rotation	  due	  to	  steric	  hindrance	  of	   the	  bulky	  side	  chain	  with	   the	  ribosomal	  tunnel.	  Thereby,	  the	  path	  of	  the	  ErmBL	  nascent	  chain	  would	  be	  changed	  and	  directed	  closer	   to	   the	   cladinose,	   which	   might	   become	   crucial	   for	   stalling	   to	   occur.	  Furthermore,	   a	   structure	  of	   ErmBL-­‐SRC	   in	   the	  presence	  of	   telithromycin	   instead	  of	  erythromycin	   would	   address	   questions	   whether	   ErmBL	   follows	   the	   same	   path	  through	   a	   ketolide-­‐bound	   exit	   tunnel	   and	  whether	   the	   interaction	   pattern	  with	   the	  ribosome,	  or	  even	  the	  mechanism	  leading	  to	  translation	  arrest,	  is	  changed.	  	  
Conformation	   of	   the	   PTC.	  According	   to	  our	   initial	  model	  based	  on	   the	   low-­‐resolution	   map	   of	   ErmBL-­‐SRC,	   the	   nascent	   chain	   stabilizes	   the	   uninduced	  conformation	  of	  the	  PTC,	  which	  is	  incompatible	  with	  tRNA	  accommodation	  at	  the	  A-­‐site.	  However,	  the	  improved	  resolution	  of	  the	  complex	  allowed	  us	  to	  more	  precisely	  assess	   the	   conformational	   state	   of	   the	   PTC	   and	   to	   revise	   our	   model	   for	   ErmBL-­‐mediated	   translation	   arrest.	   Despite	   the	   high	   resolution,	  we	   cannot	   unambiguously	  state	   that	   the	  PTC	  adopts	   a	   fully	   induced	   conformation,	   however	   the	  positioning	  of	  the	   α-­‐amino	   group	   of	   the	   aa-­‐tRNA	   in	   the	   A-­‐site	   seems	   to	   be	   sufficiently	  accommodated	   for	   nucleophilic	   attack	   onto	   the	   carbonyl	   carbon	  of	   the	  P-­‐site	   ester.	  According	  to	  the	  recent	  crystal	  structure	  of	  the	  ribosome	  captured	  in	  the	  pre-­‐peptide	  bond	   formation	   state,	   proton	   transfer	   from	   the	   attacking	   nucleophile	   to	   water	  molecule	  W1	  (coordinated	  by	  A2602	  and	  L27)	  via	  a	  proton	  wire	  formed	  by	  the	  2’-­‐OH	  of	   the	   P-­‐site	   A76	   ribose	   and	   the	   2’-­‐OH	   of	   A2451	   is	   necessary	   for	   peptide	   bond	  formation	  to	  occur	  (Polikanov	  et	  al.,	  2014b).	   In	  the	  ErmBL-­‐SRC	  we	  observe	  that	  the	  A76	  ribose	  of	   the	  P-­‐site	   tRNA	  is	  shifted	  away	  from	  the	  A-­‐site,	  possibly	  breaking	  the	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necessary	  proton	  wire	  network	  leading	  to	  inhibition	  of	  peptide	  bond	  formation.	  Since	  at	   the	   given	   resolution	   water	   molecules	   and	   protons	   are	   not	   visualized,	  interpretations	   regarding	   an	   interrupted	  proton	  wire	   remain	   speculative.	  However,	  A2602	  and	  the	  N-­‐terminus	  of	  L27	  that	  coordinate	  W1	  are	  delocalized	  in	  the	  ErmBL-­‐SRC	   structure	   and	   therefore	   W1	   cannot	   be	   coordinated,	   preventing	   initial	  deprotonation	  of	  the	  attacking	  nucleophile	  necessary	  for	  the	  catalysis	  of	  peptide	  bond	  formation.	  Furthermore,	  the	  presence	  of	  the	  aminoacylated	  tRNA	  in	  the	  A-­‐site	  and	  a	  peptidyl-­‐tRNA	  in	  the	  P-­‐site	  is	  alone	  sufficient	  to	  indicate	  that	  peptide	  bond	  formation	  has	   not	   occurred.	   X-­‐ray	   crystallographic	   structures	   of	   the	   ErmBL-­‐SRC	   for	   example	  might	  provide	  resolution	  sufficient	  to	  visualize	  single	  water	  molecules,	  however	  due	  to	  the	  basic	  pH	  necessary	  to	  crystallize	  ribosomes,	  it	  was	  so	  far	  impossible	  to	  obtain	  X-­‐ray	  structures	  of	  RNCs.	  Contrasting	  the	  mechanism	  of	  drug-­‐dependent	  stalling	  during	  translation	  of	  ErmBL,	  the	  cryo-­‐EM	  structure	  of	  ErmCL-­‐SRC	  reveals	  that	  drug-­‐dependent	  ErmCL-­‐SRC	  employ	  a	  completely	  unrelated	  mechanism	  of	  PTC	  silencing,	  namely	  via	  perturbation	  of	   the	  PTC	   active	   site.	   Thereby,	   the	   ErmCL	   nascent	   peptide	   overlaps	   in	   position	   with	  canonical	   positions	   of	   U2585,	   promoting	   an	   alternative,	   flipped	   conformation	   of	  U2585	  which	  leads	  to	  the	  loss	  of	  a	  potentially	  A-­‐site	  tRNA-­‐stabilizing	  hydrogen	  bond	  between	   the	   C4	   oxygen	   of	  U2585	   and	   the	   2’-­‐OH	  of	   the	  A-­‐site	  A76	   ribose.	   Together	  with	   shifts	   of	   A2602	   and	   the	   P-­‐site	   A76,	   ErmCL	   remodels	   the	   PTC	   making	   it	  unfavorable	   for	   tRNAs	   to	   fully	   accommodate	   at	   the	   A-­‐site	   of	   the	   PTC.	   The	   reduced	  ability	   of	   ErmCL-­‐SRC	   to	   accommodate	   tRNAs	   at	   the	   A-­‐site	   agrees	   well	   with	   the	  absence	  of	  density	  for	  A-­‐site	  tRNA	  in	  the	  cryo-­‐EM	  map	  as	  well	  as	  with	  single-­‐molecule	  FRET	  studies	  showing	  that	  ErmCL-­‐SRC	  less	  stably	  binds	  A-­‐site	  tRNA	  (Johansson	  et	  al.,	  2014).	  This	  is	  in	  contrast	  to	  our	  ErmBL-­‐SRC	  reconstructions,	  where	  stable	  binding	  of	  A-­‐site	  tRNA	  was	  observed.	  Interestingly,	  the	  overall	  conformational	  state	  of	  the	  PTC	  observed	  in	  MifM-­‐,	  TnaC-­‐,	  ErmBL-­‐	  and	  ErmCL-­‐SRC	  is	  different	  for	  all	  four	  structures.	  The	  only	  similarity	  between	  ErmCL,	  TnaC	  and	  MifM	  is	  the	  position	  of	  A2602,	  which	  appears	   to	   narrow	   down	   the	   entry	   cleft	   for	   A-­‐site	   tRNAs,	   and	   even	   prevents	  accommodation	   of	   release	   factors	   for	   MifM	   and	   TnaC.	   Notably,	   the	   flipped	  conformation	   of	   U2585	   in	   ErmCL-­‐SRC	   is	   not	   observed	   in	   any	   other	   ribosome	  structure	   solved	   to	   date.	   Therefore	   it	   seems	   likely	   that	   different	   stalling	   peptides	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induce	   unrelated	   conformational	   changes	  within	   the	  PTC,	   all	   of	  which	   culminate	   in	  PTC	  inactivation.	  	  
A-­‐site	  specificity.	  We	  show	  that	  mutation	  of	  the	  lysine	  codon	  in	  the	  A-­‐site	  of	  ErmBL	   to	   alanine	   alleviates	   translation	   arrest,	   indicating	   that	   ErmBL-­‐mediated	  ribosome	  stalling	  strongly	  depends	  on	  the	  nature	  of	  the	  amino	  acid	  attached	  to	  the	  A-­‐site	  tRNA.	  In	  sharp	  contrast,	  the	  ErmCL-­‐SRC	  exhibits	  a	  restrictive	  A-­‐site,	  namely	  that	  irrespective	  of	  the	  amino	  acid	  attached	  to	  the	  A-­‐site	  tRNA,	  the	  ribosome	  stalls	  during	  translation	  of	  ErmCL	   in	   the	  presence	  of	   erythromycin.	  Current	  knowledge	  about	  A-­‐site	  specificity	  is	  based	  on	  studies	  on	  the	  ErmAL1	  leader	  peptide	  (Ramu	  et	  al.,	  2011).	  Despite	   the	  similar	  hydrophobic	  C-­‐terminal	  amino	  acid	  sequence	  of	  ErmAL1	  (IAVV)	  compared	  to	  ErmCL	  (IFVI),	  ribosome	  stalling	  during	  translation	  of	  ErmAL1,	  unlike	  for	  ErmCL,	  strongly	  depends	  on	  the	  nature	  of	  the	  A-­‐site-­‐tRNA.	  Except	  for	  proline,	  which	  is	  known	  to	  be	  a	  poor	  peptide	  acceptor	  due	  to	  its	  imino-­‐group	  (Pavlov	  et	  al.,	  2009),	  a	  rationale	  as	  to	  how	  the	  ribosome	  distinguishes	  amino	  acids	  to	  either	  stall	  or	  continue	  translation	  of	  Erm-­‐leader	  peptides	  in	  presence	  of	  macrolides	  is	  currently	  unknown.	  It	  has	   been	   reported	   that	   the	   identity	   of	   the	   amino	   acid	   influences	   aminoacyl-­‐tRNA	  binding	  to	  the	  ribosome	  (Fahlman	  and	  Uhlenbeck,	  2004),	  however	  a	  structural	  basis	  about	   the	   specific	   placement	   of	   different	   amino	   acids	   in	   the	  A-­‐site	   remains	   elusive.	  Remarkably	   toe-­‐printing	   experiments	   using	   ErmAL1	   (selective	   A-­‐site),	   ErmCL	  (restrictive	   A-­‐site)	   as	   well	   as	   chimeras	   of	   both	   demonstrated	   that	   swapping	   the	  amino	  acid	  in	  the	  -­‐2	  position	  between	  ErmAL1	  (A)	  and	  ErmCL	  (F)	  renders	  the	  A-­‐site	  of	   the	   ErmCL_F7A-­‐SRC	   selective.	   This	   indicates	   that	   the	   -­‐2	   position	   in	   the	   nascent	  chain	   relative	   to	   its	   C-­‐terminus	   represents	   a	   key	   element	   in	  modulating	   the	   A-­‐site	  specificity.	  In	  this	  regard	  it	  is	  noteworthy	  to	  mention	  that	  the	  -­‐2	  position	  in	  the	  SecM	  leader	  peptide	   is	  also	  crucial	   for	  stalling	  (Yap	  and	  Bernstein,	  2009),	  suggesting	   that	  drug-­‐dependent	   ribosome	   stalling	   on	   ErmAL1/ErmCL	   might	   share	   similarities	   to	  drug-­‐independent	   ribosome	   stalling	   during	   translation	   of	   SecM	   (Vazquez-­‐Laslop	   et	  al.,	   2010).	   Yet,	   it	   is	   unknown,	   how	   the	   identity	   of	   a	   specific	   amino	   acid	   in	   the	   -­‐2	  position	  is	  communicated	  to	  the	  PTC.	  One	  explanation	  addressing	  this	  open	  question	  derives	  from	  our	  ErmCL-­‐SRC	  reconstruction.	  The	  phenylalanine	  residue	  F7	  in	  the	  -­‐2	  position	  of	  ErmCL	  in	  engaged	  in	  a	  strong	  stacking	  interaction	  with	  U2506	  of	  the	  23S	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rRNA.	   This	   interaction	   might	   stabilize	   the	   ErmCL	   nascent	   chain	   in	   a	   position	  overlapping	  with	  canonical	  positions	  of	  U2585	  and	  thereby	  trigger	  the	  perturbation	  of	  the	  active	  site.	  It	  is	  tempting	  to	  speculate	  that	  mutagenesis	  of	  F7	  to	  alanine	  disrupts	  this	  interaction,	  and	  thereby	  presumably	  influences	  the	  path	  of	  ErmCL	  and	  therefore	  the	  extent	  of	  PTC	  perturbation,	  which	  possibly	  renders	  the	  A-­‐site	  selective.	  Another	  option	  is	  that	  mutagenesis	  of	  F7	  to	  alanine	  alters	  the	  conformation	  of	  ErmCL	  to	  such	  an	   extent,	   that	   it	   allows	   U2585	   to	   adopt	   its	   usual	   conformation	   and	   thereby	   an	  entirely	  different	  stalling	  signal	  is	  generated	  and	  communicated	  to	  the	  PTC,	  resulting	  in	  a	  selective	  property	  of	  the	  A-­‐site.	  Another	  idea	  as	  to	  how	  the	  amino	  acid	  in	  the	  -­‐2	  position	  affects	  the	  A-­‐site	  specificity	  is	  related	  to	  the	  conformational	  state	  of	  U2506.	  U2506	  appears	  to	  adopt	  a	  defined	  state	  upon	  A-­‐site	  tRNA	  accommodation	  (Schmeing	  et	  al.,	  2005d),	  which	  is	  stabilized	  by	  stacking	  interaction	  with	  F7	  in	  ErmCL.	  It	  seems	  possible	  that	  the	  absence	  of	  this	  interaction	  by	  the	  F7A	  mutation	  allows	  flexibility	  of	  U2506,	   which	   could	   sterically	   interfere	   with	   the	   amino	   acid	   attached	   to	   the	   A-­‐site	  tRNA	   during	   accommodation	   and	   thus	   arrest	   translation	   in	   an	   amino	   acid	   specific	  manner.	  To	  structurally	  assess	  this	  issue,	  an	  ErmCL_F7A-­‐SRC	  could	  be	  generated	  and	  analyzed	  by	  cryo-­‐EM.	  It	  would	  be	  interesting	  to	  see	  whether	  the	  overall	  conformation	  of	  the	  nascent	  chain	  and/or	  U2506	  is	  affected	  by	  the	  mutation.	  	  	  In	   conclusion,	   we	   have	   demonstrated	   that	   ErmBL	   and	   ErmCL	   use	   two	   completely	  different	   mechanisms	   by	   which	   the	   ribosomal	   PTC	   gets	   inactivated.	   A	   lot	   more	  structures	  of	  other	  drug-­‐stalled	  ribosomes,	  for	  example	  ErmDL-­‐	  or	  ErmAL1-­‐SRCs	  are	  necessary	   to	   understand	  whether	   similarities	   regarding	   the	   stalling	   signal	   exist,	   or	  whether	   every	   individual	   peptide	   in	   the	   tunnel	   interacts	   with	   the	   drug	   in	   an	  individual	  way	   to	   generate	   a	   defined	   and	   individual	   peptide-­‐specific	   stalling	   signal	  that	   inactivates	   the	   PTC	   via	  many	   different	  ways.	   Overall,	   our	   studies	   demonstrate	  that	  the	  interplay	  between	  nascent	  polypeptide,	  the	  macrolide	  and	  nucleotides	  of	  the	  ribosomal	  tunnel,	  to	  generate	  a	  stalling	  signal,	  which	  is	  communicated	  to	  the	  PTC	  to	  inhibit	  peptide	  bond	  formation,	  is	  extremely	  complex	  and	  highly	  specific.	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ABSTRACT
In Gram-negative bacteria, the multi-domain protein
S1 is essential for translation initiation, as it recruits
the mRNA and facilitates its localization in the de-
coding centre. In sharp contrast to its functional im-
portance, S1 is still lacking from the high-resolution
structures available for Escherichia coli and Ther-
mus thermophilus ribosomes and thus the molec-
ular mechanism governing the S1–ribosome inter-
action has still remained elusive. Here, we present
the structure of the N-terminal S1 domain D1 when
bound to the ribosome at atomic resolution by us-
ing a combination of NMR, X-ray crystallography and
cryo-electron microscopy. Together with biochemi-
cal assays, the structure reveals that S1 is anchored
to the ribosome primarily via a stabilizing !-stacking
interaction within the short but conserved N-terminal
segment that is flexibly connected to domain D1. This
interaction is further stabilized by salt bridges involv-
ing the zinc binding pocket of protein S2. Overall,
this work provides one hitherto enigmatic piece in
the `ribosome puzzle´, namely the detailed molecu-
lar insight into the topology of the S1–ribosome inter-
face. Moreover, our data suggest novel mechanisms
that have the potential to modulate protein synthesis
in response to environmental cues by changing the
affinity of S1 for the ribosome.
INTRODUCTION
During the last decades the bacterial ribosome was at the
centre of numerous research efforts that made great strides
in elucidating the structure of the translational machinery
and the process of protein synthesis at the molecular level.
In sharp contrast, protein S1, which is essential for transla-
tion initiation in Gram-negative bacteria (1), is still lacking
from the high-resolution structures available forEscherichia
coli and Thermus thermophilus ribosomes (2). The protein
associates late during assembly of the 30S ribosomal sub-
unit (3) and interacts with a pyrimidine-rich region in the 5′
untranslated region (5′UTR) of mRNAs (4). Here, S1 un-
winds RNA structures by binding to single-stranded RNA
during thermal breathing (5). Thus, the protein shows RNA
chaperone activity (6) and is essential for the binding and
the accommodation of structured mRNAs into the decod-
ing channel (7). Notably, S1 is dispensable for translation of
leaderless mRNAs (lmRNAs) that lack a 5′UTR and hence
harbour a 5′-terminal AUG start codon (8,9).
Structurally, S1 is composed of six contiguous domains
(D1–D6; Figure 1A), which are connected via linkers pro-
viding the flexibility that is likely to play a role in recruit-
ment of mRNA transcripts to the ribosome (10). The struc-
tural organization of the single C-terminal domains (D3–
D6; Figure 1A), which interact with ssRNA (4,11), was
modelled for D3, D4 and D5 (12) and, later on, solved at
atomic resolution for D4 and D6 (13). Each of these do-
mains displays an oligosaccharide–oligonucleotide binding
(OB)-fold, consisting of two three-stranded antiparallel !-
sheets, where strand 1 is shared by both sheets, with an
"-helix that packs against the bottom of the barrel, typi-
cally oriented lengthwise along the long axis of the !-barrel
(14). Immune-electronmicroscopic studies revealed that do-
mains D3–D6 extend from the platform side of the 30S sub-
unit where the 5′-end of the mRNA would be located (15).
In contrast, the two N-terminal domains (D1, D2; Figure
1A) have no detectable RNA-binding activity but rather
provide the boundary to the ribosome (11,16). In contrast
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Figure 1. The N-terminal segment is essential for protein S1 to interact
with the ribosome in vivo. (A) Schematic of the domain organization of pro-
tein S1 and the C-terminally FLAG-tagged S1 variants used in the study.
(B) The N-terminal domain D1 of protein S1 including the flexible N-
terminal segment (NTS) and the C-terminal linker (CTL) is enlarged, and
its variants used in the study are depicted below. (C) Equimolar amounts
of S30 extracts (lanes 1 and 3) and 70S ribosomes (lanes 2 and 4) puri-
fied from E. coli strain JE28 synthesizing protein S119–106 (lanes 1 and 2)
or protein S1106 (lanes 3 and 4) were analysed for the presence of native
S1 (panel a) and proteins S1106 and S119–106 (panel b) by western blotting
using antibodies directed against S1106 (18). Western blotting of protein
S5 served as loading control (panel c). (D) Equal amounts of S30 extracts
(extr.; lanes 1, 3, 5 and 7) and ribosomes (70S; lanes 2, 4, 6 and 8) purified
fromE. coli strain JE28 upon synthesis of FLAG-tagged proteins S1 (lanes
1 and 2), S119–557 (lanes 3 and 4), S187–557 (lanes 5 and 6) or S1NTF106–557
(lanes 7 and 8) were analysed for the presence of the respective proteins by
western blotting employing anti-FLAG antibodies (panel a). Protein S5
served as loading control (panel b).
to studies that suggest a potential interaction of S1 with the
16S rRNA ((17) and references therein), several lines of evi-
dence indicate that the N-terminal region of S1 comprising
106 amino acids (S1106) is sufficient to ensure its assembly
to the 30S ribosomal subunit (10,18) by means of protein–
protein interactions via protein S2 (9,19).
Besides its pivotal role in protein synthesis, S1 acts as a
host factor component of the replicase holoenzyme of the
bacteriophage Q! (20). Interestingly, this function can be
performed by the N-terminal part of the protein compris-
ing domainsD1 andD2 (21). During the preparation of this
manuscript the structure of the Q! replicase comprising the
!-subunit, EF-Tu, EF-Ts and the N-terminal half of S1 was
published revealing that domains D1 and D2 function to
anchor S1 on the !-subunit (22). However, the structure of
S1 when assembled to the ribosome is unknown. Due to the
intrinsic flexibility of the protein, ribosomes were intention-
ally depleted for S1 to facilitate the crystallization process
for structural analyses (2). Thus, the molecular mechanism
governing the S1-ribosome interaction has still remained
elusive. Nevertheless, the E. coli S1 protein was tentatively
localized on the ribosome based on difference electron den-
sity maps between a cryo-electron microscopy (EM) struc-
ture of the E. coli 70S ribosome containing S1 and a map
based on the crystal structure of theT. thermophilus 30S that
lacked S1 (23). The results suggested that S1 binds within
the cleft at the base of the small subunit head and platform;
however, the limited resolution prevented any molecular in-
terpretation.
Here, we present the first crystal structure of the N-
terminal domain of protein S1 (comprising 86 amino acid
residues; hereafter referred to as S1NTD; Figure 1B) in com-
plex with protein S2 at 2.4–3 A˚ resolution, showing detailed
insights into the molecular basis of the S1–ribosome in-
teraction. In addition, we have visualized S1 bound to the
ribosome using cryo-EM underpinning the S1–S2 interac-
tion observed in the crystal structure. Together with func-
tional analyses, we demonstrate that a short, but highly con-
served, N-terminal segment is the primary ribosome an-
choring point for S1. This interaction is further stabilized
by salt bridges between the globular fold of S1NTD and
S2. Notably, the structure shows that the anchoring helix
is connected by a flexible hinge region with domain D1,
which mechanistically supports the dynamic movement of
S1 when bound to the 30S subunit. Moreover, our func-
tional studies suggest potential mechanisms, which might
fine tune the affinity of S1 for the ribosome in response to
environmental cues.
MATERIALS AND METHODS
Bacterial strains and plasmids
Escherichia coli strains, plasmids and oligonucleotides used
in this study are listed in the Supplementary Tables S1
and S2. Unless otherwise indicated, bacterial cultures were
grown in Luria–Bertani (LB) medium supplemented with
ampicillin (100 #g/ml). When appropriate, kanamycin (20
#g/ml) was added. Growth was monitored by measuring
the optical density at 600 nm (OD600).
Construction of plasmids
The sequence encoding the HA-tagged version of protein
S2 was amplified by polymerase chain reaction (PCR) us-
ing primers P1 and P2 employing genomic DNA of E.
coli strain MG1655 as a template. The respective products
were cleaved with NarI and XhoI and cloned under con-
trol of the Trc promoter in the corresponding sites of plas-
mid pProEX–Htb (Life Technologies) resulting in plasmid
pProEX–S2–HA. To generate plasmid pProEX–S2–S1NTD
for expression of the chimeric protein S2–S1NTD, the se-
quence encoding protein S186 was amplified with primers
P3 and P4. The PCR product was cleaved with HindIII
and ligated between the two HindIII-sites of the plasmid
pProEX–S2–HA. Plasmid pPro-S1F (18) was used as a tem-
plate to construct plasmid pPro-S1NTS!106–557F. The cod-
ing sequence for the S1 domain D1 was removed employ-
ing the Phusion site-directed mutagenesis kit (NEB) us-
ing 5′-monophosphorylated primers P5 and P6. Plasmids
pPro-S1F and pPro-S1106F (18) were used as templates to
construct plasmids pPro-S119–557F and pPro-S119–106F. The
coding sequence for the N-terminal 18 amino acids was re-
moved employing the Phusion site-directed mutagenesis kit
(NEB) using 5′-monophosphorylated primers P7 and P8.
Plasmids pPro-S1106F and pPro-S119–106Fwere used as tem-
plates to construct plasmids pPro-S186F and pPro-S119–86F.
The coding sequence for the C-terminal 18 amino acids was
removed employing the Phusion site-directed mutagenesis
kit (NEB) using 5′-monophosphorylated primers P9 and
P10. The plasmid pPro-S186F was used as a template to
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construct plasmids pPro-S186F encoding variants of S1NTD
harbouring the F5A, F9A, D39K and K43E mutations.
The respective mutations were introduced employing the
Phusion site-directed mutagenesis kit (NEB) using the 5′-
monophosphorylated primers P15/P17, P16/P17, P18/P20
and P19/P20, respectively. The sequences encoding proteins
S1106, S186 and S119–86 were amplified by PCR employing
pairs of primers P11/P13, P11/P14 and P12/P14 respec-
tively. The respective products were cleaved with NdeI and
XhoI and cloned under control of the T7 promoter in the
corresponding sites of plasmid pET22b (Novagen) yielding
plasmids pET-S1106, pET-S186 and pET-S119–86. All con-
structs were verified by sequencing (Microsynth).
Overexpression and purification of the chimeric protein S2-
S1NTD
Escherichia coli strain Tuner harbouring plasmid pProEX–
S2–S1NTD was grown in LB medium at 37◦C. Expression
of the rpsB–rpsANTD fusion gene was induced by addi-
tion of 1 mM Isopropyl-D-thiogalactopyranoside (IPTG).
The HIS-tagged chimeric protein S2–S1NTD was purified
with the TALON cobalt resin (Clontech) and subsequently
treated with AcTEV-protease (Life Technologies) and pu-
rified via a HiLoad 26/60 Superdex 200 column (GE
Healthcare) to remove the His-tag using a buffer con-
taining 100 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid)–KOH, (Potassium hydroxide) pH
7.4, 6 mMMgCl2 and 200 mMKCl. The fractions contain-
ing the chimeric protein were concentrated with an Amicon
ultra centrifugal filter unit (MWCO of 30 kDa; Millipore).
Crystallization, data collection, structure determination and
refinement
Crystals of the S2–S1NTD chimeric construct were initially
obtained in the crystallization screen JBScreen 7 (Jena Bio-
science), using the sitting-drop vapor diffusion technique
and a nanodrop-dispensing robot (Phoenix RE; Rigaku
Europe, Kent, United Kingdom). Crystallization condi-
tions were optimized to 0.1 M HEPES–KOH, pH 7.4, 3
mM MgCl2, 7.5% (w/v) PEG 6000, 3% (w/v) 2-methyl-
pentanediol-2,4, 100mMKCl using the hanging drop vapor
diffusion technique at 22◦C. The crystals were flash cooled
in liquid nitrogen prior to data collection. The data set has
been collected at the beamline I04 of the Diamond Light
Source at 100 K using a wavelength of 0.98 A˚. The data
frames were processed using the XDS package (24), and
converted to the mtz format with the program AIMLESS
(25). In assessing the data quality and establishing the res-
olution cutoff we relied on criteria based on the correlation
coefficient CC1/2 (26). The structure was solved by using
the molecular replacement pipeline program BALBES (27),
the log file indicated that atomic coordinates of S2 from 30S
subunit of E. coli (pdb accession code: 2qbf, chain B) and
the fragment of hypothetical protein PA5201 from P. aerug-
inosa (pdb accession code: 2oce) were yielded in solution.
About 90% of the model was placed using the programAU-
TOBUILD from Phenix software package (28). The struc-
ture was then refined with the REFMAC (29) and Phenix
Refine (28) and finally, the rebuilding of structure was done
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Where I¯(hkl) is the mean intensity of multiple Ii (hkl) observations of the
symmetry-related reflections, N is the redundancy.
eRcryst =
∑ ||Fobs|−|Fcalc||∑ |Fobs|
fRfree is the cross-validation Rfactor computed for the test set of reflections
(5%) which are omitted in the refinement process.
using the programCoot (30). Stereochemistry and structure
quality were also checked using the program MolProbity
(31). The figures were produced using the Pymol software
(32). Coordinates have been deposited in the protein data
bank (pdb accession code: 4toi). Data collection and refine-
ment statistics are reported in Table 1.
Purification of ribosomal subunits
Ribosomal subunits were purified based on the His-tagged
proteins L7/L12 employing Ni-NTA-agarose (33). Briefly,
E. coli strain JE28 was grown in LB medium supplemented
with kanamycin (20 #g/ml). At OD600 0.7–0.9 the cul-
ture was harvested by centrifugation at 5000g for 20 min
at 4◦C. The cell pellet was resuspended in lysis buffer (20
mM Tris·HCl, pH 7.4, 10 mMMgCl2, 30 mM NH4Cl, 100
mMKCl, 10 mM Imidazole, 1 unit/mlRNase-free DNase I
(Roche), 0.1 mM PMSF(phenylmethanesulfonylfluoride)).
The cells were disrupted by three freeze and thaw cycles
and the lysate was cleared by centrifugation at 15 000g for
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20 min at 4◦C. The extracts were applied to 10 ml of Ni-
NTA-agarose (QIAGEN) pre-equilibrated in lysis buffer,
and washed by 10 column volumes of washing buffer (20
mM Tris·HCl, pH 7.4, 10 mM MgCl2, 30 mM NH4Cl,
150 mMKCl, 20 mM Imidazole). Thereafter, the Ni-NTA-
agarose was resuspended in 10 column volumes of dissocia-
tion buffer (20 mMTris·HCl, pH 7.4, 1 mMMgCl2, 30 mM
NH4Cl, 150 mMKCl, 20 mM Imidazole) and incubated for
8 h at 4◦C. The flow-through fractions that contain the 30S
ribosomal subunits were collected and theMg2+ concentra-
tion was adjusted to 10 mM. The tetra-His-tagged 50S sub-
units were eluted by 10 column volumes of elution buffer
(20 mM Tris·HCl, pH 7.4, 10 mMMgCl2, 30 mM NH4Cl,
150 mM KCl, 150 mM Imidazole). The fractions contain-
ing ribosomal subunits were dialysed against tight-couple
(TICO) buffer (20 mMHEPES–HCl pH 7.6, 6 mMMgCl2,
30 mM NH4Cl and 4 mM !-mercaptoethanol) and con-
centrated using Amicon filter devices (MWCO of 100 kDa;
Millipore). Protein S1-depleted 30S ribosomes were pre-
pared by affinity chromatography using poly(U)-Sepharose
4B (Pharmacia) (34).
Co-purification of tetra-His-tagged ribosomes with FLAG-
tagged protein S1 variants
Escherichia coli strain JE28 cells harbouring plasmids
pProEX–HTb, pPro-S186F, pPro-S1106F, pPro-S119–86F,
pPro-S119–106F, pPro-S1F, pPro-S119–557F, pPro-S187–557F,
pPro-S1NTS!106–557F, pPro-S186FF5A, pPro-S186FF9A, pPro-
S186FD39K and pPro-S186FK43E were grown in LB broth
supplemented with 100 #g/ml ampicillin, 20 #g/ml
kanamycin and 0.5% (w/v) glucose. The synthesis of
FLAG-tagged protein S1 variants was induced by addition
of 0.1 mM IPTG at OD600 of 0.30–0.35. One hour there-
after the cells were harvested by centrifugation and lysed
by three freeze and thaw cycles in lysis buffer containing
20 mM Tris·HCl, pH 7.4, 10 mM MgCl2, 30 mM NH4Cl,
100 mMKCl, 10 mM Imidazole, 0.1 mM PMSF, 1 unit/ml
RNase-free DNase I (Roche). After centrifugation at 30
000g for 30 min at 4◦C, the extracts were applied to the Ni-
NTA agarose (QIAGEN), washed by 10 column volumes of
washing buffer (20 mM Tris·HCl, pH 7.4, 10 mM MgCl2,
30 mM NH4Cl, 150 mM KCl, 20 mM Imidazole) followed
by elution with a buffer containing 20 mM Tris·HCl, pH
7.4, 10 mMMgCl2, 30 mMNH4Cl, 150 mMKCl, 150 mM
Imidazole. The protein composition of the ribosomes was
determined by western blot analysis using anti-FLAG (Ab-
cam), anti-S1106 and anti-S5 antibodies.
Purification of 15N-labelled proteins S1106, S186 and S119–86
Escherichia coli strain Tuner (DE3) harbouring plasmids
pET-S1106, pET-S186 and pET-S119–86 were grown in M9
minimal medium supplemented with 15NH4Cl (Sigma, 1
g/l) and 100 #g/ml ampicilin. The synthesis of the re-
spective proteins was induced by addition of 1 mM IPTG
at OD600 of 0.8–0.9. Two hours thereafter the cells were
harvested by centrifugation and lysed by three freeze and
thaw cycles in lysis buffer containing 50 mMNa2HPO4, pH
8.0, 300 mM NaCl, 10 mM Imidazole, 0.1% Tween-20, 0.5
mg/ml DNase I (Roche), 20 #g/ml RNase A. After cen-
trifugation at 4◦C, 30.000g for 30 min, the S30 extracts were
applied to a Ni-NTA agarose, washed by 10 column vol-
umes of washing buffer (50mMNa2HPO4, pH 8.0, 500mM
NaCl, 20 mM Imidazole) followed by elution with elution
buffer (50 mMNa2HPO4, pH 8.0, 300 mMNaCl, 250 mM
imidazole). The eluted fractions were dialysed against phos-
phate buffered saline (PBS) buffer and a size exclusion fast
protein liquid chromatography (FPLC) was performed on a
HiLoad Sephadex 75 16/60 column (GE Healthcare). The
purified proteins were concentrated using Amicon filter de-
vices (MWCO of 3 kDa; Millipore).
Purification of protein S2-HA
Escherichia coli strain Tuner harbouring plasmid pProEX–
S2-HA was grown in M9 minimal medium supplemented
with 100 #g/ml ampicillin. The synthesis of protein S2-
HA was induced by addition of 0.1 mM IPTG at OD600
of 0.5–0.6. Four hours later, the cells were harvested and
lysed by three freeze and thaw cycles in lysis buffer contain-
ing 50 mM HEPES–KOH, pH 7.4, 3 mMMgCl2, 200 mM
KCl, 10 mM imidazole, 0.1% Tween-20, 0.5 mg/ml DNase
I (Roche), 20 #g/ml RNase A. After centrifugation at 100
000g for 30 min at 4◦C, the supernatant was applied to
Ni-NTA agarose, washed by 10 column volumes of wash-
ing buffer (50 mM HEPES–KOH, pH 7.4, 3 mM MgCl2,
250 mM KCl, 10% (w/v) glycerol, 20 mM imidazole) fol-
lowed by elutionwith elution buffer (50mMHEPES–KOH,
pH 7.4, 3 mM MgCl2, 200 mM KCl, 200 mM imidazole).
The eluted proteins were dialysed against 50 mM HEPES–
KOH, pH 7.4, 3 mMMgCl2, 150 mM KCl.
Co-purification analysis
Purified protein S2–HA was incubated with S100 extracts
prepared from the E. coli strain Tuner over-expressing the
different rpsA genes as follows. Escherichia coli cells carry-
ing the plasmids pProEX–HTb, pPro-S119–86F or plasmids
pPro-S186F containing the different point mutations (WT,
F5A, F9A, D39K or K43E) were grown in LB-Amp (100
#g/ml). 30 min after addition of 0.1 mM IPTG at OD600
of 0.4–0.5 the cells were harvested and lysed by three freeze
and thaw cycles in lysis buffer (50 mM HEPES–KOH, pH
7.4, 3 mMMgCl2, 200mMKCl, 0.1%Tween-20, 0.5 mg/ml
DNase I (Roche)). After centrifugation at 100 000g for 60
min at 4◦C, the amount of S1 protein variants was deter-
mined by quantitative western blotting. The extracts were
combined with equimolar amounts of protein S2–HA and
incubated at 37◦C for 30 min. Co-immunoprecipitation was
performed employing anti-ECS antibodies (Bethyl) cova-
lently linked to protein A magnetic beads (Life Technolo-
gies). After threewashing cycles (50mMHEPES–KOH, pH
7.4, 3 mM MgCl2, 100 mM KCl) the proteins were eluted
from the beads by boiling in Laemmli buffer, separated on
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and analysed by western blotting employ-
ing anti-FLAG (Abcam), anti-HA (Sigma) and anti-S1106
antibodies.
Generation and purification of ErmCL-SRC
The 2XermCL construct was synthesized (Eurofins, Mar-
tinsried, Germany) such that it contained a T7 promoter





Nucleic Acids Research, 2015, Vol. 43, No. 1 665
followed by a strong ribosome binding site (RBS) spaced
by seven nucleotides (nts) to the ATG start codon of the
first ermCL cistron. A linker of 22 nts separated the stop
codon of the first ermCL cistron and the start codon of the
second ermCL cistron. The linker also comprised the strong
RBS 7 nts upstream of the ATG start codon of the second
ermCL cistron, enabling initiation of translation indepen-
dent from the first ermCL cistron. Each ermCL cistron en-
coded amino acids 1–19 corresponding to ErmCL leader
peptide (GenBank accession number: V01278) present on
macrolide resistance plasmid pE194 (35). The complete se-





caaaaaataa-3′ (T7 promoter, italics; RBS, bold; ErmCL
ORF, small letters with GTA codon in P-site of stalled
ribosome shown in bold; Annealing site for complementary
DNA oligonucleotide, underlined). In vitro translation of
the 2xermCL construct was performed using the Rapid
Translation System RTS 100 E. coli HY Kit (Roche; Cat.
no. 3246817). Translations were carried-out in the presence
of 10 #M erythromycin (ERY) for 1 h at 30◦C. Control
reactions were performed in the absence of erythromycin
as well as using a monocistronic ermCL construct. Trans-
lation reactions were analysed on sucrose density gradients
(10–55% sucrose in a buffer A, containing 50 mMHEPES–
KOH, pH 7.4, 100 mM KOAc, 25 mM Mg(OAc)2, 6 mM
!-mercaptoethanol, 10 #M erythromycin and 1× Com-
plete EDTA-free Protease Inhibitor cocktail (Roche)) by
centrifugation at 154 693g (SW-40 Ti, Beckman Coulter)
for 2.5 h at 4◦C. For ErmCL–SRC purification, disome
fractions were collected using a Gradient Station (Bio-
comp) with an Econo UVMonitor (Biorad) and a FC203B
Fraction Collector (Gilson). Purified ErmCL–SRC dis-
omes were concentrated by centrifugation through Amicon
Ultra-0.5 ml Centrifugal Filters (Millipore) according
to the manufacturer’s protocol. To obtain monosomes
of the ErmCL–SRC, a short DNA oligonucleotide (5′-
ttcctccttataaaact-3′, Metabion) was annealed to the linker
between the ermCL cistrons of the disomes, generating
a DNA–RNA hybrid that could be cleaved by RNase H
(NEB) treatment at 25◦C for 1 h.
Negative-stain electron microscopy
Ribosomal particles were diluted in buffer A to a final con-
centration of 0.5 A260/ml. One drop of each sample was
deposited on a carbon-coated grid. After 30 s, grids were
washed with distilled water and then stained with three
drops of 2% aqueous uranyl acetate for 15 s. The remain-
ing liquid was removed by touching the grid with filter pa-
per. Micrographs were taken using a Morgagni transmis-
sion electronmicroscope (FEI), 80 kV, wide angle 1 KCCD
at direct magnifications of 72 K. The negative stain electron
microscopy was used to prescreen the samples and ensure
that the concentration was accurate to obtain an optimal
density and distribution of ribosomal particles for the cryo-
grids.
Cryo-electron microscopy and single particle reconstruction
Monosomes of the ErmCL–SRC were applied to 2 nm pre-
coated Quantifoil R3/3 holey carbon supported grids and
vitrified using a Vitrobot Mark IV (FEI Company). Data
collection was performed on a Titan Krios transmission
electron microscope (TEM) (FEI, Netherlands) under low-
dose conditions (∼20 e−/A˚2) at a nominal magnification
of 75 000× with a nominal defocus between -1 and -3.5
#m. Images were collected at 200 keV at a magnification
of 148 721× at the plane of CCD using a TemCam-F416
CMOS camera (TVIPS GmbH, 4096 × 4096 pixel, 15.6
#m pixel, 1 s/full frame), resulting in an image pixel size
of 1.0489 A˚ (object scale). Data collection was facilitated by
the semi-automated software EM-TOOLS (TVIPSGmbH)
as described (36). Contrast-transfer functions were deter-
mined using the SPIDER TF ED command and recorded
images were manually inspected for good areas and power-
spectra quality. Data were processed further using the SPI-
DER software package (37), in combination with an auto-
mated workflow as described previously (36). After initial,
automated particle selection based on the programSIGNA-
TURE (38) initial alignment was performed with 624 304
particles, using E. coli 70S ribosome as a reference struc-
ture (39). After removal of noisy particles (76 346 particles;
12%) and non-aligning particles (271 873 particles; 44%),
the dataset could be sorted into two main subpopulations:
The first subpopulation (153 240 particles; 25%)was defined
by the presence of non-stoichiometric densities for tRNAs
in the A-, and P-sites. The second, homogeneous subpopu-
lationwas defined by the absence of density for theA-tRNA
and the presence of stoichiometric density for the P-tRNA
(128 846 particles; 21%). This major subpopulation could
be refined to an average resolution of 7.9 A˚ according to the
Fourier Shell Correlation (FSC at a cut-off value of 0.5).
Molecular modeling and map-docking procedures
The crystal structure of the 30S subunit (pdb accession
code: 3ofo) of the E. coli 70S ribosome (40) was fitted as
a rigid body into the cryo-EM density map of the ErmCL–
SRC using UCSF Chimera (41) (fit in map function). The
molecularmodel for S1D1 was based on the crystal structure
of the S2–S1NTD complex (Figure 2) and the C-terminus of
S1 was extended (amino acids V68-A105) based on a ho-
mology model generated by HHPred (42) using the crystal
structure of eIF2" as a template (pdb accession code: 1kl9
(43)). Upon alignment of S2 of the S2–S1NTD complex to
S2 of E. coli 30S subunit (pdb accession code: 3ofo (40)),
S1D1 fitted nicely into additional density on the ErmCL–
ribosome complex (Figure 3C). The final model was ad-
justed manually using Coot (30) to fit the density of the
ErmCL–ribosome map. Crystal structures of 30S subunits
from T. thermophilus (pdb accession code: 1j5e (44)) and E.
coli (pdb accession code: 3ofo (40)) were filtered to compa-
rable resolutions using the Molmap function in Chimera.
Difference electron density maps were then calculated in
SPIDER (37) by subtracting the filtered map for T. ther-
mophilus 30S subunit (pdb accession code: 1j5e (44)) or E.
coli 30S subunit (pdb accession code: 3ofo (40)) from either
EMD-1003 (45) or the ErmCL–SRC map (Supplementary
Figure S4A–D).
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Figure 2. Interaction between S1NTD and protein S2. (A) Overview show-
ing the S2–S1NTD complex structure assembled from two protomers, with
S1NTD in blue, S2 in yellow. Zn2+ is depicted as a green sphere. This colour
code is used throughout the figures. (B) Stereo view showing the close up
of the $-stacking interaction with the aromatic ring of Phe32 of protein
S2 with Phe5 and Phe9 of S1NTH. (C) Stereo view showing the salt bridge
interactions between the core domain S1D1 and the globular domain of S2
involving the Zn2+ binding pocket. The water molecules involved in the
coordination of the Zn2+ ion are shown as red spheres.
Figure 3. Binding position of S1 on the E. coli 70S ribosome. (A) Cryo-
EM structure of a translating E. coli 70S ribosome containing additional
density for domain 1 (S1D1, blue) and domain 2 (S1D2, cyan) of riboso-
mal protein S1. Density for the large (grey) and small (pale yellow) ribo-
somal subunit, together with ribosomal protein S2 (bright yellow) is indi-
cated. (B) Initial model for the position of S1NTD obtained by aligning S2
(yellow) of the chimeric S2–S1NTD with S2 (orange) from an E. coli 30S
subunit (pdb accession code: 3ofo (40)) fitted to the cryo-EM map (grey
mesh) as a rigid body. (C) Refined model for the complete S1NTD based on
homology with eIF2" (pdb accession code: 1kl9 (43)) and fitted so as to
maintain interactions between S1 and S2 as observed in the chimeric crys-
tal structure, but also constrained by the electron density of the cryo-EM
map (grey mesh). (D) The position of S1NTD (blue) relative to the E. coli
70S ribosome at 11 A˚ (EMD-1003 (45)) based on aligning S2 (yellow) of
the chimeric S2–S1NTD with S2 (orange) from an E. coli 30S subunit (pdb
accession code: 3ofo (40)) fitted to the cryo-EMmap (grey mesh) as a rigid
body.
Figure preparation
Figures showing electron densities and atomic models were
generated using UCSFChimera (41) or Pymol (http://www.
pymol.org/) (32).
In vitro binding of FITC-labelled peptide S118 to the 30S(-S1)
subunit
The FITC–S118 peptide (FITC–
MTESFAQLFEESLKEIE-COOH) was synthesized
by Fmoc N-(9-fluorenyl)-methoxycarbonyl solid-phase
peptide synthesis and N-terminally labelled with fluores-
cein isothiocyanate (FITC). The average molecular mass of
the peptide was determined to be 2254 Da with an Applied
Biosystems Voyager System 1105 mass spectrometer. 40
pmol of 30S(-S1) subunits were incubated either with 80
pmol of native S1 or with 400 pmol of FITC–S118 in 50
#l TICO buffer at 37◦C for 30 min. After addition of
50 #l TICO buffer the samples were applied to 100 kDa
MWCO Amicon concentrators (Millipore), washed and
concentrated to 50 #l by centrifugation at 10 000g. The
retained fractions were subjected to SDS-PAGE analysis.
After staining with SYPRORuby (Invitrogen) the gels were
scanned employing a Typhoon using a 488 nm laser and
the filters of 520 nm to detect FITC and 610 nm to detect
SYPRO Ruby stained proteins, respectively.
In vitro translation
The ompA mRNA was prepared in vitro as described (9).
The in vitro translation was performed using the E. coli S30
Extract System for Linear Templates (Promega). The reac-
tions containing 1 #Ci/ml of [35S]-methionine, 0.2 #M of
ompAmRNA and 0.3 #Mof ribosomes were incubated for
60 min at 37◦C in the absence or presence of 3 or 30 #M of
purified proteins S1106, S187–194 or peptide FITC–S118, re-
spectively. The reactions were stopped by addition of SDS–
protein sample buffer and separated on SDS-PAGE. The
dried gels were exposed to a Typhoon Molecular Dynam-
ics PhosphoImager (GE Healthcare) for visualization and
quantification.
RESULTS
The N-terminal S1 domain is not a bona fide S1 domain
We first analysed the N-terminal region of S1 (S1106), which
is pivotal for the interaction with S2 (18), by multidimen-
sional heteronuclear NMR. Of the 96 resonances visible on
the 1H–15N HSQC spectrum (out of the 104 expected res-
onances) 59 could be assigned to residues Gly21 to Gly79.
The remaining 37 peaks corresponding to residues Met1 to
Pro20 and Phe80 to Glu106 (Figure 1B), exhibit the broad-
ness and poor signal-to-noise ratio indicative for structural
disorder in solution, which is in agreement with the results
of a recent NMR study on the first domain of S1 (46).
In addition, the comparison of the 1H–15N spectrum of
S1106 with the spectra of the S186 (lacking the C-terminal
linker, CTL) and S119–86 (lacking both, the CTL and the
N-terminal segment, NTS; Figure 1B; Supplementary Fig-
ure S1A) revealed that both terminal regions are not part
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of the core domain, since the resonances corresponding to
residues Gly21 to Gly79 remain unchanged within the three
spectra (Supplementary Figure S1A). Finally, using 1H, 15N
and 13C secondary chemical shifts we could determine that
the folded core of S1106 comprises only four !-strands (Sup-
plementary Figure S1B). In addition, our data show that the
N- and C-terminal regions are structurally disordered when
S1 is in apo form, i.e. when not bound to the ribosome.
The flexible S1NTS is required for ribosome binding
To dissect the role of the flexible S1NTS (residues Met1 to
Thr18) and the core domain of S1106, we analysed in vivo
the ribosome binding capacity of the truncated protein vari-
ant (S119–106; Figure 1B). Upon ectopic expression of the
rpsA106 or rpsA19–106 genes in E. coli strain JE28, 70S ri-
bosomes were affinity-purified as described in ‘Materials
andMethods’ section. Subsequent western blot analysis re-
vealed that in contrast to S1106, which completely abolishes
assembly of native S1 by blocking its binding site (Figure
1C, panel a, lane 4), S119–106 neither interacts with the 70S
ribosome (Figure 1C, panel b, lane 2), nor interferes with
binding of the native protein S1 (Figure 1C, panel a, lane
2). To further verify that the NTS is likewise vital for ri-
bosome binding of full-length protein S1, we repeated the
co-purification studies employing a full-length protein S1
lacking the NTS (S119–557; Figure 1A). Here, the ectopically
expressed S1 variants were detected via their C-terminal
FLAG-tag and therefore distinguishable from the native S1.
As expected, and in contrast to full length S1 (Figure 1D,
panel a, lane 2), S119–557 does not associate with the ribo-
some in vivo (Figure 1D, panel a, lane 4).
To further assess the role of the NTS for ribosome bind-
ing, theNTSwas fused toD2–D6 of S1 (S1NTSF106–557; Fig-
ure 1A). Consistently, the presence of theNTS enabled ribo-
some binding of protein S1NTSF106–557 lacking domain D1
(Figure 1D, panel a, lane 8), whereas the flexible linker re-
gion located between domainsD1 andD2 (residues 87–106)
did not allow ribosome binding (Figure 1D, panel a, lane
6). Taken together, these results corroborate our assump-
tion that the flexible NTS is the crucial element tethering
S1 to the ribosome, whereas the core structure of domain
D1 per se does not promote binding of S1 to the ribosome.
Crystal structure of the S2–S1NTD complex
Since S1 binds to the ribosome by means of protein-protein
interaction via protein S2 (9,19), we aimed to crystallize
S1NTD in complex with S2. After numerous attempts, we
were successful in crystallization of a chimeric protein con-
sisting of protein S2 connected to S1NTD (residues 1 to 86)
via a five-amino acid long linker (S2–S1NTD; Supplemen-
tary Figure S2A). The S2–S1NTD structure was solved and
refined to 2–3 A˚ resolution (Rwork/Rfree 18.6%/24.8%) with
one molecule of S2–S1NTD in the asymmetric unit. Data
collection and final refinement statistics are reported in Ta-
ble 1. The crystal packing analysis showed that the interac-
tion between S2 and S1NTD is formed inter-molecularly be-
tween two symmetry related molecules. The molecules are
related by a crystallographic 2-fold axis, where S2 interacts
with S1NTD of the symmetry mate (Supplementary Figure
S2B). In all subsequent structural analyses and discussions,
we will refer to the S2–S1NTD structure of the complex as-
sembled from the two protomers (Figure 2A).
The S2 component retains the two domain organization
consisting of a coiled-coil and an "/! globular part (Fig-
ure 2A). This structure can be superimposed with the struc-
ture of S2 in the context of the E. coli 30S subunit (pdb ac-
cession code: 2qbf, chain B) with a root-mean-square devia-
tion (rmsd) of 1.4 A˚ over 212 superimposed C" atoms. In
agreement with the previous knowledge that S2 is a Zn2+
binding protein (47), we also identified the Zn2+ binding
pocket within the globular domain of S2 (Figure 2A andC).
The Zn2+ binding site in S2 is partially occupied, Zn2+ be-
ing octahedrally coordinated by the side-chains of residues
Asp188, Asp204, Asp205 and His18 as well as two wa-
ter molecules. The identity of the metal was confirmed by
the presence of a characteristic peak in the anomalous dif-
ference Fourier map calculated using the data collected at
wavelength 1.28 A˚, corresponding to the Zn2+ K-edge (Sup-
plementary Figure S2C and D).
The structure of the S1NTD comprises two spatially sep-
arated structural motifs (Figure 2A): the 11 N-terminal
residues of S1NTD form an "-helix (from here on referred to
as S1NTH) that is connected to the four !-stranded globular
moiety (from here on referred to as S1D1) via a seven amino
acid residues flexible linker. Notably, the S1NTH is struc-
turally disordered in the free form (Supplementary Figure
S1) and adopts an "-helical conformation upon binding to
S2 (Figure 2A and B) through a `folding upon binding´
mechanism (48).
Interestingly, a DALI search identified the S1 domain of
the RNA binding protein Tex from Pseudomonas aerugi-
nosa (49) as the closest structural neighbour of S1NTD (Z-
score 5.1, rmsd of 4.9 A˚ over 56 equivalent C" atoms). The
S1 domain of Tex adopts the classical OB fold, and struc-
tural comparison shows that the S1NTD displays a truncated
OB fold missing the !-strand 5 and the N-terminal part of
!-strand 1, which is in the OB fold part of both !-sheets
(Supplementary Figure S2G). Further, the "-helix between
!-strands 3 and 4 at the bottom of the OB fold barrel is re-
placed by an 11 amino acid loop. Thus, S1D1 is structurally
distinct from other S1 domains as exemplified by the com-
parison with domains D4 (Supplementary Figure S2E) and
D6 (Supplementary Figure S2F) of protein S1.
Surprisingly, both the S1NTH and the S1D1 contact the
globular domain of S2. The aromatic rings of two pheny-
lalanine residues, Phe5 and Phe9 located in the S1NTH, form
a stabilizing $-stacking interaction (50) with the aromatic
ring of Phe32 located on !-strand 2 of the globular domain
of S2 (Figure 2B). In addition, the core domain S1D1 inter-
acts with S2 via two salt bridges: the side chain of Asp39
of S1D1 interacts with Arg208 of S2 (Figure 2C), whereas
the side chain of Lys43 of S1D1 protrudes towards the Zn2+
binding pocket in protein S2 and interacts via polar bonds
with the side chains of Asp188 and Asp205 thereby stabiliz-
ing their Zn2+ coordinating position (Figure 2C). Addition-
ally, Lys43 interacts with Asn203 and the C-atom of Phe16,
which is involved an aromatic stacking interaction with
His15, which is in turn packing with Phe9 in S1NTH. To val-
idate the likelihood of whether these interfaces mediate the
interaction in solution, we performed a bioinformatics anal-
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ysis with PISA (Protein Surfaces, Interfaces andAssemblies
(51)). ProbabilitymeasuresP%G,IF of specific interfaceswere
derived from the gain in solvation energy upon complex for-
mation, withP%G,IF > 0.5 indicating hydrophilic/unspecific
and P%G,IF < 0.5 to hydrophobic/specific interfaces (Sup-
plementary Table S3). Analysis of the interface between S2
and S1NTH shows that the P%G,IF values (0.176, 0.311) are
in the range of probabilities derived from typical protein in-
terfaces (0.1–0.4). In the case of S2 and S1NTD however, the
P%G,IF values>0.7 indicate a less specific interaction with a
smaller interface area (Supplementary Table S3), suggesting
that the dominant and specific stabilizing interaction in the
complex is between S2 and S1NTH. Surprisingly, all protein
S2 residues that are involved in interaction with S1NTD are
highly conserved within % -Proteobacteria and Firmicutes
(Supplementary Figure S6), despite the lack of a ribosome-
bound homolog of S1 in the phylum of Firmicutes. How-
ever, this fact goes in line with the observation thatE. coli S1
binds to Bacillus stearothermophilus ribosomes and greatly
stimulates translation of f2 RNA (52,53).
Cryo-EM structure of the S1NTD on the ribosome
We have determined a cryo-EM structure of an E. coli ribo-
some stalled during translation of the ErmCL leader pep-
tide (Figure 3A), at a resolution of ∼8 A˚ (Supplementary
Figure S3A). Fitting of the crystal structure of E. coli 70S
ribosome (40) revealed additional unassigned densities lo-
cated in the cleft between the head and platform on the
solvent side of the small subunit, adjacent to S2 (Figure
3A; Supplementary Figure S3B and C). We attributed these
additional densities to part of S1, which was biochemi-
cally shown to be present in our ErmCL–ribosome com-
plex (Supplementary Figure S3D). The location of the ad-
ditional density is in agreement with the localization of
S1 based on immunoelectron microscopy (15) and cross-
linkingmass spectrometry (10).Moreover, fitting the crystal
structure of the chimeric S2–S1NTD complex to the cryo-
EM map of the ErmCL–ribosome complex based on a
structural alignment between S2 from the chimeric S2–
S1NTD complex (yellow in Figure 3B) and S2 from the E.
coli 70S ribosome (orange in Figure 3B) places the S1NTD
into one of the unassigned densities (blue in Figure 3B).
Subsequently, we generated a molecular model for the com-
plete E. coli S1D1 (Figure 3C) based on the high sequence
homology with the N-terminal segment of eukaryotic initi-
ation factor IF2", which adopts an OB domain fold (43).
After fitting of S1D1, an additional density remains (Figure
3C), which would be compatible in size with domain D2 of
S1 (S1D2, Figure 3E), however, an unambiguous fitting of
the OB-like fold of S1D2 was not possible due to the lack of
resolution and apparent flexibility within this region of the
map.
Notably, the additional density attributed to S1 that was
recently observed in the E. coli SecM-stalled ribosome-
channel complex (54) is in excellent agreement with our lo-
calization of S1 (Supplementary Figure S3F). In contrast,
with the exception of some density for S1NTH, the cryo-EM
map of an E. coli ribosome at 11.5 A˚ (45) reveals little or
no density for S1D1 (Figure 3D). This was surprising since
a previous localization of S1 (23) was based on a difference
map between the 11.5 A˚ E. coli cryo-EM map (45) and the
crystal structure of the T. thermophilus 30S subunit, which
lacks S1 (44). In order to address this discrepancy, we re-
generated a difference map between the 11.5 A˚ E. coli cryo-
EMmap and the crystal structure of theT. thermophilus 30S
subunit, yielding a difference densitywith features similar to
that reported previously (Supplementary Figure S4A). In
addition, we also generated a difference map between the
11.5 A˚ E. coli cryo-EMmap and the crystal structure of the
E. coli 70S ribosome (40), which revealed that a large por-
tion of the density attributable to S1 in the 11.5 A˚ E. coli
cryo-EM map (23) was in fact due to the E. coli ribosomal
protein S21, which is absent in the T. thermophilus 30S sub-
unit (Supplementary Figure S4B). Moreover, aligning the
crystal structures of the E. coli 70S ribosome containing
mRNA and tRNAs (40) indicates that, after subtraction of
density attributable to S21, the remaining density is mostly
due to the mRNA and the 3′ end of the 16S rRNA (Supple-
mentary Figure S4A and B). In contrast, when difference
density maps are generated between the cryo-EM map of
the ErmCL–ribosome and theE. coli orT. thermophilus 30S
subunits, additional density that is not present in the 11.5 A˚
E. coli cryo-EM map, is observed that we have attributed
to S1D1 and S1D2 (Supplementary Figure S4C and D). The
close proximity of S1D1 and S1D2 to the 3′ end of the 16S
rRNA (Supplementary Figure S4C and D) is supported by
crosslinks to this region from S1 (55,56).
In addition to contacts with the mRNA and 3′ end of
the 16S rRNA, the electron density of the cryo-EM map
of the ErmCL-ribosome complex also reveals that S1 es-
tablishes two contacts with S2, contact one (C1) from the
S1NTH and an additional contact (C2) from S1D1 (Figure
3C). The contact C1 is consistent with the interactions be-
tween the S1NTH and the !-hairpin and helix "1 of S2, and
contact C2 would be compatible with the interaction ob-
served between S1D1 in the vicinity of the zinc bindingmotif
observed in the crystal structure of the chimeric S2–S1NTD
complex (Figure 2B and C). Thus, we believe that the inter-
actions between S1 and S2 within the chimeric S2–S1NTD
complex are physiologically relevant and reflect the interac-
tions between S1 and S2 that are observed on the ribosome.
The!-stacking interaction between S1NTH and S2 is essential
for ribosome binding
To determine the significance of the hydrophobic and elec-
trostatic contacts for the S1–S2 interaction, we scrutinized
the binding potential of different S1NTD mutants to the ri-
bosome (Figure 4A and B) or to purified protein S2 (Figure
4C andD). To evaluate the importance of the$-stacking in-
teractions we removed the aromatic rings of Phe5 and Phe9
by substituting phenylalanine by alanine residues (Figure
4B and D; S1NTDF5A, S1NTDF9A). The role of the salt
bridges between the core domain of S1NTD and S2 to ribo-
some binding was assessed by charge reversal mutations of
residues Lys43 and Asp39, respectively (Figure 4B and D;
S1NTDK43E, S1NTDD39K). The pull down experiments us-
ing either His-tagged ribosomes (33) (Figure 4B) or FLAG-
tagged S1NTD variants (Figure 4D) revealed that in the ab-
sence of the $-stacking interaction via the aromatic rings
of either Phe5 or Phe9, protein S1NTD can neither interact
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Figure 4. The $-stacking interaction between S1NTH and S2 is pivotal
for binding of S1 to the ribosome (A and B) and protein S2 (C and D).
Schematic depiction of the co-purification experiments using either His-
tagged ribosomes (33) (A) or FLAG-tagged protein S1NTD variants (C).
(B) Equal amounts of S30 extract (Input; lanes 1, 3, 5, 7, 9, 11 and 13)
and ribosomes (Elution; lanes 2, 4, 6, 8, 10, 12 and 14) purified from
E. coli strain JE28 before (lanes 1 and 2) and after synthesis of proteins
S1D1 (lanes 3 and 4), S1NTD (lanes 5 and 6), S1NTDF5A (lanes 7 and 8),
S1NTDF9A (lanes 9 and 10), S1NTDK43E (lanes 11 and 12), S1NTDD39K
(lanes 13 and 14) were tested for the presence of the respective S1 variants
indicated to the right by western blot analysis using anti-S1106 antibodies
(panels a–c). Protein S5 (panel d) served as loading control. (D) Under the
same conditions exemplified in (B) S100 extracts were prepared and sup-
plemented with purified HA-tagged protein S2 (input; lanes 1, 3, 5, 7, 9, 11
and 13). After incubation the FLAG-tagged protein S1 variants were im-
munoprecipitated by anti-FLAG antibodies (elution; lanes 2, 4, 6, 8, 10,
12 and 14; panel a) and the co-purification of protein S2 was determined
by western blot analysis using anti-HA antibodies (panel b). The amounts
of protein S1 variants were analysed employing anti-S1106 antibodies.
with the ribosome (Figure 4B, panel b, lanes 8 and 10) nor
with S2 (Figure 4D, panel a, lanes 8 and 10). In contrast,
the mutations of residues involved in electrostatic interac-
tions within the globular domain of S1NTD exhibited only
a minor effect on the assembly of S1NTD to the ribosome,
since the amounts of proteins S1NTDK43E and S1NTDD39K
that co-purifiedwith the ribosome (Figure 4B, panel b, lanes
12 and 14) were only slightly reduced when compared to
S1NTD (Figure 4B, panel b, lane 6). Correspondingly, the co-
precipitation of S2 was only marginally affected when pro-
teins S1NTDK43E and S1NTDD39K were used (Figure 4D,
panel a, lanes 12 and 14). Taken together with the results
shown in Figure 1, these data demonstrate that the stable
S1NTD–S2 interaction is primarily based on$-stacking con-
ferred by the phenylalanine residues within the S1NTH and
the phenylalanine residue at position 32 within the globular
domain of S2. The salt bridges between S1D1 and the glob-
ular domain of S2 seem to play a minor role, possibly by
stabilizing the interaction during a potential reorganization
of the S1 structure upon mRNA binding.
Free S1NTS binds to the 30S ribosomal subunit
Given the crucial role of the S1NTH in ribosome binding, we
hypothesized that its interaction with S2 is the primary an-
choring point for S1 on the 30S subunit of the ribosome.
To corroborate this assumption we assessed whether free
S1NTS can interact with the 30S subunit and consequently
impair binding of full length S1. To this end, we employed
an ultrafiltration assay described in ‘Materials and Meth-
ods’ section using a FITC-labelled S1NTS derivative to fa-
cilitate the detection of the peptide. Upon centrifugation,
Figure 5. Free S1NTS binds to the ribosome and interferes with translation
of the canonical ompA mRNA. (A) Purified S1-depleted 30S ribosomes
(30S(-S1)) were incubated in the absence (lanes 1 and 2) or in the pres-
ence of FITC labelled S1NTS (lanes 7 and 8), native protein S1 (lanes 9
and 10) or both (lanes 11 and 12). Likewise, FITC labelled S1NTS (lanes
3 and 4) or native S1 (lanes 5 and 6) were incubated in the absence of ri-
bosomes. Before (input; lanes 1, 3, 5, 7, 9 and 11) and after ultrafiltration
using 100 kDa MWCO Amicon concentrators (Millipore) samples were
taken and the presence of the respective proteins and the S1NTS peptide
in the ribosome fraction (ribosome fraction; lanes 2, 4, 6, 8, 10 and 12)
was determined by SDS-PAGE. (B) In vitro translation of ompA mRNA
in the absence (lane 1) or in the presence of a 10- or 50-fold molar excess
over ribosomes of S1NTD (lanes 2 and 3), S1D1 (lanes 4 and 5) or S1NTS
(lanes 6 and 7), respectively. The assay was performed in triplicate and one
representative autoradiograph is shown. Graph representing the quantifi-
cation of three independent assays is given below. Error bars represent the
standard deviation of the mean.
the 30S subunits are retained on the filter (Figure 5A, lane
2), whereas free S1NTS peptide (Figure 5A, lane 4) and full-
length S1 (Figure 5A, lane 6) pass through the membrane.
As expected, in the presence of S1-depleted 30S subunits
(30S(-S1)), the S1NTS peptide (Figure 5A, lane 8) and full-
length S1 (Figure 5A, lane 10) were detected in the retained
ribosome fraction, indicating an interaction with the ribo-
somal subunit. Moreover, the concomitant addition of the
FITC–S1NTS peptide and protein S1 reduces the amount of
both molecules in the ribosome fraction (Figure 5A, lane
12), corroborating the assumption that they compete for the
same binding site on the 30S subunit.
S1NTS but not S1D1 inhibits translation of canonical ompA
mRNA in vitro
Previously, we have shown that the synthesis of S1NTD in-
hibits bulk mRNA translation in E. coli in vivo presumably
because the protein binds to the ribosome and blocks as-
sembly of native S1 (18). Given that the binding of S1 to
the ribosome is dictated by the S1NTS, we next determined
whether the S1NTS peptide could also functionally inter-
fere with canonical mRNA translation. Thus, we performed
an in vitro translation assay employing the canonical ompA
mRNA, translation of which is strictly dependent on the
presence of S1 on the ribosome (8). As shown previously
(18) and in contrast to the globular S1D1 lacking the S1NTS
(Figure 5B, lanes 4 and 5), the presence of the S1NTD includ-
ing S1NTS interferes with translation of the ompAmRNA in
vitro (Figure 5B, lanes 2 and 3). Remarkably and in line with
our assumption, the addition of a 10- or 50-fold molar ex-
cess of the S1NTS peptide over the ribosome likewise results
in reduction of OmpA synthesis by 20 and 50%, respectively
(Figure 5B, lanes 6 and 7).
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Figure 6. Schematic model showing the interaction of S1 with the 30S sub-
unit. (A) In the free form the N-terminal segment of the multidomain pro-
tein S1 (spheres indicating the domains are colour-coded as in Figure 1A) is
unstructured. (B) S1 can either interact with the globular domain of pro-
tein S2 (in yellow) on the 30S subunit (in light yellow) primarily via the
N-terminal helix S1NTH, which adopts an "-helical conformation upon
binding to S2 through a ‘folding upon binding’ mechanism (48). In this
position, the protein can move in a ribosome-independent manner to scan
for RNA molecules or (C) S1 can interact directly with the mRNA, fa-
cilitate unfolding of the mRNA, and its delivery to the ribosome (5–7).
(D) Binding of mRNA induces a rearrangement of the S1 domains D3–
D5 (12) that might facilitate the correct positioning of the mRNA possibly
supported by the salt bridges between S1D1 and S2, leading to the forma-
tion of the (E) translation initiation complex. It is still in question whether
the presence of the Zn2+ ion (green sphere) affects the affinity or the topol-
ogy of S1 on the ribosome, what could potentially influence the activity or
selectivity of the ribosome for specific mRNAs. (F) Post-translational pro-
tein modifications within the region of the S1NTH or the S2 protein could
likewise influence the affinity of S1 for the ribosome. Thereby, S1-depleted
ribosomes that are selective for translation of lmRNAs could be present
under specific conditions.
DISCUSSION
One hallmark of ribosomal protein S1 is its unique flexi-
bility, which was suggested already more than 30 years ago
(57,58). As a result, the full-length protein is not amenable
to structural analysis and was thus intentionally removed
from the ribosome before crystallization (44), resulting in
the fact that the S1–ribosome interface hitherto remained
enigmatic. Here, we present the first detailed structural
analysis of the S1–S2 interface that can be rationalized in
terms of the following model. The short N-terminal seg-
ment of protein S1 is intrinsically structurally disordered
in solution (Figure 6A and Supplementary Figure S1A).
It folds partially into a perfect helical structure upon in-
teraction with the globular domain of S2 (Figure 6C) via
$-stacking involving two highly conserved phenylalanine
residues of S1 (Supplementary Figure S5). Due to the flex-
ible hinge region, the protein in its elongated conforma-
tion can scan the surrounding of the ribosome for mRNA
molecules, thereby increasing the sphere of ribosome action
(Figure 6C). In some situations, S1 may interact with the
mRNAand initiate unfolding of secondary structures in the
absence of the ribosome (5,6) as well as aid in delivery of
the mRNA to the ribosome (Figure 6B) (7). As revealed by
NMR and SAXS analyses, binding of RNA molecules in-
duces a topological rearrangement of the S1 domains D3–
D5 (12), which might further contribute to an overall re-
organization of protein S1 on the ribosome, possibly sup-
ported by the salt bridges at the boundary between the glob-
ular domains of S1 and S2, or potentially induced by the
suggested interaction of the protein S1 with the 3′-terminal
region of the 16S rRNA (17) (Figures 2C and 6D). Thereby,
S1 could be contracted in order to position themRNA close
to the mRNA track on the 30S subunit (Figure 6D) to facil-
itate formation of the translation initiation complex (Figure
6E) (7).
During the preparation of this manuscript the structure
of the Q! replicase comprising the !-subunit, EF-Tu, EF-
Ts and the N-terminal half of S1 was published (22). Inter-
estingly, again domains D1 and D2 function to anchor S1
on the !-subunit and all residues involved in the interac-
tion with the ribosome are likewise contacting the Q! repli-
case. Nevertheless, several differences in the nature of inter-
actions are evident. In contrast to the stabilizing $-stacking
interaction on the ribosome, the N-terminal segment of S1
is localized in a hydrophobic pocket of the Q! replicase,
which results in an extension of the helical structure of the
S1NTH and concomitantly with an enlargement of the in-
teraction surface. Likewise, the charged S1 residues, Asp39
and Lys43, that form the salt bridges with the globular do-
main of S2, are involved in interaction with the Q! repli-
case. Asp39 interacts with two Arg residues in the replicase,
whereas Lys43 is involved in the interaction with the main
chain carbonyl group of Ile199. Again, this interaction sur-
face is extended as the S1 residue Gly41 forms an additional
hydrogen bond with the main chain amide group of Ile199.
Taken together, these results suggest that the Q! replicase
could directly compete with S2 for the same binding sites
on protein S1.
In the course of this study, we also determined the Zn2+
binding pocket in the globular domain of ribosomal pro-
tein S2 (Figure 2C). Among the biological relevant transi-
tion metals, zinc is peculiar as it is redox inert and shows
a versatile coordination chemistry, and can hence be used
as a structural or catalytic cofactor. In protein S2, the Zn2+
ion is coordinated in an octahedral geometry by monoden-
tate carboxylates of three aspartic acid residues (Asp188,
Asp204, Asp205), one histidine residue (His18) and twowa-
ter molecules (Figure 2C). Notably, these residues are con-
served across Proteobacteria and Firmicutes, indicating the
importance of the presence of Zn2+ (Supplementary Fig-
ure S6). A search in the MESPEUS database (59) of three-
dimensional metal biosites revealed the only similar coor-
dination sphere in the L-rhamnose isomerase from Pseu-
domonas stutzeri (60), where the substrate binding site con-





Nucleic Acids Research, 2015, Vol. 43, No. 1 671
tains two metal cations. The Zn2+ binding site that is simi-
lar to the one found in S2 is considered to have a structural
role, since it stabilizes the local structure of the protein and
facilitates the correct orientation of the substrate. Thus, in
the S1/S2 complex the Zn2+ ion might lack a catalytic ac-
tivity but rather plays a structural role. However, the zinc
binding pocket is located at the S1–S2 interface, with the
Asp188 residue being properly positioned for the coordina-
tion of the zinc ion by the salt bridge with the Lys43 residue
of S1 (Figure 2C), which resides within the highly conserved
loop region connecting !-strands 2 and 3 (Supplementary
Figure S5). This result raises the possibility that the S1–
ribosome interaction might be modulated by the presence
of Zn2+ ions (Figure 6C and D). Thus, besides the regula-
tion of gene expression via metal responsive transcription
factors, the intracellular zinc concentration could likewise
affect ribosome specificity and thereby directly modulate
the translatome. This hypothesis, which could add another
level of complexity to the regulation of protein synthesis in
response to zinc homeostasis, is currently under investiga-
tion.
Recently, evidence is accumulating that ribosome het-
erogeneity provides a fast and energy efficient pathway for
bacteria to adapt protein synthesis to adverse conditions
(18,61). In particular, several studies addressed the func-
tional specificity of S1-depleted ribosomes for translation
of lmRNAs (9,62,63). Given the formation of lmRNAs
during stress conditions (61), it is conceivable that con-
ditional post-translational protein modifications affect the
small boundary between proteins S1 and S2. Thereby, the
affinity of the protein for the ribosome might be reduced
and S1-depleted ribosomes could be generated, which are
responsible for translation of lmRNAs (Figure 6F). Con-
comitantly, free protein S1 might participate in other tasks,
as already suggested either in the stabilization of certain
transcripts (64) or in trans-translation (65). This assump-
tion is supported by a comparative proteome analysis that
revealed the differential acetylation of several r-proteins in-
cluding S1 and S2 during exponential or stationary growth
phase (66). Moreover, a recent study performed to decipher
the phosphoproteome of E. coli during growth in minimal
medium (67) indicates that several residues of protein S1
are differentially phosphorylated in response to the growth
phase. Interestingly, themodification of residueThr2, which
is located in close proximity to the N-terminal ribosome an-
choring helix, was only observed in late stationary phase.
Moreover, Ser44, which is juxtapose to Lys43 that mediates
the salt bridge involving the S2 zinc binding pocket, is highly
phosphorylated at late stationary phase. Thus, we envisage
that the negative charge introduced by the phosphorylation
of Ser44 could contribute to a reorientation of Lys43, and
thereby impair the formation of the respective salt bridge.
This idea is supported by results indicative for the accu-
mulation of free ribosomal proteins S1 and L7/L12 during
stationary phase (68). Interestingly, the interaction of pro-
teins L7/L12 with the ribosome is mechanistically similar
to the S1-ribosome interaction. Proteins L7/L12 likewise
bind to the ribosome via a short N-terminal domain which
is connected to the functional domain by a flexible and un-
structured linker (69). Notably, this N-terminal ribosome
binding domain is modified in a growth phase dependent
manner, which affects the stability of the interaction (70).
Taken together, we hypothesize that the small boundary be-
tween proteins S1 and S2 could represent a target for mod-
ification in response to the growth-phase or environmental
conditions, which might affect the affinity of S1 for the ri-
bosome and consequently contributes to ribosome hetero-
geneity thereby fine-tuning protein synthesis.
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Supplementary Figure S1. NMR analysis of proteins S1106, S186, and S119-86. (A) Left panels: 
comparison of the 1H-15N HSQC spectra of proteins S1106 (red) and S186 (blue). Right panels: 
overlay of the spectra of proteins S186 (blue) and S119-86 (green). The bottom panels show close up 
views of the respective areas indicated by the dashed boxes. (B) Protein sequence alignment of 
S1106 and S1 domain D4. The position of the four β-strands of protein S1106 identified by NMR 
analysis are indicated by blue arrows. The red arrows indicate the positions of the β-strands of 
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Supplementary Figure S2. Crystal structure analysis of the chimeric S2-S1NTD protein. (A) Amino 
acid sequence of the chimeric S2-S1NTD protein used for the crystal structure analysis. The 
sequences corresponding to protein S2 (yellow), the flexible linker (black and italics) and protein 
S1NTD (blue) are indicated. (B) Dimer of the chimeric S2-S1NTD protein formed by inter-molecular 
interaction, where S2 interacts with S1NTD of the symmetry mate. S2 and S1NTD of one monomer 
are indicated in yellow and blue, and of the second monomer in light and dark grey, respectively. 
(C) Anomalous difference Fourier map showing the position of the Zn2+ ion contoured at 3.5 σ. The 
anomalous data was collected to 3 Å resolution at ID23-1 ESRF (Grenoble, France) at wavelength 
1.28 Å (9.68 keV). (D) X-ray energy scan around the absorption edge of Zn (red) and its first 
derivative depicted in blue. The energy is given in keV. Comparison of the structure of protein 
S1NTD with the domains D4 (E) and D6 (F) of protein S1 from E. coli and the S1 domain of the RNA 















































1 MATVSMRDML KAGVHFGHQT RYWNPKMKPF IFGARNKVHI INLEKTVPMF NEALAELNKI ASRKGKILFV 
71 GTKRAASEAV KDAALSCDQF FVNHRWLGGM LTNWKTVRQS IKRLKDLETQ SQDGTFDKLT KKEALMRTRE 
141 LEKLENSLGG IKDMGGLPDA LFVIDADHEH IAIKEANNLG IPVFAIVDTN SDPDGVDFVI PGNDDAIRAV 
211 TLYLGAVAAT VREGRSQDLA SQAEESLYFQ GESFAQLFEE SLKEIETRPG SIVRGVVVAI DKDVVLVDAG 






Supplementary Figure S3. Binding position of S1 on the E. coli 70S ribosome. (A) The average 
resolution of the cryo-EM map of the ErmCL-ribosome complex was 7.9 Å as determined using the 
Fourier shell correlation (FSC) cut-off value of 0.5. (B) Overview of the cryo-EM map of the ErmCL-
ribosome complex (grey mesh), with rigid-body fitted crystal structure of the 30S subunit (pdb 
accession code 3ofo) from the E. coli 70S ribosome (1) (dark grey). Ribosomal protein S2 is 
colored orange and highlighted electron densities for S1D1 (blue) and S1D2 (cyan). (C) Inset from 
(B) showing extra unaccounted for density in the cryo-EM map of the ErmCL-ribosome complex 
(grey mesh) adjacent to S2 (orange). (D) InstantBlue (Expedeon) stained 15% SDS polyacrylamide 
gel electrophoresis of the ErmCL-ribosome complex, indicating the presence of ribosomal protein 
S1 at ~60 kDa. (E) Cryo-EM map (grey mesh) of the ErmCL-ribosome complex containing 
additional density for domain 1 (S1D1, blue) and domain 2 (S1D2, cyan) of ribosomal protein S1. The 
model for S1D1 was obtained by aligning S2 (yellow) of the chimeric S2-S1NTD with S2 (orange) 
from an E. coli 30S subunit (pdb accession code 3ofo) (1) fitted to the cryo-EM map (grey mesh) as 
a rigid body. The model was refined for the complete S1NTD based on homology with eIF2α (pdb 
accession code 1kl9) (2) and fitted so as to maintain interactions between S1 and S2 as observed 
in the chimeric crystal structure, but also constrained by the electron density of the cryo-EM map 
(grey mesh). A tentative model for S1D2 (cyan) was generated based on homology with eIF2α (pdb 
accession code 1kl9) (2) and fitted into the density. (F) Electron density map (grey mesh) of a 
SecM-stalled ribosome-channel complex (3) with fitted crystal structure for S2 (orange) from an 






Supplementary Figure S4. Comparison of cryo-EM electron densities for S1 on the E. coli 70S 
ribosome. Difference electron density maps (grey mesh) calculated by (A) subtracting the filtered 
map for T. thermophilus 30S subunit (PDB ID 1J5E (4)) from EMD-1003 (5), or from (B) the 
ErmCL-SRC map as well as by subtracting the filtered map for E. coli 30S subunit (pdb accession 
code 3ofo (1)) from (C) EMD-1003 (5), or from (D) the ErmCL-SRC map. The relative positions of 
ribosomal protein S21 (green) (pdb accession code 3ofo (1)), 16S rRNA (red) and mRNA (orange) 
from (pdb accession code 4gd2 (6)), as well as S2 (S1NTD-S2; yellow), S1 domain 1 (S1NTD-S2; 
blue) and domain 2 (tentative placement of model, which was generated based on homology with 











Supplementary Figure S5. Multiple sequence alignment of the S1NTD protein of several 
representatives of the class of γ-Proteobacteria. The 100% conserved residues are indicated in 
red. The Phe5 and Phe9 residues involved in the π-stacking interaction with S2 and the Lys43 
residue contacting the zinc binding pocket of S2 are marked by red and blue arrow heads, 
respectively. The position of the NTH (green helix) and the four β-strands (blue arrows) as 
determined by crystallography are indicated above. The amino acid alignment was generated using 





Supplementary Figure S6. Multiple sequence alignment of the S2 protein of several representatives 
of the γ-Proteobacteria and Firmicutes. The 100% conserved residues are indicated in red. The 
residues involved in zinc-binding are indicated by red arrows and the residues contacting the S1NTD 
are indicated by green arrows. The amino acid alignment was generated using CLC Genomics 






Supplementary Table S1. Bacterial strains and plasmids used in this study 
_____________________________________________________________________________ 
 Relevant features Source or reference 
E. coli strains: 
JE28 MG1655::rplL-his (7) 
Tuner F– ompT hsdSB (rB– mB–) gal dcm lacY1 Novagen 
Tuner(DE3) F– ompT hsdSB (rB– mB–) gal dcm lacY1(DE3) Novagen 
 
Plasmids: 
pProEX-HTb vector for Trc driven gene expression Invitrogen 
pProEX-S2-HA encodes his- and HA-tagged S2 WT this study 
pProEX-S2-S1NTD encodes his-tagged S2-S1NTD this study 
pPro-S186F encodes FLAG-tagged S186 this study 
pPro-S1106F encodes FLAG-tagged S1106 (8) 
pPro-S119-86F encodes FLAG-tagged S119-86 this study 
pPro-S119-106F encodes FLAG-tagged S119-106 this study 
pPro-S1F encodes FLAG-tagged S1  (8) 
pPro-S119-557F encodes FLAG-tagged S119-557 this study 
pPro-S187-557F encodes FLAG-tagged S187-557  (8) 
pPro-S1NTSΦ106-557 encodes FLAG-tagged S1NTSΦ106-557 this study 
pPro-S186FF5A encodes FLAG-tagged S186, F5A this study 
pPro-S186FF9A encodes FLAG-tagged S186, F9A this study 
pPro-S186FD39K encodes FLAG-tagged S186, D39K this study 
pPro-S186FK43E encodes FLAG-tagged S186, K43E this study 
pET22b vector for T7 driven over expression Novagen 
pET-S1106        pET derivative encoding for his-tagged S1106 this study 
pET-S186 pET derivative encoding for his-tagged S186  this study 
pET-S119-86 pET derivative encoding for his-tagged S119-86                 this study 
pKS0325          ompA gene under control of T7-promoter   (9) 
____________________________________________________________________________ 
               
  
 9 
Supplementary Table S2. Oligonucleotides used in this study 
 
P1  TATAGGCGCCGAATTCGATGCAACTGTTTCC fwd primer to clone S2-HA 
P2  TATACTCGAGTTAAGCGTAATCTGGAACATCGTACTCAGCTTCTACG rev primer to clone S2-HA 
P3  TATAAAGCTTATATTTTCAGGGTGAATCTTTTGCTCAACTC fwd primer to clone S2-S1NTD 
P4  TATAAAGCTTTTACAGCAGAGTTTCACCG rev primer to clone S2-S1NTD 
P5  P-GAAACTGTTACCGGTGTTATC  fwd primer to remove S1D1-coding sequence 
P6  P-ACCCGGGCGGGTTTCG rev primer to remove S1D1-coding sequence  
P7  P-CCGGGTTCTATCGTTCG  fwd primer to remove the first 18 codons of rpsA  
P8  P-CATGGTCTGTTTCCTGTG rev primer to remove the first 18 codons of rpsA  
P9  P-GACTATAAGGATGACG fwd primer to remove the sequence coding for S187-106 
P10  P-CAGCAGAGTTTCAC rev primer to remove the sequence coding for S187-106 
P11 TATACATATGACTGAATCTTTTGCTC  fwd primer to amplify rpsA from the 1st codon 
P12  TATACATATGACCCGCCCGGGTTC  fwd primer to amplify rpsA sequence from the 19th codon 
P13  TATACTCGAGTTCAGCATCTTCGTAAGC  rev primer to amplify rpsA until 106th codon 
P14  TATACTCGAGCAGCAGAGTTTCAC  rev primer to amplify rpsA until 86th codon 
P15  P-CTCTTCAAAGAGTTGAGCGGCAGATTCAG  rev primer to introduce the mutation F5A 
P16  P-CTCTTCCGCGAGTTGAGCAAAAGATTCAG  rev primer to introduce the mutation F9A 
P17  P-TCCTTAAAAGAAATCGAAACCCGCCCG  fwd primer to introduce the mutations F5A and F9A 
P18  P-GTTAAAGCTGGTCTGAAATCTG  fwd primer to introduce the mutation D39K 
P19  P-GTTGACGCTGGTCTGGAATCTG  fwd primer to introduce the mutation K43E 






Supplementary Table S3. The PISA interface analysis. 
 
 S2 S1NTD S2/S1NTH S1NTH S2/S1D1 S1D1 
Number of 
atoms 90 (4.8)% 81 (16.8%) 
48 
(2.6%) 42 (13.6%) 
42 
(2.2%) 39 (11.1%) 
Number of 
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Antimicrobial peptides form a diverse group of molecules that are 
produced as part of the innate immune response of all multicellular 
organisms1. Among these, PrAMPs have garnered considerable atten-
tion as a possible means of countering the rapid increase in bacterial 
resistance to classical antibiotics2,3. Unlike many peptides that kill 
bacteria by disrupting their cell membrane, PrAMPs are transported 
into the cytoplasm by specialized transporters, such as SbmA in Gram-
negative bacteria4,5, where they inhibit specific intracellular targets. 
Given that such transport mechanisms are absent in mammalian cells, 
and only limited interactions with intracellular eukaryotic proteins 
have been detected, PrAMPs are generally considered to be nontoxic6 
and therefore an attractive alternative to existing antimicrobials. 
Interestingly, some PrAMPs can cross the blood-brain barrier to selec-
tively target brain cells, thus further highlighting their potential for the 
treatment of cerebral infections or for brain-specific drug delivery7.
Initial efforts to locate bacterial targets for PrAMPs led to the iden-
tification of the heat-shock protein DnaK as the prime candidate for 
inhibition8. Short proline-rich peptides (of 18–20 amino acids (aa)) 
such as oncocin, drosocin, pyrrhocoricin or apidaecin were previously 
shown to bind to this bacterial chaperone in a stereospecific manner, 
thus leading to the development of improved PrAMP derivatives with 
increased affinity for DnaK9–12. However, subsequent studies into the 
antimicrobial properties of PrAMPs13 have suggested that these pep-
tides are likely to use additional modes of action to inhibit growth. For 
example, a C-terminally truncated version of the apidaecin 1b peptide 
results in a loss of antimicrobial activity but no observable decrease 
in DnaK binding or cellular uptake13. Similarly, oncocin (Onc72 and 
Onc112) and apidaecin (Api88 and Api137) derivatives were found 
to inhibit the growth of a dnaK-deletion strain as efficiently as that of 
the dnaK-containing parental strain14. Further investigation revealed 
that these PrAMPs have an additional target within the bacterial cell, 
namely the ribosome14. Although such PrAMPs have been shown 
to bind to the ribosome and inhibit translation14, the mechanism by 
which they inhibit translation has so far not been determined.
Here, we set out to address this issue by obtaining a 3.1-Å- 
resolution X-ray crystallography structure of the Thermus ther-
mophilus 70S ribosome (Tth70S) in complex with a peptidyl (P)-site– 
bound deacylated tRNAiMet and Onc112, a representative of the 
oncocin family of PrAMPs produced by the milkweed bug (Oncopeltus 
fasciatus)15. The structure reveals that the N-terminal residues 1–12 
of Onc112 bind to the upper region of the ribosomal exit tunnel, 
overlapping the binding site for the CCA end of an aminoacyl (A)-site 
tRNA at the peptidyl transferase center. Consistently with this, 
we showed biochemically that Onc112 allows translation to initiate 
but destabilizes the initiation complex and thus prevents subse-
quent entry of affected ribosomes into the translation-elongation 
phase. Moreover, we demonstrated that although truncation of the 
C-terminal portion of Onc112 is dispensable for ribosome binding, 
it is essential for antimicrobial activity. We believe that these findings 
will provide an excellent basis for the design of improved antibacterial 
compounds, either peptidic or peptidomimetic, that inhibit transla-
tion by targeting the ribosomal exit tunnel.
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The proline-rich antimicrobial peptide Onc112 inhibits 
translation by blocking and destabilizing the initiation 
complex
A Carolin Seefeldt1,2,6, Fabian Nguyen3,6, Stéphanie Antunes1,4,6, Natacha Pérébaskine1,2, Michael Graf3,  
Stefan Arenz3, K Kishore Inampudi1,2, Céline Douat1,4, Gilles Guichard1,4, Daniel N Wilson3,5 & C Axel Innis1,2
The increasing prevalence of multidrug-resistant pathogenic bacteria is making current antibiotics obsolete. Proline-rich 
antimicrobial peptides (PrAMPs) display potent activity against Gram-negative bacteria and thus represent an avenue for 
antibiotic development. PrAMPs from the oncocin family interact with the ribosome to inhibit translation, but their mode 
of action has remained unclear. Here we have determined a structure of the Onc112 peptide in complex with the Thermus 
thermophilus 70S ribosome at a resolution of 3.1 Å by X-ray crystallography. The Onc112 peptide binds within the ribosomal  
exit tunnel and extends toward the peptidyl transferase center, where it overlaps with the binding site for an aminoacyl-tRNA.  
We show biochemically that the binding of Onc112 blocks and destabilizes the initiation complex, thus preventing entry into  
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RESULTS
Onc112 binds in a reverse orientation within the exit tunnel
We obtained the structure herein referred to as Tth70S–Onc112 by 
soaking the 19-aa Onc112 peptide (VDKPPYLPRPRPPRrIYNr-NH2, 
in which r denotes d-arginine) into crystals of Tth70S ribosomes 
in complex with a P-site–bound deacylated tRNAiMet and a short 
mRNA (Table 1). Using a minimally biased Fo − Fc map calculated 
after refinement of a model comprising Tth70S ribosomes, tRNAiMet 
and mRNA but lacking Onc112, we could see clear density that could 
be attributed to the N-terminal two-thirds of the Onc112 peptide 
(Fig. 1). Interestingly, the peptide is bound inside the tunnel with 
a reversed orientation relative to the growing polypeptide chain 
during protein synthesis, i.e., with its N terminus located near the 
peptidyl transferase center and its C terminus extending into the 
exit tunnel toward the constriction formed by ribosomal proteins 
L4 and L22. Despite the reversed orientation, the location of the 
Onc112 peptide overlaps to varying extents with the path of nascent 
polypeptide chains that have been visualized within the ribosomal 
tunnel16–18 (Supplementary Fig. 1). The conformation of Onc112 
bound to the ribosome is extended, in a manner similar to but distinct 
from that observed previously for oncocin in complex with DnaK10 
(Supplementary Fig. 2). Our CD studies suggest that, in solution, 
the Onc112 peptide adopts an essentially random conformation, 
with short stretches of poly(Pro)II helix, specifically, 6% ?-helix, 
54% random coil, 30% PPII and 6% ?-sheet (Supplementary Fig. 3).
Interaction between Onc112 and 23S rRNA of the exit tunnel
Comparison of the Tth70S–Onc112 structure with that of a Tth70S 
ribosome featuring tRNAiMet bound to the P site19 reveals that several 
nucleotides of the 23S rRNA undergo a conformational change upon 
binding of Onc112 to the ribosome (Fig. 2a). U2506 shifts to occupy 
a position similar to that observed upon binding of aminoacyl-tRNA 
to the A site of the ribosome20,21. In the presence of Onc112, 
U2585, which is very flexible in many crystal structures, adopts a 
defined position similar to that modeled in the structure of a vacant 
Escherichia coli 70S ribosome22. In addition, A2062 shifts to provide 
space for Onc112, adopting a similar conformation to that observed 
previously in the presence of the ErmBL nascent chain23. Thus, 
binding of Onc112 to the ribosome is accompanied by an induced 
fit involving several 23S rRNA nucleotides that are generally known 
for their dynamic behavior within the peptidyl transferase center and 
ribosomal tunnel.
Electron density for the Onc112 peptide was strongest for residues 
Val1–Pro8 and became weaker after Pro10, thus making it difficult to 
model the peptide beyond Pro12 (Fig. 1). We observed three sets of 
interactions between the N-terminal 10 aa of Onc112 and nucleotides 
of the 23S rRNA (Fig. 2b). The first set involves aa 1–3 of Onc112 and 
encompasses eight potential hydrogen-bond interactions (Fig. 2b,c). 
Val1 of Onc112 can form three hydrogen bonds with nucleotides of 
the 23S rRNA; two via its ?-amine to the N3 atom of C2573 and the 
O3? atom of C2507; and one via its carbonyl oxygen to the N4 atom 
of C2573. Three additional hydrogen bonds are possible between 
the side chain carboxylic acid of Asp2 and the N1 and N2 atoms of 
G2553 or the 2?-OH of C2507. The positively charged side chain of 
Lys3 extends into a negatively charged cavity, displacing a hydrated 
magnesium ion that is present at this site in other Tth70S ribosome 
structures20, and it interacts with the backbone phosphates of A2453 
(Fig. 2c) and U2493 (not shown). Substitution of Val1, Asp2 and 
especially Lys3 by alanine in Onc72 leads to a loss of antimicrobial 
activity10, whereas, as expected, a D2E mutant of Onc112 retained 
both in vitro and in vivo activity (Supplementary Fig. 4). The K3A 
substitution in Onc72 reduced its ribosome binding affinity by a 
factor of 4.3 and lowered the half-maximal inhibitory concentration 
(IC50) for in vitro translation more than 18-fold14.
The second set of interactions involves the side chains of Tyr6 and 
Leu7 of Onc112 (Fig. 2b,d). The aromatic side chain of Tyr6 estab-
lishes a ?-stacking interaction with C2452 of the 23S rRNA (Fig. 2d). 
In addition, the side chain hydroxyl of Tyr6 hydrogen-bonds with an 
undetermined ion that is coordinated by the backbone phosphate 
of U2506 and the O2 atoms of C2452 and U2504. The hydrophobic 
cavity occupied by the Tyr6 side chain also accommodates the side 
chain of Leu7 of Onc112, which packs against the phenol moiety of 
Tyr6, whereas the backbone of Leu7 forms two hydrogen bonds with 
U2506 (Fig. 2b,d). The compact hydrophobic core formed by Tyr6 
and Leu7 is likely to be key in anchoring the Onc112 peptide to the 
tunnel because mutagenesis experiments have shown that alanine 
substitution of either residue in Onc72 reduces the ribosome binding 
affinity by a factor of 7 and results in a complete loss of inhibitory 
activity on translation in vitro14. In contrast, mutation of Leu7 in 
Onc112 to cyclohexylalanine, which would preserve the hydrophobic 
environment, resulted in retention of inhibitory activity on transla-
tion in vitro but unexpectedly led to a loss of antimicrobial activity 
(Supplementary Fig. 4).
Additional interactions with the ribosome encompass the PRPRP 
motif of Onc112 (Fig. 2b) and include a ?-stacking interaction 
between the guanidino group of Arg9 of Onc112 and the base of 
C2610 (Fig. 2e). Although substitution of Arg11 with alanine in 
Onc72 also reduces the ribosome binding affinity and inhibitory 
properties of the peptide14, we observed very little density for the 
side chain of this residue, thus suggesting that it could be important 
for the overall electrostatic properties of the peptide rather than for 
a defined interaction with the ribosome (Fig. 1). The high conserva-
tion of the 23S rRNA nucleotides that comprise the ribosome-binding 
site of Onc112 is consistent with the broad spectrum of antimicrobial 
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activity displayed by this and related PrAMPs against a range of 
Gram-negative bacteria10,24.
Onc112 allows translation to initiate but blocks elongation
Comparison of the Tth70S–Onc112 structure with that of the 
Tth70S ribosome in the preattack state of peptide-bond formation20 
indicated that the binding of Onc112 to the ribosome would prevent 
accommodation of the CCA end of an incoming aminoacyl-tRNA 
via steric occlusion of the ribosomal A site at the peptidyl transferase 
center (Fig. 3a). Indeed, Asp2 of Onc112 directly interacts with 
G2553, a residue located within helix H92 of the 23S rRNA, termed 
the A loop, that normally stabilizes the A site tRNA at the peptidyl 
transferase center via Watson-Crick base-pairing with nucleotide C75 
of its CCA end.
In order to determine the step of translation that Onc112 inhibits, 
we performed cell-free protein synthesis and monitored the loca-
tion of the ribosomes on the mRNA (Fig. 3b and Supplementary 
Data Set 1), by using toe-printing assays25,26. In the absence of 
Onc112 or antibiotic, ribosomes were able to initiate at the AUG 
start codon and translate through the open reading frame, but they 
became trapped on the downstream isoleucine codon because iso-
leucine was omitted from the translation mix. In the presence of the 
antibiotics clindamycin or thiostrepton, ribosomes accumulated at 
the start codon and could not translate down to the isoleucine codon 
because these antibiotics prevent delivery and/or accommodation of 
the first aminoacyl-tRNA directly following the initiation codon27. 
We observed similar results when performing the toe-printing assay 
with increasing concentrations of the Onc112 peptide, namely a loss 
of the band corresponding to ribosomes stalled at the isoleucine 
codon and an increase in the band corresponding to the ribosomes 
accumulating at the start codon. These findings indicate that Onc112 
allows subunit joining and formation of the 70S initiation complex 
but prevents accommodation of the first aminoacyl-tRNA at the 
A site, as suggested by steric overlap between Onc112 and an A-site tRNA 
(Fig. 3a). This contrasts with a bona fide translation-initiation 
inhibitor, such as edeine, which interferes with the stable binding of 
fMet-tRNAiMet to the 30S subunit and thus prevents 70S initiation-
complex formation28, in agreement with the lack of a toe-print band 

















Figure 1 Onc112-binding site within the exit tunnel of the ribosome. 
Transverse section of the exit tunnel of the Tth70S ribosome showing the 
binding site for the Onc112 peptide (orange). Minimally biased Fo − Fc 
difference map contoured at +3.0? (blue) is observable for the  
first 12 amino acids of Onc112 (VDKPPYLPRPRPPRrIYNr-NH2;  
residues 1–12 are bold and underlined). Initiator tRNAiMet bound at  
the P site is shown in green. Inset shows the view chosen to display the 
Onc112 peptide relative to the complete 70S ribosome.
b
CCA-binding













































































Figure 2 Interactions between Onc112 and the ribosome.  
(a) Comparison of the conformation of 23S rRNA nucleotides  
(yellow) in the presence of Onc112 (orange) with their  
Onc112-free conformation (blue)19. (b–e) Overview of  
the first 12 aa of Onc112 (b) and interactions of Onc112  
(orange) with 23S rRNA nucleotides (yellow) from the A-site 
CCA-binding pocket (c), A-site crevice (d) and upper ribosomal 
exit tunnel (e), as distinguished by different background colors. 
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Onc112 destabilizes the translation-
initiation complex
We noticed that the toe-print bands at the 
start codon in the presence of Onc112 were 
consistently weaker than those observed in the presence of clindamy-
cin or thiostrepton (Fig. 3b and data not shown), thus suggesting that 
Onc112 may also perturb the placement of fMet-tRNAiMet at the P site. 
In the Tth70S–Onc112 structure, the P-site tRNA is uncharged, and its 
terminal A76 residue undergoes a conformational change that posi-
tions it ~3.4 Å away from the Onc112 peptide. In vivo, however, we 
would expect fMet-tRNAiMet to bind to the peptidyl transferase center 
in the same manner as in the Tth70S ribosome preattack complexes20, 
such that the formyl group of the fMet moiety would sterically 
clash with residues Tyr6 and Leu7 of the Onc112 peptide (Fig. 3a). 
Consequently, we used sucrose gradients to monitor disome forma-
tion upon translating a dicistronic ErmBL mRNA in vitro, in order to 
investigate the stability of the translation-initiation complex formed 
in the presence of Onc112 (Fig. 3c–g). As a positive control, we 
performed translation in the presence of the macrolide antibiotic 
erythromycin, which acts synergistically with the ErmBL polypeptide 
chain within the ribosomal tunnel to stall translation at a specific 
site on the mRNA29. Because the mRNA was dicistronic, two stalled 
ribosomes on a single mRNA led to the formation of disomes that 
could be visualized on a sucrose gradient (Fig. 3d), as shown previ-
ously16,23. We observed negligible disome formation in the absence 
of erythromycin because the ribosomes rapidly translated the short 
ORF and were released from the mRNA (Fig. 3e). As expected, thio-
strepton, which allows 70S initiation-complex formation but prevents 
elongation (Fig. 3b), also led to efficient disome formation (Fig. 3f). 
In contrast, the presence of Onc112, even at concentrations as high as 
100 ?M, resulted in only a small increase in disomes (Fig. 3g). This 
leads us to suggest that the 70S initiation complexes formed in the 
presence of Onc112 are unstable, presumably because the Onc112 
peptide encroaches onto fMet-tRNAiMet, thus causing it to dissociate 
from the ribosome under the nonequilibrium conditions (centrifuga-
















































































Figure 3 Onc112 blocks and destabilizes the 
initiation complex. (a) Structural comparison  
of Phe-tRNAPhe (blue) in the A site and  
fMet-tRNAiMet in the P site (green)20 with the 
binding site of Onc112 (orange). (b) Toe-printing 
assay performed in the absence (−) or presence  
of increasing concentrations (1 ?M, 10 ?M and 
100 ?M) of Onc112, 50 ?M clindamycin (Cli), 
50 ?M edeine (Ede) or 100 ?M thiostrepton (Ths). 
Sequencing lanes for C, U, A and G and the 
sequence surrounding the toe-print bands 
(arrows) when ribosomes accumulate at the 
AUG start codon (green, initiation complex) or 
the isoleucine codon (blue, stalled elongation 
complex) are included for reference, as illustrated 
graphically. The uncropped gel image for the  
toe-printing assay is in Supplementary Data Set 1. 
(c–g) Schematic (c) showing the dicistronic 
ErmBL mRNA that was used to monitor disome 
formation with sucrose gradients in the presence (d) 
or absence (e) of 20 ?M erythromycin (Ery) or the 
presence of 20 ?M thiostrepton (f) or 100 ?M 
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Figure 4 Characterization of Onc112, its C-terminally truncated derivatives and its membrane transporter in Gram-negative bacteria. (a,b) Effect of 
Onc112 (red) and C-terminally truncated Onc112 derivatives Onc112 ?C7 (green) and Onc112 ?C9 (purple) on overnight growth of E. coli strain 
BL21(DE3) (a) and the luminescence resulting from the in vitro translation of Fluc (b). (c) Effect of Onc112 on overnight growth of E. coli strain 
BW25113 (blue) or BW25113?sbmA (orange). In a and c, error bars represent mean ? s.d. for triplicate experiments, whereas the experiment in b 
was performed in duplicate, with the plotted points representing the mean value. The growth or luminescence measured in the absence of peptide was 
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Onc112 C terminus is needed for uptake, not ribosome binding
The lack of density for the C terminus of Onc112 (residues 13–19) 
hinted that this region is dispensable for ribosome binding, yet its 
high degree of conservation suggested that it may nevertheless be 
necessary for antimicrobial activity. In order to assess the role of the 
C-terminal region of Onc112, we prepared truncated versions of this 
peptide, Onc112 ?C7 and Onc112 ?C9, which lacked the last 7 and 
9 aa, respectively. We then determined the half-minimal inhibitory 
concentration (MIC50) for the growth of E. coli strain BL21(DE3) in 
the presence of full-length Onc112 and compared it with those of 
the truncated Onc112 ?C7 and Onc112 ?C9 derivatives (Fig. 4a). 
As expected, the full-length Onc112 displayed good activity, inhibit-
ing growth with an MIC50 of 10 ?M, a value similar to that reported 
previously14. In contrast, truncation of 7 or 9 aa from the C terminus 
of Onc112 led to a complete loss of inhibitory activity, even at con-
centrations above 100 ?M (Fig. 4a). To ascertain whether the trun-
cated Onc112 peptides could still bind to the ribosome and inhibit 
translation, we monitored in vitro translation of firefly luciferase 
(Fluc) by measuring luminescence after 60 min of translation in the 
presence of increasing concentrations of either full-length Onc112 
or the truncated Onc112 ?C7 and Onc112 ?C9 derivatives (Fig. 4b). 
As expected, the full-length peptide displayed excellent activity, inhib-
iting translation of Fluc with an IC50 of 0.8 ?M (Fig. 4b), a value 
similar to that reported when the same system was used for well- 
characterized translation inhibitors such as chloramphenicol30. In 
contrast to their lack of antimicrobial activity (Fig. 4a), both truncated 
Onc112 peptides displayed some inhibitory activity with the in vitro– 
translation system (Fig. 4b), albeit with a reduced efficiency relative 
to that of full-length Onc112. Specifically, the Onc112 ?C7 peptide 
consisting of residues 1–12 of Onc112 had an IC50 of 5 ?M, which was 
only six times greater than that of full-length Onc112, a result consist-
ent with our structure-based prediction that these residues comprise 
the major ribosome binding determinants. In contrast, the Onc112 
?C9 peptide consisting of aa 1–10 of Onc112 had an IC50 of 80 ?M, 
which was 16 times greater than that of Onc112 ?C7 and two orders 
of magnitude greater than that of full-length Onc112. These results 
illustrate the contribution of Arg11 to efficient ribosome binding and 
translation inhibition, as reported previously14.
Figure 5 Mechanism of action and overlap  
of Onc112 with antibiotics that target  
the large subunit of the ribosome. (a) Model  
for the mechanism of action of Onc112.  
(1) Onc112 binds within the exit tunnel  
of the ribosome with a reverse orientation  
relative to a nascent polypeptide chain.  
(2) Onc112 allows formation of a  
translation-initiation complex but  
prevents accommodation of the  
aminoacyl-tRNA (aa-tRNA) at the  
A site of the peptidyl transferase  
center. (3) The initiation complex  
is destabilized, thus leading to dissociation  
of the fMet-tRNAiMet from the P site.  
Although full-length Onc112 can  
efficiently penetrate the bacterial  
cell membrane by using the SbmA  
transporter (4), C-terminal truncation  
of Onc112 reduces its antimicrobial  
activity (5), presumably owing to  
impaired uptake. (b) Relative  
binding position of Onc112 (orange) on the ribosome, compared with those of well-characterized translation inhibitors chloramphenicol (purple)32,33, 
clindamycin (green)33, tiamulin (yellow)34 and erythromycin (blue)32,33 as well as an A site–bound Phe-tRNAPhe (ref. 20).
Although the inner-membrane protein SbmA has been shown to be 
responsible for the uptake of the eukaryotic PrAMPs Bac7 and PR39 
(refs. 4,5), the only insect PrAMP tested so far was apidaecin Ib4. 
In order to assess the role of SbmA in the uptake of Onc112, we compared 
the growth of an E. coli strain lacking the sbmA gene (?sbmA) with the 
parental strain BW25113 in the presence of increasing concentrations of 
Onc112 (Fig. 4c). As expected, the full-length Onc112 displayed excel-
lent activity against the susceptible SbmA-containing parental strain, 
inhibiting growth with an MIC50 of 8 ?M (Fig. 4c), a value similar 
to that observed with the BL21(DE3) strain (Fig. 4a). In contrast, the 
?sbmA strain displayed increased resistance to Onc112, such that even 
with 100 ?M Onc112, growth was reduced by only 20% (Fig. 4c). These 
findings indicate that SbmA is indeed necessary for the uptake of 
Onc112 into Gram-negative bacteria, such as E. coli, and provide fur-
ther support for the proposition that the SbmA transporter is involved 
in the mechanism of action of the entire group of the PrAMPs4.
DISCUSSION
From our structural and biochemical data, we propose a model to 
explain the mechanism by which PrAMPs such as oncocin inhibit 
translation (Fig. 5a). We have shown that the binding of Onc112 to 
the ribosomal exit tunnel allows formation of the 70S initiation com-
plex but prevents accommodation of the aminoacyl-tRNA into the 
A site (Fig. 5a, steps 1 and 2). Additionally, we propose that Onc112 
destabilizes the postinitiation complex by inducing dissociation of 
fMet-tRNAiMet from the P site (Fig. 5a, step 3). Finally, our data also 
suggest that positively charged residues distributed along the entire 
length of the Onc112 sequence are necessary for ensuring the efficient 
SbmA-mediated uptake of Onc112 into the cell, whereas residues 
from the N-terminal moiety of Onc112 are responsible for targeting 
this peptide to the ribosome (Fig. 5a, steps 4 and 5). We believe that 
this mechanism of action is likely to be the same for other PrAMPs, 
such as drosocin, pyrrhocoricin and apidaecin, which share many of 
the residues of Onc112 that are important for its ribosome binding 
and antimicrobial function.
The binding site for Onc112 within the ribosomal exit tunnel 
overlaps with the binding sites for a majority of the antibiotics 
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chloramphenicols, pleuromutilins (for example, tiamulin) and lincosa-
mides (for example, clindamycin), which inhibit peptide-bond forma-
tion by preventing the correct positioning of the tRNA substrates, as 
well as the macrolides (for example, erythromycin), which abort trans-
lation by interfering with the movement of the nascent polypeptide 
chain through the ribosomal exit tunnel27. Given the substantial spa-
tial overlap that exists between the binding sites for these antibiotics 
and the regions of the tunnel that interact with Onc112 (Fig. 5b) 
and presumably with several other PrAMPs, it appears likely that 
such antimicrobial peptides represent a vast, untapped resource for 
the development of new therapeutics. Several strategies have been 
pursued to design improved or entirely new antimicrobials that target 
the exit tunnel of the ribosome31. One approach consists of modi-
fying existing antibiotics to create semisynthetic compounds that 
possess enhanced antimicrobial properties, including better affinity 
for mutated or modified ribosomes, the ability to evade drug modi-
fication or degradation pathways, increased solubility, improved 
uptake and reduced efflux. Other strategies involve designing chi-
meric antibiotics from drugs with adjacent binding sites (for example, 
macrolide-chloramphenicol or linezolid-sparsomycin) or developing 
entirely new scaffolds, as exemplified by the oxazolidinone linezolid. 
The ability to produce new scaffolds based on peptides, such as 
Onc112, that display potent activity against a diverse range of Gram-
negative bacteria represents an exciting avenue for the development 
of future antimicrobials.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Coordinates and structure factors have been depos-
ited in the Protein Data Bank under accession code 4ZER.
Note: Any Supplementary Information and Source Data files are available in the online 
version of the paper.
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ONLINE METHODS
Peptide synthesis. Commercially available reagents were used throughout 
without purification. N,N-dimethylformamide (DMF, peptide synthesis– 
quality grade) was purchased from Carlo Erba, and piperidine and trifluoroacetic 
acid (TFA) were purchased from Alfa Aesar. Rink amide PS resin was purchased 
from PolyPeptide Laboratories. N,N?-diisopropylcarbodiimide (DIC), Oxyma 
and all standard N-Fmoc–protected l and d amino acids were purchased from Iris 
Biotech. N-Fmoc-cyclohexylalanine-OH (Fmoc-Cha-OH) was purchased from 
PolyPeptide laboratories. RP-HPLC–quality acetonitrile (CH3CN, Sigma-Aldrich) 
and MilliQ water were used for RP-HPLC analyses and purification. Analytical 
RP-HPLC analyses were performed on a Dionex U3000SD with a Macherey-
Nagel Nucleodur column (4.6 × 100 mm, 3 ?m) at a flow rate of 1 ml min−1 
at 50 °C. The mobile phase was composed of 0.1% (v/v) TFA-H2O (solvent A) 
and 0.1% TFA-CH3CN (solvent B). Purification was performed on a Gilson 
GX-281 with a Macherey-Nagel Nucleodur VP250/21 100–5 C18ec column 
(21 × 250 mm, 5 ?m) at a flow rate of 20 mL min−1. The solid-phase syntheses 
of peptides were conducted on an automated Liberty Blue System synthesizer 
(CEM ?Waves S.A.S.). 1H NMR spectra were recorded on a DPX-400 NMR 
spectrometer (Bruker Biospin) with a vertical 9.4T narrow-bore/ultrashield 
magnet operating at 400 MHz for 1H observation by means of a 5-mm direct 
QNP 1H/13C/31P/19F probe with gradient capabilities (Supplementary Fig. 5). 
ESI-MS analyses were carried out on a Thermo Exactive from the Mass 
Spectrometry Laboratory at the European Institute of Chemistry and Biology 
(UMS 3033–IECB), Pessac, France (Supplementary Fig. 5).
All peptides were synthesized on Rink Amide PS resin (0.79 mmol/g) with 
a five-fold excess of reagents for the coupling step (0.2 M N-Fmoc–amino acid 
solution (in DMF) with 0.5 M DIC (in DMF) and 1.0 M Oxyma (in DMF)). 
Coupling of N-Fmoc–protected l- and d-arginine-OH was performed twice at 
25 °C without microwaves for 1,500 s. Other amino acid couplings were 
performed first at 90 °C, 170 W, 115 s then at 90 °C, 30 W, 110 s. Fmoc removal 
was performed with a solution of 20% piperidine in DMF at 75 °C with 155 W 
for 15 s then 90 °C, 35 W, 50 s. After completion of the synthesis, the pep-
tide resin was washed three times with DCM. Cleavage was performed by 
treatment with 5 mL of a freshly prepared TFA/TIS/H20 solution for 240 min 
at room temperature. The resin was then filtered off, and the TFA solution was 
concentrated under reduced pressure. The crude products were precipitated as 
TFA salts in the presence of Et2O and purified with the appropriate gradient 
(10–30% of B in 20 min) by semipreparative RP-HPLC. The compounds were 
freeze dried, and TFA was exchanged with HCl by two repetitive freeze-drying 
cycles in 0.1 N HCl solution35.
The list of peptides prepared for this study and details concerning their 
synthesis is as follows: 
Onc112. H-Val-Asp-Lys-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Arg- 
(d-Arg)-Ile-Tyr-Asn-(d-Arg)-NH2 (2,389.85 g mol−1). Synthesis of Onc112 (0.1-
mmol scale): 24 mg (10% yield); RP HPLC tR 4.11 min (gradient 10–50% of B 
in 10 min); ESI HRMS (m/z): found 1,195.70 [M + 2H]2+, 797.47 [M +3 H]3+, 
598.35 [M + 4H]4+, and 478.88 [M + 5H]5+.
Onc112 ?C7. H-Val-Asp-Lys-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-NH2 
(1,433.73 g mol−1). Synthesis of Onc112 ?C7 (0.15-mmol scale): 79.4 mg (37% 
yield); RP HPLC tR 3.54 min (gradient 10–50% of B in 10 min); ESI HRMS (m/z): 
[M + H]+ calcd for C67H108H20O15, 1,433.83758 found 1,433.84017, with 717.42 
[M + 2H]2+ and 478.61 [M + 3H]3+.
Onc112 ?C9. H-Val-Asp-Lys-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-NH2  
(1,180.42 g mol−1). Synthesis of Onc112 ?C9. (0.1-mmol scale): 22.6 mg 
(19% yield); RP HPLC tR 4.78 min (gradient 10–50% of B in 10 min); ESI HRMS 
(m/z): [M + H]+ calcd for C56H89H15O13, 1,180.63370 found 1,180.68368, with 
[M + 2H]2+ 590.84 and [M + 3H]3+ 394.23.
Onc112 D2E. H-Val-Glu-Lys-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-
Arg-(d-Arg)-Ile-Tyr-Asn-(d-Arg)-NH2 (2,403.88 g mol−1). Synthesis of Onc112 
D2E (0.05-mmol scale): 11.6 mg (10% yield); RP HPLC tR 5.75 min (gradient 
10–50% of B in 10 min); ESI HRMS (m/z): found 1316.70 [M + 2H]2+, 840.14 
[M + 3H]3+ and 601.86 [M + 4H]4+.
Onc112 L7Cha. H-Val-Asp-Lys-Pro-Pro-Tyr-Cha-Pro-Arg-Pro-Arg-Pro-Pro-
Arg-(d-Arg)-Ile-Tyr-Asn-(d-Arg)-NH2 (2,429.92 g mol−1). Synthesis of Onc112 
L7Cha (0.05-mmol scale): 6.9 mg (6% yield); RP HPLC tR 5.28 min (gradient 
10–50% of B in 10 min); ESI HRMS (m/z): found 1,252.18 [M + 2H]2+, 822.80 
[M + 3H]3+ and 608.36 [M + 4H]4+.
CD spectroscopy. CD spectra of peptides were recorded on a J-815 Jasco 
spectropolarimeter (Jasco France). Data are expressed in terms of total molar 
ellipticity in deg cm2 dmol−1. CD spectra for the Onc112 peptide were acquired 
at four different concentrations in phosphate buffer (pH 7.6, 10 mM) between 
180 and 280 nm with a rectangular quartz cell with a path length of 1 mm (Hellma 
110-QS 1 mm) averaging over two runs. Secondary-structure proportion was 
estimated from the CD spectra with the deconvolution program CDFriend 
(S. Buchoux (Unité de Génie Enzymatique et Cellulaire, UMR 6022 CNRS-
Université de Picardie Jules Verne) and E. Dufourc (Université de Bordeaux, 
CNRS, Institut Polytechnique de Bordeaux, UMR 5248 Institut de Chimie 
et Biologie des Membranes et des Nano-objets (CBMN); available upon request), 
unpublished). This program uses standard curves obtained for each canonical 
structure (?-helix, ?-sheet, helix-polyproline type II and random coil) with LiKj 
(alternated hydrophobic leucine and hydrophilic/charged lysine residues) pep-
tides of known length, secondary structure and CD spectra. The program imple-
ments a simulated annealing algorithm to get the best combination of ?-helix, 
?-sheet, helix-II and random coil that exhibits the lowest normalized r.m.s. devia-
tion with respect to the experimental spectrum36–38. The algorithm yielded the 
following assessment for the Onc112 peptide: 54% random coil, 30% helix-PPII, 
6% ?-helix and 6% ?-sheet content.
Purification of T. thermophilus 70S ribosomes. Tth70S ribosomes were purified 
as described previously39 and resuspended in buffer containing 5 mM 
HEPES-KOH, pH 7.5, 50 mM KCl, 10 mM NH4Cl, and 10 mM Mg(CH3COO)2 
to yield a final concentration of 26–32 mg/mL. For storage, Tth70S ribosomes 
were flash frozen in liquid nitrogen and kept at −80 °C.
Preparation of mRNA and tRNAiMet. Synthetic mRNA with the sequence 
5?-GGC AAG GAG GUA AAA AUG CGU UUU CGU-3? was obtained from 
Eurogentec. This mRNA contains a Shine-Dalgarno sequence and an AUG start 
codon followed by several additional codons. E. coli tRNAiMet was overexpressed 
in E. coli HB101 cells and purified as described previously40.
Complex formation. A ternary complex containing Tth70S ribosomes, mRNA 
and deacylated tRNAiMet was formed by mixing of 5 ?M Tth70S ribosomes with 
10 ?M mRNA and incubating at 55 °C for 10 min. For the next step, 20 ?M 
tRNAiMet was added, and the mixture was incubated at 37 °C for 10 min. Before 
the complexes for crystallization were used, the sample was incubated at room 
temperature for at least 15 min. All complexes were centrifuged briefly before 
use for crystallization. The final buffer conditions were 5 mM HEPES-KOH, 
pH 7.6, 50 mM KCl, 10 mM NH4Cl and 10 mM Mg(CH3COO)2.
Crystallization. Published conditions were used as a starting point for screen-
ing crystallization conditions by vapor diffusion in sitting-drop trays at 20 °C 
(refs. 20,39). Crystallization drops consisted of 3 ?l of ternary complex and 3–4 ?l 
of reservoir solution containing 100 mM Tris-HCl, pH 7.6, 2.9% (v/v) PEG 20000, 
7–10% (v/v) MPD and 175 mM arginine. Crystals appeared within 2–3 d and 
grew to ~1,000 × 100 × 100 ?m within 7–8 d. For cryoprotection, the concen-
tration of MPD was increased in a stepwise manner to yield a final concentra-
tion of 40% (v/v). The ionic composition during cryoprotection was 100 mM 
Tris-HCl, pH 7.6, 2.9% (v/v) PEG 20000, 50 mM KCl, 10 mM NH4Cl and 10 mM 
Mg(CH3COO)2. Tth70S–Onc112 complexes were obtained by soaking 10–20 ?M 
of Onc112 dissolved in the final cryoprotection solution overnight at 20 °C. 
Crystals were then flash frozen in a nitrogen cryostream at 80 K for subsequent 
data collection.
Data collection and processing. Diffraction data were collected at beamline 
ID29 of the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. 
A complete data set was obtained by merging 0.1° oscillation data collected at 
100 K with a wavelength of 0.97625 Å from multiple regions of the same crystal. 
Initial data processing, including integration and scaling, were performed with 
XDS41. All of the data collected could be indexed in the P212121 space group, 
with unit-cell dimensions around 210 Å × 450 Å × 625 Å and an asymmetric 
unit containing two copies of the Tth70S ribosome.
Model building and refinement. Initial phases were obtained by molecular 
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a high-resolution structure of the Tth70S ribosome (PDB 4Y4O). Restrained 
crystallographic refinement was carried out with Phenix43 and consisted of a 
single cycle of rigid-body refinement followed by multiple cycles of positional 
and individual B-factor refinement. Rigid bodies comprised four domains from 
the small 30S subunit (head, body, spur and helix h44) and three domains from 
the large 50S subunit (body, L1 stalk and the C terminus of ribosomal protein 
L9). Noncrystallographic symmetry restraints between the two copies of the 
Tth70S ribosome in the asymmetric unit were also applied during refinement. 
After confirming that a single tRNA was bound to the P site and that additional 
density corresponding to the Onc112 peptide was visible inside the exit tunnel 
in a minimally biased Fo − Fc map, a model for Onc112 was built with Rapper44 
and Coot45. The models for the tRNA and mRNA were obtained from a high-
resolution structure of the Tth70S ribosome preattack complex (PDB 1VY4). 
Further refinement and model validation were carried out in Phenix and on the 
MolProbity server46, respectively. In the final model, 0.65% of protein residues 
were classified as Ramachandran outliers, and 94.38% had favorable backbone 
conformations.
In vitro–translation assay. The inhibition of firefly luciferase (Fluc) synthesis 
by Onc112 was assessed with an E. coli lysate–based transcription-translation 
coupled assay (RTS100, 5Prime) as described previously for other translational 
inhibitors30. Briefly, 6-?L reactions, with or without Onc112/antibiotic were 
mixed according to the manufacturer’s description and incubated for 1 h at 30 °C 
with shaking (1,000 r.p.m.). 1 ?L of each reaction was stopped with 7 ?L kan-
amycin (50 ?g/?l) and then diluted with 40 ?L of luciferase assay substrate 
(Promega) into a white 96-well chimney flat-bottom microtiter plate (Greiner). 
The luminescence was then measured with a Tecan Infinite M1000 plate reader. 
Relative values were determined by defining the luminescence value of the sample 
without inhibitor as 100%.
Growth inhibition assays. Determination of the minimal inhibitory concentration 
(MIC) of Onc112 was performed as described previously for other antibiotics30. 
Specifically, an overnight culture of E. coli strain BL21(DE3) (Invitrogen), 
BW25113 or Keio deletion strain BW25113?sbmA (plate 61, well 10E)47 was 
diluted 1:100 to an OD600 of ~0.02, and 200 ?L of the diluted cells was then trans-
ferred into individual wells of a 96-well plate (Sarstedt). Either 10 ?L of Onc112, 
Onc112 derivative peptide or water was added to each well. Plates were then incub-
ated overnight in a thermomixer (Eppendorf) at 37 °C/350 r.p.m. The OD600 was 
measured in a Tecan Infinite M1000 plate reader, and the relative growth was 
calculated by defining the growth of samples without antibiotic as 100%.
Toe-printing assay. The position of the ribosome on the mRNA was monitored 
with a toe-printing assay based on an in vitro–coupled transcription-translation 
system with the PURExpress in vitro protein synthesis kit (NEB)26. Briefly, each 
translation reaction consisted of 1 ?L solution A, 0.5 ?L ?isoleucine + tryptophan 






start codon ATG, catch isoleucine codon ATT and stop codon TAA in bold, 
the hns40aa ORF underlined and primer-binding sites in italics) and 0.5 ?L 
additional agents (nuclease-free water, Onc112 or antibiotics). Translation was 
performed in the absence of isoleucine at 37 °C for 15 min at 500 r.p.m. in 1.5-mL 
reaction tubes. Ile-tRNA aminoacylation was further prevented by the use of the 
Ile-tRNA synthetase inhibitor mupirocin. After translation, 2 pmol Alexa647-
labeled NV-1 toe-print primer (5?-GGTTATAATGAATTTTGCTTATTAAC-3?) 
was added to each reaction and incubated at 37 °C without shaking for 5 min. 
Reverse transcription was performed with 0.5 ?L of AMV RT (NEB), 0.1 ?L 
dNTP mix (10 mM) and 0.4 ?L Pure System Buffer and incubated at 37 °C for 
20 min. Reverse transcription was quenched and RNA degraded by addition 
of 1 ?L 10 M NaOH and incubation for at least 15 min at 37 °C and then was 
neutralized with 0.82 ?L of 12 M HCl. 20 ?L toe-print resuspension buffer and 
200 ?L PN1 buffer were added to each reaction before treatment with a QIAquick 
Nucleotide Removal Kit (Qiagen). The Alexa647-labeled DNA was then eluted 
from the QIAquick columns with 80 ?L of nuclease-free water. A vacuum 
concentrator was used to vaporize the solvent, and the Alexa647-labeled DNA 
was then dissolved into 3.5 ?L of formamide dye. The samples were heated to 
95 °C for 5 min before being applied onto a 6% polyacrylamide (19:1) sequencing 
gel containing 7 M urea. Gel electrophoresis was performed at 40 W and 2,000 V 
for 2 h. The GE Typhoon FLA9500 imaging system was subsequently used to 
scan the polyacrylamide gel.
Disome formation assay. The disome formation assay was performed as 
described previously16,23. Briefly, in vitro translation of the 2xermBL construct 
was performed with the Rapid Translation System RTS 100 E. coli HY Kit (Roche). 
Translations were carried out for 1 h at 30 °C and then analyzed on 10–55% 
sucrose-density gradients (in a buffer containing 50 mM HEPES-KOH, pH 7.4, 
100 mM KOAc, 25 mM Mg(OAc)2 and 6 mM ?-mercaptoethanol) by centrifuga-
tion at 154,693g (SW-40 Ti, Beckman Coulter) for 2.5 h at 4 °C.
Figure preparation. Figures showing electron density and atomic models were 
generated with PyMOL (http://www.pymol.org/).
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Supplementary Figure 1 
Overlap of Onc112 with nascent polypeptide chains in the ribosome exit tunnel. 
Comparison of the binding position of Onc112 (orange) with (a) ErmCL (green), (b) TnaC (blue) and Sec61E (red) nascent chains. In 
(a)-(c), the CCA-end of the P-tRNA is shown in white and in (b) the two tryptophan molecules are in cyan. 
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Supplementary Figure 2 
Comparison of Tth70S–Onc112 with the DnaK–oncocin complex. 
The conformation of residues Lys3–Pro10 of the Oncocin peptide O2 (cyan, VDKPPYLPRPRPPROIYNO–NH2, where O represents 
ornithine) in complex with DnaK (white surface representation) was compared with residues Val1–Pro12 of Onc112 (orange) from the
ribosome-bound Onc112 structure. 
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Supplementary Figure 3 
Conformation of the Onc112 peptide in solution. 
Far-UV circular dichroism (CD) spectra of the Onc112 peptide at concentrations ranging from 20 to 200 PM. 
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Supplementary Figure 4 
Inhibitory activity of Onc112 peptide derivatives. 
(a-b) Effect of Onc112 (red) and Onc112 derivatives Onc112–L7Cha (blue) and Onc112–D2E (olive) on (a) the overnight growth of 
E. coli strain BL21(DE3) and (b) the luminescence resulting from the in vitro translation of firefly luciferase (Fluc). In (a), the error bars 
represent the standard deviation (s.d.) from the mean for a triplicate experiment (n=3). In (b), the experiment was performed in 
duplicate (n=2). The growth or luminescence measured in the absence of peptide was assigned as 100%. 
 
Nature Structural & Molecular Biology: doi:10.1038/nsmb.3034 
Supplementary Figure 5 
Validation of Onc112 and derivatives. 
(a) Electrospray ionization high resolution mass spectrometry (ESI-HRMS) and reverse phase (RP) high performance liquid
chromatography (HPLC), and (b) 1H nuclear magnetic resonance (NMR) spectra of the Onc112 peptide. (c-f) ESI-HRMS and RP HPLC 
of the (c) Onc112–'C9, (d) Onc112–'C7, (e) Onc112–L7Cha and (f) Onc112–D2E peptides. 
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Tetracycline antibiotics and resistance 
mechanisms
Abstract: The ribosome and protein synthesis are major 
targets within the cell for inhibition by antibiotics, such 
as the tetracyclines. The tetracycline family of antibiot-
ics represent a large and diverse group of compounds, 
ranging from the naturally produced chlortetracycline, 
introduced into medical usage in the 1940s, to second 
and third generation semi-synthetic derivatives of tetracy-
cline, such as doxycycline, minocycline and more recently 
the glycylcycline tigecycline. Here we describe the mode 
of interaction of tetracyclines with the ribosome and 
mechanism of action of this class of antibiotics to inhibit 
translation. Additionally, we provide an overview of the 
diverse mechanisms by which bacteria obtain resistance 
to tetracyclines, ranging from efflux, drug modification, 
target mutation and the employment of specialized ribo-
some protection proteins.
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Introduction: the ribosome as a 
target for antibiotics
The ribosome is one of the major targets within the bacte-
rial cell for antibiotics, with a diverse range of antibiotics 
that have been discovered and shown to inhibit a variety 
of distinct steps during protein synthesis (Sohmen et al., 
2009a,b; Wilson, 2009, 2013). This wealth of biochemical 
and structural data has demonstrated that the majority of 
antibiotics interact with the functional centers of the ribo-
some: Many clinically important antibiotics bind at or near 
to the peptidyltransferase center (PTC) on the large riboso-
mal subunit where peptide bond formation occurs; these 
include the chloramphenicols, pleuromutilins (retapamu-
lin), oxazolidinones (linezolid), lincosamides (lincomy-
cin), macrolides (erythromycin), ketolides (telithromycin) 
and streptogramins (quinupristin and dalfopristin). On 
the small ribosomal subunit, antibiotic binding sites are 
clustered along the path of the mRNA and tRNAs, for 
example, spectinomycin, streptomycin, aminoglycosides 
(kanamycin), tuberactinomycins (viomycin) and tetra-
cyclines (doxycycline) (Sohmen et  al., 2009a,b; Wilson, 
2009, 2013). This review focuses on the latter class of 
antibiotics, the tetracyclines, which bind at the decoding 
center of the small subunit, i.e., where the codon of the 
mRNA is recognized by the anticodon of the tRNA. There 
have been many excellent reviews on different aspects of 
tetracycline inhibition and tetracycline resistance mecha-
nisms (Roberts, 1996; Chopra and Roberts, 2001; Connell 
et al., 2003b; Thaker et al., 2010; Nelson and Levy, 2011), 
so here we focus on the most recent biochemical and 
structural insights with an emphasis on aspects related 
directly to the translation machinery.
The tetracycline class of antibiotics
Discovery and chemical structure of 
tetracyclines
The first compound belonging to the tetracycline family, 
chlortetracycline, was discovered in 1948 by Dr. Benja-
min Duggar working at Lederle Laboratories (American 
Cyanamid) (Duggar, 1948). Chlortetracycline (Figure  1A) 
was isolated from Streptomyces aureofaciens, and called 
aureomycin because of the gold coloring of the bacteria 
(Duggar, 1948). Shortly afterwards, in the early 1950s 
Alexander Finlay from Pfizer discovered oxytetracycline 
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(Figure 1B), a secondary metabolite of soil bacteria Strep-
tomyces rimosus from the Terra Haute, Indiana, and there-
fore called ‘terramycin’ (Finlay et  al., 1950). Although 
both antibiotics were already on the market, their chemi-
cal structure remained elusive until 1953. The chemi-
cal  structures of chlortetracycline and oxytetra cycline 
(Figure  1A and B) were the results of joint efforts of a 
Pfizer team, together with the Nobel Prize  laureate, Robert 
B. Woodward (Stephens et al., 1952, 1954;  Hochstein et al., 
1953).
The basis of these structures is the DCBA naph-
thacene core comprising four aromatic rings (inset to 
Figure 1), therefore this family of antibiotics was named 
‘tetracyclines’ (Stephens et  al., 1952). It was noted that 
compared with oxytetracycline, chlortetracycline lacks 
a hydroxyl group at the C5 position of ring B and has a 
chlorine atom substituent present at the C7 position of 
ring D (Figure 1A and B). Moreover, as a result of chemical 
modifications, Pfizer-Woodward described C7-deschloro 
derivative of chlortetracycline, with a higher potency 
against bacterial pathogens, which was called ‘tetracy-
cline’ (Figure 1C, teracyn) (Conover et al., 1953), because 
it is the simplest member of the ‘tetracycline’ family of 
antibiotics. Subsequently, tetracycline was also detected 
in the broth of S.  aureofaciens (Backus et al., 1954) and 
S. rimosus (Perlman et al., 1960), consistent with the dis-
covery that tetracycline is a precursor of chlortetracycline 
( McCormick et al., 1960).
Soon after the discovery of first generation tetracy-
clines, Pfizer and Lederle began developing the second 
generation tetracycline compounds with improved phar-
macokinetic properties, increased antimicrobial potency 
and decreased toxicity. A series of chemical modifications 
of ring C led Pfizer to the semi-synthesis of methacycline 
(Boothe et al., 1959; Blackwood et al., 1961), which was 
further used as a precursor for the synthesis of doxycycline 
(Figure 1D; Vibramycin) (C6-deoxy-tetracycline) (Stephens 
et al., 1963), one of the most commonly used tetracyclines 
to date. Additionally, Lederle analyzed biogenesis mutants 
of chlortetracycline in S. aureofaciens, and discovered the 
precursor demeclocycline (C6-demethyl-C7-chlorotetracy-
cline) (McCormick et al., 1957), which was further reduced 
to sancycline (C6-demethyl-C6-deoxytetracycline), a tet-
racycline with the minimal chemical features necessary 
to retain antimicrobial activity ( McCormick et al., 1960). 
Subsequently, sancycline was converted to C7-amino-
sancycline or minocycline (Figure  1E; Minocin) (Martell 
and Boothe, 1967), the most powerful tetracycline of that 
period, and the last tetracycline to be introduced into the 
market in the 20th century.
Figure 1 Chemical structures of tetracyclines.
Chemical structures of (A–C) first generation tetracyclines. (A) chlortetracycline (aureomycin), (B) oxytetracycline (terracycline) and (C) 
tetracycline (teracyn), (D–E) second generation tetracyclines; (D) doxycycline (vibramycin) and (E) minocycline (minocin), and (F–G) third 
generation tetracyclines; (F) the glycylcycline tigecycline (tygacil), (G) the aminomethylcycline omadacycline (PTK 0796) and (H) the fluoro-
cycline eravacycline (TP-434). The numbers in parentheses indicates the year the antibiotic was discovered/reported. The inset of the DCBA 
naphthacene core provides the carbon atom assignments for rings A–D.
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Emerging antibiotic resistance renewed interest in 
the development of a third generation of tetracyclines. In 
the late 1980s, Lederle (later Wyeth) reopened the tetra-
cycline program. Already known tetracycline derivatives 
were re-evaluated and their action revisited according 
to the recent knowledge about tetracycline action (Tally 
et  al., 1995), leading to a focus on modifications of the 
C7 and C9 positions of ring D of the sancycline core. 
The breakthrough came with the synthesis of a series of 
C9-aminotetracyclines bearing a glycyl moiety (Sum et al., 
1994), leading to the development of a new class of third 
generation tetracyclines, referred to as glycylcyclines. 
A glycyl derivative of minocycline, tigecycline (Figure F; 
Tygacyl) (Petersen et al., 1999), with a t-butyl amine group 
was one of the most potent antimicrobials and is the first 
tetracycline introduced into the market in over 40 years. 
Currently, two additional third generation tetracyclines 
are in phase III clinical trials: Omadacycline (PTK 0796; 
Figure 1G) is a 9-alkylaminomethyl derivative of minocy-
cline (aminomethylcycline) (Draper et al., 2013) and was 
developed by Paratek Pharmaceuticals, which applies 
transition metal-based chemistry to produce tetracycline 
derivatives (Nelson et al., 2003). Conversely, Tetraphase 
Pharmaceuticals utilized Meyers’ chemistry (Sun et  al., 
2008) to obtain the fluorocycline eravacycline (TP-434; 
Figure 1H), which bears C7-fluoro and C9-pyrrolidinoace-
toamido modifications of ring D (Grossman et al., 2012).
The binding site of tetracycline on the 30S 
subunit and 70S ribosome
X-ray structures of tetracycline in complex with the 
Thermus thermophilus 30S subunit provided the first 
direct visualization of the drug binding sites (Figure 2A) 
(Brodersen et al., 2000; Pioletti et al., 2001). In the first 
study, the crystals were soaked in 80 µm tetracycline and 
the structure determined to 3.4 Å revealed two tetracycline 
binding sites on the 30S subunit (Brodersen et al., 2000). By 
contrast, in the second study crystals were soaked in 4 µm 
tetracycline and the resulting structure at 4.5 Å reported 
six distinct tetracycline binding sites (Pioletti et al., 2001). 
However, only one tetracycline binding site was common 
between the two studies, termed the ‘primary binding 
site’ (Tet1), which is located at the base of the head of the 
30S subunit (Figure 2A), and was subsequently verified 
biochemically (Connell et al., 2002). The identification of 
multiple lower occupancy secondary binding sites (Tet2) 
was not unexpected, as earlier biochemical evidence indi-
cated that tetracyclines have multiple binding sites on the 
small and large subunit (Gale et al., 1981). For example, 
tetracycline binding enhances the reactivity of U1052 and 
C1054 of the 16S rRNA present in the primary binding site, 
but also protects the nucleotide A892, located in one of 
the secondary binding sites, from chemical modification 
(Moazed and Noller, 1987). Recently, an X-ray structure 
of tetracycline bound to an initiation complex compris-
ing the T. thermophilus 70S ribosome bound with P-site 
tRNAfMet and mRNA was determined at 3.5 Å (Jenner et al., 
2013). Interestingly, only one molecule of tetracycline was 
bound to the 70S ribosome, namely at the primary binding 
site (Figure 2B) and no secondary binding sites were 
observed (Jenner et al., 2013), re-emphasizing the higher 
affinity and occupancy of the primary binding site relative 
to the secondary binding sites.
In the primary binding site, tetracycline utilizes the 
hydrophilic surface of the molecule to interact with the 
irregular minor groove of helix 34 (h34) and the loop of 
h31 of the 16S rRNA (Figure 2C). This is consistent with the 
observations that alterations of the hydrophilic surface 
(C1–C4, C10–C12) of tetracycline abolish the antimicro-
bial activity of the drug, whereas the hydrophobic surface 
(C5–C9) is more amenable to modification without loss of 
inhibitory activity (Nelson, 2001), as seen in many natural 
product tetracyclines (Figure 1). The hydrophilic side of 
tetracycline establishes hydrogen-bond interactions with 
the phosphate-oxygen atoms of nucleotides C1054, G1197 
and G1198 in h34 of the 16S rRNA, directly and/or via coor-
dination of a magnesium ion (Mg1) (Figure 2C) (Brodersen 
et al., 2000; Pioletti et al., 2001; Jenner et al., 2013). The 
possibility of an additional magnesium ion (Mg2) medi-
ating the interaction between the phosphate backbone of 
G966 in h31 and ring A of tetracycline was proposed based 
on the recent 70S structure (Jenner et  al., 2013). These 
findings are consistent with the earlier studies indicating 
the importance of divalent magnesium for binding of tet-
racycline to the ribosome (White and Cantor, 1971).
The interaction of tetracycline with the backbone of 
the rRNA, rather than by establishing sequence-specific 
nucleobase interactions (Figure 2C), is consistent with 
the broad-spectrum activity of tetracycline antibiotics 
( Bradford and Jones, 2012). The single interaction between 
ring D of tetracycline and the nucleobase of C1054 of the 
16S rRNA involves stacking interactions (Figure 2C) and 
is therefore unlikely to be sequence-specific. The high 
structural conservation of the tetracycline binding site in 
eukaryotic ribosomes (Ben-Shem et al., 2011) is consistent 
with the documented inhibitory activity of tetracycline 
against eukaryotic translation in vitro (Budkevich et al., 
2008). Thus, antibiotic uptake probably makes a larger 
contribution to the natural resistance of eukaryotic cells 
to tetracyclines.
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Figure 2 Binding site of tetracyclines on the ribosome.
(A) Primary (Tet1) and secondary (Tet2) binding sites of tetracycline on the 30S subunit (Brodersen et al., 2000; Pioletti et al., 2001). (B) 
Binding site of tetracycline/tigecycline (Tet1/Tig) on the 70S ribosome (30S, yellow; 50S, blue) (Jenner et al., 2013) relative to mRNA (teal), 
A-tRNA (orange) (Voorhees et al., 2009). h44 of the 16S rRNA and H69 of the 23S rRNA are indicated for reference. (C) Interaction of tetra-
cycline within the primary binding site (Jenner et al., 2013). The charged side of tetracyclines coordinates magnesium ions to interact with 
the backbone of residues h34 and h31. (D) Binding position of tetracycline (Jenner et al., 2013) relative to mRNA (teal) and A-tRNA (orange) 
(Voorhees et al., 2009). (E) Interaction of tigecycline within the primary binding site, illustrating the additional interaction between the 
C9-substitution of tigecycline and C1054 of the 16S rRNA (Jenner et al., 2013). (F) Binding position of tigecycline (Jenner et al., 2013) relative 
to mRNA (teal) and A-tRNA (orange) (Voorhees et al., 2009).
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The mechanism of action of tetracyclines 
during translation
During translation, aminoacyl-tRNAs are delivered to 
the ribosome by the elongation factor EF-Tu. A proof-
reading process ensues that monitors correctness of the 
interaction between the anticodon of the aminoacyl-
tRNA and the A-site codon of the mRNA. Selection of the 
correct or cognate tRNA stimulates the GTP hydrolysis 
activity of EF-Tu, resulting in conformational changes 
in EF-Tu that lead to dissociation of EF-Tu·GDP from the 
ribosome, and the concomitant accommodation of the 
aminoacyl-tRNA into the A-site. The primary binding 
site of tetracycline is located within the decoding center 
of the small subunit and overlaps in position with the 
anticodon loop of an A-site bound tRNA (Figure 2B 
and D). Specifically, rings C and D of tetracycline steri-
cally clash with the first nucleotide of the anticodon 
of the tRNA that interacts with the third (or wobble) 
base of the A-site codon of the mRNA (Figure 2D). The 
competition for ribosome binding between tetracycline 
and A-tRNA was observed during the crystallization of 
the tetracycline-70S complex, where initial co-crystal-
lization studies using 60 µm tetracycline and five-fold 
excess of tRNAfMet (over ribosomes) led to non-specific 
binding of tRNAfMet to the A-site, rather than tetracy-
cline (Jenner et al., 2013). To obtain electron density for 
tetracycline, co-crystallization experiments were per-
formed with higher concentrations of tetracycline (300 
µm) coupled with lower excess (1.5-fold) of tRNAfMet. 
These findings are consistent with biochemical experi-
ments demonstrating that tetracycline inhibits binding 
of tRNAs to the ribosomal A-site, but not the ribosome-
stimulated EF-Tu GTPase activity (Gale et  al., 1981; 
 Blanchard et  al., 2004). Specifically, single molecule 
FRET experiments indicate that in the presence of tetra-
cycline (40 µm; 10 × Kd), aminoacyl-tRNA accommoda-
tion is efficiently blocked, resulting in repetitive ternary 
complex binding and release events (Blanchard et al., 
2004; Geggier et al., 2010; Jenner et al., 2013). Indeed, 
the overlap between tetracycline and A-tRNA is similar 
regardless of whether the A-tRNA is still bound to EF-Tu 
in an initial selection state or whether the A-tRNA has 
fully accommodated into the A-site on the 70S ribosome.
Second generation tetracycline derivatives: 
doxycycline and minocycline
Second generation tetracyclines, such as doxycycline and, 
in particular, minocycline, exhibit superior antimicrobial 
activities compared to tetracycline against a range of Gram-
negative (e.g., Escherichia coli and Pseudomonas aerugi-
nosa) and especially Gram-positive (Staphylococcus aureus 
and Enterococcus faecalis) bacteria (Bradford and Jones, 
2012), including some strains of tetracycline-resistant 
bacteria (Testa et al., 1993; Sum et al., 1994). Consistently, 
minocycline has a ∼20-fold higher affinity to the ribosome 
than tetracycline (but 5-fold lower than tigecycline) and 
inhibits in vitro translation 2–7-fold more efficiently than 
tetracycline (Bergeron et  al., 1996; Olson et  al., 2006). 
The similarity in chemical structure between minocycline 
and tetracycline (Figure 1) and the ability of minocycline 
to compete with tetracycline for ribosome binding (Olson 
et al., 2006), suggests that minocycline binds analogously 
to the ribosome as tetracycline. Presumably the improved 
binding properties of minocycline result from presence of 
the C7-dimethylamido group on ring D that may facilitate 
stacking interactions with C1054 (Figure 2C). Addition-
ally, second generation tetracyclines, such as minocycline, 
are more lipophilic than their parent compounds and as 
a result display better absorption and pharmacokinetic 
parameters (Agwuh and MacGowan, 2006).
Third generation tetracycline derivatives: 
glycylcyclines and tigecycline
The third generation of tetracycline derivatives includes 
the glycylcyclines, which bear an N,N-dimethylglycyla-
mido (DMG) moiety on the C9 position of ring D (Figure 1F) 
(Barden et al., 1994; Sum et al., 1994). Compared to first 
(e.g., tetracycline) and second generation tetracyclines 
(e.g., minocycline), the 9-DMG derivatives of minocycline 
(termed tigecycline or DMG-MINO) (Figure 1F) and san-
cycline (DMG-DMDOT) display improved inhibitory activi-
ties against a wide range of Gram-positive and negative 
bacteria and in particular have similar minimal inhibitory 
concentrations against susceptible and resistant bacterial 
strains (Testa et al., 1993; Barden et al., 1994; Sum et al., 
1994). Consistently, glycylcyclines, such as tigecycline, 
exhibit ∼10–30 fold lower half inhibitory concentrations 
(IC50) during in vitro translation compared with tetracy-
cline (Bergeron et al., 1996; Olson et al., 2006; Grossman 
et al., 2012; Jenner et al., 2013) as well as having improved 
ribosome binding properties. Specifically, DMG-DMDOT 
and DMG-DOX bind to the ribosome with a ∼5-fold higher 
affinity than tetracycline (Bergeron et al., 1996), whereas 
tigecycline has been reported to have a ∼10–100-fold 
higher binding affinity for the ribosome compared to tet-
racycline (Olson et al., 2006; Grossman et al., 2012; Jenner 
et al., 2013).
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A 3.3 Å resolution X-ray structure of tigecycline bound 
to the T. thermophilus 70S ribosome reveals that tigecycline 
binds to the decoding center on the 30S subunit analo-
gously to tetracycline (Figure 2B) (Jenner et al., 2013). No 
secondary binding sites were observed (Jenner et al., 2013). 
Moreover, unlike tetracycline, crystallization in the pres-
ence of 60 µm tigecycline and 5-fold excess of tRNAfMet (over 
ribosomes) was sufficient to yield clear electron density for 
the drug and prevent non-specific binding of tRNAfMet to 
the A-site, thus re-emphasizing the higher binding affinity 
of tigecycline for the ribosome compared to tetracycline. 
As expected, based on the common features of the chemi-
cal structures of tetracycline and tigecycline (Figure 1C 
and F),  tigecycline uses the polar face of the drug to estab-
lish an analogous network of hydrogen-bond interactions 
with two Mg2+ ions and the phosphate-oxygen backbone 
of h34 and h31 of the 16S rRNA (Figure 2E). The similarity 
in binding site of tigecycline with tetracycline is also sup-
ported by the competition between tigecycline and tetracy-
cline for ribosome binding (Olson et al., 2006; Grossman 
et al., 2012; Jenner et al., 2013), as well as the similarity in 
chemical footprinting and hydroxyl-radical cleavage pat-
terns generated in the presence of either drug (Moazed and 
Noller, 1987; Bauer et al., 2004). However, in the case of 
tigecycline, ∼10-fold lower concentrations of the drug were 
required compared to tetracycline in order to generate the 
same modification patterns (Bauer et al., 2004).
The major differences between tigecycline and tetracy-
cline are the 7-dimethylamido and 9-t-butylglycylamido sub-
stitutions attached to ring D of tigecycline (Figure 1F). While 
the 7-dimethylamido moiety does not appear to establish 
interactions with the ribosome, the glycyl nitrogen atom of 
the 9-t-butylglycylamido moiety of tigecycline stacks with the 
π-orbital of nucleobase C1054 (Figure 2E). The remainder of 
the 9-t-butylglycylamido moiety of tigecycline adopts a very 
rigid conformation (although it does not make any appar-
ent contact with the ribosome), which may contribute to the 
stacking interaction with C1054. Indeed, the interaction of 
tigecycline with C1054 appears to further enhance the stack-
ing interaction between C1054 and U1196 (Figure 2E), similar 
to what is seen when tRNA is bound to the A-site ( Schmeing 
et  al., 2009). Thus, the stacking interaction between the 
9-t-butylglycylamido moiety of tigecycline and C1054 and 
U1196, which is lacking or less optimal in tetracycline (Figure 
2E), provides a structural basis for the improved ribosome 
binding properties of  tigecycline. Additionally, the 9-t-butyl-
glycylamido moiety of tigecycline significantly increases 
the steric overlap of tigecycline and the anticodon loop of 
the A-tRNA (Figure  2F), compared to the modest overlap 
observed between tetracycline and the A-tRNA (Figure 2D). 
Collectively, the enhanced binding affinity of tigecycline, 
together with the increased steric overlap with the A-tRNA, 
provides a likely explanation for the increased effectiveness 
of tigecycline (2 µm) to prevent stable binding of the ternary 
complex EF-Tu·GTP·aa-tRNA to the A-site, compared to 40 
µm tetracycline (Jenner et al., 2013).
Third generation tetracycline derivatives: 
omadacycline and eravacycline
Two additional third generation tetracycline derivatives 
with C9 substitutions on ring D, which display broad-spec-
trum activity against tetracycline-susceptible and -resistant 
bacterial strains, are in phase III clinical trials. Omadacy-
cline is an aminomethylcycline (Figure 1G) developed by 
Paratek Pharmaceuticals (Boston, MA, USA; Draper et al., 
2013). Competition studies with radiolabeled tetracycline 
indicate that omadacycline has a 2-fold higher affinity for 
the ribosome than tetracycline and, consistently, omadacy-
cline inhibits in vitro translation at 2-fold lower drug con-
centrations than tetracycline (Draper et  al., 2013; Jenner 
et  al., 2013). Eravacycline (Tetraphase Pharmaceuticals, 
Watertown, MA) is a glycylcycline bearing a fluorine atom at 
position C7 and a pyrrolidinoacetamido group at the C9 of 
ring D (Figure 1H). Competition studies with radiolabelled 
tetracycline indicate that eravacycline has 10-fold higher 
affinity for the ribosome than tetracycline and inhibits in 
vitro translation at 4-fold lower drug concentrations than 
tetracycline (Grossman et al., 2012). The similar ribosome 
binding affinity of eravacycline (0.2 µm) and tigecycline 
(0.2 µm) (Grossman et al., 2012; Jenner et al., 2013) and the 
reduced affinity of compounds with amide bond replace-
ments in the 9-position, such as omadacycline (2 µm) 
(Draper et al., 2013; Jenner et al., 2013) and 9-propylpyr-
rolidyl-7-fluorocyline (4 µm) (Jenner et al., 2013) is consist-
ent with an important role of the amide to strengthen the 
stacking interactions of the C9 substitution with C1054. 
Introduction of an additional aromatic ring E to generate 
pentacyclines (Sun et al., 2010) also improves the binding 
and inhibitory properties of the drug relative to tetracycline 
(Jenner et al., 2013), further supporting the hypothesis that 
stacking interactions with C1054 enhance the binding and 
inhibitory properties of tetracycline derivatives.
Tetracycline resistance mechanisms
There are four main mechanisms by which bacteria can 
acquire resistance to tetracyclines (Table 1). In addi-
tion, innate mechanisms exist because some bacteria 
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Table 1 Tetracycline resistance determinants.
Efflux   Ribosomal 
protection
  Degradation   rRNA 
mutations
tetA   tet31   tetM   tetX   G1058C
tetB   tet33   tetO   tet37   A926T
tetC   tet35   tetQ     G927T
tetD   tet38   tetS     A928C
tetE   tet39   tetT     ∆G942
tetG   tet40   tetW    
tetH   tet41   tetB(P)    
tetJ   tet42   tet32    
tetK   tet45   tet36    
tetL   tetAB(46)   tet44    
tetA(P)   tcr3   otrA    
tetV   otrC   tet    
tetY   otrB      
tetZ        
tet30        
are naturally more resistant to tetracyclines due to dif-
ferences in the permeability of the cell membrane. For 
example, Gram-negative bacteria are naturally resistant 
to several antibiotics because of the presence of a 
lipopolysaccharide containing outer membrane layer. 
In addition, the presence of small molecule transport-
ers can also act on drugs to differing extents in differ-
ent bacteria, conferring resistance by pumping the drugs 
out of the cell. Of the acquired resistance mechanisms, 
the most prevalent tetracycline resistance mechanism 
is efflux, with 28 distinct classes of efflux pumps identi-
fied so far (Table 1). Following closely are the so-called 
ribosome protection proteins, which bind to the ribo-
some and remove the drug from its binding site, with 12 
distinct classes reported (Table 1). Less prevalent resist-
ance mechanisms include two distinct genes that encode 
monooxygenases, which modify tetracyclines and 
promote their degradation, and mutations within the 
16S rRNA that reduce the binding affinity of the drug for 
the ribosome (Table 1). In addition, a novel tetracycline 
resistance determinant, tetU, encoded on the plasmid 
pKq10 in E.  faecium has been reported to confer some 
tetracycline resistance (Ridenhour et al., 1996), however, 
a recent study questions the validity of this conclusion 
(Caryl et al., 2012).
Efflux pumps to expel tetracycline from 
the cell
The 28 different classes of efflux pumps (Table 1) present in 
Gram-negative and Gram-positive bacteria fall into seven 
defined groups based primarily on sequence homology 
(Guillaume et al., 2004). By far the largest group are the 
group 1 drug-H+ antiporters containing 12 transmembrane 
helices, and comprise the well characterized tetracycline 
efflux pumps, such as TetA, the most frequently occurring 
tetracycline-resistance determinant in Gram-negative bac-
teria. Although no structures exist for tetracycline efflux 
pumps, the high homology of the group 1 efflux pumps 
like TetA with the major facilitator superfamily (MFS) of 
secondary active transporters, implies a similar mem-
brane topology and structural ‘inward-outward’ mecha-
nism of action within the cell membrane (Figure 3A). Such 
efflux proteins exchange a proton (H+) for the tetracycline 
molecule against a concentration gradient (Piddock, 
2006). Most tetracycline efflux pumps confer resistance 
to tetracycline, but are less effective against second gene-
ration doxycycline and minocycline, and confer little or 
no resistance to third generation glycylcyclines, such as 
tigecycline (Chopra and Roberts, 2001). For example, the 
MIC of E. coli strain DH10B expressing the TetA efflux 
pump is  > 128 µg/ml for tetracycline, 32 µg/ml for doxycy-
cline, 8 µg/ml for minocycline and 1 µg/ml for tigecycline 
( Grossman et al., 2012). Nevertheless, laboratory-derived 
mutations in tetA and tetB have been generated that can 
confer some glycylcycline resistance, but at the expense of 
tetracycline resistance (Guay et al., 1994).
In many cases, there is a fitness cost associated with 
the expression of antibiotic resistance genes, therefore 
many bacteria regulate the expression of the resistance 
gene(s) using translational attenuation, transcriptional 
attenuation and translational coupling (Chopra and 
Roberts, 2001). Another mechanism that is used for regu-
lation of tet resistance genes is negative control by a Tet 
repressor protein (TetR) (Hillen and Berens, 1994; Saenger 
et al., 2000). In the absence of tetracycline, TetR binds as 
a homodimer to two tandemly orientated tet operators to 
block transcription of the efflux pump (Figure 3B), such 
as observed in the structure of the TetR-DNA complex 
(Figure 3C) (Orth et al., 2000). However, in the presence 
of tetracycline, the drug binds to TetR, which dissociates 
from the tet operator, thus inducing transcription and 
induction of expression of the TetA efflux pump (Figure 3B) 
(Saenger et al., 2000). In some cases, the tetR gene is also 
encoded directly in front of the efflux pump, and there-
fore TetR will rebind the tet operator only when insuffi-
cient amounts of tetracycline are in the cell and re-block 
transcription of its own gene and that of the downstream 
efflux pump (Hillen and Berens, 1994). Crystal structures 
of tetracycline in complex with the TetR homodimer 
reveal that tetracycline binds to the C-terminal effector-
binding domain and induces conformational changes in 
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the N-terminal helix-turn-helix DNA-binding domain of 
TetR (Hinrichs et al., 1994; Kisker et al., 1995). The confor-
mational changes lead to an increase in the separation of 
the DNA-binding domains such that interaction with the 
tet operator sequence of the DNA is precluded (Figure 3D) 
(Orth et al., 2000; Saenger et al., 2000). Although glycyl-
cyclines, such as tigecycline, can bind to the C-terminal 
effector-binding domain of TetR, this interaction induces 
only a limited conformational change in the DNA-binding 
domain (Figure 3E) (Orth et  al., 1999), consistent with 
the reduced (5-fold) induction of TetR-regulated TetA 
expression observed in the presence of tigecycline com-
pared to tetracycline (Orth et al., 1999).
Modification of tetracyclines leads to drug 
degradation
The tetX and tet37 tetracycline resistance determinants 
encode FAD-requiring monooxygenases (Figure 4A) 
that confer resistance to tetracyclines through modifica-
tion of the drug (Speer et al., 1991; Yang et al., 2004). The 
Figure 3 TetR-mediated regulation of the tetracycline resistance TetA efflux pump.
(A) Schematic for mechanism of action of efflux pump TetA, illustrating that efflux of tetracycline (but not tigecycline) is coupled to proton 
transport. The homology model for the TetA efflux pump was generated by HHPred (Söding et al., 2005) based on similarity with the 
proton-driven MFS transporter YajR from Escherichia coli (PDB ID 2WDO) (Jiang et al., 2013). (B) Schematic for TetR-mediated regulation of 
TetA, illustrating that tetracycline binding to the TetR homodimer leads to activation of transcription of the tetA gene. (C–E) Structures of 
TetR homodimer in complex with (C) DNA (Orth et al., 2000), (D) tetracycline (Hinrichs et al., 1994; Kisker et al., 1995) and (E) tigecycline 
(Orth et al., 1999). In (D), the binding of tetracycline to the C-terminal effector domain induces conformational changes in the DNA-binding 
domain (arrowed) that leads to loss of interaction with the DNA.
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mono oxygenases utilize NADPH and O2 to hydroxylate 
position C11a located between ring B and C of  tetracyclines 
(Figure  4B). The hydroxylated form of the drug has 
 significantly altered chemical properties that perturb 
the magnesium coordination properties of the drug and 
presumably therefore reduce the drugs affinity for the 
 ribosome. Moreover, the hydroxylated tetracycline under-
goes a non-enzymatic decompo sition. The requirement of 
O2 for the mono oxygenase activity means that the resistance 
mechanism only operates in bacteria growing in aerobic 
conditions.
Crystal structures indicate that monooxygenases, 
such as TetX, recognize the common core of the tetracy-
clines, specifically moieties present on rings A and B of 
the drug (Volkers et al., 2011, 2013), thus explaining why 
these enzymes also modify tetracycline derivatives, such 
as the glycylcycline tigecycline (Moore et al., 2005), which 
has an identical ring A and B arrangement as  tetracycline 
(Figure  1C and F). Moreover, the ring D substitutions 
present in glycylcyclines protrude from the active site 
(Figure 4A) and therefore do not prevent binding and 
 modification of these derivatives by the TetX enzyme 
(Volkers et al., 2013). While C11a-hydroxytigecycline has 
an MIC of 64 µg/ml against E. coli compared to 0.5 µg/
ml for tigecycline, the presence of the tetX gene in E. coli 
results in an MIC of only 2 µg/ml for tigecycline but 128 µg/
ml for tetracycline (Moore et al., 2005; Grossman et al., 
2012). This suggests that even if tigecycline is a substrate 
for TetX, the enzymatic reaction is severely impaired 
with tigecycline compared to tetracycline. Furthermore, 
there have not been any reports to date of TetX in clini-
cal isolates conferring tetracycline resistance therefore, at 
present, TetX is unlikely to influence the effectiveness of 
new glycylcyclines, such as tigecycline.
Ribosome mutations conferring resistance to 
tetracyclines
Mutations conferring resistance to tetracycline antibiotics 
have been reported within the 16S rRNA. The first reported 
mutation was a G1058C substitution in h34 of the 16S rRNA 
of clinical isolates of the Gram-positive bacteria Propioni-
bacterium acnes (Ross et al., 1998). These bacterial isolates 
encode three homozygous copies of the rRNA bearing the 
G1058C substitution, resulting in an increased MIC for tet-
racycline as well as for doxycycline and minocycline (Ross 
et  al., 1998). Some resistance (4-fold increase in MIC) to 
tetracycline was also observed when the 16S rRNA operon 
bearing the G1058C substitution was overexpressed from a 
plasmid in a wildtype E. coli strain bearing seven copies of 
the susceptible 16S rRNA operon (Ross et al., 1998). Over-
expression of the G1058C rRNA operon in an E. coli strain 
lacking the seven rRNA operons produced an 8-fold increase 
in MIC for tetracycline and tigecycline (Bauer et al., 2004). 
Consistently, tetracycline has a lower affinity for ribosomes 
Figure 4 Tetracycline resistance via drug modification and degradation.
(A) Overlay of structures of the TetX monooxygenase (yellow) in complex with tigecycline (green) (Volkers et al., 2013) or tetracycline (blue) 
(Volkers et al., 2011). (B) Reaction pathway for TetX-mediated hydroxylation of tetracycline, which requires cofactors FAD, NADPH2 and O2. 
(C–D) FAD and residues of TetX recognize moieties of ring A and B of (C) tigecycline (Volkers et al., 2013) and (D) tetracycline (Volkers et al., 
2011) to mediate hydroxylation of position C11a (arrowed), which leads to degradation of the drugs.
Brought to you by | Max-Planck-Gesellschaft - WIB6417
Authenticated | 141.14.18.81
Download Date | 4/17/14 10:51 AM
568      F. Nguyen et al.: Tetracycline antibiotics and resistance mechanisms
bearing the G1058C mutations than wildtype ribosomes 
(Nonaka et  al., 2005). In wildtype bacterial ribosomes, 
G1058 forms a base-pair interaction with U1199 in h34, 
which would be disrupted by a G1058C mutation. Therefore, 
the decreased affinity of tetracycline for G1058C containing 
ribosomes most likely results from local conformational per-
turbations of the neighboring nucleotides G1197 and G1198 
that are involved in direct interactions with tetracycline as 
well as in the coordination of a Mg2+ ion (Figure 2C).
Tetracycline resistance mutations have also been 
identified within the stem loop of helix 31 of the 16S rRNA 
in Helicobacter pylori strains, with the triple mutation 
A965U/G966U/A967C conferring high-level resistance 
against tetracycline (Dailidiene et al., 2002; Trieber and 
Taylor, 2002) as well as an increased MIC for doxycycline 
and minocycline (Gerrits et al., 2002). Overexpression of 
the 965AGA-UUC967 triple mutation containing rRNA operon 
in an E. coli strain lacking the seven rRNA operons pro-
duced a 4-fold increased MIC for tetracycline and tigecy-
cline (Bauer et al., 2004). Studies performing systematic 
site-directed mutagenesis of positions 965–967 indicate 
that the strength of the tetracycline resistance was gener-
ally proportional to the severity of the changes relative to 
the wildtype sequence, i.e., with single and double muta-
tions tending to confer lower level resistance than triple 
mutations (Gerrits et al., 2003; Nonaka et al., 2005). Con-
sistently, binding of tetracycline was the least efficient 
to ribosomes bearing the triple mutation (AGA-UUC), 
although still reduced for ribosomes bearing single muta-
tions (e.g., AGC or GGA) when compared with wildtype 
(AGA) ribosomes (Nonaka et  al., 2005). The decreased 
affinity of tetracycline for ribosomes bearing mutations in 
positions 965–967 most likely arises from perturbations in 
the conformation of the loop of helix 31, thus disrupting 
the interaction between the phosphate-oxygen of G966 of 
the 16S rRNA and the Mg2+ ion that is coordinated by ring 
A of tetracycline (Figure 2C). It is noteworthy that although 
the AGA-UUC triple mutation and G1058C cause a similar 
fold increase in the MIC for tigecycline and tetracycline, 
the absolute MIC90 of tigecycline for G1058C (1 µg/ml) and 
AGA-UUC (0.5 µg/ml) is still 16-fold lower when compared 
with the respective MIC90s for tetracycline (Bauer et al., 
2004), consistent with the increased affinity and effective-
ness of tigecycline over tetracycline.
Factor-assisted protection: ribosome protec-
tion proteins
To date, there are 12 distinct classes of ribosome protec-
tion proteins (RPPs) that confer resistance to tetracycline 
(Table 1), with the best-characterized being TetO and TetM 
(reviewed by Connell et al., 2003a). TetO is usually found 
on plasmids present in Campylobacter species, but has 
also been discovered chromosomally in several Gram-
positive organisms, e.g., Streptococcus and Staphylococcus 
(Roberts, 1994). In contrast, TetM, which is usually present 
on conjugative transposons (such as Tn916 and Tn1545), 
was first identified in Streptococcus sp., but has subse-
quently been found in a wide variety of Gram-positive 
and Gram-negative species (Roberts, 1994). The different 
classes of RPPs have high homology with one another; for 
example, TetO from Campylobacter jejuni displays  > 75% 
identity ( > 85% similarity) with TetM from E. faecalis. The 
presence of mosaic RPPs comprising regions from dis-
tinct RPP classes have also been reported, for example the 
novel mosaic tetS/M gene identified in foodborne strains 
of Streptococcus bovis (Barile et al., 2012). In general, RPPs 
are thought to have derived from otrA, which confers tet-
racycline resistance in the natural producer of oxytetracy-
cline, Streptomyces rimosus (Doyle et al., 1991).
Sequence alignments indicate that RPPs are GTPases 
with the most significant homology (∼25% identity and 
∼35% similarity) to translation factor EF-G (Burdett, 1991), 
which has allowed homology models for RPPs such as 
TetM to be generated (Dönhöfer et al., 2012) (Figure 5A–D). 
However, RPPs, such as TetM, cannot complement tem-
perature sensitive E. coli EF-G (or B. subtilis EF-Tu) mutants 
(Burdett, 1991) and thus RPPs are considered paralogs of 
EF-G that have attained the specialized function to improve 
translation in the presence of tetracycline (Connell et al., 
2003a) (Figure 5E). Analogous to EF-G, biochemical 
studies indicate that TetM and TetO bind to both GTP and 
GDP (Burdett, 1991; Taylor et al., 1995), and that mutation 
of the conserved Asn128 of the nucleotide binding G4 motif 
within the G domain of TetO results in reduced tetracycline 
resistance (Grewal et al., 1993), consistent with the impor-
tance of GTP binding for RPP action. Moreover, binding 
of TetO and TetM to the ribosome requires GTP or GDPNP, 
and does not occur with GDP (Dantley et al., 1998; Trieber 
et al., 1998). The GTPase activities of both TetM and TetO 
are stimulated (10–20-fold) by the presence of ribosomes 
(Burdett, 1991; Taylor et al., 1995; Connell et al., 2003b), 
however the release of tetracycline from the ribosome by 
TetM or TetO can occur in the presence of non-hydrolyz-
able GTP analogs, such as GDPNP (Burdett, 1996; Trieber 
et al., 1998; Connell et al., 2002). This indicates that GTP 
hydrolysis is not strictly necessary for tetracycline release, 
but rather for dissociation of the RPP from the ribosome. 
Curiously, the ribosome-dependent GTPase of TetM, but 
not of EF-G, is slightly stimulated by the presence (up 
to 1 mM) of tetracycline (Burdett, 1996). In contrast, the 
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ribosome-dependent GTPase activity of TetM and TetO is 
inhibited by thiostrepton (Connell et al., 2003b; Starosta 
et al., 2009; Mikolajka et al., 2011) and the toxin α-sarcin 
(Connell et  al., 2003b), as observed previously for other 
translation factors, such as EF-G (Wilson, 2009).
TetO binds preferentially to the POST translocational 
state ribosome (Connell et al., 2003b), which is expected as 
during translation elongation, it is the POST state ribosome 
that is stabilized by the action of tetracycline to prevent 
delivery of aa-tRNA to the ribosomal A-site (Figure 5E). Cryo-
electron microscopy (EM) structures of TetM (Figure 6A) and 
TetO (Figure 6B) in complex with ribosome reveal that RPPs 
occupy a similar binding site as EF-G (Figure 6C) (Spahn 
et al., 2001; Dönhöfer et al., 2012; Li et al., 2013), consist-
ent with the competition observed between TetM and EF-G 
for ribosome binding (Dantley et al., 1998). As EF-G binds 
to the PRE translocational state and specifically stabilizes 
a rotated ribosome with hybrid site tRNAs before convert-
ing it into a POST state (Figure 5E), RPPs are unlikely to 
compete with EF-G during translation in the cell. Competi-
tion between RPPs and EF-G/EF-Tu might however explain 
the inhibition observed when high concentrations of RPPs 
are used in in vitro translation systems (Trieber et  al., 
1998).
Although no crystal structures of RPPs exist to date, the 
cryo-EM structure of the TetM·70S complex (Figure 6A) was 
sufficiently resolved (∼7 Å resolution) as to allow docking of 
a molecular model for the TetM protein, generated based on 
homology with EF-G (Figure 5A–D) ( Dönhöfer et al., 2012). 
This exercise led to the discovery of a conserved C-terminal 
extension (CTE) in RPPs that adopts a short α-helix, which 
is absent in EF-G ( Figure  5 A–D). Truncation of the CTE 
abolished the ability of TetM to confer resistance to tetra-
cycline in E. coli, indicating the critical importance of the 
Figure 5 Tetracycline resistance mediated by ribosome protection proteins.
(A) Schematic comparing the domain arrangement of EF-G and the RPP TetM. (B–D) Comparison of (B) the crystal structure of Thermus ther-
mophilus EF-G (PDB ID 2WRI) (Gao et al., 2009) with a homology model for TetM [colored as in (A); PDB ID 3J25 (Dönhöfer et al., 2012)] and 
(D) superimposition of (B) and (E). (E) Schematic illustrating the translation elongation cycle (green) and cycle of tetracycline inhibition and 
TetM-mediated tetracycline resistance (blue).
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short α-helix for TetM function (Dönhöfer et al., 2012). On 
the ribosome, the CTE of TetM is observed to be sandwiched 
between domain IV of TetM and helix 44 (h44) of the 16S 
rRNA (Figure 6D), consistent with chemical patterns in h44 
observed upon TetO binding (Connell et al., 2002;  Dönhöfer 
et al., 2012). Although the CTE of TetO was modeled dif-
ferently in the 10 Å resolution cryo-EM structure of the 
TetO·70S complex (Figure 6E) (Li et al., 2013), the electron 
density of the TetO·70S map suggests that the CTE of TetO 
does in fact adopt a short α-helix and interact with h44 as 
observed in the TetM-70S structure (Figure 6D and E), and 
consistent with the high identity ( > 75%) between TetM and 
TetO. A similar discrepancy was also observed for loop 1 of 
domain IV, which was modeled in an extended conforma-
tion in the TetO-70S complex (Figure 6D) and proposed to 
form, together with surrounding rRNA nucleotides, a cor-
ridor which the tetracycline molecule navigates during its 
release from the ribosome (Li et al., 2013). However, careful 
inspection of the cryo-EM maps of both the TetO and TetM 
complexes does not support an extended conformation, 
but rather suggests that loop 1 adopts a kinked conforma-
tion for both TetO and TetM in order to establish interac-
tions with the CTE (Figure 6D and E). In contrast, both the 
TetO·70S and TetM·70S structures are in agreement with 
respect to an interaction between loop 2 of domain IV and 
nucleotides in h34 (Dönhöfer et al., 2012; Li et al., 2013), 
consistent with the chemical protections of h34 observed 
upon TetO binding to the ribosome (Connell et al., 2002; 
Connell et al., 2003b).
In the first cryo-EM structure of a TetO·70S complex 
at 16 Å, density for TetO was not observed to overlap 
with tetracycline in the primary binding site, leading to 
the proposal that the RPPs remove tetracycline from the 
ribosome, not directly, but by inducing a local distur-
bance in h34 (Spahn et  al., 2001). However, the subse-
quent higher resolution RPP·70S structures reveal that 
loop 3 of domain IV interacts with the vicinity of C1054 
of the 16S rRNA (Dönhöfer et al., 2012; Li et al., 2013), and 
thus directly encroaches upon the binding site of tetra-
cycline (Figure  7A and B), and more extensively tigecy-
cline (Figure 7C) (Jenner et al., 2013). This suggests that 
residues within loop 3 of RPPs are involved in directly dis-
lodging tetracycline from its binding site. Alanine scan-
ning mutagenesis of loop 3 of domain IV of TetM however 
did not reveal any single critical amino acid, but rather the 
double Y506A/Y507A mutation was required to abolish 
TetM-mediated tetracycline resistance (Dönhöfer et  al., 
2012). Surprisingly, despite the high sequence conserva-
tion of loop 3 across different RPPs (Figure 7D), a single 
mutation Y507A was reported to inactivate C. jejuni TetO 
(Li et al., 2013). The system used to assess the tetracycline 
resistance however yielded only ∼2-fold changes in MIC 
for the wildtype TetO protein (Li et al., 2013), whereas  > 10-
fold differences were observed with wildtype TetM (Dön-
höfer et al., 2012). Therefore, a reanalysis of C. jejuni TetO 
and Listeria monocytogenes TetS was performed, reveal-
ing that like TetM, these RPPs confer a  > 10-fold increase 
in MIC compared to the parental strain, and that while the 
Figure 6 Structures of TetM, TetO and EF-G in complex with the 70S ribosome.
(A–C) Cryo-EM structures of (A) TetM (blue) (Dönhöfer et al., 2012) and (B) TetO (orange) (Li et al., 2013) on the ribosome, compared with (C) 
the binding position of EF-G (red) (Gao et al., 2009). (D–F) Cryo-EM map (grey) of the (D) TetM·70S (Dönhöfer et al., 2012) complex or (E, F) 
TetO·70S (Li et al., 2013) complex, with molecular model for domain IV of (D, F) TetM (blue) (Dönhöfer et al., 2012) and (E) TetO (orange) (Li 
et al., 2013).
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single mutation Y507A reduces the MIC, the Y506A/Y507A 
double mutation was necessary to completely inactivate 
TetO and TetS (Figure 7E and F), as reported previously 
for TetM (Dönhöfer et al., 2012). Based on these findings, 
it is tempting to speculate that these aromatic tyrosine 
residues in loop 3 establish stacking interactions with 
C1054 to dislodge tetracycline from its binding, however, 
higher resolution structures of RPP·70S complexes will be 
required to validate this hypothesis.
The enhancement of C1054 to chemical modification 
that is observed upon TetO binding remains subsequent 
to dissociation of TetO from the ribosome, suggesting that 
Figure 7 The role of Loop 3 of domain IV of RPPs for tetracycline resistance.
(A) Overview of relative position of TetM (blue) (Dönhöfer et al., 2012), tetracycline/tigecycline (red) (Jenner et al., 2013) and 30S subunit 
(yellow). (B–C) Relative binding positions of loop 3 of domain IV of TetM (Dönhöfer et al., 2012) compared to (B) tetracycline (blue) and 
(C) tigecycline (green) (Jenner et al., 2013). (D) Sequence alignment of RPPs showing conservation of loop 3 (red box) of domain IV (black 
boxes indicate identical residues, grey boxes indicate similar residues). (E–F) Growth curves of wildtype E. coli strain BL21 (-TetO or -TetS, 
black) in the presence of increasing concentrations of tetracycline (0–128 µg/ml) compared with the WT strain harboring a plasmid encod-
ing wildtype (E) C. jejuni TetO (+TetO WT, red) or (F) L. monocytogenes TetS (+TetS WT, red), or single (blue) or double (green) mutants. 
 Experiments were performed as described in (Dönhöfer et al., 2012).
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RPPs may imprint a defined conformation of C1054 in the 
ribosome, which on one the hand prevents rebinding of 
tetracycline and on the other hand favors delivery of the 
aa-tRNA by EF-Tu (Connell et al., 2002, 2003a,b). In this 
context, it is interesting to note that mutations in the miaA 
gene of E. coli interfere with the ability of TetM and TetO 
to confer tetracycline resistance (Burdett, 1993; Taylor 
et al., 1998). The miaA gene encodes an enzyme involved 
in the modification of tRNA position A37, which is located 
3’ adjacent to the anticodon of tRNAs that decode codons 
starting with U (Esberg and Bjork, 1995). The modifica-
tion [2-methylthio-N6-(D2-isopentenyl)adenosine] has 
been shown to stabilize the anticodon-codon interaction 
by improving stacking interactions (Vacher et al., 1984), 
and the lack of this modification significantly reduces the 
affinity of these tRNAs for the ribosome as well as reduc-
ing the efficiency and fidelity of translation (Vacher et al., 
1984; Esberg and Bjork, 1995). Thus, the lower level of 
tetracycline resistance in E. coli miaA mutants suggests 
that RPP induced alterations within the decoding site that 
promote binding of modified tRNAs are unfavourable for 
binding of the unmodified aminoacyl-tRNAs.
Although RPPs increase the MIC for tetracycline, 
doxycycline and minocycline, these proteins have little or 
no effect on the potency of third generation tetracyclines, 
such tigecycline, eravacycline and omadacycline (Gross-
man et al., 2012; Draper et al., 2013; Jenner et al., 2013). 
The ability of third generation tetracyclines to over-
come TetM action does not appear to be related only to 
an increase in binding affinity compared to tetracycline, 
since omadacycline displays a similar affinity to azacy-
cline, which does not overcome TetM action (Jenner et al., 
2013). The C9-moiety of the third generation tetracyclines 
might therefore contribute not only to the binding affinity 
of the drug, but also enhance the on-rate of the drug as 
well as sterically hinder residues within loop 3 of the TetM 
from accessing nucleotide C1054 to dislodge the drug from 
its binding site on the ribosome (Figure 7C). It will be inter-
esting to see whether alterations within loop 3 of domain 
IV can give rise to RPPs that confer resistance against third 
generation tetracyclines, such as tigecycline.
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Ribosome protection proteins (RPPs) confer resistance to tetracy-
cline by binding to the ribosome and chasing the drug from its
binding site. Current models for RPP action are derived from 7.2- to
16-Å resolution structures of RPPs bound to vacant or nontranslat-
ing ribosomes. Here we present a cryo-electron microscopy recon-
struction of the RPP TetM in complex with a translating ribosome
at 3.9-Å resolution. The structure reveals the contacts of TetMwith
the ribosome, including interaction between the conserved and
functionally critical C-terminal extension of TetM with a unique
splayed conformation of nucleotides A1492 and A1493 at the decod-
ing center of the small subunit. The resolution enables us to un-
ambiguously model the side chains of the amino acid residues
comprising loop III in domain IV of TetM, revealing that the tyrosine
residues Y506 and Y507 are not responsible for drug-release as
suggested previously but rather for intrafactor contacts that appear
to stabilize the conformation of loop III. Instead, Pro509 at the tip of
loop III is located directly within the tetracycline binding site where
it interacts with nucleotide C1054 of the 16S rRNA, such that RPP
action uses Pro509, rather than Y506/Y507, to directly dislodge and
release tetracycline from the ribosome.
ribosome | antibiotic | tetracycline | resistance | TetM
The ribosome is one of the major targets for antibiotics withinthe bacterial cell (1, 2). A well-characterized class of broad-
spectrum antibiotics in clinical use are the tetracyclines, which
bind to elongating ribosomes and inhibit delivery of the EF-
Tu•GTP•aa-tRNA ternary complex to the A-site (1, 3). X-ray
crystal structures of ribosomal particles in complex with tetra-
cycline have revealed that the primary drug binding site is lo-
cated in helix 34 (h34) of the 16S rRNA, overlapping the binding
position of the anticodon-stem loop of an A-site tRNA (4–6).
The widespread use of tetracyclines has led to an increase in
tetracycline resistance among clinically relevant pathogenic
bacteria, thus limiting the medical utility of many members of
this class (7). Drug efflux and ribosome protection are the most
common tetracycline resistance mechanisms acquired by bacteria
(8) and have led to the development of the third generation of
tetracycline derivatives, such as tigecycline, which display en-
hanced antimicrobial activity and overcome both the efflux and
ribosome protection resistance mechanisms (6, 9–11).
To date, there are 12 distinct classes of ribosome protection
proteins (RPPs) that confer resistance to tetracycline, with the
most prevalent and best characterized being TetO and TetM
(3, 8, 12). The different classes of RPPs have high homology
with one another; for example, Campylobacter jejuni TetO dis-
plays >75% identity (>85% similarity) with Enterococcus faecalis
TetM. Based on the presence of conserved nucleotide binding
motifs, RPPs are grouped together within the translation factor
superfamily of GTPases (13). Accordingly, TetO and TetM
catalyze the release of tetracycline from the ribosome in a GTP-
dependent manner (14, 15). Biochemical studies indicate that,
although GTPase activity is necessary for multiturnover of RPPs,
GTP hydrolysis is not strictly required to dislodge tetracycline
because the drug is also released when nonhydrolysable GTP
analogs are used (14, 15).
Nonhydrolysable GTP analogs have been used to trap RPPs
on the ribosome for structural analysis by cryo-EM. The first
structure of an RPP-ribosome complex was a cryo-EM re-
construction of a TetO•70S complex at 16-Å resolution. This
structure revealed that TetO binds analogously to the ribosome
as translation elongation factor EF-G (16), consistent with
the significant homology (∼25/35% identity/similarity) between
RPPs and EF-G (17). Because the electron density for TetO did
not come within 6 Å of the tetracycline-binding site (16), TetO
was suggested to chase the drug from the ribosome by in-
ducing conformational changes within h34 (12, 16, 18). In con-
trast, two subsequent structures at higher resolution, a TetM•70S
complex at 7.2 Å (19) and a TetO•70S complex at 9.6 Å (20),
revealed electron density for the RPPs directly overlapping with the
tetracycline binding site. Based on the homology with EF-G, mo-
lecular models for the RPPs were generated and docked into the
cryo-EM maps, suggesting that residues within loop III of
domain IV of TetM/TetO come into direct contact with the
tetracycline molecule (19, 20). Consistently, mutagenesis studies
identified specific residues within loop III that are critical for
RPP activity (19–21), in particular the conserved tyrosine resi-
dues Y506 and Y507 (19, 20). However, the exact role of these
tyrosine residues and a detailed molecular understanding of the
mechanism by which RPPs dislodge tetracycline from its binding
site was not possible at the reported resolutions.
Here we present a cryo-EM structure of TetM in complex with
a translating ribosome at an average resolution of 3.9 Å. Local
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resolution calculations indicate that the majority of the core of
the ribosome and domain IV of TetM extends toward 3.5 Å,
enabling bulky side chains to be modeled. We provide a detailed
account of the interactions between TetM and the ribosome, in
particular revealing a complex network of interactions of the
C-terminal helix and domain IV of TetM with the ribosomal
decoding site and intersubunit bridge B2a. The structure reveals
that Pro509 at the tip of loop III, rather than the previously
identified tyrosine Y506 and Y507, overlaps the binding site of
tetracycline and is therefore directly involved in releasing tetra-
cycline from the ribosome.
Results and Discussion
Cryo-EM Structure and Molecular Model of a TetM•RNC. In our
previous study (19), the TetM•70S complex was formed using
vacant 70S ribosomes, which led to high heterogeneity because
the vacant ribosomes adopted both rotated and nonrotated states.
Moreover, because TetM only interacts with the nonrotated ri-
bosomes, the heterogeneity reduced the overall occupancy of
TetM on the ribosome. A further reduction in occupancy resulted
from the presence of tigecycline, the binding of which (contrary to
initial expectations; refs. 16 and 19) was mutually exclusive with
TetM binding (19). As a result, the final reconstruction of the
TetM•70S complex was derived from only 52,701 (12%) of the
initial 406,687 particles and yielded a resolution of 7.2 Å (19). To
reduce sample heterogeneity and increase the TetM occupancy,
we omitted tigecycline and formed a complex between TetM and
a translating, rather than vacant, 70S ribosome. We have pre-
viously prepared and determined cryo-EM structures of 70S
ribosomes stalled during translation of Erm leader peptides
by the presence of the macrolide antibiotic erythromycin (22–24).
These studies revealed that the ErmCL-stalled ribosome is an
ideal substrate for TetM binding because the ribosome adopts a
nonrotated conformation with a peptidyl-tRNA in the P-site and a
vacant A-site (22, 24). Therefore, the ErmCL-stalled ribosomes
were bound with TetM in presence of the nonhydrolysable GTP
analog, GDPCP, and the resulting sample was subjected to multi-
particle cryo-EM (Materials and Methods).
Data were collected on a Titan Krios transmission electron
microscope, fitted with a Falcon II direct electron detector, and
processed with the SPIDER software package (25). After re-
moval of nonaligning and edge particles, in silico sorting re-
vealed the presence of two subpopulations of ribosomes bearing
peptidyl-tRNA in the P-site, and either a vacant A-site (25%) or
an A-site occupied by TetM (75%) (SI Appendix, Fig. S1A). The
latter volume, which we term the TetM•ribosome nascent chain
complex (TetM•RNC), contained 78,186 particles and was re-
fined further to produce a final cryo-EM map of the TetM•RNC
(Fig. 1A) with an average resolution of 3.9 Å (based on the
Fourier shell correlation cutoff at 0.143, SI Appendix, Fig. S1B).
Similar to our recent cryo-EM structure of the ErmCL-RNC
(22), local resolution calculations indicate that the ribosomal
core of the TetM•RNC extends to 3.5 Å (SI Appendix, Fig. S1 C
and D). The resolution of domains I-V of TetM was pre-
dominantly between 3.5–4.5 Å (Fig. 1B), but with some regions
extending to >5 Å, indicating flexibility as observed recently
for other ribosome-bound ligands (26–29). Strand separation in
β-sheets and the pitch of helices is observed, allowing a more
accurate and complete backbone model to be presented for all
639 residues in domains I–V of TetM (Fig. 1C).
Moreover, the high resolution of the ribosome enabled us to
more precisely map the sites of interaction with TetM (Fig. 1D
and SI Appendix, Table S1) compared with previous reports (16,
19, 20). Overall, the interactions of TetM are similar to those for
translation GTPases, such as EF-G (30), such that on the 50S
subunit, the G domain of TetM contacts the sarcin-ricin loop
(SRL, H95 of the 23S rRNA) and ribosomal protein L6, whereas
the G′ subdomain interacts with one of the C-terminal domains
of L7 (Fig. 1 D and E and SI Appendix, Fig. S2 A–F). Domain V
of TetM inserts into the cleft formed by H43/H44 of the
Fig. 1. Cryo-EM reconstruction of TetM•RNC. (A) Cryo-EM density map of the TetM•RNC, with TetM (orange), 30S (yellow), 50S (gray), and P-tRNA (green).
(B and C) Extracted cryo-EM density for TetM colored according to local resolution (B) and with fitted polyalanine model into the density (gray mesh) for
domains I (G domain), G′ subdomain, II, III, IV, V, and C-terminal extension (CTE) (C). (D) Overview of the TetM•RNC showing cryo-EM density with fitted
models for 30S (yellow) and 50S (gray) subunits, and TetM (orange). Ribosomal proteins contacting TetM are colored (S12, brown; L6, cyan; L7, yellow; L10,
red; L11, violet). (E) Model for the TetM•RNC with rRNA helices that interact with TetM colored (h34, green; h44, pink; H43/H44, dark green; H69, light blue;
H95, dark blue). (F) Side-view of E. (G) Side view of E with zoom onto 16S rRNA helices h34 (green) and h44 (pink) and 23S rRNA helix H69 (blue) that directly
interact with domain IV and the CTH of TetM (orange).
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23 rRNA and L11, overlapping the binding site of thiostrepton (31)
(SI Appendix, Fig. S2 A–F) and explaining the inhibition of TetM
by this antibiotic (32–34). On the small subunit, domain III of
TetM contacts ribosomal protein S12 (Fig. 1 D and E), whereas
domain IV of TetM wedges between the head and body of the
30S, reaching into the decoding center where contacts with h34
(head) and h44 (body) of the 16S rRNA are observed, as well as
between the C-terminal extension of TetM and H69 of the 23S
rRNA (Fig. 1 F and G).
Interaction of Domain IV of TetM with the 30S Subunit. Domain IV
of TetM comprises a four-stranded β-sheet and two α-helices,
with an overall βββαβα topology. Three loops (termed Loop I, II,
and III) protrude from the distal end of domain IV of TetM (Fig.
2A). The proline-rich loop I, located between β24 and β34, was
modeled differently in the recent TetM- and TetO-bound ribo-
some structures (3, 19, 20). In our structure, loop I adopts a bent
conformation to establish interactions with the C-terminal helix
αACTE of TetM (Fig. 2A), similar to that predicted previously for
TetM (19), but quite unlike the extended conformation sug-
gested for TetO (20) (SI Appendix, Fig. S3 A–D). We believe that
a bent conformation of loop I of TetO would be more consistent
with the electron density for the TetO•70S complex as well as
with the high sequence conservation between TetO and TetM
(SI Appendix, Fig. S3 A–F). Moreover, the extended conforma-
tion modeled for the TetO•70S structure is incompatible with
the presence of mRNA (SI Appendix, Fig. S3A), suggesting that
loop I is unlikely to form part of a corridor that tetracycline
navigates during its release from the ribosome (20).
The density for Loop II between β44 and αA4 is poorly or-
dered, however interaction with helix 34 of the 16S rRNA is
apparent, with residues Ser465 and Leu466 of TetM coming into
close proximity with the backbone of C1209 and the nucleobase
of C1214 (Fig. 2B). This finding is in agreement with the pro-
tection of C1214 from DMS modification upon TetO binding to
the ribosome (18, 32). With the exception of Gly467, the residues
of loop II are not highly conserved and mutagenesis of these
residues exhibited only moderate affects on TetM activity (SI
Appendix, Fig. S3 G and H). We note, however, that shortening
of the loop by removal of two amino acids was previously shown
to completely inactivate TetO (20).
Interaction of TetM at the Ribosomal Decoding Site. The C-terminal
extension (CTE) of TetM comprises a short 11-aa α-helix (resi-
dues 627–637) connected to domain V by a flexible linker (Fig.
2C), consistent with previous reports (19). Sequence alignments,
secondary structure predictions, as well as the electron density
for the TetO•70S complex (SI Appendix, Fig. S4 A–F) lead us to
suggest that the topology of the CTE observed here for TetM is
a conserved feature of all RPPs. The C-terminal helix (CTH)
is likely to stabilize domain IV of TetM on the ribosome, as we
observe contact between the CTH and A1913 located at the tip
of H69 of the 23S rRNA (Fig. 2C). A1913 adopts a very defined
position, similar to that observed when A-tRNA or A/T-tRNA
(in complex with EF-Tu) is bound to the ribosome (35, 36) (Fig.
2D and SI Appendix, Fig. S4 G and H), but distinct from the
conformation observed in the absence of A-tRNA where A1913
inserts into h44 of the 16S rRNA (6) (Fig. 2D). Although nu-
cleotides A1492 and A1493 of h44 exhibit some flexibility
Fig. 2. Interactions of domain IV and the CTH of TetM. (A) Overview of domain IV (orange) and the C-terminal extension (cyan) of TetM, indicating in-
teraction of loops I-III with rRNA helices h34, h44 and H69 as well as loop I with the C-terminal helix (CTH) of TetM. (B) Proximity of loop II residues (Cα atoms
shown as yellow spheres) to the nucleotides C1209, C1051 and C1214 of h34 of the 16S rRNA. (C and D) Interaction of the CTH of TetM (orange) with nu-
cleotide A1913 of H69 of 23S rRNA (deep blue). In D, the positions of A1913 with ribosome lacking A-tRNA (green, PDB 4G5U; ref. 6) or containing A-tRNA
(blue, PDB 3TVE; ref. 36) or A/T-tRNA (pink, PDB 2XQE; ref. 35) are shown. (E and F) Flipped-out conformations of nucleotides A1492 and A1493 of h44 of the
16S rRNA (blue) upon TetM (orange) binding to the ribosome. In F, the positions of A1492 and A1493 with ribosome lacking A-tRNA (green, PDB 4G5T; ref. 6)
or containing A-tRNA (blue, PDB 3TVF; ref. 36) or A/T-tRNA (pink, PDB 2XQD; ref. 35) are shown.








(SI Appendix, Fig. S4 I and J), both nucleotides clearly adopt
preferred conformations when TetM is bound, such that both
nucleotides are flipped-out of h44 and extend toward Loop I and
the CTH, respectively, of TetM (Fig. 2E). The flipping of A1492
and A1493 by TetM binding was suggested previously at 7.2 Å
(19) to resemble the conformation observed during decoding of
the mRNA–tRNA duplex (35–37) (Fig. 2F). At higher resolu-
tion, however, it is evident that the exact conformations of A1492
and A1493 are distinct and the nucleotides adopt an unusual
splayed conformation (Fig. 2 E and F), which to our knowledge
has not been observed before. The most similar conformation for
A1493 was observed in the P-tRNA bound ribosome with a va-
cant A-site (Fig. 2F); however, in this structure, A1492 remains
buried within h44. Although the resolution of the previous
TetO•70S structures (16, 20) was insufficient to unambiguously
assign the conformational state of A1492 and A1493, biochemical
studies suggest that binding of TetO to the ribosome also flips
A1493 from h44, as indicated by exposure of A1408 of the 16S
rRNA to DMS modification (18, 19). Because removal of the
CTH by truncation of 17 amino acids inactivates TetM (19), it is
likely that the interaction of TetM, and presumably TetO, with
A1492 and A1493 is critical for stabilization of the RPP on the
ribosome.
Pro509 of Loop III of TetM Directly Encroaches Upon the Tetracycline-
Binding Site. Loop III of TetM linking β54 to helix αB4 is the best
resolved part of the TetM structure with a local resolution pre-
dominantly around 3.5 Å, which enabled the bulky aromatic
sidechains, such as tyrosines and phenylalanines, to be modeled
(Fig. 3 A and B). In contrast to the previous TetM/O•70S re-
constructions at lower resolution (19, 20), where the density for
Loop III was ambiguous (SI Appendix, Fig. S5 A and B), we are
confident of the register of the amino acids within Loop III of
TetM as well as the orientation of the side chains in most cases
(Fig. 3 A and B and SI Appendix, Fig. S5C). Based on this model,
Pro509 at the tip of loop III stacks against C1054 within h34 of
the 16S rRNA (Fig. 3C), explaining the protection of C1054
from DMS modification observed upon TetO binding to the ri-
bosome (18). C1054 comprises part of the primary tetracycline-
binding site and establishes stacking interactions with ring D of
tetracycline (4–6) (Fig. 3D). Our structure indicates that Pro509
of Loop III of TetM clashes with tetracycline and is therefore
directly responsible for dislodging the drug from the ribosome
(Fig. 3D). This contrasts with previous suggestions that the two
conserved tyrosines, Y506 and Y507, within loop III of TetM are
directly involved in tetracycline release (19, 20). It is worth
noting that although Pro509 is identical in all available RPP
sequences, Y506 and Y507 are substituted with Phe/Val and
Ser/Phe/Arg, respectively, in some RPPs (SI Appendix, Fig. S5D).
Our structure would also suggest that shortening loop III would
remove the overlap with tetracycline, consistent with the lack of
activity of TetO mutants where two residues were deleted from
loop III (20). Although tigecycline exhibits an even greater
overlap with TetM (Fig. 3E), we believe that, in addition to the
increased affinity of tigecycline compared with tetracycline (10,
11, 38), the C9-glycyl substituent of tigecycline hinders access of
the loop III residues to C1054 and thus contributes to tigecyclines
ability to overcome TetM-mediated resistance (6, 11).
Stabilization of Loop III Is Critical for TetM Activity. Given that
Ser508 and Pro509 located at the tip of Loop III are invariant
in all available RPP sequences (SI Appendix, Fig. S5D), it is
somewhat surprising that these and neighboring residues can be
mutated to alanine with little or no effect on RPP activity (3, 19).
Similarly, the double SP508-509/AA and triple SPV508-510/
AAA mutants of TetM were also shown to retain tetracycline
resistance activity (19). In silico mutagenesis based on our re-
fined model indicated that if loop III of the triple SPV508-510/
AAA mutant adopts the same conformation as the wildtype
TetM then the backbone of Ala509 would maintain a steric clash
with tetracycline (Fig. 4A), providing a possible explanation for
the retention in activity of the mutant. In contrast, mutation
of Y506/Y507 completely inactivates TetM/TetO (3, 19, 20),
indicating an important role for these tyrosine residues. Indeed,
in our structure, both tyrosines are involved in intradomain in-
teractions linking loop III with loops I and II (Fig. 4B). Specif-
ically, Y507 comes within 3.5 Å of E435 within loop I and the
side chain OH of Y506 is within hydrogen bonding distance to
Fig. 3. The role of loop III in TetM in tetracycline resistance. (A and B) Extracted Cryo-EM density of loop III of domain IV in TetM (gray mesh) with molecular
model for loop III (A) and colored according to local resolution (B). (C) Stacking interaction of P509 at the tip of loop III (orange) with nucleotide C1054 of h34 of
the 16S rRNA (blue). (D and E) Comparison of the binding positions of loop III of TetM domain IV (orange) with (D) tetracycline (Tet) and (E) tigecycline (Tig; ref. 6).
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the carbonyl of G467 in loop II, as well as to the ribose 2’ OH
of C1051 in h34 of the 16S rRNA (Fig. 4B). Collectively, these
results suggest that the role of Y506 and Y507 within loop III is
to stabilize the conformation of loop III.
To further investigate the importance of the stabilization of
loop III for TetM activity, we analyzed the activity of two addi-
tional TetM mutants: The first mutations were introduced
at position F516. F516 is invariant in all RPP sequences (SI
Appendix, Fig. S5D), and the phenylalanine side chain is well
resolved within the hydrophobic core of loop III, where it clamps
the proximal end of helix αB4 to the distal end of strand β54
(Figs. 3A and 4C). To monitor activity of TetM, the growth of
wild-type Escherichia coli strain BL21 (−TetM) in the presence
of increasing concentrations of tetracycline (0–128 μg/mL) was
compared with the same strain bearing a plasmid overexpressing
either Enterococcus faecalis TetM (+TetM) or one of the TetM
variants (Fig. 4D). In the absence of TetM, the wild-type
Escherichia coli strain (black circles) is sensitive to tetracycline
with a minimal inhibitory concentration (MIC50) of ∼0.6 μg/mL,
whereas as before (19), overexpression of Enterococcus faecalis
TetM (red circles) raises the MIC50 by 14-fold to ∼10 μg/mL
(Fig. 4D). Although mutation of F516 to alanine (F516A) had a
modest affect on TetM activity (MIC50 ∼3 μg/mL), mutation of
F516 to the negatively charged Asp (F516D) led to a complete
loss of activity (Fig. 4D), consistent with the importance of F516
for providing a hydrophobic environment to maintain the de-
fined conformation of loop III necessary for tetracycline release.
Another possible source of stabilization of Loop III is the
Fig. 4. Stabilization of loop III in TetM via intra-TetM interactions ensures TetM activity. (A) Relative binding position of TetM triple mutant SPV508-510AAA
(orange) and tetracycline (Tet, red; ref. 6). (B) Tyrosine residues Y506 and Y507 of loop III of TetM domain IV (orange) stabilize the conformation of loop III via
interactions with G467 of loop II, 16S rRNA residue C1051 and residue E435 of loop I, respectively. (C) Localization of TetM residue F516 within the hy-
drophobic pocket formed by loop III. (D) Growth curves of wildtype E. coli strain BL21 (black) in the presence of increasing concentrations of tetracycline
(0-128 μg/mL) compared with the wildtype strain harboring a plasmid encoding wildtype TetM (red) and TetM single mutants F516A (green) and F516D
(brown). (E) Interaction between the sidechain V510 of loop III of TetM with the invariant tryptophan (W442) located in loop I. (F) as in D but with TetM
mutant W442A (orange) and the double mutants W442A/Y506A (brown), W442A/Y507A (green), W442A/S508A (olive), W442A/P509A (blue) and W442A/
V510A (violet). In D and F, the error bars represent the SD from the mean for three independent experiments.
Fig. 5. Schematic model for TetM-mediated tetra-
cycline resistance. (A and B) Upon TetM binding to
tetracycline bound ribosomes, the proline residue
P509 located at the tip of loop III of domain IV is
directly responsible for chasing the drug off the ri-
bosome by interacting with its binding site nucleo-
tide C1054 of the 16S rRNA. (B) TetM binding to the
ribosome leads to interaction of the C-terminal helix
(CTH) with 23S rRNA nucleotide A1913 (dark blue)
and induces 16S rRNA decoding nucleotides A1492
and A1493 (blue) to flip out of helix 44 (h44) of the
16S rRNA. Intramolecular interactions that stabilize
the conformation of loop III are represented as green
clamps with C1 illustrating the interaction Y506/G467,
C2 for Y507/E435 and C3 for V510/W442.








interaction between the side chain of V510 and an invariant
tryptophan (W442) located within loop I (Fig. 4E). Although
mutation of W442 to alanine (W442A) alone did not affect the
activity of TetM, the presence of the W442A mutation made
loop III sensitive to secondary mutations. In particular, muta-
tions of S508 or P509 to alanine in the context of W442A
abolished TetM activity (Fig. 4F), whereas wild-type activity was
observed for TetM with single S508A or P509A mutations (19).
Collectively, these results illustrate the importance of the struc-
tural integrity of loop III in the positioning residues S508 and
P509 located at the tip of loop III, which is necessary for efficient
tetracycline resistance.
Conclusion
In conclusion, our structure enables a molecular model to be
presented for how TetM confers resistance to tetracycline by
dislodging the drug from its binding site on the ribosome (Fig. 5
A and B): Specifically, Pro509 within loop III of domain IV of
TetM directly overlaps in position with ring D of tetracycline and
thus dislodges the drug from the ribosome. TetM is proposed to
prevent rebinding of tetracycline by altering the conformation of
nucleotides such as C1054 within the drug binding site that
persist following TetM dissociation (12, 18, 19, 32). Within the
constraints of the current resolution, TetM does not appear to
alter the conformation of C1054 to prevent drug rebinding (SI
Appendix, Fig. S5E), however, we cannot rule out that such an
alteration occurs during GTP hydrolysis and dissociation of
TetM from the ribosome. Previous studies identified two con-
served tyrosines within loop III of TetM as being important for
tetracycline resistance (3, 19, 20). Here we show that these ty-
rosine residues are not directly involved in displacing the drug
from its binding site, but rather act like clamps (termed C1 and
C2) that stabilize the loop III of domain IV of TetM by estab-
lishing intradomain interactions with loop I and II of TetM (Fig.
5A). We also identify an additional clamp C3 between loop I and
III that is important for stabilization of loop III. Additionally,
domain IV of TetM is positioned on the ribosome for tetracy-
cline displacement via interaction of loop I and the CTH with
residues located within intersubunit bridge B2a, namely, A1913
of H69 of the 23S rRNA and a splayed conformation of decoding
site nucleotides A1492 and A1493 (Fig. 5B). We believe that the
molecular details and mechanism of action reported here for
TetM will be conserved for other ribosome protection proteins,
such as TetO, that also confer resistance to tetracycline.
Materials and Methods
Enterococcus faecalis TetM was purified as described (34) and bound to
ErmCL-RNC (22). Cryo-EM data were collected using the EPU software on a
Titan Krios TEM (FEI) and processed using the SPIDER software package (25).
The backbone model of Enterococcus faecalis TetM was initially generated
using HHPred (39), then manually fitted using Chimera (40) and refined
using Coot (41) and PHENIX (42). A structure of the Escherichia coli 70S ri-
bosome (43) was fitted the cryo-EM density using Chimera (40), manually
adjusted and then refined with Coot (41). Site-specific mutations were in-
troduced into the tetM gene using KOD Xtreme Hot Start Polymerase
according to the manufacturers instructions and minimal inhibitory con-
centrations were determined as described (11, 19). Detailed materials and
methods can be found in the SI Appendix, SI Materials and Methods.
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SI Materials and Methods 
Purification of TetM protein 
Enterococcus faecalis TetM from TnFO1 (Q47810) was cloned into pET-46 Ek/LIC 
(Novagene) with an N-terminal 6x histidine tag. The plasmid was transformed into E. coli 
BL21(DE3) (Novagene) and incubated at 37°C/120 rpm overnight in 20 mL LB medium 
containing 100 µg/mL ampicillin. A volume of 20 mL overnight culture was used to inoculate 
1.6 L of LB medium containing 100 µg/mL ampicillin. The culture was grown at 37°C/120 rpm 
to an OD600 of 0.3. The temperature was then reduced to 30°C and 16 mL of ethanol was added 
until the OD600 value reached 0.6. Expression of TetM was induced by adding 1.6 ml of 1mM 
IPTG. After 2hrs, cells were harvested by centrifugation at 3000 x g for 15 min at 4°C and 
subsequently resuspended in 25 mL Lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 5 mM 
Imidazole, pH 8.0). Cells were lysed using the M-110L Microfluidizer (Microfluidics) and the 
lysate cleared by centrifugation at 17000 x g for 15 min at 4°C. The cleared lysate was then 
incubated at 4°C for 1h with 1 mL Ni-NTA agarose beads (Machery-Nagel) and loaded onto a 
20 mL Econopac Chromatography column (Biorad). Beads were washed twice with 5 mL 
Wash buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 8.0) and eluted in 2 mL 
Elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM Imidazole, pH 8.0). The eluate was 
further purified by gel filtration using a SuperdexTM 75 pg column (Amersham) and GF buffer 
(50 mM Hepes, 100 mM KCl, 200 mM NaCl, 10 mM MgCl2, 5 mM ß-Mercaptoethanol, 10% 
Glycerol). 
 
Site directed mutagenesis 
Site directed mutagenesis was performed using the whole plasmid PCR method. Primers are 
attached in Supplementary Table 2.  E. faecalis tetM on pET-46 Ek/LIC (Novagene) was used 
as a template. Double mutants W442A + loop III were produced using loop III mutants as 
templates (1). KOD XtremeTM Hot Start Polymerase (Novagene) was used in the following 
PCR program: 94°C 2 min; 20x (98°C 10sec, 63°C 30sec, 68°C 7min); 68°C 7min. 
 
Generation and purification of ErmCL-SRC 
ErmCL-SRC was generated following the same procedure as previously described (2). The 
2XermCL construct contained a T7 promoter followed by a strong ribosome binding site (RBS) 
spaced by 7 nucleotides (nts) to the ATG start codon of the first ermCL cistron. A linker of 22 
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nts separated the stop codon of the first ermCL cistron and the start codon of the second ermCL 
cistron. The linker also comprised the strong RBS 7 nts upstream of the ATG start codon of the 
second ermCL cistron, enabling initiation of translation independent from the first ermCL 
cistron. Each ermCL cistron encoded amino acids 1-19 corresponding to ErmCL leader peptide 
(Genbank accession number V01278) present on macrolide resistance plasmid pE194 (3, 4). In 
vitro translation of the 2xermCL construct was performed using the Rapid Translation System 
RTS 100 E. coli HY Kit (Roche) and was carried-out in the presence of 10 µM erythromycin 
(ERY) for 1h at 30 °C. The ErmCL-SRC was purified from the disome fractions on sucrose 
gradients and concentrated using Amicon Ultra-0.5 mL Centrifugal Filters (Millipore). 
Monosomes of the ErmCL-SRC were obtained by annealing a short DNA oligonucleotide (5’-
ttcctccttataaaact-3’, Metabion) to the linker between the ermCL cistrons of the disomes, 
generating a DNA-RNA hybrid that was cleaved by RNase H (NEB) treatment in buffer A at 
25°C for 1h. The ErmCL-SRC monosomes were then purified and concentrated using the 
Amicon Ultra-0.5 mL Centrifugal Filters (Millipore).  
 
Generation of TetM●RNCs 
The ErmCL-SRC (0.5 µM) was incubated with a 4-fold excess (2 µM) of purified recombinant 
TetM protein in the presence of 500 µM GDPCP in buffer A (50 mM HEPES-KOH, pH7.4, 
100mM KOAc, 25mM Mg(OAc)2, 6mM β-mercaptoethanol, 100 µM evernimicin and 10 µM 
erythromycin) for 30 min at 30°C. Thereafter, the binding reaction was diluted using buffer A 
to yield a final ribosome concentration of 4 A260/ml for cryo-grid preparation. 
 
Cryo-electron microscopy and single particle reconstruction 
The TetM●RNC (4 A260/ml) was applied to 2 nm pre-coated Quantifoil R3/3 holey carbon 
supported grids and vitrified using a Vitrobot Mark IV (FEI Company). Data collection was 
performed using the EPU software at NeCEN (Leiden, Netherlands) on a Titan Krios 
transmission electron microscope (TEM) (FEI, Holland) equipped with a Falcon II direct 
electron detector at 300 kV with a magnification of 125,085x, a pixelsize of 1.108 Å and a 
defocus range of 0.9-2.2 µm. The data were provided as a series of seven frames (dose per 
frame is 4 e-/Å2) from which we summed frames 1-6 (accumulated dose of 24 e-/Å2) after 
alignment using Motion Correction software (5). Images were processed using a frequency-
limited refinement protocol that helps prevent over-fitting (6), specifically by truncation of high 
frequencies (in this case at 7-8 Å using a Butterworth filter). Power spectra and defocus values 
were determined using the SPIDER TF ED command and recorded images were manually 
inspected for good areas and power-spectra quality. Data were processed further using the 
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SPIDER software package (7), in combination with an automated workflow as described 
previously (8). After initial, automated particle selection based on the program SIGNATURE 
(9), initial alignment was performed with 127,205 particles, using E. coli 70S ribosome as a 
reference structure (2). After removal of noisy particles (22,207 particles), the dataset could be 
sorted into two main subpopulations using an incremental K-means-like method of 
unsupervised 3D sorting (10): The first subpopulation (26,814 particles; 25%) was defined by 
the presence of stoichiometric density for P-site tRNA. The second, major subpopulation 
(78,186 particles; 75%) was defined by the presence of stoichiometric densities for P-tRNA and 
TetM (SI Appendix, Figure S1A), and could be refined further to produce a map with an 
average resolution of 3.9Å (0.143 FSC, SI Appendix, Figure S1B). The final refined map was 
subjected to the program EMBFACTOR (11) in order to apply an automatically determined 
negative B-factor for sharpening of the map. Local resolution calculations were performed 
using Resmap (12) revealing that the resolution of the majority of the core of the 30S and 50S 
subunits extended to 3.5 Å (SI Appendix, Figure S1C).  
 
Molecular modelling and map-docking procedures 
The initial molecular model for the 70S ribosome of the TetM●RNC was based on the cryo-EM 
structure of an E. coli 70S ribosome (PDB ID 5AFI, (13)). The 30S and 50S subunits were 
fitted as rigid bodies and were manually adjusted and refined in Coot (14). The model for the 
C-terminal domain of L7 was based on a rigid body fit of the NMR structure of L7/L12 
(1RQU, (15)). The molecular model for TetM was initially based on a homology model using 
EF-G as a template (generated by HHPred (16) and Modeller (17)). The model was split into 
five domains, which were individually fitted into the EM density as rigid bodies and then 
manually adjusted and refined using Coot (14) and PHENIX (18). Since the resolution of 
domains I-III and V of TetM was insufficient to model the amino acid side chains, only a 
backbone trace was generated. Domain IV of TetM was resolved up to 3.5 Å allowing the 
bulky amino acid side-chains in loop III to be modelled.  
 
Figure preparation 
Figures showing electron densities and atomic models were generated using UCSF Chimera 
(19) and PyMOL Molecular Graphics System (Version 1.5.0.4 Schrödinger, LLC). 
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Supplementary Figures 
 
Figure S1 Cryo-EM reconstruction of the TetM•RNC. (A) In silico sorting of the 
TetM•RNC dataset. After removal of non-aligning and edge particles, sorting of the dataset 
yielded two homogenous sub-datasets. The vast majority of the particles (75%; 78,186 particles 
in total) contained stoichiometric density for P-tRNA as well as for TetM and this 
subpopulation was chosen for refinement. (B) Fourier-shell correlation curve of the refined 
final map, indicating the average resolution of the TetM•RNC is 3.9 Å. (C) Overview of the 
TetM•RNC colored according to the local resolution as calculated using ResMap (12). (D) 
Histogram generated by ResMap showing the number of voxels of the cryo-EM map of the 
TetM•RNC distributed across the resolution bins ranging from 3.5 Å to 6.0 Å. 
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Figure S2 Interaction of TetM with the large ribosomal subunit. (A) Interaction of the G 
domain of TetM with the sarcin-ricin loop (SRL) of the 23S rRNA (blue). The switch 1 
(yellow) and switch 2 (purple) loops are indicated, as is the putative position for the GDPCP 
molecule (green). (B) Comparison of the conformation of switch 1 and 2 loops of TetM with 
equivalent region of EF-G (PDB ID 4CR1). Putative density for GDPCP molecule (grey mesh) 
corresponds with the position of the GDPNP molecule (green) from the EF-G structure (PDB 
ID 4CR1) aligned to the TetM based on the G domain. (C) Interaction between the C-terminal 
domain of L7/L12 (yellow) and the G’ domain of TetM (orange). (D) Overview of TetM 
(orange) showing interaction with L7 (yellow) and L11 (green). (E) Interaction between L11 
(green) and domain V of TetM (orange). (F) Overlap in the binding site of domain V of TetM 
(orange) with the antibiotic thiostrepton (cyan). In panels (A) and (C-E), the cryo-EM density 
for the TetM-RNC is shown as a grey mesh. 
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Figure S3 Analysis of loops I and II of domain IV of TetM. (A-D) Cryo-EM map (grey 
mesh) of (A, D) TetO•70S complex (20), (B) TetM•70S complex (1) and (C) TetM•RNC, with 
molecular model for loop I of domain IV of (A) TetO (yellow, (20)), (B) TetM (grey, PDB 
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3J25, (1)) and (C, D) the revised molecular model for loop I of domain IV of TetM based on 
the cryo-EM map of the TetM•RNC at 3.9 Å resolution (orange). (E) Logo-Plot of residues 
433-443 of loop I of domain IV of TetM, numbered according to Enterococcus faecalis TetM. 
(F) Sequence alignment of residues 433-443 of loop I of Enterococcus faecalis TetM and 
Campylobacter coli TetO. (G) Logo-plot of residues 464-470 forming loop II of TetM domain 
IV. (H) Growth curves of wildtype E. coli strain BL21 (black) in the presence of increasing 
concentrations of tetracycline (0-128 µg/ml) compared with the wildtype strain harboring a 
plasmid encoding wildtype TetM (red) or TetM single mutants S465G (blue), L466G (brown), 
G467A (olive) and Y468G (green). 
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Figure S4 Interaction of the C-terminal helix of TetM with the ribosomal decoding center  
(A) Sequence alignment of residues 619-639 of the C-terminal helix (CTH) of Enterococcus 
faecalis TetM and Campylobacter coli TetO. (B) PSIPRED secondary structure prediction with 
sequence (AA), prediction (Pred) and confidence (Conf) as indicated. (C-F) Cryo-EM map 
(grey mesh) of (C, F) TetO•70S complex (20), (D) TetM•70S complex (1) and (E) TetM•RNC, 
with molecular model for the CTH of (C) TetO (yellow, (20)), (D) TetM (grey, PDB 3J25, (1)) 
and (E, F) the revised molecular model for loop I of domain IV of TetM based on the cryo-EM 
map of the TetM•RNC at 3.9 Å resolution (orange). (G-I) Identical views as Fig. 2C-F but 
including electron density colored according to the local resolution. (J) As (I) but with a higher 
threshold level for the electron density map. 
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Figure S5 Structures of loop III of domain IV in TetO and TetM. (A-C) Cryo-EM map 
(grey mesh) of (A) TetO•70S complex (20), (B) TetM•70S complex (1) and (C) TetM•RNC, 
with molecular model for loop III of domain IV of (A) TetO (yellow, (20)), (B) TetM (grey, 
PDB 3J25, (1)) and (C) the revised molecular model for loop I of domain IV of TetM based on 
the cryo-EM map of the TetM•RNC at 3.9 Å resolution (orange). (D) Logo-Plot of residues 
504-517 of loop III of domain IV of TetM, numbered according to Enterococcus faecalis TetM. 
(E) Cryo-EM density (grey mesh) the TetM•RNC with molecular models for TetM (orange), 
and a comparison of the conformation of C1054 of the 16S rRNA from the TetM•RNC (blue) 
with the tetracycline-bound conformation (cyan, (21)).  
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Domain Region Residue Region Residue 
     
loop between 11 
and A1 
V12 23S rRNA, H95 (SRL) G2661 
loop between 
A1 and 21 
G53 23S rRNA, H95 (SRL) G2663 
loop between 31 
and B1 
H78 23S rRNA, H95 (SRL) A2662 
loop between 
41 and C1 
K102 23S rRNA, H95 (SRL) A2657 
C1 A107 23S rRNA, H95 (SRL) G2661 
loop between 51 
and D1 
Q132 23S rRNA, H95 (SRL) A2657 
G  
 
loop between 51 
and D1 
G134 L6 V91, G92 
BG M190,S191 L7-CTD, helix α4 V69       G’ 
 BG G192,L193 L7-CTD, helix α4 V88 
32 R278 16S rRNA, h5 (body) U368 
52 T292 16S rRNA, h5 (body) U358 II 
62 L304 16S rRNA, h5 (body) A55 
III A3 D363 S12 H77 
loop II between 
44 and A4 
S465, L466, 
G467 








16S rRNA, h34 (head) backbone C1051  
U1052, C1054  
loop III 
between 54 and 
B4 




between 54 and 
B4 
R517 16S rRNA, h18 (body) C519 
A5 Y555 23S rRNA, H43/H44 A1095 
A5 K560 23S rRNA, H89 U2473 
25  L570 L11  
310-helix 
G28, Q29 
B5 T594, F595 L6 K175, K176 
B5 T594, F595 23S rRNA, H95 (SRL) A2660 
V 
B5 N598, G599 23S rRNA, H95 (SRL) A2660 







C5 R632 23S rRNA, H69 C1913 
CTE 
C5 F635, N636 23S rRNA, H69 C1914 
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Construct Primer sense/ antisense (5’ – 3’) 
TetM W442A 
 
5’-GTGCCGCCAAATCCTTTCGCGGCTTCCATTGGTTTATCTGTATCACCGCTTC-3’   
5’-GATAAACCAATGGAAGCCGCGAAAGGATTTGGCGGCACTTCGATGTGAATG-3’   
TetM S465G 
 
5’-CAGTATGAGAGCTCGGTTGGCCTTGGATACTTAAATCAATCATTTC-3’   
5’-GATTTAAGTATCCAAGGCCAACCGAGCTCTCATACTGCATTCCAC-3’   
TetM L466G  5’-GAGAGCTCGGTTTCTGGCGGATACTTAAATCAATCATTTCAAAATG-3’   
5’-GATTGATTTAAGTATCCGCCAGAAACCGAGCTCTCATACTGCATTC-3’   
TetM G467A 
 
5’-GAGCTCGGTTTCTCTTGCGTACTTAAATCAATCATTTCAAAATGCAG-3’   
5’-GAAATGATTGATTTAAGTACGCAAGAGAAACCGAGCTCTCATACTGCATTC-3’  
TetM Y468G  
 








5’-GTTAGTACCCCAGCAGATGATCGGATGCTTGCTCCTATTGTATTGGAAC-3’   
5’-CAATAGGAGCAAGCATCCGATCATCTGCTGGGGTACTAACAGGGCTATAG-3’   
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Molecular basis for erythromycin-dependent
ribosome stalling during translation of the
ErmBL leader peptide
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In bacteria, ribosome stalling during translation of ErmBL leader peptide occurs in the
presence of the antibiotic erythromycin and leads to induction of expression of the
downstream macrolide resistance methyltransferase ErmB. The lack of structures of
drug-dependent stalled ribosome complexes (SRCs) has limited our mechanistic under-
standing of this regulatory process. Here we present a cryo-electron microscopy structure of
the erythromycin-dependent ErmBL-SRC. The structure reveals that the antibiotic does not
interact directly with ErmBL, but rather redirects the path of the peptide within the tunnel.
Furthermore, we identify a key peptide–ribosome interaction that defines an important relay
pathway from the ribosomal tunnel to the peptidyltransferase centre (PTC). The PTC of the
ErmBL-SRC appears to adopt an uninduced state that prevents accommodation of Lys-tRNA
at the A-site, thus providing structural basis for understanding how the drug and the nascent
peptide cooperate to inhibit peptide bond formation and induce translation arrest.
DOI: 10.1038/ncomms4501
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During protein synthesis, nascent polypeptide chainscan modulate the efficiency of translation1. Nascentpolypeptide-mediated translation regulation can be an
intrinsic property of the nascent chain1 or can depend on the
additional presence of a ligand, for example, a macrolide
antibiotic such as erythromycin (ERY)2,3. Biochemical and
genetic studies of several drug-dependent regulatory peptides
have provided initial models for how interactions within the
ribosomal tunnel can relay back to the peptidyltransferase centre
(PTC) to induce translation arrest2,3. Interestingly, biochemical
characterization of distinct Erm leader peptide-stalled ribosome
complexes (SRCs) indicates that fundamental differences exist in
their mechanisms of translational arrest: for example, mutations
of 23S rRNA nucleotides A2062 and A2503 abolish stalling with
ErmAL1 and ErmCL, but have no influence on ErmBL- and
ErmDL-mediated translation arrest4. Furthermore, different
regulatory peptides appear to have a different sensitivity to the
chemical structure of the antibiotic4–6. The lack of structural
information has made it difficult to explain these conceptually
important distinctions and provide models of drug-dependent
stalling to a sufficient level of molecular detail.
Here we have characterized structurally and biochemically
the requirements for ribosome stalling during translation of the
ErmBL leader peptide. Similar to other inducible macrolide
resistance genes, ermB is controlled by programmed arrest of
translation of the leader peptide ErmBL (Fig. 1a). Previous studies
demonstrated that polymerization of the ErmBL nascent chain
halts when the Asp codon (D10) of the ermBL open-reading
frame (ORF) enters the ribosomal P-site and the Lys (K11) codon
is placed in the A-site4,7 (Fig. 1a). Consistently, our findings
indicate that the ErmBL-SRC contains an ErmBL-transfer RNA
in the P-site and Lys-tRNA in the A-site, and thus stalling results
from inability of the ribosome to catalyse peptide bond
formation. On the basis of our cryo-electron microscopy (EM)
structure of the ErmBL-SRC, we suggest that peptide bond
formation does not occur because the accommodation of
Lys-tRNA at the A-site of the PTC is corrupted. Moreover, we
identify critical residues in ErmBL and in the ribosome, which we
propose to be important for maintaining the PTC in an
uninduced and thus inactive state.
Results
Cryo-EM structure of the ErmBL-SRC. To assess whether the
ErmBL-SRC contains the nascent chain attached to tRNAAsp in
the P-site or to tRNALys in the A-site, in vitro translation of
ErmBL was performed in the presence of ERY and either radi-
olabelled aspartate or lysine. Analysis of the ErmBL nascent chain
shows that radiolabelled Asp, but not Lys, was incorporated into
the peptidyl-tRNA of the SRC (Fig. 1b). Thus, the ribosome stalls
because it is unable to catalyse formation of a peptide bond
between the 10-amino-acid-long ErmBL nascent chain attached
to the tRNAAsp in the P-site and the incoming Lys-tRNALys
(Fig. 1a). To unravel the structural basis for ErmBL-mediated
stalling, we generated ErmBL-SRC for analysis using cryo-EM.
For previous structures of drug-independent SRCs, the nascent
chains were of sufficient length to exit the ribosomal tunnel,
enabling purification of the SRC using N-terminal affinity
tags8–10. In contrast, the peptides controlling macrolide resistance
genes, including the 10-amino-acid-long ErmBL nascent chain,
are too short to exit the tunnel, making preparation of SRC
by N-terminal affinity tagging impossible. Consequently, we
established a SRC purification technique employing a bicistronic

















































Figure 1 | Cryo-EM structure of the ErmBL-stalled ribosome complex. (a) Schematic for ermBL-dependent regulation of ermB translation in the
presence of erythromycin (ERY). (b) In vitro translation of ErmBL using either 14C-Asp or 14C-Lys in the absence (" ) or presence (E) of 50mM ERY.
In the control samples (B), where translation was carried out in the absence of ERY, but in presence of borrelidin (a Thr-tRNA synthetase inhibitor),
translation arrest occurred after an 11-amino-acid nascent chain was polymerized (such that codon 12 is in the A-site, which is one codon further compared
with the natural stall site), thereby providing a mobility marker and confirming14C-Lys incorporation in the absence of ERY. (c) The bicistronic 2! ermBL
mRNA was translated in vitro in the presence of 10mM ERY to generate ErmBL-SRC disomes. (d) Complementary DNA oligo and RNase H cleavage
converts disomes to monosomes, as shown by sucrose density centrifugation and negative stain EM. (e) Surface and cross-section of the ErmBL-SRC,
containing 30S (yellow), 50S (coloured according to local resolution), A-tRNA (orange), P-tRNA (green) and ERY (red). Inset shows electron density
for ERY (grey mesh) with fitted crystal structure (PDB3OFR)11.
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The ORFs were separated by a 22-nucleotide linker and each had
a strong ribosome-binding site (RBS) (Fig. 1c). In vitro translation
of 2! ermBL leads to the formation of disomes (one ribosome
per cistron, two ribosomes per mRNA), as evident from sucrose
gradient analysis and negative-stain EM (Fig. 1d). Importantly,
disome formation is strictly dependent on the presence of
ERY and does not occur on monocistronic ermBL mRNAs
(Supplementary Fig. 1). To avoid orientation bias during cryo-
EM analysis, the disomes were converted into monosomes by
cleavage of the linker using an antisense DNA oligonucleotide
and RNase H (Fig. 1c,d).
Cryo-EM and single-particle reconstruction of the resulting
ErmBL-SRC, coupled with in silico sorting (Supplementary
Fig. 2), yielded one major homogeneous subpopulation of
ribosomes bearing tRNAs in the A- and P-sites (Fig. 1e). Local
resolution indicates that most of the ErmBL-SRC map, in
particular the core region encompassing the PTC and ribosomal
tunnel, reaches a resolution of 4.5 Å (Fig. 1e and Supplementary
Fig. 3). Consistent with this resolution, distinct features of the
electron density for ERY, such as the lactone ring, desosamine
and cladinose sugars, can be unambiguously resolved (Fig. 1e).
Moreover, rigid-body fitting of the crystal structure of ERY in
complex with the Escherichia coli ribosome11 indicates that the
drug is bound to its canonical position11,12 in the ErmBL-SRC
(Fig. 1e).
The path of ErmBL through the ribosomal tunnel. Additional
density in the ErmBL-SRC, which we assign to the ErmBL
nascent chain, is observed within the ribosomal tunnel extending
from the CCA-end of the P-tRNA (Fig. 2a). Unlike the nascent
chains of TnaC8 and SecM10 that extend throughout the entire
length of ribosomal tunnel (Fig. 2b,c), the 10-amino-acid-long
ErmBL occupies only the upper third of this conduit (Fig. 2a).
Moreover, the unique path of the ErmBL nascent chain enables it
to bypass the tunnel-bound ERY (Fig. 2d). In contrast, the
nascent chains of SecM- and TnaC-SRC, as well as of other
ribosome-nascent chain complexes9,13–15, adopt conformations
that would be sterically obstructed by the drug (Fig. 2e,f).
Although ermBL translation by the ERY-bound ribosome stalls at
the 10th codon, the conformation of the ErmBL polypeptide
within the tunnel (Fig. 2a) illustrates the general principle of how
a specific subset of polypeptides can bypass ERY to be translated
on drug-bound ribosomes16.
Closer examination of the ErmBL-SRC structure indicates an
apparent lack of contact between ErmBL and ERY (Fig. 2d). This
is distinct from the direct interaction between the nascent chain
and the drug that was proposed for ErmCL, based on the
observation that removal or modification of the C3 cladinose
sugar abolishes ErmCL stalling17,18. Therefore, we tested whether
ErmBL stalling is sensitive to structural modifications of the
antibiotic cofactor. In excellent agreement with the structural
predictions, ErmBL stalling could be induced not only by ERY,
but also by a wide range of tunnel-binding macrolides, including
those which failed to induce ErmCL-SRC formation17, for
example, solithromycin, which lacks the C3 cladinose, as well as























































Figure 2 | Path of the ErmBL compared with TnaC and SecM nascent chains. (a–c) Comparison of cryo-EM structures of ErmBL-SRC, TnaC-SRC8
and SecM-SRC10, with a transverse section of the 50S subunit (grey) displaying the path of the respective nascent chains through the ribosomal
tunnel. (d–f) Paths of the (d) ErmBL (teal), (e) TnaC8 (purple) and (f) SecM10 (brown) nascent chains. Erythromycin (ERY)11 is coloured red in (d)
ErmBL-SRC, whereas the superimposed position of ERY is coloured white in (e) TnaC-SRC and (f) SecM-SRC.
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sugar (Fig. 3). As expected, antibiotics josamycin and
clindamycin, which overlap with the A-site and inhibit
formation of the first peptide bond11,12,19 (Fig. 3), and
quinupristin, which overlaps with the path of ErmBL12,20
(Fig. 3), did not allow the drug-bound ribosome to reach the
ermBL stall site (Fig. 3).
Interaction between ErmBL and the ribosomal tunnel. To
ascertain which residues of ErmBL interact with the ribosomal
tunnel, a model for nascent chain was built (Fig. 4a). Since the
resolution does not allow us to model sidechains, we present only
a backbone model for the ErmBL nascent chain. On the basis of
this model, three interactions with the ribosomal tunnel are
predicted: one from the C terminus (V9-D10) of ErmBL with
U2585, a second in the vicinity of R7 with U2586 and a third
between F4 and U2609 (Fig. 4a). Local resolution indicates that
the C terminus of ErmBL (M6-D10) is very stable, providing
more confidence in the placement of the backbone model,
whereas in contrast, the N-terminal residues (M1-Q5) are flexible
to such an extent that modelling of M1 and L2 was not possible
due to lack of density and alternative models for the N-terminal
are therefore possible (Fig. 4b). Consistently, alanine-scanning
mutagenesis of ErmBL demonstrated that C-terminal residues,
namely, R7 and V9-D10, are critical for stalling, whereas the
N-terminal residues are not (Fig. 4c). The most distal contact
from the PTC between F4 and U2609 (Fig. 4a,b) does not appear
to be functionally important because neither the F4A mutation,
nor the U2609C alteration affected the efficiency of stalling
(Fig. 4c; Supplementary Fig. 4).
In contrast, the second contact, between R7 and U2586,
plays an important role, since disruption of this interaction by the
R7A mutation in ErmBL significantly diminishes stalling
(Fig. 4a,c). Strikingly, changes in the ribosomal interacting
partner (U2586A/G/C) were able to restore the efficiency of
translation arrest for the ErmBL-R7A mutant (Fig. 4d). The fact
that the U2586 mutations (U2586A/G/C) were unable to restore
stalling for the ErmBL-V9A or -D10A mutants (Fig. 4e) and that
stalling of the ErmBL-R7A mutant could not be compensated by
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Figure 3 | Superimposition of various antibiotics relative to ErmBL. (a) Detection of ribosome stalling by toe-printing during translation of ermBL,
in the presence of the antibiotics erythromycin (ERY), ITR-054 (054), oleandomycin (OLE), solithromycin (SOL), azithromycin (AZM), josamycin (JOS),
clindamycin (CLN) and quinupristin (QUI). The arrowed toe-print band indicates that ErmBL arrests translation with the Asp (D10) codon (boxed) located
in the P-site. (b) Chemical structures of ERY, macrolides ITR-054 (054), OLE, the ketolide SOL and the azalide AZM compared with the macrolide JOS,
the lincosamide CLN and the streptogramin B QUI. Differences between ERY and respective drugs are highlighted. (c) ErmBL-SRC map (grey mesh)
with molecular model for ErmBL-tRNA (teal), 23S rRNA (blue) and ERY (red, PDB3OFR11). (d–h) as in (c), but with relative binding positions of (d) AZM
(green, PDB1M1K19), (e) SOL (yellow, PDB3ORB42), (f) JOS (purple, PDB2O44), (g) CLN (orange, PDB3OFZ11) and (h) QUI (pink, PDB1SM1 (ref. 20)).
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re-emphasizes the specificity and importance of the R7-U2586
interaction for the mechanism of ErmBL stalling. This also
provides support for our model for the C-terminal portion of the
ErmBL nascent chain and in particular the placement of R7.
Notably, the identity of the tunnel nucleotide A2062, which is
critical for ErmCL- and ErmAL1-mediated ribosome stalling, was
not important for the formation of the ErmBL-SRC4,18 (Fig. 4e
and Supplementary Fig. 4). The ErmBL-SRC structure shows
the lack of direct contact between A2062 and the nascent
chain (Fig. 4b), providing a plausible explanation for the clear
distinction between the drug-dependent translation arrest
directed by different stalling peptides.
The conformation of the PTC of the ErmBL-SRC. The third
contact between the ErmBL nascent chain and the ribosome
engages the peptide residues V9/D10 with U2585 of the 23S
rRNA. Previous crystallographic analysis of model complexes
showed that accommodation of the CCA-end of the A-site tRNA
requires movement of the PTC nucleotides U2584 and U2585 to
achieve the ‘induced fit’ state of the PTC and provide room for
the A-tRNA21–23 (Fig. 5a). The crystal structures of the 50S
structure with the PTC in either the uninduced or the induced
state were fitted to the electron density for the 50S subunit of the
ErmBL-SRC as a rigid body (Fig. 5a). Together with difference
electron density maps (Supplementary Fig. 5), this procedure
suggests that U2584 and U2585 have not shifted sufficiently and
remain in an uninduced-like conformation in the ErmBL-SRC,
probably due to the interaction of U2585 with the ErmBL nascent
chain. The local resolution of the ErmBL map is 4.5 Å, which is
sufficient to distinguish movements of 0.9–1.1Å24–26. Because the
differences in the nucleotide positions between the induced and
uninduced states are in the order of 1–2Å, we are rather
confident that our data would allow us to conclude that the
functional state of the PTC in ErmBL-SRC differs from its classic
induced state.
Although higher resolution will be necessary to validate the
exact placement of the PTC residues, its deviation from the fully
functional state in the ErmBL-SRC and unaccommodated state of
the A-tRNA (Fig. 5a) provide an explanation for the translational
arrest, since the fully accommodated state is required for
efficient nucleophilic attack and fast peptide bond formation
(Fig. 5b). Moreover, an unaccommodated state of A-tRNA in the
ErmBL-SRC is consistent with the finding that Lys encoded by
the A-site codon of the SRC is not incorporated into the ErmBL
nascent chain (Fig. 1b). Although the density corresponding to
the A-site amino acid was mostly lacking, we verified bio-
chemically that the A-site tRNA fully retains its aminoacyl moiety
through the entire purification protocol (Supplementary Fig. 6).
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Figure 4 | Interactions of the ErmBL nascent chain with the ribosome. (a) Interactions of ErmBL (teal) with 23S rRNA (blue) within the exit tunnel of the
ribosome. (b) Local resolution map of view shown in (a). (c) Alanine-scanning mutagenesis of ErmBL and effect of mutant peptides on ribosome stalling
(arrowed) in the presence (þ ) and absence (" ) of erythromycin (ERY) as determined by toe-printing. (d) Toe-printing of wild type (wt) and mutant
(R7A) ErmBL on E. coli ribosomes with wt or mutated 23S rRNA nucleotide 2586, in the presence (þ ) or absence (" ) of ERY. All the reactions contained
borrelidin, a Thr-tRNA synthetase inhibitor, which, in the absence of ERY-dependent arrest at the Asp (D10) codon, causes translation arrest at the Lys
(K11) codon. (e) Influence of the U2586A mutation on stalling efficiency with the wt and mutant ErmBL peptides (an average of two independent
experiments; error bars represent the standard deviation of the mean). (f) The mutations of A2062 do not affect ErmBL stalling, nor rescue stalling
impaired by the R7A mutation.
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of the Lys residue of the A-tRNA and reinforces the notion of
the ‘inappropriate’ placement of the PTC acceptor substrate
(Fig. 5a,b). Because the ribosome accelerates peptide bond
formation primarily through accurate positioning of the reacting
components27,28, high flexibility of the acceptor substrate would
be incompatible with fast peptidyl transfer. Mutation of the SRC
acceptor amino acid from lysine to alanine reduced the efficiency
of translation arrest (Fig. 4c), suggesting that the nature of the
A-tRNA amino acid influences the ability of aminoacyl-tRNA to
be accommodated in the A-site.
Discussion
Our biochemical and structural insights allow us to propose a
model for the concerted action of the drug and the nascent chain
in inhibiting the PTC functions: During canonical translation, for
example, of ErmBL in the absence of ERY, the nascent
polypeptide chain passes freely through the ribosomal tunnel,
exploring many conformations most of which are compatible
with efficient peptide bond formation. However, in the presence
of the macrolide molecule, the path of the nascent chain is
restricted because some of the previously accessible routes are
obstructed by the drug. In the constrained conformational space
the peptide is compelled to establish specific and long-lived
contacts with the tunnel wall (R7-U2586) and at the PTC (V9-
D10 with U2585) (Fig. 5c). These contacts stabilize the improper
(uninduced) state of U2585, which in turn precludes accom-
modation of the Lys-tRNA in the A-site and thus prevents
peptide bond formation (Fig. 5d).








































































Figure 5 | The uninduced state of the PTC and an unaccommodated A-tRNA in the ErmBL-SRC prevent peptide bond formation. (a,b) During
accommodation of the A-tRNA, U2585 and U2584 undergo conformational changes (arrowed) necessary for peptide bond formation21–23. In the
ErmBL-SRC, the electron density suggests that U2585 retains an unaccommodated state (orange, PDB1VQ6)21–23, thus preventing proper placement
of the A-tRNA in the PTC (blue, PDB1VQN)21–23. (b) Electron density between the ErmBL nascent chain (dark mesh) and U2585 indicates that the
C-terminal amino acids of ErmBL directly interact with U2585, likely restricting its movement. (c,d) Model for the translation of ErmBL (c) in the absence
of erythromycin (ERY) (canonical translation), and (d) translation arrest in the presence of ERY (stalling). In (d), the drug restricts the conformational
space available for the ErmBL nascent chain such that interactions with U2586 and U2585 are established. We propose that this prevents movement
of U2585 from the uninduced to induced state, and thus hinders accommodation of the A-tRNA and peptide bond formation.
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In conclusion, our analysis of the ErmBL-SRC establishes a
basic framework for understanding how the combined action of
the nascent peptide and a small molecule cofactor may induce
programmed translation arrest. It will be interesting to extend
these insights by comparing the ErmBL-SRC structure with other
drug-dependent SRCs, such as ErmCL, which have principally
different antibiotic- and tunnel sensor requirements. Collectively,
it appears that there are several alternative ways to inhibit
translation via the cooperative action of nascent peptides and
tunnel-binding antibiotics.
Methods
Generation and purification of ErmBL-SRC. The 2! ermBL construct was syn-
thesized (Eurofins, Martinsried, Germany) such that it contained a T7 promoter
followed by a strong RBS spaced by 7 nucleotides (nts) to the ATG start codon of
the first ermBL cistron (Fig. 1a). A linker of 22 nts separated the stop codon of the
first ermBL cistron and the start codon of the second ermBL cistron (Fig. 1c). The
linker also comprised the strong RBS 7 nts upstream of the ATG start codon of the
second ermBL cistron, enabling initiation of translation independent from the first
ermBL cistron (Fig. 1c). Each ermBL cistron encoded amino acids 1–17 corre-
sponding to ErmBL leader peptide (Genbank accession number K00551) present
on macrolide resistance plasmid pAM77 (ref. 29). The complete sequence of
2! ermBL construct is:
(T7 promoter, italics; RBS, bold; ErmBL ORF, shaded grey with GAT codon in
P-site of stalled ribosome shown in bold; annealing site for complementary DNA
oligonucleotide, underlined). In vitro translation of the 2! ermBL construct was
performed using the Rapid Translation System RTS 100 E. coli HY Kit (Roche; Cat.
No. 3246817). Translations were carried out in the presence of 10 mM ERY for 1 h
at 30 !C. Control reactions were performed in the absence of ERY as well as using a
monocistronic ermBL construct (Supplementary Fig. 1). Translation reactions were
analysed on sucrose density gradients (10–55% sucrose in a buffer A, containing
50 mM HEPES-KOH, pH 7.4, 100mM KOAc, 25mM Mg(OAc)2, 6 mM
b-mercaptoethanol, 10 mM ERY and 1!Complete EDTA-free Protease Inhibitor
cocktail (Roche)) by centrifugation at 154,693g (SW-40 Ti, Beckman Coulter) for
2.5 h at 4 !C (Fig. 1d). For ErmBL-SRC purification, disome fractions were
collected using a Gradient Station (Biocomp) with an Econo UV Monitor (Biorad)
and a FC203B Fraction Collector (Gilson). Purified ErmBL-SRC disomes were
concentrated by centrifugation using Amicon Ultra-0.5ml Centrifugal Filters
(Millipore) according to the manufacturer’s protocol. To obtain monosomes
of the ErmBL-SRC, a short DNA oligonucleotide (50-ttcctccttaaaact-30 ,
Metabion) was annealed to the linker between the ermBL cistrons of the disomes,
generating a DNA–RNA hybrid that could be cleaved by RNase H (New England
Biolabs) treatment in buffer A at 25 !C for 1 h (Fig. 1c). The RNase H-cleaved
disome material was directly applied to the cryo-grids without any further
purification.
Aminoacylation status of tRNALys in the ErmBL-SRC. RNA from three
A260 units of the disome peak, subjected to exactly the same procedures as
required for preparation for cryo-EM, was extracted by acidic phenol, ethanol
precipitated and dissolved in 6 ml NaOAc, pH 4.0. The isolated RNA was then
resolved by electrophoresis in an 8 cm long (1mm thick) 14% acidic denaturing
gel30 alongside with deacylated tRNALys and aminoacyl-tRNA markers. After
electrophoresis for 24 h at 50V in the cold room, the RNA was transferred to a
Hybond Nþ membrane (GE Healthcare) by electroblotting and probed with a
[32P]-50-labelled DNA oligonucleotide complementary to tRNALys:
(GTCGTGCAGGATTCGAACCTGCGACCAATTGATTAAAAGTCAACTGC
TCTACCAACTGAGCTAACGACCC).
Negative-stain EM. Ribosomal particles were diluted in buffer A to a final con-
centration of 0.5 A260ml" 1. One drop of each sample was deposited on a carbon-
coated grid. After 30 s, grids were washed with distilled water and then stained with
three drops of 2% aqueous uranyl acetate for 15 s. The remaining liquid was
removed by touching the grid with filter paper. Micrographs were taken using a
Morgagni transmission electron microscope (FEI Company), 80 kV, wide angle 1 K
charge-coupled device at direct magnifications of 72K.
Cryo-EM and single-particle reconstruction. Monosomes of the ErmBL-SRC
were applied to 2 nm pre-coated Quantifoil R3/3 holey carbon-supported grids and
vitrified using a Vitrobot Mark IV (FEI Company). Data collection was performed
on a Titan Krios transmission electron microscope (FEI Company) under low-dose
conditions (about 20 e" per Å2) at a nominal magnification of ! 75,000 with a
nominal defocus between " 1 and " 3.5 mm. Images were collected at 200 keV at a
magnification of ! 148,721 at the plane of charge-coupled device using a
TemCam-F416 CMOS camera (TVIPS GmbH, 4,096! 4,096 pixel, 15.6 mm pixel,
1 s per full frame), resulting in an image pixel size of 1.0605Å (object scale). Data
collection was facilitated by the semi-automated software EM-TOOLS (TVIPS
GmbH) as described31. Contrast-transfer functions were determined using the
SPIDER TF ED command and recorded images were manually inspected for good
areas and power-spectra quality. Data were processed further using the SPIDER
software package32, in combination with an automated workflow as described
previously31. After initial, automated particle selection based on the programme
SIGNATURE33, initial alignment was performed with 1,344,100 particles, using E.
coli 70S ribosome as a reference structure34. After removal of noisy particles
(527,625 particles; 39%), the data set could be sorted into three main
subpopulations (Supplementary Fig. 2) using an incremental K-means-like method
of unsupervised 3D sorting35: the first subpopulation (353,318 particles; 26%) was
defined by the presence of the L1 stalk adopting an ‘in’ conformation and the
presence of non-stoichiometric density for tRNAs in the A-, P- and E-sites. The
second and third subpopulations were defined by the presence of the L1 stalk
adopting an ‘out’ conformation and the absence of density for the E-tRNA. The
minor subpopulation contained only P-tRNA, but due to the small particle
numbers (113,413 particles; 8%) could only be refined to B7Å resolution (with a
Fourier shell correlation (FSC) cutoff of 0.5). In contrast, the major subpopulation
(349,744 particles; 26%) contained both A- and P-tRNAs and could be refined to
an average resolution of 6.6 Å (0.5 FSC) and a local resolution extending to 4.5 Å
for the core of the 30S and 50S subunit (Supplementary Fig. 3). Local resolution
was computed within a softened sphere (radius of 22 Å) at each voxel, as described
previously36, using the 0.5 FSC of two reconstructions; namely, from the first 50%
of the particles and then the remaining 50%.
Molecular modelling and map-docking procedures. The molecular model for the
ribosomal proteins and rRNA of the ErmBL-SRC was based on the 50S subunit from
the crystal structure of ERY bound to the E. coli 70S ribosome (PDB3OFR)11 and
obtained by performing a rigid-body fit into the cryo-EM density map of the ErmBL-
SRC using UCSF Chimera37 (fit in map function). The conformations of 23S rRNA
nucleotides U2584 and U2585 were taken from the equivalent nucleotides of the
Haloarcula marismortui 50S subunit in complex with the unaccommodated A-site
tRNA mimic (PDB1VQ6)21,22 after the PDB was fitted as a rigid body into the
ErmBL-SRC density map. The conformation of U2506 was similar to the equivalent
nucleotide of the H. marismortui 50S subunit in complex with the accommodated
A-site tRNA mimic (PDB1VQN)21,22, however, required manual rotation of the base
to prevent clashing with the unaccommodated position of U2585. In contrast, the
conformation of A2062 present in the ErmBL-SRC is unique, being distinct from the
tunnel ‘in’ (PDB3CC2)38 and tunnel ‘out’ (PDB1VQ6)21,22 conformations observed in
previously reported ribosome structures. The conformation of A2062 in the ErmBL-
SRC is most closely related to conformations of this nucleotide observed in the
Thermus thermophilus 70S ribosome (PDB2J01)39. To investigate the conformational
state of the PTC of the ErmBL-SRC, crystal structures of H. marismortui 50S subunit
in complex with model peptide bond substrates (Fig. 5a,b) were fitted into the cryo-
EM density map of the ErmBL-SRC as a rigid body using UCSF Chimera37. The
model for the ErmBL nascent polypeptide chain was generated and manually fitted
into the density using Coot40. PDBs for the unaccommodated (PDB1VQ6) and
accommodated (PDB1VQN) state of the PTC were filtered to 4.5Å to using the
Molmap function in Chimera. Difference electron density maps were then calculated
by subtracting the filtered maps for 1VQ6 from 1VQN (Supplementary Fig. 5a) or
ErmBL from 1VQN (Supplementary Fig. 5b).
Figure preparation. Figures showing electron densities and atomic models were
generated using UCSF Chimera37.
Toe-printing assay. The DNA templates containing T7 promoter, RBS and the
ErmBL-coding ORF (wild type or the mutants) were generated by crossover PCR.
The toe-printing analysis of drug-dependent ribosome stalling was carried out as
described18. Briefly, the DNA templates (0.1 pmol) were used in a total volume of
5 ml of PURExpress (New England Biolabs) cell-free transcription–translation
reactions. Samples were incubated for 15min at 37 !C, followed by addition of the
[32P]-labelled NV1 toe-printing primer designed to anneal B100 nucleotides
downstream from the anticipated ribosome-stalling site. The primer was extended
by reverse transcriptase and the reaction products were analysed in sequencing
gels. In experiments with mutant ribosomes, the ‘D ribosome’ version of the
PUREXpress kit was supplemented with ribosomes (10 pmol per reaction) isolated
from the SQ171 E. coli strain carrying the plasmid expressing E. coli rrnB operon
with the engineered mutations in the 23S rRNA gene. Mutant ribosomes were
purified as described41.
Cell-free translation and analysis of peptidyl tRNA. Translation of the ermBL
ORF for peptidyl tRNA analysis was carried out in the E. coli S30 cell-free
transcription–translation system (Promega). PCR-generated DNA template car-
rying the ermBL gene (shown in blue) under the control of the Ptac promoter
(green) had the following structure:
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The DNA template (0.1–0.5 pmol) was translated in a 5 ml reaction containing
100mCi of [14C]-Asp or [14C]-Lys (specific activity of both: 208 mCimmol" 1)
(American Radio Chemicals) following the manufacturer’s protocol. When
required, translation reactions were carried out in the presence of 50 mM ERY or
borrelidin. After 30min incubation at 37 !C, samples were analysed in a 16%
bis-tris polyacrylamide gel using MES running buffer (as described in http://
openwetware.org/Sauer:bis-Tris_SDS_PAGE based on US patent 6,162,338). Gels
were dried and exposed overnight to a phosphorimager screen.
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Supplementary Figure 1 Generation of ErmBL-SRC disomes 
a, Sucrose gradient profiles of in vitro translation reactions of the bicistronic ermBL 
mRNA performed in the (a) absence and (b) presence of 10 µM erythromycin. c, Sucrose 
gradient profiles of in vitro translation reactions of the monocistronic ermBL mRNA 




Supplementary Figure 2 In silico sorting of the ErmBL-SRC 
During the processing of the cryo-EM dataset of the ErmBL-SRC, several subpopulations 
of 70S ribosomes with differences in their tRNA occupancy and their conformational 
state could be separated subsequent to removal of noisy particles. The predominant 
homogenous population (26%) with stoichiometric occupancy of A- and P-tRNAs 




Supplementary Figure 3 Average and local resolution determination of the ErmBL-
SRC.  
a, Overview of the ErmBL-SRC with 30S (yellow), 50S (grey), A-tRNA (orange) and P-
tRNA (green) highlighted. b, Average resolution of the ErmBL-SRC was 6.6 Å using the 
Fourier shell correlation (FSC) cut-off value of 0.5. c, Local resolution displayed on the 
ErmBL-SRC with the 50S subunit cut (as depicted in inset) to reveal the ribosomal tunnel. 
d, as in c, but with 30S (yellow), A-tRNA (orange), P-tRNA (green) and erythromycin 





Figure 4 Mutations of 23S rRNA residues do not affect ErmBL-stalling. 
23S rRNA nucleotides were chosen for mutagenesis on the basis of their proximity to the 
ErmBL nascent chain (a) and the ability of the mutant ribosomes to support cell growth. 
Mutant rRNA was expressed from an rrnB operon on a plasmid in the SQ171 strain that 
lacks chromosomal rrn alleles1,2 and the mutant ribosomes were isolated followed the 
published procedures3. b, The ribosomes were used in toeprinting assays, which were run 
in the absence (-) or presence (+) of 50 PM of erythromycin (Ery). The toeprint band 
indicated by the arrow represents ribosomes arrested with the Asp (D10) ermBL codon in 




Figure 5 Difference density maps of ErmBL-SRC  
a, Electron density maps were generated for the uninduced (orange, PDB1VQ6)4-6 and 
induced (blue, PDB1VQN)4-6 state of the PTC and a difference density map was 
generated (red mesh). Overlaid is the cryo-EM density map of the ErmBL-SRC (grey 
mesh). b, Electron density map was generated for the induced (blue, PDB1VQN)4-6 state 
of the PTC and a difference density map was generated (red mesh) by subtracting the 
cryo-EM density map of the ErmBL-SRC. For reference the uninduced state of the PTC 
(orange, PDB1VQ6)4-6 and the cryo-EM density map of the ErmBL-SRC (grey mesh) is 
also included. c, Electron density map was generated for the uninduced (orange, 
PDB1VQ6)4-6 state of the PTC and a difference density map was generated (red mesh) by 
subtracting the cryo-EM density map of the ErmBL-SRC. For reference the induced state 
of the PTC (blue, PDB1VQN6)4-6 and the cryo-EM density map of the ErmBL-SRC 
(grey mesh) is also included. The cross correlation coefficient between the nucleobase of 
U2584 increases from 70% to 94% when comparing the fit between the induced and 
uninduced state with the ErmBL map. 
 6 
 
Figure 6 The ErmBL-SRC contains Lys-tRNALys in the A-site and not deacylated 
tRNALys. Analysis of the aminocylation status of the A-site bound tRNALys in the 
ErmBL-SRC. Total RNA was extracted from the disome (ErmBL-SRC) material, 
fractionated in a denaturing acidic gel and subjected to Northern blotting using an 
oligonucleotide probe specific for tRNALys (lane 1). Lys-tRNALys marker (lane 2) was 
prepared by incubating total E. coli tRNA with a mixture of aminoacyl-tRNA synthetases 
in the PURExpress cell-free translation system lacking ribosomes (New England Biolabs). 
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During protein synthesis, nascent polypeptide
chains within the ribosomal tunnel can act in cis to
induce ribosome stalling and regulate expression of
downstream genes. The Staphylococcus aureus
ErmCL leader peptide induces stalling in the pres-
ence of clinically important macrolide antibiotics,
such as erythromycin, leading to the induction of
the downstream macrolide resistance methyltrans-
ferase ErmC. Here, we present a cryo-electron
microscopy (EM) structure of the erythromycin-
dependent ErmCL-stalled ribosome at 3.9 A˚ resolu-
tion. The structure reveals how the ErmCL nascent
chain directly senses the presence of the tunnel-
bound drug and thereby induces allosteric confor-
mational rearrangements at the peptidyltransferase
center (PTC) of the ribosome. ErmCL-induced pertur-
bations of the PTC prevent stable binding and
accommodation of the aminoacyl-tRNA at the
A-site, leading to inhibition of peptide bond forma-
tion and translation arrest.
INTRODUCTION
Nascent polypeptide-mediated translation regulation can be an
intrinsic property of the nascent chain or require an additional
ligand, such as an amino acid or antibiotic (Ramu et al., 2009;
Va´zquez-Laslop et al., 2011a). Similar to other inducible macro-
lide resistance genes, the Staphylococcus aureus ermC gene is
controlled by programmed arrest during translation of the up-
stream ermCL leader peptide (Horinouchi and Weisblum, 1980;
Iord!anescu, 1976; Shivakumar et al., 1980) (Figure 1A): In
the absence of erythromycin, ErmC expression is repressed
because the ribosome-binding site (RBS) and AUG start codon
of the ermC mRNA are sequestered in a stem-loop structure
(Figure 1A). However, in the presence of subinhibitory concen-
trations of erythromycin, ribosomes translating the ErmCL leader
peptide become stalled, leading to an alternative stem-loop
structure in the mRNA that exposes the RBS and start codon
of the ermC gene and thus allows ribosome binding and induc-
tion of ErmC expression (Figure 1A).
Previous studies demonstrated that polymerization of the
ErmCL nascent chain halts because the ribosome is unable
to catalyze peptide bond formation between the 9 aa long
ErmCL-tRNAIle (codon 9) in the ribosomal P-site and Ser-tRNASer
(codon 10) in the A-site (Johansson et al., 2014; Va´zquez-Laslop
et al., 2008) (Figure 1A). Mutations of specific ErmCL amino acid
residues located in the ribosomal exit tunnel of the ErmCL-SRC
reduce or abolish stalling, as domutations of certain rRNA nucle-
otides that comprise the tunnel wall (Johansson et al., 2014;
Mayford and Weisblum, 1989; Va´zquez-Laslop et al., 2008,
2010, 2011b). Additionally, the chemical structure of the macro-
lide antibiotic can influence ribosome stalling (Va´zquez-Laslop
et al., 2008, 2011b). Collectively, these findings indicate that
ribosome stalling results from interactions between the ErmCL
leader peptide, the macrolide, antibiotic and components of
the ribosomal tunnel (Va´zquez-Laslop et al., 2011a); however,
a structural basis for this complex interplay is lacking.
To elucidate the nature of these interactions and ascertain
how they lead to inactivation of the PTC of the ribosome, we
generated ErmCL-SRC for structural analysis by cryo-electron
microscopy (EM). The structure reveals the path of the ErmCL
nascent polypeptide chain and its interactions with specific
23S rRNA nucleotides U2506, U2586, and A2062 within the ribo-
somal tunnel. Moreover, ErmCL is observed to directly interact
with the cladinose sugar of erythromycin, thus revealing how
the nascent chain monitors the presence of the tunnel-bound
drug. Collectively, these interactions appear to stabilize a unique
conformation of the ErmCL nascent chain that induces global re-
arrangements at the peptidyltransferase center (PTC) of the ribo-
some, which in turn prevent stable binding and accommodation
of the A-tRNA, and thus induce translational arrest.
RESULTS
Cryo-EM Structure of the ErmCL-SRC
The ErmCL-SRC was generated by translation of a dicistronic
2XermCL mRNA in the presence of 10 mM erythromycin using
an E. coli lysate-based in vitro translation system. The ErmCL-
SRC disomes were isolated by sucrose gradient purification,
converted to monosomes, and directly applied to cryogrids (Fig-
ure S1 available online), as performed previously for the ErmBL-
SRC (Arenz et al., 2014). Data collection was performed on a
Titan Krios TEM fitted with the Falcon II direct electron detector
(FEI, Netherlands), and images were processed with SPIDER
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(Frank et al., 1996) (see Experimental Procedures). In silico sort-
ing of cryo-EM images yielded one major homogeneous sub-
population of ribosomes bearing a P-tRNA but lacking A-tRNA
(Figures 1B and 1C), which contrasts with the previous cryo-
EM reconstruction of the ErmBL-SRC that contained tRNAs in
both the A- and P-sites (Arenz et al., 2014). The ErmCL-SRC
has an average resolution of 3.9 A˚, while local resolution calcula-
tions indicate that the ribosomal core reaches 3.5 A˚ (Figures 1D
and S1). Rigid-body docking of crystallographic structures of the
E. coli ribosome (Pulk and Cate, 2013) reveals excellent agree-
ment with the cryo-EM map, such as strand separation in b
sheets (Figure 1E) and the pitch of a helices (Figure 1F) within
the ribosomal proteins, as well as density for the majority
of the amino acid side chains (Figures 1E and 1F). Additionally,
the rRNA backbone and nucleotides are well-resolved, as well
as the position of many magnesium ions (Figures 1G and 1H).
The distinct features of the electron density allowed the CCA-
end of the P-tRNA to be accurately placed and a model for
residues 3–9 of the ErmCL leader peptide to be built de novo
(Figure 1C).
Critical Interactions of ErmCL with Components of the
Ribosomal Tunnel
The overall path of the ErmCL nascent chain within the ribosomal
tunnel is shifted toward erythromycin when compared with the
path of ErmBL (Arenz et al., 2014) (Figure S2). Four sites of con-
tact are observed between the ErmCL nascent chain and com-
ponents of the ribosomal tunnel (Figures 2A, 2B, and S3): At
the C terminus of ErmCL, U2506 interacts with V8 and stacks
upon the aromatic side chain of F7, whereas I6 interacts with
U2586 (Figure 2A). These contacts are likely to be important,
since mutations to alanine in the conserved ‘‘IFVI’’ motif (I6–I9)
of ErmCL severely reduce ribosome stalling (Johansson et al.,
2014; Va´zquez-Laslop et al., 2008). Although mutation of
U2586 to A, C, or G did not affect wild-type ErmCL stalling
(Figure 2C), the stalling efficiency of the I6A-ErmCLmutant could
be partially rescued by the U2586 mutations (Figure 2C). This
functional interplay between U2586 and I6 is consistent with
the direct interaction observed in the structure (Figure 2A). To
investigate this contact further, we generated all possible amino
acid substitutions at position 6 of ErmCL and monitored the
efficiency of stalling by toe-printing (Figure S4). The results indi-
cated that the hydrophobic amino acids M, V, and L (and to a
lesser extent the charged amino acid E) at position 6 maintained
efficient ribosome stalling, whereas all other substitutions further
reduced the stalling efficiency.
An interaction is also observed from the N terminus of ErmCL
with A2062 (Figure 2D); however, due to the poor density (indi-
cating flexibility) of the N terminus (Figure S3), we can only tenta-
tively assign this interactionwith A2062 to I3 and could notmodel
the very N-terminal residues M1-G2. While alanine scanning
mutagenesis indicates that the nature of the N-terminal residues
Figure 1. Cryo-EM Structure of the ErmCL-SRC
(A) Schematic for ermCL-dependent regulation of ermC translation in the presence of erythromycin (ERY).
(B) Transverse section of the ErmCL-SRC, with 30S (yellow), 50S (gray), P-tRNA (green), ErmCL (teal), and ERY (red).
(C) Zoom showing electron density (gray) and model for the ErmCL nascent chain (teal) attached to CCA-end of the P-tRNA (green).
(D) As (B), but colored according to local resolution.
(E–H) Examples of electron density in the ErmCL-SRC map including (E) b strands and (F) a helix in ribosomal proteins, (G) rRNA helix, and (H) coordinated Mg2+
ions. See also Figure S1.
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G2-S5 is not critical for ribosome stalling (Johansson et al., 2014;
Va´zquez-Laslop et al., 2008), truncation of more than two N-ter-
minal residues of ErmCL notably reduced stalling (Va´zquez-
Laslop et al., 2008), suggesting that the I3 position is at least
sterically important for the stalling mechanism. In this regard,
we note that in the ErmCL-SRC, A2062 is stabilized in a confor-
mation that lies flat against the tunnel wall (Figures 2B and S3),
whereas the A2062 conformation that protrudes into the
tunnel lumen observed in the majority of ribosome structures
(Va´zquez-Laslop et al., 2010), including the ErmBL-SRC (Arenz
et al., 2014), would sterically clash with the ErmCL nascent chain
(Figure 2D). In the flat conformation, the N7 of A2062 is within
hydrogen bonding distance of the exocyclic amino group of
A2503 (Figure 2B), suggesting that the steric role of the N termi-
nus of ErmCL may be to induce the previously noted interaction
between A2062 and A2503 (Va´zquez-Laslop et al., 2010).
Consistently, mutations of A2062U/C or A2503G dramatically
reduce ErmCL stalling (Va´zquez-Laslop et al., 2010; Va´zquez-
Laslop et al., 2008). In the absence of conformational changes
with previously proposed relays from A2062/A2503 back to the
PTC (Va´zquez-Laslop et al., 2010), we favor a model whereby
A2062/A2503 exert an effect on the PTC via the ErmCL nascent
chain.
Drug Sensing by the ErmCL Nascent Chain within the
Ribosomal Tunnel
In the ErmCL-SRC, erythromycin is bound in the canonical posi-
tion (Dunkle et al., 2010; Tu et al., 2005), as observed previously
in the ErmBL-SRC (Arenz et al., 2014). However, unlike the
ErmBL-SRC (Arenz et al., 2014), direct contact is observed be-
tween ErmCL and the drug (Figures 2E and S3), possibly be-
tween the backbone N of F7 and the C40 0-OH of the cladinose
sugar of erythromycin; however, higher resolution will be
required to verify this. Biochemical experiments support ErmCL
monitoring for the presence and the structure of the drug; specif-
ically, ErmCL-mediated stalling was observed in the presence of
other cladinose-containing macrolides but not in the presence
of ketolide antibiotics, such as telithromycin, which lack the
C3-cladinose (Va´zquez-Laslop et al., 2008, 2011b) (Figure S4).
Moreover, macrolides bearing modifications of the C3-cladinose
are also impaired for ErmCL-mediated ribosome stalling (Va´z-
quez-Laslop et al., 2011b).
Inactivation of the PTC of the Ribosome by ErmCL
To understand how the interaction of ErmCL with erythromycin
and rRNA components of the exit tunnel prevents stable binding
of the A-tRNA and therefore leads to inhibition of peptidyl-trans-
fer, we compared the PTC of the ErmCL-SRC with crystal
structures of the ribosome in different states of peptide bond
formation (Schmeing et al., 2002, 2005a, 2005b; Voorhees
et al., 2009) (Figure 3A). While the overall conformation of the
PTC is similar between ErmCL and the crystal structures, a few
clear differences are evident. In the fully functional ribosome,
U2585 rotates by 19! upon A-tRNA accommodation (i.e., when
moving from the unaccommodated [uninduced] to the accom-
modated [induced] state) (Schmeing et al., 2002, 2005a,
Figure 2. Interaction of the ErmCL Nascent Chain within the Ribosomal Tunnel
(A and B) ErmCL (teal) contacts (arrowed) with 23S rRNA nucleotides (A) U2506, U2586, and (B) A2062.
(C) Toe-printing of wild-type (wt) andmutant (I6A) ErmCL translation on E. coli ribosomes with wt (U2586) or U2586A/C/Gmutants, in the presence (+) or absence
(") of ERY. All reactions contained the Thr-tRNA synthetase inhibitor borrelidin, which halts translation at the Thr (T11) codon in the absence of ERY-induced
arrest at the Ile (I9) codon. Error bars represent one SD of the mean.
(D) Spacefill representation of ErmCL (teal) illustrating the steric clash with A2062 positions from PDB3OFR (Dunkle et al., 2010) (yellow) and ErmBL-SRC (PDB ID
3J5L, gray) (Arenz et al., 2014). For comparison, the A2062 position in ErmCL-SRC is shown (blue).
(E) Sensing of the C3 cladinose sugar of ERY (Dunkle et al., 2010) (red) by the ErmCL nascent chain (teal). See also Figures S2–S4.
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2005b) (Figure 3A). Surprisingly, U2585 adopts a dramatically
different conformation in ErmCL-SRC, such that it is rotated by
80! compared to the unaccommodated state, and is flipped
into a pocket formed by U2584/G2583 and G2608 (Figures 3A
and 3B). This is reminiscent of the large rotation (180!) of
U2585 observed upon streptogramin binding to the Deinococ-
cus radiodurans 50S subunit (Harms et al., 2004); however, the
final position is distinct (Figure S3). The positions of U2585 in
the fully accommodated state would sterically clash with the
ErmCL nascent chain, which may be the cause of the flipped
state of U2585 in the ErmCL-SRC (Figure 3B). This contrasts
with the ErmBL-SRC, where the path of the ErmBL nascent chain
is compatible with (and even proposed to stabilize) the position
of U2585 in the unaccommodated state (Arenz et al., 2014)
(Figure 3C).
In the Haloarcula marismortui 50S crystal structures, U2506 is
also observed to undergo a shift upon A-tRNA accommodation,
such that the base interacts with U2585 (Schmeing et al., 2002,
2005a, 2005b) (Figure 3D). In the ErmCL-SRC, U2506 adopts a
position similar to (but distinct from) U2506 in the accommo-
dated state, which establishes interactions with residues V8
and F7 of ErmCL and is thereby presumably stabilized by the
shifted conformation of the nascent chain (Figure 3D). Further-
more, A2602 is observed to undergo a slight shift upon A-tRNA
accommodation (Figure 3E). In the ErmCL-SRC, A2602 appears
to adopt a defined position (Figure S3), similar to the unaccom-
modated state but slightly shifted toward the A-tRNA (Figure 3E),
which may also influence A-tRNA stability. During binding and
accommodation of the A-tRNA, the ribose 20OHof A76maintains
hydrogen bonding distance to the C4 oxygen of U2585 (Schme-
ing et al., 2005a; Schmeing et al., 2005b; Schmeing et al., 2002),
which is also observed for the unaccommodated A-tRNA in the
ErmBL-SRC (Arenz et al., 2014). In contrast, this contact is not
possible with the flipped position of U2585 in the ErmCL-SRC
(Figure 3F).
DISCUSSION
Collectively, our biochemical and structural findings lead us to
propose a model for ErmCL-mediated drug-dependent ribo-
some stalling (Figure 4): While the exact conformation of the
ErmCL peptide within the ribosomal tunnel in the absence of
erythromycin has yet to be determined, biochemical studies indi-
cate that peptide bond formation between Ser-tRNA in the A-site
and the ErmCL-tRNA in the P-site can occur (Johansson et al.,
2014; Va´zquez-Laslop et al., 2008) (Figure 4A).
Figure 3. Conformational Changes at the PTC of the ErmCL-SRC
(A and B) Flipped conformation of 23S rRNA nucleotide U2585 in ErmCL-SRC (teal) compared to canonical position of U2585 in the uninduced (PDB1VQ6,
orange) and induced (PDB1VQN, yellow) states of the PTC (Schmeing et al., 2005a, 2005b).
(C) Comparison of ErmCL (teal) and ErmBL (PDB3J5L, tan) (Arenz et al., 2014) nascent chains and respective U2585 positions.
(D and E) Relative positions of (D) U2585 and U2506, and (E) A2602 in ErmCL-SRC (teal), uninduced (PDB1VQ6, orange), and induced (PDB1VQN, yellow) states
of the PTC (Schmeing et al., 2005a, 2005b). In (E), A2602 position of ErmBL-SRC (PDB3J5L, tan) (Arenz et al., 2014) is included for reference.
(F) The flipped U2585 position in ErmCL-SRC (teal) prevents stabilization of the A-tRNA as observed in the uninduced (PDB1VQ6, orange) and induced
(PDB1VQN, yellow) state of the PTC (Schmeing et al., 2005a, 2005b). See also Figure S3.
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However, in the presence of erythromycin, the ErmCL nascent
chain interacts with the drug and adopts a unique conformation
that is stabilized via interactions with specific rRNA components
of the tunnel such as U2586, U2506, and A2062 (Figure 4B). In
this stalled state, the ErmCL nascent chain precludes the canon-
ical position of U2585 and promotes an alternative flipped
conformation, which together with shifted P-tRNA and A2602
positions remodels the PTC making it unfavorable for the
A-tRNA to fully accommodate and therefore leads to disso-
ciation and translation arrest (Figure 4B). The absence of
Ser-tRNA in the A-site of the ErmCL-SRC (Figure 1B) is consis-
tent with previous single-molecule fluorescence experiments
demonstrating that the A-site of ErmCL-SRC has a reduced
capability to stably bind A-tRNA (Johansson et al., 2014). This
contrasts with the structures of ErmBL- and SecM-stalled ribo-
somes, where stable tRNA binding was observed at the ribo-
somal A-site (Arenz et al., 2014; Bhushan et al., 2011).
In conclusion, our study illustrates how the ribosome can
employ the ErmCL nascent chain to monitor the presence of
erythromycin and induce allosteric conformational rearrange-
ments within the PTC active site, leading to translational stalling
and regulation of expression of downstream genes. The distinct
mechanisms of drug sensing and active site perturbation utilized
by ErmCL and ErmBL (Arenz et al., 2014) raise the question as to
whether similar mechanisms are utilized by other drug-depen-
dent stalling systems.
EXPERIMENTAL PROCEDURES
Generation and Purification of ErmCL-SRC
ErmCL-SRC were generated following the same procedure as previously
described (Arenz et al., 2014). The 2XermCL construct was synthesized (Euro-
fins,Martinsried) such that it contained aT7promoter followedby a strong ribo-
somebinding site (RBS) spacedby7nt to theATGstart codonof the firstermCL
cistron. A linker of 22 nt separated the stop codon of the first ermCL cistron and
the start codon of the second ermCL cistron. The linker also comprised the
strong RBS 7 nt upstream of the ATG start codon of the second ermCL cistron,
enabling initiation of translation independent from the first ermCL cistron. Each
Figure 4. Schematic Model of ErmCL-Medi-
ated Translation Arrest
(A) In the absence of erythromycin (-ERY), Ser-
tRNA accommodates at the A-site enabling pep-
tide bond formation with the ErmCL-tRNA in the
P-site.
(B) In contrast, in the presence of erythromycin,
the ErmCL nascent chain adopts a distinct
conformation that promotes conformational re-
arrangements of 23S rRNA nucleotides A2062 and
A2602 and, most dramatically, flipping of U2585.
Collectively, this global rearrangement of the PTC
prevents stable binding and accommodation of
Ser-tRNA at the ribosomal A-site and thus results
in translational arrest.
ermCL cistron encoded amino acids 1–19 corre-
sponding to ErmCL leader peptide (GenBank
accession number V01278) present on macrolide
resistance plasmid pE194 (Iord!anescu, 1976;
Narayanan and Dubnau, 1985). The complete




CACAGTTCATTATCAACCAAACAAAAAATAA-30 (T7 Promoter, italics; RBS,
bold; the ATC codon in the P-site of the stalled ribosome is shown in
bold; annealing site for complementary DNA oligonucleotide, underlined).
In vitro translation of the 2xermCL construct was performed using the
Rapid Translation System RTS 100 E. coli HY Kit (5PRIME; catalog number
2401110).
Translation reactions were analyzed on sucrose density gradients (10%–
55% sucrose in a buffer A, containing 50 mM HEPES-KOH [pH 7.4],
100 mM KOAc, 25 mM Mg(OAc)2, 6 mM b-mercaptoethanol, 10 mM erythro-
mycin, and 1 3 Complete EDTA-free Protease Inhibitor cocktail [Roche]) by
centrifugation at 154,693 3 g (SW-40 Ti, Beckman Coulter) for 3 hr at 4!C.
For ErmCL-SRC purification, disome fractions were collected using a Gradient
Station (Biocomp) with an Econo UV Monitor (Biorad) and a FC203B Fraction
Collector (Gilson). Purified ErmCL-SRC disomes were concentrated by centri-
fugation through Amicon Ultra-0.5 ml Centrifugal Filters (Merck-Millipore)
according to the manufacturer’s protocol. To obtain monosomes of the
ErmCL-SRC, a short DNA oligonucleotide (50-ttcctccttataaaact-30, Metabion)
was annealed to the linker between the ermCL cistrons of the disomes, gener-
ating a DNA-RNA hybrid that could be cleaved by RNase H (NEB) treatment
in buffer A at 25!C for 1 hr. After cleavage of the disomes, ErmCL-SRC
monosomes were again purified and concentrated by centrifugation through
Amicon Ultra-0.5 ml Centrifugal Filters (Merck-Millipore) according to the
manufacturer’s protocol.
Negative-Stain EM
Ribosomal particles were diluted in buffer A to final concentrations of 0.5
A260/ml up to 5 A260/ml in order to determine the optimal ribosome density
for cryo-EM. One drop of each sample was deposited on a carbon-coated
grid. After 30 s, grids were washed with distilled water and then stained with
three drops of 2% aqueous uranyl acetate for 15 s. The remaining liquid was
removed by touching the grid with filter paper. Micrographs were taken using
aMorgagni transmission electron microscope (FEI), 80 kV, wide angle 1K CCD
at direct magnifications of 72K.
Cryo-EM and Single-Particle Reconstruction
A total of 4 A260/ml monosomes of the ErmCL-SRC were applied to 2 nm pre-
coated Quantifoil R3/3 holey carbon supported grids and vitrified using a
VitrobotMark IV (FEI Company). Data collection was performed at NeCEN (Lei-
den) on a Titan Krios transmission electron microscope (TEM) (FEI, Eindhoven)
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equipped with a Falcon II direct electron detector at 300 kV with a magnifica-
tion of 125,0853, a pixel size of 1.108 A˚, and a defocus range of 0.7–1.2 mm.
The data are provided as a series of seven frames (dose per frame of 4 e"/A˚2)
from which we summed frames 2–5 (accumulated dose of 20 e"/A˚2) after
alignment using Motion Correction software (Li et al., 2013). Images were pro-
cessed using a frequency-limited refinement protocol that helps prevent over-
fitting (Scheres and Chen, 2012), specifically by truncation of high frequencies
(in this case, at 8 A˚). As reported and expected (Scheres and Chen, 2012), we
find that using this processing regime the 0.143 FSC value provides a good
indicator for the true average resolution of the map. Additionally, the local
resolution of the map was calculated using ResMap (Kucukelbir et al., 2014).
Power-spectra and defocus values were determined using the SPIDER TF
ED command, and recorded images were manually inspected for good areas
and power-spectra quality. Data were processed further using the SPIDER
software package (Frank et al., 1996), in combination with an automated work-
flow as described previously (Becker et al., 2012). After initial, automated par-
ticle selection based on the program SIGNATURE (Chen and Grigorieff, 2007),
initial alignment was performed with 419,113 particles using E. coli 70S ribo-
some as a reference structure (Arenz et al., 2014). After removal of noisy
particles (47,340 particles; 11%), the data set could be sorted into two main
subpopulations using an incremental K-means-like method of unsupervised
3D sorting (Loerke et al., 2010):
The major subpopulation (285,841 particles; 68%) was defined by the pres-
ence of stoichiometric densities for P-tRNA and could be refined to an average
resolution of 3.9 A˚ (0.143 FSC) and a local resolution extending to 3.5 A˚ for the
core of the 30S and 50S subunit as computed using ResMap (Kucukelbir et al.,
2014) (Figure S1). The final map was subjected to the program EM-BFACTOR
(Ferna´ndez et al., 2008) in order to apply an automatically determined negative
B-factor for sharpening of the map.
Molecular Modeling and Map-Docking Procedures
Themolecular model for the ribosomal proteins and rRNA of the ErmCL-SRC is
based on the molecular model for the 50S subunit from the recent crystal
structure of the E. coli 70S ribosome (PDB ID 4KIX) (Pulk and Cate, 2013)
and obtained by performing a rigid body fit into the cryo-EM density map of
the ErmCL-SRC using UCSF Chimera (Pettersen et al., 2004) (fit in map func-
tion). Similarly, the position of erythromycin was identical to that observed pre-
viously (Dunkle et al., 2010; Tu et al., 2005) and obtained by rigid body fit of
PDB3OFR (Dunkle et al., 2010) into the cryo-EM density map of the ErmCL-
SRC. The overall fit of the crystal structures were in very good agreement
with the electron density of ErmCL-SRC, and since exclusively the conforma-
tions of important nucleotides of the PTC and the exit tunnel are crucial to inter-
pret the molecular mechanism leading to stalling on ErmCL, only these 23S
rRNA nucleotides (A2602, G2583, U2584, U2585, U2586, U2506, and
A2062), were manually shifted/rotated where necessary into their respective
densities using Coot (Emsley and Cowtan, 2004), whereas the rest of the
rigid-body-fitted crystal structure remained unchanged. The conformation of
A2602 observed in ErmCL-SRC is distinct from the ‘‘up’’ conformation
observed in ErmBL-SRC (PDB3J5L) (Arenz et al., 2014) and from the
‘‘down’’ conformation (in PDB1VQN) (Schmeing et al., 2005a, 2005b). As
such, its conformation resembles an intermediate state between ‘‘up’’ and
‘‘down.’’ The conformation of U2506 is similar to its conformation in
(PDB1VQN) (Schmeing et al., 2005a, 2005b); however, slight manual rotation
of the base was required to get an optimal fit. Different conformations of
A2062—e.g., the ‘‘down’’ (PDB2WRJ) (Gao et al., 2009) and ‘‘tunnel-in’’
(PDB3I8F) (Jenner et al., 2010) —conformations sterically clash with the
ErmCL nascent chain, whereas the ‘‘up’’ conformation present in the Haloar-
cula marismortui 50S subunit in complex with model peptide bond substrates
(e.g., PDB1VQN) (Schmeing et al., 2005a,2005b) was similar to the conforma-
tion of A2062 observed in the ErmCL-SRC. Most notably, U2585 adopts a
unique and novel ‘‘flipped out’’ position, which is very different to previously
observed positions for U2585 (i.e., U2585 in the uninduced [PDB1VQ6] or
[PDB1VQN] induced state of the PTC) (Schmeing et al., 2005a, 2005b). In
the novel, ‘‘flipped-out’’ conformation, U2585 is rotated approximately 80!
when compared to its canonical position. In order to regularize the rRNA back-
bone surrounding U2585, neighboring nucleotides G2583, U2584, and U2586
were slightly adjusted in the model for ErmCL-SRC. Besides 23S rRNA nucle-
otides, the CCA-end of the P-tRNA, in particular A76, wasmanually adjusted in
order to fit the density, since previously reported conformations observed in
crystal structures of the Haloarcula marismortui 50S subunit in complex with
model peptide bond substrates did not fit the density when fitted as a rigid
body together with the 50S subunit. The molecular model for the ErmCL
nascent polypeptide chain was modeled and refined into the density using
Coot (Emsley and Cowtan, 2004).
Figure Preparation
Figures showing electron densities and atomic models were generated using
UCSF Chimera (Pettersen et al., 2004).
Toe-Printing Assay
The DNA templates containing T7 promoter, ribosome binding site, and the
ErmCL coding ORF (wild-type or the mutants) were generated by crossover
PCR. The toeprinting analysis of drug-dependent ribosome stalling was car-
ried out as described (Va´zquez-Laslop et al., 2008). Briefly, the DNA templates
(0.1 pmol) were used in a total volume of 5 ml of PURExpress (NEB) cell-free
transcription-translation reactions. Samples were incubated for 15 min at
37!C, followed by addition of the [32P]-labeled NV1 toe-printing primer de-
signed to anneal #100 nt downstream from the anticipated ribosome stalling
site. The primer was extended by reverse transcriptase, and the reaction prod-
ucts were analyzed in sequencing gels. In experiments withmutant ribosomes,
the ‘‘D ribosome’’ version of the PUREXpress kit was supplemented with ribo-
somes (10 pmol per reaction) isolated from the SQ171 E. coli strain carrying the
plasmid expressing E. coli rrnB operon with the engineered mutations in the
23S rRNA gene. Wild-type and mutant ribosomes were purified as described
(Ohashi et al., 2007).
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SUPPLEMENTAL FIGURES 
 
Figure S1 Average and local resolution determination of the ErmCL-SRC, related 
to Figure 1. (A) Schematic for ermCL-dependent regulation of ermC translation in the 
presence of erythromycin (ERY). (B,C) The bicistronic 2XermCL mRNA was translated 
in vitro in the presence of 10 µM ERY in order to generate (B) ErmCL-SRC disomes, 
which were (C) converted to monosomes by annealing of complementary DNA oligo and 
RNase H cleavage, as shown by sucrose density centrifugation and negative stain EM. 
(D) Local resolution (Kucukelbir et al., 2014) displayed on the ErmCL-SRC with a 
transverse section through the 50S subunit (as depicted in the insert), 30S (yellow), P-
tRNA (green) and erythromycin (red). (E) Average resolution of the ErmCL-SRC was 
4.6 Å using the Fourier shell correlation (FSC) cut-off value of 0.5. Since the microscopy 
images were processed in the absence of spatial frequencies higher than 8 Å, the FSC cut-
off value of 0.143 was used for average resolution determination of 3.9 Å (Scheres and 
Chen, 2012). The overall fit of the 50S model to the ErmCL-SRC map is indicated by the 
FSC calculation between the model and map (red curve). (F) Histogram generated by 
ResMap (Kucukelbir et al., 2014) showing that the local resolution of the final map 
predominantly ranges from 3.5-4.0 Å.  
 
 
Figure S2 Comparison of the path of the ErmCL and ErmBL nascent chains 
through the ribosomal tunnel, related to Figure 2. (A-D) Comparison of cryo-EM 
structures of (A,B) ErmCL-SRC and (C,D) ErmBL-SRC (Arenz et al., 2014) with 30S 
(yellow) and transverse section of the 50S subunit (grey), illustrating the path of the 
respective nascent polypeptide chains trough the ribosomal tunnel. Enlargements with 
density (grey mesh) and molecular models for the ErmCL (teal) and ErmBL (green) 
nascent chains, erythromycin (ERY, red) and 23S rRNA nucleotides (blue). 
 
 
Figure S3 Electron density for selected regions of the PTC and tunnel, related to 
Figure 2 and 3. (A-C) Views of the ErmCL nascent chain (teal), 23S rRNA nucleotides 
(blue), and erythromycin (Dunkle et al., 2010) (red) in the ribosomal tunnel of the 
ErmCL-SRC. Views identical to those shown in Fig. 2A,B,E, respectively, but including 
electron density (grey mesh). (D) Electron density (grey mesh) for the defined position of 
A2602 in the ErmCL-SRC. (E) Unique conformation of 23S rRNA nucleotide U2585 in 
ErmCL-SRC (teal) compared to its positions observed in the uninduced (PDB1VQ6, 
orange) and induced (PDB1VQN, yellow) state of the PTC (Schmeing et al., 2005a; 
Schmeing et al., 2005b). Insert show electron density for nucleotides G2583-U2586 
coloured according to local resolution (Kucukelbir et al., 2014). (F,G) Electron density 
for G2583-U2586 in (G) ErmBL-SRC (Arenz et al., 2014) and (G) TnaC-SRC indicating 
the absence of electron density for the flipped position of U2585 and presence of electron 
density for canonical position of U2585. (H) Comparison of U2585 conformations in the 
uninduced (PDB1VQ6, orange) and induced (PDB1VQN, yellow) state of the PTC 
(Schmeing et al., 2005a; Schmeing et al., 2005b), as well as in ErmCL-SRC (teal) and 
streptogramin-bound ribosomes (PDB1SM1) (Harms et al., 2004).  
 
 
Figure S4 Superimposition of telithromycin antibiotic relative to ErmCL, related to 
Figure 2. (A) Interaction between I6 and U2586 in the ErmCL-SRC. (B) Quantification 
of the stalling efficiency of mutations at position I6 of ErmCL based on toe-printing 
assays. (C,D) Chemical structures of (C) erythromycin (ERY) and (D) telithromycin 
(TEL) showing, various alterations of the lactone ring and the absence of the C3 
cladinose sugar in telithromycin. (E-H) Relative position of (E,F) erythromycin and 
(G,H) telithromycin to ErmCL. Spacefill representations of ErmCL and (F) ERY 
(Dunkle et al., 2010) and (H) TEL (Dunkle et al., 2010) illustrate the proximity of the C3 
cladinose sugar of erythromycin to ErmCL, which is absent in the superimposition of 
telithromycin due to the lack of the C3 cladinose. 
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SUMMARY 
During protein synthesis, nascent polypeptide chains within the ribosomal tunnel 
can act in cis to induce ribosome stalling and regulate expression of downstream genes. 
The Streptococcus sanguis ErmBL leader peptide induces stalling in the presence of 
clinically important macrolide antibiotics, erythromycin and telithromycin, leading to the 
induction of the resistance methyltransferase ErmB. Here, we report cryo-electron 
microscopy structures at 3.6 Å resolution of ErmBL-stalled ribosome complexes in the 
presence of erythromycin, with or without Lys-tRNA bound in the A-site. The structures 
reveal that the ErmBL nascent chain adopts an unusual conformation within the 
ribosomal tunnel, with the C-terminal Asp10 sidechain in a previously unseen rotated 
position. While the Lys-tRNA in the A-site is optimally positioned, peptide bond 
formation cannot occur because the ribose A76 of the peptidyl-tRNA in the P-site is 
shifted from its canonical position. Thus, in addition to a structural basis for polypeptide-
mediated translational arrest, these reconstructions also provide structural insight into the 











Ribosomes are the protein synthesizing machines of the cell. The active site for 
peptide bond formation, the peptidyltransferase center (PTC) is located on the large 
ribosomal subunit 1,2. During translation elongation, peptide bond formation occurs when 
a peptidyl-tRNA is located at the P-site and an aminoacyl-tRNA at the A-site of the PTC. 
The  α-amino group of the aminoacyl-tRNA makes a nucleophilic attack onto the 
carbonyl carbon of the peptidyl-tRNA, transferring the peptidyl moiety onto the A-tRNA 
and prolonging the nascent polypeptide chain by one amino acid 1,2. As the nascent 
polypeptide chain is synthesized, it passes through a tunnel located on the large ribosomal 
subunit and emerges on the solvent side where protein folding occurs 3. A growing body 
of evidence has revealed that the ribosomal tunnel is not a passive conduit for the nascent 
polypeptide chain but rather plays an important role in protein folding, co-translational 
targeting and translation regulation 3. 
Nascent polypeptide-mediated translation regulation can be an intrinsic property 
of the nascent chain, such that the amino acid sequence of the polypeptide is sufficient to 
modulate the rate of translation, and in some cases even induce translation arrest 4. Well-
characterized bacterial examples include the MifM and SecM leader peptides, which 
interact with the ribosomal tunnel to induce translational stalling 5,6 and thereby regulate 
expression of a downstream gene in the operon 4,7. Nascent polypeptide-mediated 
translation regulation can also require the presence of an additional ligand or co-factor 
4,8,9. Well-characterized examples include the TnaC leader peptide, which requires the 
presence of free tryptophan for stalling to occur 10,11, and the Erm leader peptides, which 
induce translation stalling in the presence of the macrolide antibiotics 8,9.  
In the case of Erm peptides, the translational arrest in the leader peptide leads to 
expression of the downstream macrolide resistance determinant, usually a 
methyltransferase that confers resistance by methylating A2058, a 23S ribosomal RNA 
nucleotide that comprises part of the macrolide binding site within the ribosomal tunnel. 
For example, in Streptococcus sanguis the expression of the ErmB methyltransferase is 
controlled by programmed arrest during translation of the upstream ermBL leader peptide 
12-14 (Figure 1A): In the absence of erythromycin, ErmB expression is repressed because 
the ribosome-binding site (RBS) and AUG start codon of the ermB mRNA are 
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sequestered in a stem-loop structure (Figure 1A). However, in the presence of sub-
inhibitory concentrations of erythromycin, ribosomes translating the ErmBL leader 
peptide become stalled, leading to an alternative stem-loop structure in the mRNA that 
exposes the RBS and start codon of the ermB gene and thus allows ribosome binding and 
induction of ErmB expression (Figure 1A). The drug-dependent nature of the stalling 
ensures that expression only occurs when the drug is present, which is critical for survival 
because of the fitness cost associated with the methylation of A2058 15.  
Previous studies demonstrated that polymerization of the ErmBL nascent chain 
halts because the ribosome is unable to catalyze peptide bond formation between the 10 
amino acid long ErmBL-tRNAAsp (codon 10) in the ribosomal P-site and Lys-tRNALys 
(codon 11) in the A-site 16 (Figure 1A). The ErmBL-dependent translational arrest occurs 
with both macrolides (e.g. erythromycin) and ketolides (e.g. telithromycin) 16, which 
contrasts with other leader peptides, such as ErmCL, where stalling is specific for 
macrolides 9,17. Mutagenesis studies identified four residues within ErmBL (Arg7, Val9-
Lys11) that are critical for stalling 16. Interestingly, the compromised stalling efficiency 
of the ErmBL-R7A mutant could be rescued by compensatory mutations within U2586 
(but not A2062) of the 23S rRNA. The first structural insights into how the ErmBL leader 
peptide, the macrolide antibiotic and the ribosomal tunnel cooperate to inactivate the PTC 
of the ribosome were derived from a cryo-electron microscopy (cryo-EM) structure of the 
ErmBL-SRC at 4.5-6.6 Å resolution 16. On the basis of this structure, it was suggested 
that peptide bond formation cannot occur because the ErmBL nascent chains stabilizes an 
uninduced state of the ribosome that prevents accommodation of Lys-tRNA at the A-site.  
Here we present cryo-EM structures of the ErmBL-stalled ribosome complex in 
the presence and absence of A-tRNA, with a resolution of 3.1-3.6 Å. The structures 
reveal a complex network of potential hydrogen bonding interactions between the C-
terminal region of ErmBL and nucleotides of the 23S rRNA, explaining the importance 
of these residues for translational stalling. The ErmBL nascent chain adopts a unique path 
within the ribosomal tunnel that enables it to bypass the tunnel-bound macrolide. The 
unique path of ErmBL arise because of an unusual rotated conformation of the C-
terminal Asp10 residue, which is unlike that seen previously in any cryo-EM or X-ray 
crystallography structures. The conformation of the ErmBL nascent chain induces 
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distortions in the terminal A76 of the P-tRNA, preventing nucleophilic attack by the 
accommodated A-tRNA, and thus leading to translation arrest. In addition to providing 
insights into nascent chain mediated translation arrest, the ErmBL-stalled ribosome 





RESULTS AND DISCUSSION 
Cryo-EM structures of ErmBL-stalled ribosome complexes 
The ErmBL-stalled ribosomal complexes (SRCs) were generated by translation of 
a dicistronic 2XermBL mRNA in the presence of 20 µM erythromycin using an E. coli 
lysate-based in vitro translation system. The ErmBL-SRC disomes were then isolated by 
sucrose gradient purification, converted to monosomes, re-isolated and applied to 
cryogrids, as described previously 16,18. Data collection was performed on a Titan Krios 
TEM fitted with the Falcon II direct electron detector (FEI, Netherlands) and images 
were processed with SPIDER 19 (see Experimental Procedures). In silico sorting of cryo-
EM images yielded two major homogeneous subpopulations of ribosomes bearing P-
tRNA and E-tRNAs, but differing in the presence (termed ErmBL-APE-SRC; 85,393 
particles, 33%) or absence (termed ErmBL-PE-SRC; 75,839 particles, 30%) of A-tRNA 
(Figure 1B and Figure S1). Both subpopulations could be refined to an average 
resolution of 3.6 Å (using a Fourier shell correlation (FSC) cut-off of 0.143, Figure S2), 
with local resolution calculations indicating that the ribosomal core reaches towards 
3.1 Å (Figure 1C and Figure S2). At this resolution, base separation is clearly observed 
for rRNA nucleotides (Figure 1D), as is the density for the majority of the amino acid 
side chains in ribosomal proteins (Figure 1E). Density is also observed for the lysyl side 
chain attached to the CCA-end of the A-tRNA as well as for the ErmBL leader peptide 





Figure 1 Cryo-EM structure of the ErmBL-SRC. (A) Schematic for ermBL-dependent regulation of 
ermB translation in the presence of erythromycin (ERY). (B) Cryo-EM maps of the ErmBL-APE-SRC and 
ErmBL-PE-SRC, with 30S (yellow), 50S (grey), A-tRNA (orange), P-tRNA (green) and E-tRNA 
(magenta). (C) Transverse sections of the cryo-EM maps of the ErmBL-APE-SRC and ErmBL-PE-SRC, 
coloured according to local resolution. (D-F) Examples of electron density (grey mesh) of the ErmBL-
APE-SRC map illustrating (D) base separation within an rRNA helix, (E) side chains of a ribosomal 
protein α-helix, (F) aminoacylated-CCA-end of the A-tRNA (orange) and ErmBL-peptide attached to the 
CCA-end of the P-tRNA (green).  
 
A molecular model for the ErmBL nascent chain  
The ErmBL nascent chains of both ErmBL-SRCs were well resolved within the 
ribosomal tunnel, as indicated by local resolution (Figure 2A,B and Figure S3). 
Moreover, the electron density for ErmBL in the ErmBL-PE-SRC was basically identical 
to that in the ErmBL-APE-SRC (Figure S3), indicating that the presence of the A-tRNA 
does not influence the conformation of the ErmBL nascent chain. With the exception of 
the side chain of Asn8 for which we observe no density, we are able to present a 
complete model for the ErmBL nascent chain residues Val3-Asp10. In contrast, the N-
terminus of ErmBL appears to be flexible, consistent with the worse local resolution of 
this region, thus preventing the N-terminal Met1 residue from being modeled and 
allowing only the backbone for Leu2 to be tentatively assigned (Figure 2A,B and Figure 
S3). The overall backbone trace of the ErmBL nascent chain within the ribosomal tunnel 
reported here is similar to the path reported previously for ErmBL based on a 4.5-6.6 Å 
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cryo-EM map 16 (Figure S4). Specifically, ErmBL adopts a unique conformation that 
enables it to by-pass the macrolide erythromycin bound within the tunnel without 
contacting it (Figure 2C). This is consistent with biochemical studies demonstrating that 
ErmBL stalling occurs with a variety of different macrolides and thus appears insensitive 
to the chemical nature of the drug 16. The ErmBL path is distinct from that reported for 
the drug-dependent ErmCL stalling peptide 18, which establishes intimate interactions 
with the drug (Figure 2D), consistent with the findings that ErmCL stalling occurs with 
macrolide antibiotics containing a C3-cladinose sugar, such as erythromycin, but not with 
ketolides, such as telithromycin that lack the C3-cladinose 9,17. This contrasts with the 
available structures of other polypeptide chains within the ribosomal tunnel 5,6,20-24, which 
revealed paths that would be sterically obstructed by the presence of the macrolide, as 
exemplified here by the TnaC nascent chain 20 (Figure 2E). As noted 16, the path of the 
ErmBL illustrates the principle as to how specific amino acid sequences allow translation 





Figure 2 Path of ErmBL within the ribosomal tunnel. (A,B) Atomic model of ErmBL nascent chain 
including the CCA-end of the P-tRNA (green) with electron density represented as (A) grey mesh and (B) 
coloured according to local resolution. (C,E) Transverse sections of the ribosomal tunnel (grey) illustrating 
the path of (C) ErmBL (green), relative to (D) ErmCL (yellow, 18) and (E) TnaC (pink, 20), and ERY (red 
mesh).  
 
Interactions of ErmBL within the ribosomal tunnel 
In contrast to the previous reconstruction of ErmBL 16, the significantly higher 
resolution of the ErmBL-SRCs reported here permits a detailed analysis of the 
interactions of ErmBL nascent chain with components of the ribosomal tunnel (Figure 
3A). The majority of the interactions are localized within the last four C-terminal amino 
acids of ErmBL, namely Arg7-Asp10, which collectively establish a total of nine 
potential hydrogen bond interactions with nucleotides of the 23S rRNA: Asp10 can form 
three hydrogen bonds, one from the backbone carboxyl oxygen with the N3 of U2585 
and two from the side chain oxygens of Asp10 with the N1 and/or N2 of G2061 as well 
as the N3 of U2506 (Figure 3B). These interactions are likely to be important since 
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mutation of Asp10 to Ala abolishes translational stalling 16. The backbone carboxyl of 
Asn8 is within hydrogen bonding distance of the ribose 2’OH of A2062, whereas no 
density is observable for the side chain, consistent with the report that Asn8Ala mutations 
do not affect ErmBL stalling 16. Indeed, we note that the most favored rotamers for the 
Asn side chain would sterically clash with the desosamine sugar of erythromycin, 
presumably causing the Asn8 sidechain to adopt multiple other less defined states, 
explaining the absence of density (Figure 3C).  
The well-resolved density for the Arg7 side chain can be explained by the 
multiple interactions that this positively charged residue establishes by protruding into a 
negatively charged rRNA pocket of the tunnel wall (Figure 3D). Specifically, four 
hydrogen bonds are possible with the two terminal amino groups of Arg7, namely to the 
phosphate oxygens of A2063 and A2441, the bridging ribose oxygen of A2439 and the 
ribose 2’OH of U2586 (Figure 3D). In addition, the backbone of NH of Arg7 is within 
hydrogen bonding distance of the O2 of U2586. While mutation of Arg7Ala abolishes 
stalling, compensatory mutations of U2586 were able to restore stalling 16, supporting the 
intimate association between these two entities. What is unclear from the structure is why 
the Val9Ala mutation also abolishes ErmBL stalling activity 16. In the ErmBL-SRC, the 
sidechain of Val9 is well resolved, yet does not appear to come into close proximity of 
any components of the ribosomal tunnel (Figure 3E). We speculate that the Val9 side 
chain may therefore be important for indirectly promoting the correct conformation of the 
ErmBL nascent chain: one possibility is that Val9 provides some steric constraints that 
are necessary for the Arg7 side chain to be optimal oriented, since these two residues 
spatially neighbor each other within the ribosomal tunnel. 
In contrast to the C-terminus, the N-terminal half of ErmBL (residues Leu2-Met6) 
are not critical for stalling and can individually be mutated to alanine without loss of 
activity 16. This is consistent with the poor density and worse local resolution in this 
region, suggesting that the N-terminus of ErmBL is flexible and does not adopt a single 
defined conformation. The sequence of the N-terminus MLVFQM is also very 
hydrophobic and therefore provides limited possibilities for hydrogen bonding 
interactions. Instead, the Phe4 and Met6 side chains appear to pack against the U2609-
A752 and U1782-U2586 base pairs, respectively (Figure 3E). The only potential 
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hydrogen bonding interactions are from the backbone carboxyl of Val5 and the C9 
hydroxyl of the lactone ring of erythromycin. However, the lactone ring itself is relatively 
poorly resolved in this region and therefore it is hard to envisage how this could be an 
important stabilizing interaction.  
 
 
Figure 3 Interaction of the ErmBL nascent chain within the ribosomal tunnel. (A-F) Interactions of 
ErmBL (green) with 23S rRNA nucleotides (blue). In (D) different rotamers of the N8 side chain are 
illustrated, cryo-EM map of the ErmBL-SRC is shown as a grey mesh and ERY is shown in red. Potential 
hydrogen bonds are indicated as dashed lines. 
 
Rotation of Asp10 and an alternate path of the ErmBL 
To understand how interactions of ErmBL within the ribosomal tunnel lead to 
translational arrest by preventing peptide bond formation with the incoming Lys-tRNA in 
the A-site, we compared the ErmBL-SRC with all available X-ray crystallography 
structures of ribosomal states with aminoacylated-tRNAs in the P-site. To date, this 
consists of structures of the Haloarcula marismortui 50S subunits bearing CC-puromycin 
(CC-pmn) or CC-Phe-caproic-acid-biotin (CC-pcb) tRNA analogs 27-30 and of Thermus 
thermophilus 70S ribosomes bearing fMet-tRNA 31 or Phe-tRNA 2. In every single case, 
the side chain of the Phe or fMet attached the P-tRNA is observed having the same 
orientation (Figure 4A,B), namely, pointing towards the direction of A2062. Surprisingly, 
the Asp10 side chain attached the P-tRNA in the ErmBL-SRC is rotated by 180° 
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compared to the Phe/fMet side chains in the crystal structures (Figure 4A,B), with the 
consequence that the ErmBL nascent chain is oriented towards A2062. One possibility is 
that this simply reflects differences between a peptidyl-tRNA as in the case of ErmBL 
and an aminoacyl-tRNA as in the crystal structures, therefore, we also compared the 
ErmBL-SRC with structures of other ribosomal states bearing peptidyl-tRNAs in the P-
site. There are currently four available cryo-EM structures of ribosomes bearing peptidyl-
tRNAs of sufficient resolution so as to be able to determine the orientation of the amino 
acid attached to the P-tRNA, namely, the TnaC-SRC 20, ErmCL-SRC 18, Sec61beta 24 and 
the MifM-SRC 5. In all four structures, the amino acid side chain attached the P-tRNA is 
oriented analogously to the Phe/fMet side chain in the crystal structures (Figure 4C-F). 
This finding suggests that the difference is not related to the length of the peptide on the 
P-tRNA, and also excludes difference in species since the ErmCL- and TnaC-SRC were 
also formed using E. coli ribosomes 18,20. Moreover, the rotation is unlikely to be related 
to the nature of the amino acid since an Asp residue is also directly attached to the P-
tRNA in the MifM-SRC 5. This leads us to conclude that the 180° rotation of the Asp10 
residue in the ErmBL-SRC is likely to be a consequence of its context within the ErmBL 
nascent chain. It would therefore seem logical to assume that the interactions that 
stabilize the ErmBL in a specific conformation have an important influence on mediating 
the rotated state of Asp10 and/or vice versa. 
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Figure 4 Rotation of the C-terminal amino acid and an alternate path for ErmBL. (A-B) Orientation 
of ErmBL and Asp10 side chain (green), compared with (A) CC-Phe-caproic-acid-biotin (CC-pcb), CC-
puromycin (CC-Pmn) tRNA analogs (29, PDB 1VQ6, pink and 1VQN, purple, 27, PDB 1Q86, teal), or Phe-
tRNA (2, PDB 2WDL, blue), or with (B) Thermus thermophilus 70S ribosomes bearing fMet-tRNA (31, 
PDB 4QCM, brown, (Polikanov 2015 in press), PDB 4Z3R, yellow). (C-F) Alternate path of ErmBL 
(green) compared to (C) ErmCL (18, PDB 3J7Z, yellow), (D) MifM (5, PDB 3J9W, light blue), (E) TnaC (20, 
PDB 4UY8, pink) and (F) Sec61β (24, PDB 3J92, dark blue) relative to the position of ERY (red). 
 
A-tRNA accommodation at the PTC of the ErmBL-SRC 
To understand how the unorthodox pathway of the ErmBL nascent chain could 
lead to inhibition of peptidyl-transferase activity, we compared the PTC of the ErmBL-
SRC with crystal structures of the ribosome in different states of peptide bond formation 
28-31. Initially, we focused on the A-tRNA, since it was previously proposed that ErmBL 
stabilized an unaccommodated Lys-tRNA at the A-site of the PTC 16. In contrast to the 
previous study, the higher resolution enables us to more accurately place the CCA-end of 
the A-tRNA and also model the lysyl moiety (Figure 5A), which was not observed 
before. Comparison of the position of the CCA-end of the Lys-tRNA in ErmBL-SRC 
with the unaccommodated C-pmn (Figure 5B) and accommodated CC-pmn (Figure 5C) 
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on the H. marismortui 50S subunit 28-30, as well as with accommodated CCA-end of the 
Phe-tRNA in the T. thermophilus pre-attack complexes 2,31, suggests that the Lys-tRNA 
in the ErmBL-SRC is in a fully or near-fully accommodated state. The A-tRNA is shifted 
by 1.3 Å between the unaccommodated and accommodated state, when measuring the 
displacement using the ribose oxygen atom (Figure 5D). In comparison, the Lys-tRNA in 
the ErmBL-SRC is shifted by 0.9 Å and 0.6 Å relative to the unaccommodated and 
accommodated state, respectively.  
Accommodation of the A-tRNA is accompanied by corresponding conformational 
changes within the 23S rRNA nucleotides of the PTC, specifically, shifts in U2506 and 
U2584-U2585 are thought to be diagnostic for A-tRNA binding 28-30. In the ErmBL-PE-
SRC, there is no clear density for U2506 (Figure 5E), however, upon binding of Lys-
tRNA to the A-site, as in the ErmBL-APE-SRC, U2506 adopts a defined conformation 
(Figure 5F), which is similar to that observed in the accommodated state (Figure 5G). In 
both the ErmBL-SRC structures, the density for U2585 is weaker than other PTC 
nucleotides, but appears to predominantly adopt an intermediate position between the 
accommodated and unaccommodated U2585 states (Figure 5H). We note that regardless 
of whether the Lys-tRNA is fully or near-fully accommodated, the refined model of the 
Lys-tRNA in the ErmBL-APE-SRC positions the  α-amino group similarly to the 
accommodated pre-attack A-tRNAs (arrowed in Figure 5C) ready for nucleophilic attack 
of the P-tRNA. However, the presence of the lysyl moiety on the A-tRNA is alone 
sufficient to indicate that the nucleophilic attack has not occurred, consistent with the 
previous biochemical evidence indicating that the lysine amino acid does not get 




Figure 5 A-site tRNA accommodation at the PTC of the ErmBL-APE-SRC. (A-D) Atomic model for 
the CCA-end of the A-site tRNA (orange) in the ErmBL-APE-SRC with (A) electron density (grey mesh), 
compared with (B) unaccommodated (29, PDB 1VQ6, pink) and (C) accommodated A-tRNA states (31, 
PDB 4QCM, brown; 29 PDB 1VQN, purple), and (D) with both. (E-G) Position of 23S rRNA nucleotide 
U2506 (blue) in (E) ErmBL-PE-SRC and (F) ErmBL-APE-SRC including electron density (grey mesh) 
and (G) compared with the uninduced (29, PDB 1VQ6, pink) and induced (29, PDB 1VQN, purple) states of 
the PTC. (H) Comparison of 23S rRNA nucleotide U2585 in ErmBL-APE-SRC (blue), the uninduced (29, 
PDB 1VQ6, pink) and induced (29, PDB 1VQN, purple) states of the PTC. The nascent chain and A-tRNA 
in ErmBL are shown in green and orange, respectively. 
 
Perturbation of the P-tRNA by ErmBL prevents peptide bond formation 
Comparison of the CCA-end of the P-tRNA in the ErmBL-SRC (Figure 6A,B) 
with the accommodated position of CC-Pmn 29, Phe-tRNA 2 or fMet-tRNA 31 reveals a 
shift of 1-2 Å for the ribose and nucleobase of A76 (Figure 6C,D), which was also 
evident at lower resolution 16. This suggests that peptide bond formation may be 
prevented because of a perturbed position of the P-tRNA, rather than an 
unaccommodated A-tRNA as proposed previously 16. We note that the distance for the 
nucleophilic attack of the  α-amino group of the Lys-tRNA onto the carbonyl-carbon of 
the P-tRNA is 4.1 Å in the ErmBL-SRC (Figure 6E), whereas the equivalent distances in 




Figure 6 Perturbation of the P-tRNA by ErmBL prevents peptide bond formation. (A-D) Atomic 
model for the CCA-end of the P-site tRNA (green), including (A,C,D) electron density (grey mesh), in the 
ErmBL-APE-SRC, and compared with (B) P-tRNAs in the pre-peptide bond formation state (31, PDB 
4QCM, brown; 2, PDB 2WDK, blue), with (C,D) zoom onto the ribose of A76. (E,F) Relative orientation 
of the A-site α-amino group and the P-site carbonyl carbon in (E) ErmBL-APE-SRC and (F) the pre-attack 
state (31, PDB 4QCM, brown). (G,H) Network of hydrogen bonds creating a proton wire that enables 
peptide bond formation, according to Polikanov et al 31. 
 
The most recent model for peptide bond formation, based on high resolution X-ray 
crystallography structures, suggests that for the nucleophilic attack to proceed, proton 
transfer is necessary from the attacking nucleophile to a water molecule (W1) via a 
proton wire formed by the 2′-OH of the P-site A76 ribose and the 2′-OH of A2451 31 
(Figure 6G). In the pre-attack complexes, nucleotide A2602 and the N-terminal regions 
of L27 become ordered 2,31, which together with the OP1 of A76 of the A-tRNA and the 2’ 
OH of A2451, coordinate W1 31 (Figure 6G). In the ErmBL-SRC, we observe no density 
for A2602 or for the N-terminus of L27, suggesting that the W1 is not coordinated 
(Figure 6H). Stabilization of the very N-terminus of L27 has only been observed in the 
pre-attack structures due to interaction of the side chain of His3 of L27 with the O1P of 
C75 of the A-tRNA and the backbone carboxyl of Ala2 of L27 with the N6 of A76 of the 
P-tRNA 2,31. This simultaneous interaction of L27 with the A- and P-tRNA is not possible 
in the ErmBL-SRC because of the shifted position of the nucleobase of A76 of the P-
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tRNA (Figure 6H). Moreover, the positioning of the ribose 2’ OH of the A76 of the P-
tRNA is also critical for peptide bond formation 32-34, and therefore it is easy to envisage 
how perturbations of the ribose positioning of the P-tRNA as seen in ErmBL can disrupt 
the proton shuttle/wire. 
 




Based on our cryo-EM structures of the ErmBL-SRC, we propose a model for 
how the ErmBL nascent chain, together with the macrolide erythromycin and 
components of the ribosomal tunnel, interplay to inactivate the PTC and induce 
translational arrest (Figure 7). In the absence of erythromycin, crystal structures suggest 
that following accommodation of an aminoacyl-tRNA at the A-site of the PTC, the  α-
amino group of the A-tRNA is positioned to make nucleophilic attack onto the carbonyl-
carbon of the peptidyl-tRNA in the P-site (Figure 7A). For this nucleophilic attack to 
proceed, proton transfer is necessary from the attacking nucleophile to a water molecule 
(W1, which is coordinated by L27 and A2602), via a proton wire formed by the 2′-OH 
of the P-site A76 ribose and the 2′-OH of A2451 (Figure 7A).  In all structures to date, 
the side chain of the C-terminal amino acid, which is attached to the P-tRNA, is oriented 
such that all nascent polypeptide chains follow a similar pathway through the ribosomal 
tunnel. This canonical pathway, which we term pathway P1, is sterically occluded by the 
presence of macrolide antibiotics, explaining why this class of antibiotics induces 
peptidyl-tRNA drop-off for most nascent polypeptide chains 35-37 
In the presence of erythromycin, we propose that the conformations adopted by 
ErmBL are restricted, presumably due to the reduced diameter of the ribosomal tunnel, 
which in turn promotes interaction of critical residues, such as Arg7 of ErmBL, with 23S 
rRNA nucleotides on one side of the ribosomal tunnel (Figure 7B). In addition, we 
observe that Asp10 of ErmBL adopts an unusual rotated conformation, which together 
with the Arg7 interaction, stabilizes the ErmBL nascent chain in an alternative pathway 
P2, rather than using the canonical pathway P1. Pathway P2 is directed away from the 
tunnel-bound drug, providing an explanation as to why ErmBL-stalling occurs with both 
macrolides and ketolides 16. In contrast to previous suggestions 16, the Lys-tRNA in the 
ErmCL-SRC appears to be sufficiently accommodated at the A-site of the PTC such that 
nucleophilic attack onto the P-tRNA is possible (Figure 7B). Instead, we observe that the 
A76 ribose of the P-tRNA is perturbed, presumably as a consequence of the unusual 
rotation of Asp10 and conformation of the ErmBL nascent chain. We propose that the 
perturbed A76 of the P-tRNA prevents coordination of the water molecules necessary for 
catalyzing peptide bond formation (Figure 7B) 31, in agreement with the lack of density 
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for A2602 and the N-terminus of L27, which ultimately traps the ribosome in a pre-attack 
state and thereby stalls translation. 
In conclusion, this study illustrates how the ribosome can employ the ErmBL 
nascent chain, together with antibiotic erythromycin, to prevent peptide bond formation 
via P-tRNA perturbation. Inhibition by P-tRNA perturbation has been suggested 
previously for the SecM stalling sequence 6, however the limited resolution precluded a 
molecular basis for this stalling mechanism. Recent cryo-EM structures of the drug-
dependent ErmCL-SRC have revealed a completely unrelated mechanism of PTC 
silencing, namely, via inducing allosteric conformational rearrangements within the PTC 
active site 18. It will be interesting to investigate other drug-dependent stalling systems to 
ascertain whether these systems use similar mechanisms to induce translational arrest or 




Generation and purification of ErmBL-SRC 
ErmBL-SRC were generated following the same procedure as previously described 16. 
The 2XermBL construct was synthesized (Eurofins, Martinsried, Germany) such that it 
contained a T7 promoter followed by a strong ribosome binding site (RBS) spaced by 7 
nucleotides (nts) to the ATG start codon of the first ermBL cistron. A linker of 22 nts 
separated the stop codon of the first ermBL cistron and the start codon of the second 
ermBL cistron. The linker also comprised the strong RBS 7 nts upstream of the ATG start 
codon of the second ermBL cistron, enabling initiation of translation independent from 
the first ermBL cistron. Each ermBL cistron encoded amino acids 1-17 corresponding to 
ErmBL leader peptide (Genbank accession number K00551) present on macrolide 
resistance plasmid pAM77 from Streptococcus sanguis strain a1 38. The complete 




TACTATTTTGAAATAA-3’ (T7 Promoter, italics; RBS, bold; ErmBL ORF, shaded 
grey with GAT codon in P-site of stalled ribosome shown in bold; Annealing site for 
complementary DNA oligonucleotide, underlined). In vitro translation of the 2XermBL 
construct was performed using the Rapid Translation System RTS 100 E. coli HY Kit 
(5PRIME; Cat. No. 2401110). Translation reactions were analyzed on sucrose density 
gradients (10%-55% sucrose in a buffer A, containing 50  mM HEPES-KOH, pH 7.4, 100
  mM KOAc, 25  mM Mg(OAc)2, 6  mM β-mercaptoethanol, 10 µM erythromycin and 1× 
Complete EDTA-free Protease Inhibitor cocktail (Roche)) by centrifugation at 154,693 x 
g (SW-40 Ti, Beckman Coulter) for 3 h at 4°C. For ErmBL-SRC purification, disome 
fractions were collected using a Gradient Station (Biocomp) with an Econo UV Monitor 
(Biorad) and a FC203B Fraction Collector (Gilson). Purified ErmBL-SRC disomes were 
concentrated by centrifugation through Amicon Ultra-0.5 mL Centrifugal Filters (Merck-
Millipore) according to the manufacturer´s protocol. To obtain monosomes of the 
ErmBL-SRC, a short DNA oligonucleotide (5’-ttcctccttataaaact-3’, Metabion) was 
annealed to the linker between the ermBL cistrons of the disomes, generating a DNA-
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RNA hybrid that could be cleaved by RNase H (NEB) treatment in buffer A at 25°C for 
1h. After cleavage of the disomes, ErmBL-SRC monosomes were again purified and 
concentrated by centrifugation through Amicon Ultra-0.5 mL Centrifugal Filters (Merck-
Millipore) according to the manufacturer´s protocol.  
 
Negative-stain electron microscopy 
Ribosomal particles were diluted in buffer A to final concentrations of 0.5 A260/ml up to 5 
A260/ml in order to determine the optimal ribosome density for cryo-EM. One drop of 
each sample was deposited on a carbon-coated grid. After 30 seconds, grids were washed 
with distilled water and then stained with 3 drops of 2% aqueous uranyl acetate for 15 
seconds. The remaining liquid was removed by touching the grid with filter paper. 
Micrographs were taken using a Morgagni transmission electron microscope (FEI), 
80 kV, wide angle 1K CCD at direct magnifications of 72K. 
 
Cryo-electron microscopy and single particle reconstruction 
4 A260/ml monosomes of the ErmBL-SRC were applied to 2 nm pre-coated Quantifoil 
R3/3 holey carbon supported grids and vitrified using a Vitrobot Mark IV (FEI 
Company). Data collection was performed at NeCEN (Leiden, Netherlands) on a Titan 
Krios transmission electron microscope (TEM) (FEI, Eindhoven, Netherlands) equipped 
with a Falcon II direct electron detector at 300 kV with a magnification of 125,085x, a 
pixel size of 1.108 Å and a defocus range of 0.7-1.2 µm. The data are provided as a series 
of seven frames (dose per frame of 4 e-/Å2) from which we summed frames 2-5 
(accumulated dose of 28 e-/Å2) after alignment using Motion Correction software 39. 
Images were processed using a frequency-limited refinement protocol that helps prevent 
over-fitting 40, specifically by truncation of high frequencies (in this case at 8 Å). As 
reported and expected 40, we find that using this processing regime the 0.143 FSC value 
provides a good indicator for the true average resolution of the map. Additionally, the 
local resolution of the map was calculated using ResMap 41. Power-spectra and defocus 
values were determined using the SPIDER TF ED command and recorded images were 
manually inspected for good areas and power-spectra quality. Data were processed 
further using the SPIDER software package 19, in combination with an automated 
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workflow as described previously 42. After initial, automated particle selection based on 
the program SIGNATURE 43, initial alignment was performed with 285,462 particles, 
using E. coli 70S ribosome as a reference structure 16. After removal of noisy particles 
(30,093 particles; 11%), the dataset of 255,369 particles could be sorted into two main 
subpopulations using an incremental K-means-like method of unsupervised 3D sorting 
(Figure S1)44: A minor sub-population (94,139 particles, 37%) containing stoichiometric 
density for the P-tRNA, lacking E-tRNA (L1 stalk in the “out” position) and containing 
sub-stoichiometric density for the A-tRNA, which was not sorted further due to the low 
particle numbers. The major subpopulation (161,231 particles; 63%) was defined by the 
presence of stoichiometric densities for P- and E-tRNAs but sub-stoichiometric density 
for the A-tRNA. This population was further sorted into two additional sub-populations, 
both containing stoichiometric densities for the P- and E-tRNAs (L1 stalk in the “in” 
position) and differing by the presence (termed ErmBL-APE-SRC) or absence of A-
tRNA (ErmBL-PE-SRC). Both sub-populations could be refined to an average resolution 
of 3.6 Å (0.143 FSC) and a local resolution extending towards 3.0 Å for the core of the 
30S and 50S subunit as computed using ResMap 41 (Figure S2). The final maps were 
subjected to the program EM-BFACTOR 45 in order to apply an automatically 
determined negative B-factor for sharpening of the map. 
 
Molecular modeling and map-docking procedures 
The molecular model for the ribosomal proteins and rRNA of the ErmBL-SRC is based 
on the molecular model for the 50S subunit from the recent crystal structure of the E. coli 
70S ribosome (PDB ID 4KIX) 46 and obtained by performing a rigid body fit into the 
cryo-EM density map of the ErmCL-SRC using UCSF Chimera 47 (fit in map function). 
Similarly, the position of erythromycin was identical to that observed previously 48,49 and 
obtained by rigid body fit of PDB3OFR 49 into the cryo-EM density map of the ErmCL-
SRC. The overall fit of the crystal structures were in very good agreement with the 
electron density of ErmCL-SRC and since exclusively the conformations of important 
nucleotides of the PTC and the exit tunnel are crucial to interpret the molecular 
mechanism leading to stalling on ErmCL, only these 23S rRNA nucleotides (A2602, 
G2583, U2584, U2585, U2586, U2506, A2062), were manually shifted/rotated where 
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necessary into their respective densities using Coot 50, whereas the rest of the rigid-body-
fitted crystal structure remained unchanged. The conformation of A2602 observed in 
ErmCL-SRC is distinct from the “up” conformation observed in ErmBL-SRC (PDB3J5L) 
16 and from the “down” conformation in (PDB1VQN) 28,29 as such its conformation 
resembles an intermediate state between “up” and “down”. The conformation of U2506 is 
similar to its conformation in (PDB1VQN) 28,29, however slight manual rotation of the 
base was required to get an optimal fit. Different conformations of A2062, e.g. the “down” 
(PDB2WRJ) 51 and “tunnel-in” (PDB3I8F) 52 conformations sterically clash with the 
ErmCL nascent chain, whereas the “up” conformation present in the 
Haloarcula marismortui 50S subunit in complex with model peptide bond substrates (e.g. 
PDB1VQN) 28,29 was similar to the conformation of A2062 observed in the ErmCL-SRC. 
Most notably, U2585 adopts a unique and novel “flipped out” position, which is very 
different to previously observed positions for U2585, i.e. U2585 in the uninduced 
(PDB1VQ6) or (PDB1VQN) induced state of the PTC 28,29. In the novel, “flipped-out” 
conformation U2585 is rotated approximately 80° when compared to its canonical 
position. In order to regularize the rRNA backbone surrounding U2585, neighboring 
nucleotides G2583, U2584 and U2586 were slightly adjusted in the model for ErmCL-
SRC. Besides 23S rRNA nucleotides, the CCA-end of the P-tRNA, in particular A76, 
was manually adjusted in order to fit the density, since previously reported conformations 
observed in crystal structures of the Haloarcula marismortui 50S subunit in complex 
with model peptide bond substrates did not fit the density when fitted as a rigid body 
together with the 50S subunit. The molecular model for the ErmCL nascent polypeptide 
chain was modeled and refined into the density using Coot 50.  
 
Figure preparation 





Supplemental Information includes Figures S1-S4 and Supplemental References can be 
found with this article online at http://... 
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Table 1: Refinement and Model Statistics  
Data Collection and Refinement ErmBL-APE-SRC ErmBL-PE-SRC 
Particles  85,393 75,839 
Pixel size (Å) 1.108 1.108 
Defocus range (µm)  1.0-2.4 1.0-2.4 
Voltage (kV) 300 300 
Electron dose (e-/Å-2) 28 28 
Map sharpening B factor (Å2) -147.40 -140.09 
Resolution (Å, 0.143 FSC) 3.6 3.6 
Model Composition   
Non-hydrogen atoms 146778 145176 
Protein residues 5626 5626 
RNA bases 4761 4696 
Validation (proteins)   
Poor rotamers (%) 0.00 0.00 
Ramachandran outliers (%) 2.68 2.68 
Ramachandran favored (%) 89.95 89.99 
Bad backbone bonds (%) 0.00 0.00 
Bad backbone angles 0.00 0.00 
MolProbity score 1.89 (81st percentile) 1.88 (82nd percentile) 
Validation (nucleic acids)   
Correct sugar puckers (%) 99.67 99.78 
Bad backbone conformations (%) 14.18 14.30 
Bad bonds (%) 1.06 1.06 
Bad angles 0.00 0.00 













Figure S1 In silico sorting scheme of the ErmBL-SRC cryo-EM dataset. After removal of non-aligning 
and edge particles, sorting of the dataset yielded two homogenous sub-datasets. The first (30%; 75,839 
particles in total) contained stoichiometric density for P- and E-tRNAs (ErmBL-PE-SRC) and the second 





Figure S2 Average and local resolution determination of ErmBL-SRC´s (A-D) Cryo-EM 
reconstruction of (A) ErmBL-APE-SRC bearing A-tRNA (orange), P-tRNA (green) and E-tRNA (pink) 
and (B) the surface or (C) the transverse section coloured according to local resolution. (D) Average 
resolution of the ErmBL-APE-SRC was 4.3 Å using the Fourier shell correlation (FSC) cut-off value of 0.5. 
Due to image processing in the absence of spatial frequencies higher than 8 Å, the FSC value of 0.143 was 
used for average resolution determination of 3.9 Å 40. (E-H) Cryo-EM reconstruction of (E) ErmBL-APE-
SRC bearing A-tRNA (orange), P-tRNA (green) and E-tRNA (pink) and (F) the surface or (G) the 
transverse section coloured according to local resolution. (H) Average resolution of the ErmBL-APE-SRC 
was 4.3 Å using the Fourier shell correlation (FSC) cut-off value of 0.5. Due to image processing in the 
absence of spatial frequencies higher than 8 Å, the FSC value of 0.143 was used for average resolution 






Figure S3 Cryo-EM densities for the ErmBL nascent chain in both ErmBL-SRCs (A-L) Isolated cryo-
EM densities with atomic model for ErmBL nascent chains (green) from (A-F) ErmBL-APE-SRC and (G-
L) ErmBL-PE-SRC with electron density (B,E,H,K) coloured according to local resolution or (C,F,I,L) 





Figure S4 Improvement ErmBL-SRC map and model. (A-C) Isolated cryo-EM density (grey mesh) of 
the initial ErmBL-SRC reconstruction (16, EMD-5771) with Cα backbone trace (A) of initially reported for 
ErmBL nascent chain (PDB 3J5L, green) and (B) of the new atomic model  and (C) including amino acid 
side chains. (D) Isolated cryo-EM density (grey mesh) of the new ErmBL-APE SRC reconstruction 
including atomic model for ErmBL nascent chain residues V3-D10 (green). 
 
 
